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Abstract
Background: Scarce information exists about whether the relationship between multimorbidity
and cognitive decline has changed over the past decades.
Objectives: 1) To summarize knowledge about the association of multimorbidity and cognitive
decline by performing a systematic review. 2) To estimate the association between multimorbidity
in two cohorts selected three decades apart. 3)To identify which multimorbidity combinations have
the strongest associations with cognitive decline 4) To identify protective factors that reduce the
risk of cognitive decline in the presence of multimorbidity.
Methods: We performed a systematic review following the PRISMA statement. We then
addressed objectives 2-4 by analyzing data from two longitudinal studies. The Canadian Study of
Health and Aging (CSHA, n = 497) collected a baseline in 1991. The Canadian Longitudinal Study
of Health and Aging (CLSA, n = 23654) had a baseline in 2015. Both studies collected information
on several chronic conditions and used validated measures of different cognitive domains. Incident
dementia was available in the CSHA only. Statistical models included multilevel linear and logistic
regression and classification and regression trees (CART).
Results: We identified 19 publications evaluating the relationship between multimorbidity and
cognitive decline, of which 17 studies reported statistically significant results for this association.
We found no association between multimorbidity and cognitive scores in the CSHA, while in the
CLSA, we found associations with frontal function (ß:–0.049) and RAVLT (ß:–0.05). We did not
find an association between multimorbidity and 5-year dementia incidence in the CSHA. In the
CLSA, CART identified cardiopathies and stroke as part of the multimorbidity combinations
associated with the lowest cognitive test scores. Finally, in the CSHA, physical activity decreased
dementia risk (OR = 0.45, 95% CI: 0.20–0.98).
Conclusion: Our systematic review supports the association between multimorbidity and cognitive
decline without evidence of change over time. We found an association of multimorbidity on
cognitive scores only in the ongoing CLSA; future research should clarify this apparent increasing
effect of multimorbidity on cognition. We noticed that multimorbidity combinations containing
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cardiopathies and stroke were associated with low cognitive scores. Finally, we found that regular
exercise reduced the risk of dementia in multimorbidity patients.

Keywords
Multimorbidity; Multiple Chronic Health Conditions; Cognitive Decline; Cognitive impairment;
Multilevel Analysis.
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Summary for Lay Audience
Background: An increasing number of older adults live with more than one chronic disease at the
same time, a concept known as multimorbidity. In the past few decades, we have learnt that
multimorbidity may increase the chances of loss of mental capacity and developing dementia. Our
objectives were to evaluate if this relationship has changed in the past three decades. We began by
searching for all the published papers on the topic using a systematic review. Then we analyzed
data collected about thirty years apart in Canada to see if certain combinations of diseases increase
the possibility of mental decline. We also looked for characteristics that could protect people with
multimorbidity from developing dementia.
Methods: We searched published research to see how many previous researchers have looked at
this topic. We analyzed data from two community studies in Canada. First, the Canadian Study of
Health and Aging (CSHA, 1991–1996), and second, the Canadian Longitudinal Study on Aging
(CLSA, 2015–2018). We determined whether people with multimorbidity have a higher risk of
cognitive decline or lower scores on mental tests using appropriate statistical analyses that let us
control for factors other than multimorbidity that may be responsible for cognitive decline. We
used different statistical methods to see if we got similar or different results.
Results: We found 19 articles on the topic, of which 17 suggest that multimorbidity increases
cognitive deterioration. We found that in the CSHA, there was no association, whereas in the
CLSA, there was an association between multimorbidity and lower cognitive scores. We found that
one of the statistical methods, called Classification and Regression Trees (CART) found multiple
combinations of diseases associated with worse cognitive scores. We noticed that many disease
combinations linked with low cognitive scores included heart diseases and stroke. Finally, for the
protective factors, we found that exercise reduced the risk of dementia almost by half in the CSHA.
In the CLSA, we did not have enough information to corroborate this association.
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Figure 54: CART of CLSA Rey Auditory Verbal Learning Test Delayed Recall at baseline – All
cohort

345

Figure 55: CART of CLSA Rey Auditory Verbal Learning Test Delayed Recall at baseline –
Female subgroup
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Figure 56: CART of CLSA Rey Auditory Verbal Learning Test Delayed Recall at baseline – Male
subgroup
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Figure 57: CART of CLSA Rey Auditory Verbal Learning Test Delayed Recall at baseline –
Participants 65 years and older subgroup
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Figure 58: CART of CLSA Rey Auditory Verbal Learning Test Delayed Recall at baseline –
Participants younger than 65 years subgroup
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Figure 59: CART of CSHA Rey Auditory Verbal Learning Test Delayed Recall Change between
baseline and first follow-up – All cohort
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Figure 60: CART of CSHA Rey Auditory Verbal Learning Test Delayed Recall Change between
baseline and first follow-up – Female subgroup
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Figure 61: CART of CSHA Rey Auditory Verbal Learning Test Delayed Recall Change between
baseline and first follow-up – Male subgroup
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Figure 62: CART of CLSA Rey Auditory Verbal Learning Test Delayed Recall Change between
baseline and first follow-up – All cohort
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Figure 63: CART of CLSA Rey Auditory Verbal Learning Test Delayed Recall Change between
baseline and first follow-up – Female subgroup
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Figure 64: CART of CLSA Rey Auditory Verbal Learning Test Delayed Recall Change between
baseline and first follow-up – Male subgroup
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Figure 65: CART of CLSA Rey Auditory Verbal Learning Test Delayed Recall Change between
baseline and first follow-up – Participants 65 years and older subgroup
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Figure 66: CART of CLSA Rey Auditory Verbal Learning Test Delayed Recall Change between
baseline and first follow-up – Participants Younger than 65 years subgroup
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Figure 67: CART of Dementia Diagnosis at the First follow-up in the CSHA all cohort
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Figure 68: CART of Dementia Diagnosis at the First follow-up in the CSHA in the Female
subgroup
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Figure 69: CART of Dementia Diagnosis at the First follow-up in the CSHA in the Male subgroup
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Figure 70: CART of CIND Diagnosis at the First follow-up in the CSHA all cohort
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Figure 71: CART of CIND Incident Diagnosis at the First follow-up in the CSHA in the Female
subgroup
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Figure 72: CART of CIND Incident Diagnosis at the First follow-up in the CSHA in the Male
subgroup
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Chapter 1

1

Introduction and Aim

Life expectancy has increased over the past century, and mortality from diseases has decreased.
This increase in life expectancy has fostered the simultaneous occurrence of multiple chronic
conditions in the same individual, a concept known as multimorbidity. Multimorbidity has become
a common experience for middle-aged and older individuals. Worldwide, about one in three adults
live with multiple chronic conditions; this figure increases to three out of four among older adults1.
Simultaneously, this population’s aging has also resulted in more than double the prevalence of
dementia and cognitive decline during the past three decades2. Additionally, we recognize that the
risk of cognitive decline is associated with having multiple chronic diseases3. Furthermore,
longitudinal studies have suggested that as the number of morbidities increases, cognitive test
scores decline4. However, when evaluating the multimorbidity impact on cognitive decline, there
is insufficient knowledge of the variation through the past few decades, the combinations of chronic
diseases with higher risk and the potential protective factors in the population.
Hence, this thesis is intended to evaluate how multimorbidity was associated with the variation in
cognitive test scores and the incidence of dementia in community-dwelling Canadians. We also
analyzed if the association between multimorbidity and cognitive decline had changed over the
past three decades. Also, we wanted to recognize which chronic disease combinations were more
likely associated with cognitive decline. Finally, we evaluated potential protective factors that
might reduce the incidence of cognitive decline among people with multimorbidity.
We used the Canadian Study of Health and Aging (CSHA) and the Canadian Longitudinal Study
on Aging (CSLA), two landmark longitudinal studies conducted in Canada over the past three
decades. Both studies’ authors measured multimorbidity as well as cognition and its evolution
through the aging process.
We organized the present dissertation into nine chapters. In this first chapter, we introduce the
research topics and aims of the dissertation. In the second chapter, we present a literature review
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to contextualize the reader about the multimorbidity concept, cognitive decline, and the interplay
between them. Then, in the third chapter, we present the methods and results of our systematic
review of the association between multimorbidity and cognitive decline. Next, in the fourth chapter,
we offer our research objectives and the questions to guide them. In the fifth chapter, we describe
our research methods for each objective. In the first part of the sixth chapter, we present the
complete results of our study, and at the end of the chapter, we summarize the most relevant
findings of our research. In the seventh chapter, we discuss our results, strengths and limitations
and propose implications for future research. In the eighth chapter, we expose our conclusion and
the takeaway message as the final highlights. Finally, the ninth chapter presents our references.
Now, I am presenting our research objectives.

1.1 Research objectives
In this thesis we aimed to estimate the strength and direction of the association between
multimorbidity and cognitive decline. The primary objective was to determine if the
multimorbidity association with cognition has changed over the past three decades when
comparing the CSHA and CLSA cohorts. Another aim was to explored which multimorbidity
combinations were strongly related to cognitive decline in the CSHA and the CLSA. Finally, we
examined which protective factors in patients with multimorbidity were associated with less
cognitive decline.
Our research has contributed to understanding the pathways of the association of multimorbidity
with cognitive decline in Canadian participants of the CSHA and the CLSA, two landmark studies
on ageing.

1.1.1 Primary objective
The primary objective was to evaluate the relationship between multimorbidity and cognition and
how it has changed in the past 30 years in community-dwelling Canadians. We used the baseline
multimorbidity and the cognitive evaluation measured during the baseline and the first follow-up,
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comparing the CSHA and CLSA cohorts. We addressed the objectives through the following
research questions:
1. Has the prevalence of the major known risk factors for cognitive decline changed between
the CSHA and CLSA cohorts? Has the prevalence of the major multimorbidity
combinations changed?
2. Has there been a change in the adjusted incidence of cognitive decline when comparing the
CSHA and CLSA cohorts?
3. Has the strength of association between the baseline multimorbidity and incident cognitive
decline changed between the CSHA and CLSA cohorts?
4. Is there a qualitative difference in the association the between baseline multimorbidity and
cognitive decline measured during the first follow-up when comparing the CSHA and
CLSA cohorts?

1.1.2 Secondary objectives
1.1.2.1 Secondary objective one
The first secondary objective was to explore which baseline dyads and triads in multimorbidity
combinations were associated with the diagnosis of dementia or cognitive score decline, in the first
follow-up, among participants in the CSHA and CLSA.
We investigated if, in cognitive decline, there is a phenomenon analogous to that observed in
death5, disability6, and health resources utilization7, where different combinations of
multimorbidity carry different risks of developing the outcome. It seemed important to perform
stratified analysis by sex and life-course group owing to the expected heterogeneity in the
multimorbidity combinations.
The life course approach establishes distinct bounded life stages that are socially or biological
determined8, and it tries to identify the underlying biological and behavioural processes that define
those stages9. The age groups included were mid-life adults aged 45–64 and older adults aged 65
years and older. We evaluated this objective using the following questions:
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1. Which are the multimorbidity combinations with higher prevalence in the CSHA and CLSA
cohorts? Have the multimorbidity combinations with the highest prevalence changed over
the past three decades?
2. What are the baseline multimorbidity combinations associated with cognitive decline at the
first follow-up in the CSHA and CLSA cohorts?
3. Are there differences by sex in the baseline multimorbidity combinations associated with
cognitive decline at the first follow-up in the CSHA and CLSA cohorts?
4. Are there differences by age group in the baseline multimorbidity combinations associated
with cognitive decline at the first follow-up in the CLSA cohort?

1.1.2.2 Secondary objective two
The second secondary objective was to explore the baseline factors that protect patients from
cognitive decline by the first follow-up among the CSHA and CLSA comprehensive cohort
participants. The specific questions for secondary objective two were as follows:
1. Which factors measured at the baseline appear to protect participants in the CSHA and
CLSA comprehensive cohort from cognitive decline at the first follow-up?
2. Are differences by sex among the protective factors for cognitive decline among
participants in the CSHA and CLSA comprehensive cohort?
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Chapter 2

2

Literature Review

2.1 Multimorbidity
The overarching concept of morbidity encompasses any departure from a state of health10. The
WHO defines health as "a state of complete physical, mental and social well-being and not merely
the absence of disease or infirmity" 11.
Historically, the morbidity concept was understood as a "mono-morbidity" because it was
uncommon to endure more than one symptomatic chronic condition. Health care progress during
the twentieth century allowed patients to survive major diseases and accumulate more than one
chronic health condition at the same time12. Nevertheless, these other co-occurring chronic
conditions were assumed to be less important than the initial "index" disease. This disease hierarchy
configured the concept of "comorbidity"13. Under this paradigm, there is one primary chronic
disease, and any other disease, acute or chronic, can modify, mask or alter the course or the
treatment of this index condition. Nevertheless, in this paradigm, the index disease is the root
condition influencing the overall morbidity burden as well as the centre of treatment.
Then, we recognized that patients were accumulating more than one "major" chronic disease at one
time and that all chronic diseases undermined the patients' wellbeing14. Therefore, the paradigm
shifted to an understanding of morbidity as the simultaneous "co-occurrence of multiple diseases
and medical conditions within one person". This novel and integral concept, proposed in the
modern conception by van der Akker in 1996, is known as multimorbidity15.

2.1.1 Definition of multimorbidity
There is an agreement that the multimorbidity disease count should be at least two. Regarding the
diseases to be included, there is no consensus as yet16. In 2018, the Academy of Medical Sciences
proposed a harmonization framework17:
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"The co-existence of two or more chronic conditions, each one of which is either:
•

A physical non-communicable disease of long duration, such as cardiovascular disease or
cancer.

•

A mental health condition of long duration, such as a mood disorder or dementia.

•

An infectious disease of long duration, such as HIV or hepatitis C."

The concept of "conditions" is preferred because it encompasses all these risk factors and diseases.
All diseases are conditions, but not all conditions are diseases. Some conditions are just "potential"
events18. Further, the multimorbidity concept does not imply causal or hierarchical associations
among chronic conditions. This approximation translates into a holistic approach and the ability to
model unique complex health profiles19. Also, the multimorbidity approach includes conditions
known to increase the risk of specific target outcomes to allow the comprehensive analysis of the
patient's needs and resource utilization and to detect how the known and unknown risk chronic
conditions interact in the emergence of the target outcomes20.

Operative approach to multimorbidity
No universal operative framework to define multimorbidity exists21, and there are several
alternative approaches. These alternative strategies may lead to different estimates of
multimorbidity prevalence, measuring diverse parts of the multimorbidity construct22. Researchers
have implemented two main approaches: lists for counting diseases and weighted scores or
indexes22.
A recent systematic review found no standard number for disease counting, ranging from four to
102 conditions. The same publication stated that for indexes and weighted scores, there are at least
35 distinct methods constructed using different sets of criteria and designed to measure different
outcomes16. Comparisons of lists and indexes are scarce, but list counting more closely follows the
multimorbidity definition, which eases the interpretation23.

6
December 13, 2022

2.1.2 Multimorbidity differences by sex.
That said, current information reveals that multimorbidity susceptibility is non-homogeneous in
different groups within a population. Previous research has shown that women suffer
multimorbidity more frequently than men, and this disparity changes during the life course 24. In
both sexes, individuals under 35 years have a low prevalence of multimorbidity. Then the
prevalence steadily increases in both men and women. Nevertheless, this increase is steeper in
women, and around the fifth decade, the gap is the greatest. At this age, multimorbidity prevalence
is 7% higher among women. Then, the difference disappears in the older adults when both sexes
present a prevalence of multimorbidity over 75%25.
Also, multimorbidity patterns might differ by sex. Women report experiencing more mental or
mixed mental and physical conditions than do men25.

2.1.3 Multimorbidity differences by age group
Multimorbidity increases as individuals grow older, owing to the accumulation of chronic diseases.
Nevertheless, multimorbidity patterns differ in comparisons of different age groups. In a Danish
population, younger individuals have a preponderance of musculoskeletal and mental health
patterns. By contrast, among older participants, metabolic and cardiovascular disease are the most
common multimorbidity patterns26.

2.2 Change in multimorbidity over the decades.
Emerging research is showing that morbidity patterns are not static over time. Crimmins proposed
a model with three categories to explain the change over the decades in individual chronic diseases.
The first one is the expansion of morbidity that occurs when disease incidence is unchanged but
mortality decreases. The second is an equilibrium that becomes evident when the disease
prevalence appears to be stable over the decades. Finally, disease compression occurs when the
forces that decrease one disease mortality also delay its incidence. The result is that the disease is
“compressed” at the end of life. The evidence indicates that these three processes occur in different
chronic diseases27.
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In addition, there is evidence suggesting that the attributable fraction of outcomes of chronic
diseases is changing. For example, the cardiovascular mortality attributable to diabetes increased
from 46.0 to 60.2 per 100000 person-years when comparing 2000 with 201628.
Also, during recent decades, advances in treatments have resulted in some diseases like cancer and
HIV transiting from fatal to chronic diseases. Nevertheless, these “new chronic” diseases are
precursors of other chronic diseases and disabilities29.
As a result, it is possible that even if the percentage of multimorbidity has been unchanged during
the past few decades, the disease combinations themselves might have changed because some
chronic conditions are expanding and others are compressing. Moreover, lifestyle patterns have
changed over the past three decades. Researchers should consider this change when evaluating
potential protective factors among people living with multimorbidity, because those factors could
be evolving.
Consequently, we should employ different approximations to answer the overarching question of
whether there was a change in the association of multimorbidity with cognitive decline over the
past three decades. This approach should include evaluating the shift in prevalence of
multimorbidity and the number of diseases. Further, it should explore the variation of
multimorbidity patterns associated with the outcome in the whole population and stratified sex and
age. Finally, it must investigate if there is a change in the protective factors for cognitive decline
in participants with multimorbidity.

2.3 Cognitive decline
2.3.1 What we understand as cognition
Cognition is the capability of an organism to perceive its environment, process its challenges and
emerge with solutions that are more elaborate than simple reflexes 30. Although cognition is present
at different levels in many other animal species, higher cognitive processes allow us to be the
dominant species on Earth 31.
Researchers cluster cognitive capacities into six main domains in humans32 according to their
functional and biological substrate. These domains are attention, executive function, memory,
language, visuospatial and constructional ability and social cognition 33. For this study, we have
evaluated the executive function, language and memory domains.
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2.3.2 Cognition domains
Executive function
Executive function involves a series of cognitive processes needed when humans must face
complex situations that are not possible or wise to solve with automatic processes, requiring effort
to undertake the most appropriate response. It involves three central decision-making systems:
inhibition, interference control and working memory. It allows us to think flexibly, manipulate
information, eliminate what is irrelevant, plan, self-monitor and adjust behaviours according to that
objective. Also, the executive function encompasses mechanisms that are responsible for emotional
and motivational processes that are fundamental in selecting, defining and directing goals34.
Language
Language allows us to “enter other minds” and construct collective endeavours. No other animal
species on Earth has such a complex tool to communicate. It is so rich that it allows us to learn
from individuals long dead and teach generations yet to born35. We assimilate language into
speaking and listening. However, oral communication is just one modality of it. Even if we judge
language as a communication tool, this is an incomplete definition because we use language within
our minds to elaborate our thoughts and feelings. Some authors propose that language is a coding
mechanism that provides a framework of phonemes, words and sentences that can be used at the
internal and external level36.
Language mechanism has a natural capacity that can be applied to any language in any modality;
this capacity is composed of vocabulary, grammar and syntactic rules. Vocabulary has two main
properties a meaning and a phonological – orthographic form. Grammar and syntax control the
order of the vocabulary to create the expected message37. An analogous process is present for
generating and comprehending language and the different modalities (speaking, writing, listening
and reading). Finally, language is lateralized in most humans with a heavy preponderance to the
left hemisphere.
Memory
Memory is the "capacity to store and retrieve information"38, and it is fundamental for the other
cognitive domains. Investigators divide memory into short-term memory, which allows us to store
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information to finish a task, and long-term memory, which allows a permanent record of the
information. Long-term memory is called declarative memory when people are aware of the
memory and non-declarative memory when the information encoded is unconscious. Further, we
divide declarative memory into episodic memory, which is the memory of past experiences, and
semantic memory, which stores the information learned in life. The main non-declarative memory
is the procedural memory, which allows us to learn motor programs that afterwards we can perform
automatically39.
Attention
The first domain is attention which can be defined as the ability of an individual to select, fix and
localize the essential information presented to them at any point in time40. Then this information is
stored in the closely-related working memory to analyze it. The working memory is a short-term
memory that keeps information in an active state, allowing it to be used for other purposes, and it
is shared with the executive function41. Three other components are accepted as parts of the
attention. First is the top-down sensitivity control, which is the mental property of amplifying and
improving the quality of the information that is getting attention. Second, the bottom-up salience
filter forces the mind to give importance to strong or different stimuli. Finally, the competitive
selection compares stimuli to select the ones with the best quality, intensity and relevance, filtering
out noise40.
Visuospatial and constructional ability
Visuospatial and constructional abilities are closely related. They are composed of two processes,
first is the input of images for perception, storage, retrieval and transformation, concatenated with
the skills for understanding spatial relations, visualization, and spatial scanning42. The second
process is the generation of an adequate output which can transform unidimensional cognitive units
into multidimensional patterns and actions43. In conclusion, it can be understood as the cognitive
domain to acknowledge and act in a multidimensional space.
Social cognition
The most recently recognized domain of cognition, social cognition, refers to the whole range of
processes needed to decode other individuals and to gather social information, which allows us to
infer others’ emotional or mental states to make a better decisions following social and group
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norms. It has three main domains. The first is the social perception that allows us to distinguish
between objects and persons. The second is social understanding, which is the skills needed to
decode other humans’ mental states and intentions toward us. Finally, social decision-making is
the ability to make the most appropriate and profitable decision for the social context44.

2.3.3 Cognition through the life cycle
Cognition is an evolutive process through life, with an “n” shape, that starts with development in
the early years, followed by a plateau during adulthood and senescence during the late years.
Nevertheless, the trajectories of different cognitive functions are non-uniform45. Some cognitive
functions like processing speed, prospective short-term memory and divided attention peak early
during life, followed by a slow decline, while other functions like language and visuospatial
function do not trend to decay46; some functions such as vocabulary and comprehension peak late
during life, and other functions like mathematical ability appears to increase during all the life
course47.
Rudimentary cognitive functions characterize newborns. Then during childhood, there is a rapid
development of higher cognitive abilities48, that trend to stabilize in early adulthood. Under the
current paradigm, cognitive functions follow two patterns during development. First, the
crystallized pattern is those functions that develop during childhood with progressive accumulation
until adulthood and then stability in the late stages. Second, the fluid abilities increase in power
and complexity until early adulthood, then display a progressive decline through the rest of our
life46. The typical example of a crystalized function is language, and for a fluid pattern is the
processing speed49.
Nevertheless, there is a great variation between individuals in the same population. Some of the
strongest predictors of poor cognitive performance in late life are early-life-related characteristics
like general intelligence and education. This overlapping hinders the distinction between normal
cognitive aging and dementia; however, individuals within the population are expected to follow
their trajectories, while patients with cognitive decline can be detected by a decreasing path within
the population 45.
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Cognitive reserve
Some individuals appear to be more susceptible to cognitive decline than others. Cognitive decline
in ageing usually becomes visible around the 7th decade of life. We think it is related to an
underlying accumulation of progressive brain damage over decades50, as healthy elders generally
have progressive thinning of gray matter and diminishing white matter volume also51.
Nevertheless, people with more atrophy and alteration in the brain regions with higher synaptic
plasticity tend to have lower test scores and a higher risk of dementia50. These findings support the
theory that there are multiple pathways to cognitive decline in late life and that mechanisms must
exist that ease the impact of brain structural changes.
The term cognitive reserve encompasses all the uncoupling between brain damage associated with
dementia and its clinical presentation. This Cognitive reserve should have a structural brain reserve,
a network of on-hold brain circuits, and a mind-enhancing response recruiting alternative processes
and routes52. This distinction between Cognitive and brain reserve is an attempt to understand the
process of cognitive reserve further, dividing it into single components that can be further evaluated
and potentially targeted for future enhancement. First, the cognitive reserve encompasses all the
potential alternative cognitive networks and all these training and enhancement networks available
to every subject. This includes higher education access and a full and exciting lifestyle. Second is
the brain reserve, which is the neuronal capital directly related to the neural structure, synaptic
density and physical brain preservation53.
This hypothetic mechanism can explain how people with similar structural damage can present
different levels of clinical cognitive decline and how other insults, like co-occurring morbidities,
can induce the development of measurable cognitive decline. On the other hand, controlling risk
factors and an enriched life course can increase cognitive reserve, effectively protecting individuals
from cognitive decline54.

2.3.4 Successful cognitive ageing
The initial focus of research was evaluating the factors associated with cognitive decline, but there
is a group of people that preserve their cognition and mental performance beyond 65 years without
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diminishing it. Traditionally, researchers interpret successful cognitive aging and cognitive decline
as opposites. However, the risk factors associated with both outcomes are not necessarily the
same55.
There are several different definitions of successful ageing, but the most commonly used and
accepted was created by the National Institutes of Health’s Cognitive and Emotional Health
Project; they defined it as ‘‘Not just the absence of cognitive impairment, but the development and
preservation of the multi-dimensional cognitive structure that allows the older adult to maintain
social connectedness, and an ongoing sense of purpose, and the abilities to function independently,
to permit functional recovery from illness and injury, and to cope with residual cognitive
deficits.’’56. In this definition, they create an approach that includes not only the traditional
preservation of cognitive test scores in neuropsychological tests but also keeping functional
independence at the personal and interpersonal levels while maintaining resilience to the potential
damage that could result in diminishing cognitive performance.
Another consequence of this multidomain definition is that we can define successful ageing using
different criteria like performance thresholds, comparisons with normative population data, or
comparisons with previous individual performance57. For each one of these potential definitions,
there are different examples. The threshold approximation could be performed using a score of 26
or more in the Montreal Cognitive Assessment (MoCA) test as a boundary

58

, which has been

established as normal in previous studies. This approximation presents the advantages of ease to
use and generability for the comparisons but also creates the challenges of using the same cut-off
point for a broad population in which many factors can modify the score (for example, Age and
Education Level)57.
T The second approximation is the normative data; this approach requires applying batteries of
cognitive tests. It has the advantage that we can obtain specific norms for different population
segments and describe the characteristic associated with the group with successful and nonsuccessful cognitive ageing. However, this approach also has limitations, like requiring specialized
settings to perform the batteries and the fact that cognitively normal people are not usually
measured with cognitive batteries59. The third approach that uses past performance as the
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benchmark to measure cognition requires the existence of baseline cognitive measures of a
representative group from the population. This characteristic can be fulfilled by longitudinal
studies57,60. For our present study, this is a promising approach.
Current theory and knowledge show that successful cognitive ageing work through two
complementary mechanisms that prevent loss and facilitate the enhancement of the cognitive
installed capacity61, taking advantage of the cognitive and brain reserve to attain cognitive
maintenance53. In a sense, successful cognitive ageing aims to keep a total number of functional
neurons and circuits above the threshold at which cognitive decline will be evident61. This
approximation is the justification for the multimodal intervention programs in people 65 years and
older that include healthy lifestyles, rich and engaging environments and social inclusion. The
leading example is the FINGER strategy, which was designed in Finland, has recently expanded
to worldwide countries, and is currently testing in a randomized trial the hypothesis that multimodal
interventions decrease the risk of cognitive decline62.

2.3.5 What we understand for cognitive decline
In contrast to successful cognitive ageing is cognitive decline, a central topic for this thesis. Several
authors define cognitive decline using different approximations. The classical approximation
embraced by the American Psychological Association states that cognitive decline is the “reduction
in one or more cognitive abilities, such as memory, awareness, judgment, and mental acuity, across
the adult lifespan.”63. Others define cognitive decline in terms of the impact of it in performing
cognitive tasks or retaining functional independence64, while others interpret it as a natural process
associated with aging65. However, from most of these definitions we can extract some common
themes. First, Cognitive decline requires that the subjects achieve a higher level of cognitive
development, or at least near their maximum level of potential cognitive skills; one frequently
common associated requirement is that the person is an adult66. This can be summarized as that
people developed cognitive abilities during neurodevelopment and then lost them. Second, in most
definitions, is a hint that the diminishing in cognition is beyond the expected for the population
group. This criterion can be fulfilled by the loss of functional independence67, scoring below the
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threshold of population norm in standardized cognitive tests68, or a greater than anticipated
decrease in own cognitive trajectory69.
These common themes in the definition conduct us to interpret the cognitive decline in at least two
different dimensional constructs. First is the cognitive decline explained in the dimension of
independence, functionality, and perceived functionality as primary categorizing factors and
cognitive test scores as supplementary. This has been the case for the most common approximation
from clinical practice70. In this case, we create a broad spectrum in which at one end are completely
independent people with no cognitive complaints, and at the other end are the patients with fullblown severe dementia characterized by complete dependence. Between those two ends are the
following categories: a) Subjective cognitive decline: fully independent, cognitive complaints and
normal scores in neuropsychological testing. b) Mild Cognitive Impairment (MCI): Fully
independent, cognitive complaints and abnormal scores in neuropsychological testing. c) Moderate
dementia: some dependence, abnormal scores in neuropsychological testing. This approximation
was so intuitive for clinicians that the most commonly used scale for cognitive disease
classification, the Global Deterioration Scale71, uses a seven-level categorical approximation in
which we can classify every one of these categories (with four categories for dementia).
Subjective cognitive decline is a category that was recognized recently in 2014. People in this
category perceive that they are presenting cognitive decrease and request evaluation, but the
neuropsychological testing shows normal performance. From the clinical point of view, these
individuals can be considered healthy. Nevertheless, studies with follow-up to four years have
shown that these persons have an increased risk of 27% to progress to MCI72. This finding suggests
that some individuals present with subjective cognitive decline as the first symptom of progressive
cognitive decline.
The following category is Mild Cognitive Impairment, in which people also complain about their
cognitive performance. When tested with neuropsychological batteries, at least one score is below
the norm expected value for the population group. However, in this case, the individual is
completely independent in all activities73. Here we can extract that the only difference between
subjective cognitive decline and MCI is that in the former, there is no abnormal score in any
neuropsychological test.
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The last category of this approximation is dementia. In this case, the patient is no longer
independent, defined as “Interfere with the ability to function at work or at usual activities,”
meaning the patient now needs someone’s help to fulfill all his activities(16). Here the difference
between MCI and dementia is that in the former, the individual can function in everyday situations.
The second construct to approximate cognitive decline is the use of selected neuropsychological
scores to measure the presence of cognitive decline, defined as scores below a threshold, as lower
scores compared with a reference group74, or scores failing below a standardized score when
comparing baseline and follow-up measures75. This approximation is more often used in
epidemiological and public health research.
When we compare both approximations, we should be aware that although both measure cognitive
decline, they do not represent the same dimensions. This means that the group selected by the two
approximations is not entirely overlapping. We could have individuals that will be considered with
cognitive decline in one construct and non-cognitive decline in the other.

2.3.6 Evaluation of cognition
In order to evaluate any cognitive characteristic we need to be able to measure it. The measuring
process essentially means making a characteristic of an object, or condition tangible by comparing
it with a reference76.
However, not all measurements are the same since the nature of the objects to be measured is
different. On the one hand, some characteristics have a direct or natural unit to be measured, such
as measuring height with a meter or measuring weight with a scale. On the other hand, many of the
measurement objectives in health are not directly observable due to their physical or chemical
characteristics. They are complex situations that we need to measure but are not directly
observable. It is in this situation that the concept of “construct” appears. In essence, a construct is
the reflection of an idea or a perception of the functioning of a process that we generate in our
mind, leading to the creation of a distinctive concept that we can measure. This measurable concept
must reflect an underlying reality that is at a level that we cannot directly measure or that is a
process that emerges from joining other simpler phenomena77.
16
December 13, 2022

In our case, cognition is a construct we developed to name and encompass all the emergent
properties that make us thinking beings. We have created the cognition construct as a multilayer
phenomenon in which each layer adds a higher level of complexity. On the top layer of the
construct, we have the whole cognitive process; in the next layer, we created the constructs of the
six cognitive domains already described; and in the next layer, we have implemented constructs
for this domain's subprocesses. For example, the executive function has three core subdomains:
inhibitory control, working memory and interference control78. As we can see, we can attain an
explanation of the cognition construct using the generally high-level approximation or tapping into
the constructs of its constituent domains.
Creating any construct measurement, including the cognition construct, requires several steps. The
first step is the conceptualization which is the process by which we define the meaning of the
construct and its constituent terms79. The second step is operationalization, which consists of
converting the conceptualized attribute we are interested in measuring to be represented as a
number or category80. In this step, we make measurable what was not measurable before; now, we
can give a numerical or category value to this construct that we need to evaluate. But giving it a
number does not mean it correctly represents the phenomenon we want to assess. in this step, we
usually devise the items that will constitute the instrument; also, select the scale in which we are
going to measure and report the instrument, and seek opinions about the items to assess the "face
validity" which is a subjective understanding and group validity that the instrument should work
because it seems theoretically plausible81.
Now we advance into the third step, which consists of validating, which means confirming that the
instrument obtained in the operationalization is "valid" in this case, valid means that it measures
what we want to measure in an adequate way and without bias. This third process has multiple
edges since the phenomenon we are interested in is complex. We want to see with different methods
differ from other constructs, if the results are reliable when used several times, if different observers
find similar results, etc. This is a longer process than the process of obtaining the instrument, but
without having obtained the instrument it is not possible to carry out its validation82. Additionally,
when validating an instrument, it must be explicitly agreed which dimensions will be validated
since this agreement allows determining in which situations the measurement instrument we
obtained can be applied.
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There is a fourth process that sometimes is confused with the validation step. This process is the
attainment of normative data. This data summarizes the usual results and the outliers using the
selected instrument and for the specific population from which we took a sample83. After this step,
we obtain the expected cutoff points for our people, but this does not mean that the instrument is
valid unless the third step is fulfilled. We can simultaneously obtain the information to elaborate
the normative data when we validate an instrument. However, sometimes instruments are
transitioned into clinical settings without complete validation and only with the population norms,
which increases uncertainty around the measurement.
All the previous process allows us to develop a test that will enable us to explore different aspects
of cognition. Also, this necessity to explore cognition is the study field of one division of
psychology called clinical neuropsychology84. For this reason, cognitive evaluation tools are called
neuropsychological tests and the process of measurement of cognition is called neuropsychology
evaluation.
Neuropsychologists associate different but complementary tests when they evaluate cognitive
performance. These tests have been previously validated and should have population norms. The
neuropsychologists select tests that allow them to explore the different cognitive domains. These
cognitive or neuropsychological batteries include tests that should cover most of the cognitive brain
function. Usually, they provide redundancy in the coverage of each domain. Also, the individual
tests within the battery have coordinated population norms to allow a complementary interpretation
between the tests85. The objective of a neuropsychological assessment is to establish the current
cognitive state of the participant, track deterioration or progress and provide information for the
differential diagnosis. However, one setback of the neuropsychological evaluation is that it is timeconsuming and requires highly trained professionals86.
Due to these limitations for the complete neuropsychological testing, in clinical settings, other
health professionals use general cognitive screening tools like the MoCA; these screening tests
evaluate the cognitive function globally and allow to determine which patients might be having
cognitive problems. Although these screening tests are sometimes used to diagnose patients, the
ideal use is to select which patients should undergo a complete neuropsychological evaluation.
Most of the time, but not always, neuropsychologists working in research settings or clinical
practice also use screening tests at the beginning of the assessment; yet, this is not a universal
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practice and depends on the objective of the evaluation87. Additionally, it is inefficient to perform
a complete neuropsychological assessment in large surveys and longitudinal studies because it is
resources and time-consuming. In this case, investigators select a few cognitive tests that can be
quickly and reliably applied to explore some aspects of cognition in the sample88. They often use
a prespecified group of cognitive tests; however, there is no universal protocol, and this
heterogeneity between the selected tests hampers the comparison between studies.
In longitudinal studies, cognitive assessments have been reported and analyzed differently; some
studies have used the cognitive scores individually to assess each of the domains the test explores.
Other studies have used cognitive test scores to present a global outcome. Other studies have used
the cognitive test in support of neurologic or psychiatric assessment to obtain a clinical
classification of each participant. This decision appears to depend on the main objective of the
study (specific cognitive deterioration vs global ageing), the size of the sample and the resources
available89.
Another aspect of cognitive assessment in longitudinal studies is variability in the cognitive
domains evaluated. Most studies perform at least one global cognitive scale, and the most
commonly assessed domains are memory, language and executive function90. In the case of the
longitudinal studies that we analyzed, those where the three common domains evaluated.
For the first domain, which was the executive function, the cohorts used The Digit Symbol
Substitution Test (DSST) in the CSHA and the Mental Alternation Test (MAT) in the CLSA. . The
DSST commands patients to evaluate a series of non-alphabetic symbols and replace these symbols
with numbers using a key on the top of the page that explain which number should replace every
symbol. The final score is the count of the number of correct matchings within the test time, which
Is usually 90 seconds91. The second study used MAT, which measures oral mental alternation. The
test has three phases: first, reciting numbers from one to twenty at fast as possible—second, reciting
the alphabet as fast as possible. Third: ascending, alternating between numbers and letters. The
final count is the number of correct ascending alternations among numbers and letters performed
by a patient within 30 seconds92. Both methods were designed to evaluate the executive function
domain. One characteristic that could induce some differences is that DSST requires writing the
answer, and MAT is an oral test.
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Both studies used the Animal Naming Test (ANT) for the second language domain. The ANT is a
test from a family of tests that measure verbal fluency as a form to evaluate language retrieval and
expression. This family of test can evaluate two different parts of the language domain; phonemic
fluency, which requires retrieving words from the same phonemic category (e.g. words starting
with the letter F), and semantic fluency, which need retrieving words from the same semantic
category (e.g. animals)93. The verbal fluency tests are highly sensitive to any deterioration of
language function. They are easy to perform under any circumstance because the only requirement
is measuring the number of words that fulfill the criteria in 60 seconds94. In these two cohorts,
investigators used the ANT, the form of the test that uses animals as a semantic category and is one
of the most used versions in cognitive evaluation95.
Both tests used the Rey Auditory-Verbal Learning Test (RAVLT) for the third memory domain,
which evaluates auditory memory recording, storage and short-term retrieval. The classical test
consists of a list of 15 words read to the participants; then, the participants repeat as many words
as they can remember. This process is repeated five times, then after a time span of at least five
minutes before a delayed recovery of words is tested. The initial phase measures the immediate
memory span, followed by a learning curve that could be analyzed, and the delayed phase evaluates
the retention skills96.

2.4 The relation between multimorbidity and cognitive decline
Several researchers have found an association between multimorbidity and cognitive decline in
adults, bringing multiple outcomes. Those outcomes range from clinical diagnoses of mild
cognitive impairment97 or dementia98 and changes in cognitive test scores4. There is no published
systematic literature synthesis evaluating the multimorbidity association with cognitive decline.
To illustrate, the Health and Retirement Study followed adults older than 50 years in the US for 14
years. This study measured the multimorbidity weighted index (MWI) and multiple
neuropsychological tests. The authors found that for every point of increase in the MWI, there was
a decline in neuropsychological tests4.
Multimorbidity and cognitive decline have a complex relationship in which they share the same
risk factors, and some of these factors have complex relationships. However, presenting
multimorbidity is a risk factor for cognitive decline. It is open to debate whether the changes in
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multimorbidity prevalence, patterns and treatments have modified the association with cognitive
decline.

2.5 Longitudinal studies as the source of information
2.5.1 The Canadian Study of Health and Aging
The first cohort is the CSHA, whose authors recruited 10,263 participants from the five geographic
regions of Canada. All participants were 65 years or older at the time of recruitment in
1991{Citation}, and they underwent two follow-ups in 1996 and 200199. The study’s main
objective was to evaluate cognition and dementia, but the authors also collected data on other
chronic diseases in addition to sociodemographic information. The authors assessed cognition
through standardized neuropsychological tests100.

2.5.2 The Canadian Longitudinal Study on Aging
The second cohort is the CLSA, designed to evaluate Canada’s aging profile from mid-life to older
adults (45–85 years). Investigators set up the study to address the complex interrelations happening
during the aging process, including relevant measures for cognition, frailty, chronic diseases and
disability101.

2.6 Rationale to assess the change in the association of multimorbidity with
cognitive decline in the last three decades
All previous information indicates that multimorbidity is an evolving phenomenon. We anticipate
that currently, patients are experiencing a higher frequency of multimorbidity 102. Also, the risk of
health-related consequences derived from these chronic diseases and their combinations is
changing due to improvements in health care.
Broadly speaking, there is an increase in the prevalence of adults suffering multimorbidity, while
at the same time, the prevalence of impairment derived from chronic conditions remains stable103.
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The advances in health care have decreased the mortality from chronic diseases without modifying
their incidence, resulting in a higher prevalence of chronic diseases. Also, health care advances and
multidisciplinary care for chronic diseases have reduced the incidence of disabilities. However,
owing to the increased prevalence of chronic diseases, the net effect is a stable prevalence of poor
health-related outcomes in patients with chronic diseases104. We can conclude that the most
frequent chronic conditions have become modifiable, and the individual risk for patients from a
negative health outcome has decreased. However, it is not clear if this translates into better
outcomes at the population level.
As a result of all these changes, we expect that in the CLSA cohort there are weaker associations
for each chronic condition. However, we expect a higher proportion of people with multimorbidity
and a higher number of chronic conditions per person. Further, some conditions, like cancer and
HIV, have become leading chronic conditions because treatments for them have decreased their
threat to mortality but with the price of increased prevalence of long-term health impairment.
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Chapter 3

3

Systematic Review

To better inform and contextualize our research, we performed a systematic review of the
association between multimorbidity and cognitive decline. Initially, we searched for systematic
reviews on the topic before starting the project. To our knowledge, there was no published
systematic evaluation of the current evidence measuring the association between multimorbidity
and cognitive decline in adults.

3.1 Objective
The systematic review objective was to quantify the association of multimorbidity with cognitive
decline in adults in the published literature through a systematic review. This systematic review
step was preliminary to the data analysis of the CSHA and CLSA results. We explored this
objective through the following questions:
1) What are the published estimates of the statistical association of multimorbidity and the
diagnosis of cognitive decline?
2) Is there an association between the number of chronic conditions and the diagnosis of
cognitive decline in adults?
3) Are there differences between the association of multimorbidity with the diagnosis of mild
cognitive impairment or dementia in adults when comparing cross-sectional and
longitudinal studies?

3.2 Methods
We performed a systematic review following the PRISMA statement protocol for systematic
review and meta-analysis; PROSPERO register number (CRD42020167253).
Description of the search strategy
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Keywords used for the systematic search were "multimorbidity", "multiple chronic conditions",
"cognitive decline", "cognitive impairment", "dementia", "cognitive dysfunction" and
"Alzheimer's disease" for searching the following databases: Medline/Pubmed, Embase,
PsychINFO, CINAHL, LILACS – IBECS, Scopus, ProQuest Dissertation and Theses Global, and
OpenGrey. We reviewed publications starting on January 1, 1996, when the current concept of
multimorbidity was introduced. We excluded comorbidity because we wanted to use the precise
and standard definition of multimorbidity 105. We included the most common spelling variations,
derived words, and MESH terms; we present the complete search strategy in Appendix Table 9-1.
We did not apply restrictions by language. Finally, we expanded the search by reviewing all the
included references to identify additional articles that fulfill the inclusion criteria.
We performed the initial search on April 13, 2020, and we updated it on May 15, 2021.
Study selection
We considered for full-text review all the references retrieved. We included observational studies,
including cross-sectional, case-control, cohorts and prospective studies. We evaluated the
published report of the selected studies. We contacted the authors for additional unpublished data,
using the information provided in the articles.
We included studies that evaluated adult participants, defined as 18 years or older. Operatively we
have defined multimorbidity as the co-existence of more than one chronic condition within the
same patient, used to analyze the following combinations: dichotomy of two or more chronic
diseases, dichotomy of three or more chronic diseases, the count of the number of chronic diseases
or standardized indexes that the author has stated are measuring multimorbidity. Appendix Table
9-2 presents the full inclusion and exclusion criteria.
Our outcome indicated cognitive decline, defined as clinical cognitive impairment, dementia
(including specific dementia diagnosis) or the change in the scores of individual
neuropsychological test results or batteries of tests.
Two independent reviewers (JCVG, IS, JW or JDTR) screened every identified reference abstract
to define full-text retrieval. A third evaluator resolved all disagreements. Next, we retrieved all
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identified abstracts in full text, and two reviewers (JCVG, IS, JW or JDTR) evaluated every study
for eligibility for the systematic review. A third evaluator resolved inclusion disagreements. We
used the Rayyan software106 to assist in screening and selecting references.
Data extraction
We extracted the following information from each report: First author; year of publication; study
design; study objective; reported characteristics, such as sample size, mean age, gender, country,
ethnicity; multimorbidity distribution; multimorbidity criteria; cognitive tests; cognitive
impairment definition; diagnostic criteria for cognitive impairment; dementia distribution; and the
association of multimorbidity with cognitive decline. We created an extraction form using
Microsoft Forms and exported the results to Microsoft Excel.
Risk of bias
We qualified the risk of bias by duplicate, using the Joanna Briggs Institute (JBI) Critical Appraisal
Tools for every included design107. The JBI tools offer specific tools for prevalence, crosssectional, case-control and cohort designs. Each criterion is qualified as “yes”, “no”, “unclear” or
not applicable. In the overall appraisal of the risk of bias, we concluded there was a high risk of
bias if at least one criterion had a high risk of bias; an unclear risk of bias if at least one criterion
had an unclear risk of bias, without any criteria of high risk of bias; and low risk of bias if all
criteria had a low risk of bias.
Data synthesis.
We present a narrative synthesis of findings. Also, we present information from each included
study, including author, year, country, design, risk of bias, participant characteristics,
multimorbidity definition, cognitive impairment definition and results. We did not perform a metaanalysis because the included studies were highly heterogeneous regarding the included
populations, the definition of multimorbidity and cognitive decline assessment. We have included
an annexed pdf document with the “Microsoft Forms” template used to collect information.
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3.3 Results
3.3.1 Literature search
We identified a total of 2655 references. A total of 1222 references were duplicates, and we
removed them. Then, we screened 1433 references with title/abstracts, and we evaluated 48
references for full-text retrieval and reading. We included a total of 16 references. Then, we
reviewed the references of the included articles, considered 17 for abstract evaluation, and then
nine additional references were considered for inclusion and retrieved in full text. We included
three of these references.
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1

3

Identification

2

Identification of studies via databases and registers
Records identified from:
Databases (n = 7)
Total Registers (n=2655)

Records
removed
before
screening:
Duplicate records removed (n =
1222)

Identification of studies via other methods
Records identified from:
Citation searching. Number of
studies that references where
evaluated (n = 17)

4
5
Records screened(n = 1433)

6

Records excluded**(n =1389)

8
9

Screening

7
Reports sought for retrieval(n =
48)

Reports sought for
retrieval (n = 9)
Reports not retrieved(n = 0)

10
Reports assessed for eligibility(n
= 48)

Included

12

14

(n = 0)

Reports excluded: n=6

11

13

Reports not retrieved (n=0)

Reports excluded: n=32
No measure of CD (n =8)
Abstract of included article (n = 7)
No measure of MM, or no group
without MM (n=6)
No association of MM & CD (n =9)
Other (n=2)

Reports assessed for
eligibility (n = 9)

No CD
(n=6)

measurement

Studies included in review: (n =
19)

15
16

*Consider, if feasible to do so, reporting the number of records identified from each database or register searched (rather than the total number across all databases/registers).

17
18
19

**If automation tools were used, indicate how many records were excluded by a human and how many were excluded by automation tools. From: Page MJ, McKenzie JE, Bossuyt PM, Boutron I,
Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021;372:n71. doi: 10.1136/bmj.n71. For more information, visit:
http://www.prisma-statement.org/
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Figure 1: PRISMA 2020 flow diagram for the systematic Review
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3.3.2 Description of studies included in this systematic review
Nineteen studies fulfilled inclusion criteria108–121,98,122,123,97,4 and included data from 90,606
participants. In the Figure 1, we present the PRISMA flow diagram. Table 3-1 summarizes the
main information from the included studies. Most of the studies originated from the United States
of America (n = 8), followed by Sweden (n = 3) and Taiwan (n = 2); all other countries contributed
to one study, and another study collected data from five countries. Nine studies were longitudinal
design, four were cohorts, four were cross-sectional and two were case-control.
All studies recruited participants from community settings. Authors of 10 studies analyzed
participants in ongoing population registers; authors of five examined patients with cognitive
decline (AD or MCI) who came from memory clinics or were followed by specialized groups in
dementia. Two studies’ authors assessed participants from population-based surveys, one team
evaluated administrative data, one recruited the children of AD patients and one included only
patients with Down syndrome (DS). The sample size ranged from 102–32,715 participants. Table
3-2 presents the main reason for excluding the references retrieved in full text and excluded from
the results.
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Table 3-1: Characteristics of studies included in the Systematic Review

FIRST
AUTHOR

YEAR COUNTRY STUDY
DESIGN

AARTS

2011

Netherlands

AUBERT

2015

BAYEN

SETTING

CRITICAL
N
APPRAISAL
RISK
OF
BIAS

FEMALE AGE
ETHNICITY
%
(MEAN)

Longitudinal Communitydwelling

Unclear

1763

50.3

55.4

C

France

Cohort

Memory
Clinic

Unclear

170

74.4

83.3

C

2018

US

CaseControl

Administrative High
data

878

48.8

57

C, H

BRATZKE

2018

US

Longitudinal Parents with High
AD registry

1285

70.1

53.7

C

CARACCIOLO

2013

Sweden

CaseControl

Twin Registry

Low

11379 55.4

73.1

C

CHEN

2017

Taiwan

Crosssectional

Memory
Clinic

High

137

59.9

77.6

Ch

DORAISWAMY 2002

US

Crosssectional

Memory care Unclear
centres

679

67.2

83.6

C

FABBRI

2016

US

Longitudinal Communitydwelling

Low

756

48.3

73.8

C

GRANDE

2021

Sweden

Longitudinal Communitydwelling

Low

2478

64.3

75

C
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IHLE

2018

Switzerland

Longitudinal Communitydwelling

High

897

NR

74.3

C

KAO

2021

Taiwan

Cohort study Memory
Clinic

Unclear

175

60.6

77.7

Ch

KOROUKIAN

2017

US

Longitudinal Communitydwelling

High

18913 54.3

NR

C, B, H

KOYANAGI

2018

5 LMIC

Crosssectional

Survey

High

32715 51.7

62.1

NR

LEE

2021

US

Crosssectional

Communitydwelling

Unclear

637

57.1

81.2

C, B, H

MELIS

2013

Sweden

Longitudinal Communitydwelling

Low

989

76.7

83

C

SHANG

2019

Australia

Longitudinal Communitydwelling

High

212

100

56.4

NR

SOLOMON

2011

Romania

Cohort

Memory
Clinic

High

102

61.8

70.9

C

VASSILAKI

2015

US

Cohort

Communitydwelling

Low

2176

49.4

78.5

NR

WEI

2019

US

Longitudinal Communitydwelling

Low

14265 60

66.6

C, B, H
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Continuation: Characteristics of studies included in the Systematic Review
FIRST
AUTHOR

MULTIMORBIDITY LIST OF NUMBER
MM
DEFINITION
DISEASES CONDITIONS PREVALENCE
(%) OR COUNT

COGNITIVE
OUTCOME

COGNITIVE TEST
OR BATTERY

AARTS

Count 2+

yes

96

55.90%

Test
change

AUBERT

CCI

NA

NA

CCI mean 2.6

Dementia (AD)

MMSE

BAYEN

Count

yes

26

mean 2.9

Dementia

NR

BRATZKE

Clusters

yes

40

NR

MCI

WASI, BNT, COWA,
WRAT3,
RAVLT,
WMSIII,
WCS64,
WAISIII,
SCWT,
TMT

CARACCIOLO

Count 2+

yes

136

NCI 49%; CIND CIND
58%

TELE,
CERAD

CHEN

CIRS-G

NA

NA

NR

Dementia

MMSE

DORAISWAMY CIRS-G

NA

NA

CIRS-G mean 5.5

Dementia

MMSE

FABBRI

Count 2+

yes

13

mean 2.5

Test
change

GRANDE

Clusters

yes

60

mean 4.4

Dementia

IHLE

Count

no

NR

mean 1.26

Test
change

scores VVL, LDST

MMSE,

scores LFT, BVRT, CVLT,
DST, DSST, TMT,
MMSE
MMSE

scores TMT
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KAO

CIRS-G

yes

NA

CIRS-G median: 7

Dementia

MMSE, CDT

KOROUKIAN

Count 3+

no

14

69.90%

MCI
Dementia

KOYANAGI

Count 2+

yes

10

49.80%

MCI

LEE

Count 2+

yes

6

51.20%

CIND
Dementia

and NR

MELIS

Count 2+

yes

28

non-dementia
Dementia
4.7%;
dementia
11.3%

NR

SHANG

Count 2+

no

NR

NR

CERAD

SOLOMON

CIRS-G

NA

NA

mean: CDR1: 8; Dementia
CDR 2: 7CDR 3: 8

VASSILAKI

Count 2+

yes

17

86.60%

MCI
Dementia

WEI

MWI

NA

NA

MWI mean 4.4

Test
change

and TICS
CERAD, WAIS

CD

MMSE
and WAIS,
WMS-R,
TMT, DSST, BNT,
TICS

scores TICS, WRT, 7s
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continuation: Characteristics of studies included in the Systematic Review
First Author

CD
criteria

Cognitive
status (%)

Association of multimorbidity on cognitive decline

Aarts

Change in
scores

NA

Verbal Memory decrease associated with CD & Cancer. Processing speed decrease associated with CD, CVD, Mov.
Disorders & Cancer

Aubert

NINCSADRDA

AD 100%

CCI associated with RCD: OR 1.30 (CI95%: 1.02 to 1.65)

Bayen

ICD10

Dementia:
39.8%

MM mean higher in dementia (3.7 ± 2.7) compared with patients without dementia (2.5 ± 2.2); p-value 0.001).

Bratzke

Clinical
diagnosis

MCI:
20.9%

No differences between the two groups. Prevalence of aMCI in the MM 12.87% vs 11.8 in the healthy. The anMCI in
MM is 6.5% Vs 6.8% in healthy.

Caracciolo

DSM-IV

CIND
25.4%

Model 1 unmatched case-control GGE model: Adjusted CIND OR 1.4 (95%CI: 1.3 to 1.7). Model 2 Conditional logistic
regression: CIND OR 1.3 (95%CI: 0.9 to 2.0)

Chen

Clinical
diagnosis

Dementia
100%

CIRS-G severity index was associated with lower MMSE scores (p=0.01). However, CCI (p=0.14) and comorbidity
count (p=0.43) not associated

Doraiswamy

NINCSADRDA

MCI
36.2%,
Dementia:
63.8%

A higher MM count was associated with lower MMSE scores after adjusting for age, gender, education, and care setting
(p= .0001).

Fabbri

Change in
scores

NA

Participants with MM had poorer performance on DSST and TMT B At baseline.
Longitudinal results: Participants who had faster accumulation of chronic diseases had a significantly greater
longitudinal rate of decline in category (P = .01) and letter (P = .01) fluency, TMT-A (P = .08) and TMT-B (P = .07)

Grande

DSM-IV

Dementia
20.4%

Five major MM patterns: Neuropsychiatry (n=183), cardiovascular (n=243), sensory impairment/ cancer (n=384) and
respiratory/metabolic/musculoskeletal
(n=503),
and
unspecific
(n=1165).
Risk of dementia for MM patters vs non-MM participants: Neuropsychiatric HR 2.09 (1.19 to 3.64), cardiovascular
2.02 (1.99 to 3.41), sensory impairment/ cancer HR 1.67 (1.02 to 1.98), respiratory/metabolic/musculoskeletal HR 1.21
(0.73 to 1.98) and unspecific HR 1.24 (0.79 to 1.97)
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Ihle

Change in
scores

NR

Higher MM count predicted increase in TMT completion time (i.e., steeper cognitive performance decline, b = 1.99,
Δχ2 = 11.57, Δdf = 1, p < .001)

Kao

DSM-IV,
NIA-AA
2011,
CDR

NR

Using GEE 1-point CIRS-G increase was associated with -3.10 (CI95%:−4.96 to −1.23) decrease in MMSE and a 0.92
(CI95%: −1.48 to −0.37) decrease in CDT. No association between CCI and MMSE or CDT.

Koroukian

Clinical
diagnosis

MCI
1.93%,
Dementia
1.84%

Individuals with MM3+ increased from 36.4% (IC95%: 35.1-37.8) among individuals with no CI to 53.0%
(CI95%:47.0- 59.1) in MCI and 71.3% (CI95%: 66.4-76.3) dementia. MM3 association with MCI (OR 1.27; CI95%:
0.93 to 1.74), and dementia (OR 3.66; CI95%: 2.49 to 5.37)

Koyanagi

NINCSADRDA

MCI 15.3%

Increase in the risk of MCI with an increased number of MM. For 2 Chronic conditions OR 1.37 (CI95%: 1.14-1.63),
three Chronic conditions OR 1.75 (CI95%: 1.43 – 2.14) and four or more chronic conditions OR 2.07 (CI95%: 1.70 –
2.52)

Lee

DSM-IV

CIND
27.8%,
Dementia
34.4%

Association of 2 or more MM on cognition: CIND OR 1.48 (CI95%: 0.94, 2.34). Dementia OR 1.16 (CI95%: 0.63,
2.11). Association of 3 or more MM on cognition. CIND OR 2.47 (CI95%: 1.42, 4.31). Dementia OR 1.29 (CI95%:
0.62, 2.70)

Melis

DSM-III

Incident
dementia
45%

Dementia patients have a lower cognitive function at baseline (21.88, p,0.001) and a steeper decline over time with an
estimated increase in linear change rate in dementia patients of 21.91 (p,0.001).

Shang

Change in
scores

CD 5.6%,
11.7% &
18.5%

Participants with MM had a higher likelihood of cognitive decline (OR 3.86; CI95%:1.06 to 14.06) than those with no
conditions. The association remained after adjustment for age, education, and Apolipoprotein E genotype (OR 3.80;
CI95%: 1.00 to 14.48)

Solomon

NINCSADRDA ,
CDR

Dementia
100%

A Higher baseline CIRS-G score was associated with an increased rate of cognitive decline. In the truncated regression,
an increase of 1 point in the CIRS-G was associated with a decrease of 0.15 points in the MMSE (p.value 0.006)

Vassilaki

DSM-IV

Incident
MCI
or

Over a median follow-up of 4 (interquartile range 2.4–6.6) years, 583 participants developed incident MCI or dementia.
MM was associated with a greater risk of MCI (HR 1.38, 95% CI 1.05 to 1.82) after adjusting for sex and education.
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Wei

Change in
scores

dementia
26.8%

Stratified analyses were only significant for men (HR = 1.53, 95% CI = 1.01 to 2.31); women (HR = 1.20, 95% CI =
0.83–1.74).

NR

After adjustment, a one-point increase in MWI was associated with a decline in the TICSm score of −0.034 TICSm
(CI95%I: −0.043 to −0.029). MWI was also associated with faster rates of decline TICSm of−0.003( CI95%: −0.005
to −0.002) /year faster. MWI was associated with acute declines in immediate recall of −0.014(95% CI: −0.016 to
−0.011) and delayed recall of −0.014(CI95%: −0.018 to −0.011).

NR: Not Reported. NA: Not Applicable. MM: Multimorbidity. Ethnicity: B: Black; C: Caucasian / White; Ch: Chinese / Taiwanese; H: Hispanic.
Multimorbidity criteria: CCI: Charlson Comorbidity Index; CIRS-G: Cumulative Illness Rating Scale-Geriatric; MWI: Multimorbidity-Weighted Index.
Cognitive outcomes. AD: Alzheimer’s Disease; CD: Cognitive Decline, CIND: Cognitive Impairment non-Dementia; RCD: Rapid Cognitive Decline;
aMCI: Amnesic MCI; anMCI: Non-amnesic MCI. Cognitive test: ANT: Animal Naming Test; RAVLT: Rey Auditory Verbal Learning Test; BNT: Boston
Naming Test; BVRT: Benton Visual Retention Test; CDT: Clock drawing Test; CERAD: Consortium to Establish a Registry for Alzheimer’s Disease;
COWA: Controlled Oral Word Frequency / Verbal Fluency test; CRT: Card Rotations Test; CVLT: California Verbal Learning Test; DGS: Digit Span;
DSST: Digit Symbol Substitution Test; LDST: Letter Digit Substitution Task; MMSE: Mini-Mental State Examination; SCWT: Stroop Color and Word
Test; TICS: Telephone Interview Cognitive Status; TMT-A, TMT-B: Trail Making Test part A and B; VVLT: Visual Verbal Learning Test; WAIS-III:
Wechsler Adult Intelligence Scale-III; WASI: Wechsler Abbreviated Scale of Intelligence;WCST-64: Wisconsin Card Sorting Test–64; WME: Wechsler
Memory Scale; WRAT3: Wide Range Achievement Test Reading Test.
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Table 3-2: Articles retrieved in full text excluded from the review, including original search and
evaluation of other sources
Author and year
Reason for exclusion
Adams 2017124

It did not include a measure of cognition or cognitive impairment

Atti 2011125

It did not measure cognition

Bacellar 2021126

Descriptive study about MM in many neurological conditions

127

It did not evaluate Multimorbidity, only individual conditions

128

Bayen 2018

Conference abstract of an included article

Blaum 2002129

Low cognitive performance is determinate from a non-validated
questionnaire. Descriptive measures between MM and Cognition, the
outcome was an association with frailty/disability, not cognition.

Borson 2010130

A scale validation study

Chen 2017 131

It is non-specific about MM. The MM and Cognition association from the
same group included

Ekdahl 2016132

Do not measure the association of MM in cognition.

Grande 2020133

Thesis of an included article

Bauer 2014

134

Gravell 2018
135

The outcome is Parkinson Disease

Hsu 2016

Conference abstract of an included article

Jacob 2019136

Subjective cognitive complaint

Kalpouzos 2012137

The outcome is hippocampal volume

Liao 2014138

The outcome is brain volume

139

Liu 2018

The authors used a dichotomic exposure of non-healthy.

Lyketsos 2005140(p2)

The association was measured with individual conditions, not with MM

Mendes 2017 141

No cognitive outcome, only images, congress abstract

Mendes 2018142

No cognitive outcome, only images

143

Melis 2015

Conference abstract of an included article
144

Montejo 2016

No cognitive measurement, the outcome is subjective memory complain

Moreno-Gaviño 2012145

It measures the interaction between cognitive symptoms (including delirium)
and chronic diseases

Nguyen 2007146

No MM measurement, only clusters of diseases.

Patrick 2002147

No measurement of association

Sadak 2012A148

No measurement of association

149

Sadak 2012B

It is impossible to know which patients had Multimorbidity

Stirland 2019150

The outcome is CSF measure, not cognition

Timmermans 2019151

No cognitive outcome
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Tonelli 2017152

It measures the interaction of MM and Dementia on other outcomes

Vassilaki 2015153

Conference abstract of an included article

154

The outcome is imaging markers

155

Vassilaki 2019

The outcome is images, not cognitive decline

Vogelgsang 2018156

No MM measure only some diseases

Wang 2018157

Association measured with individual variables

Vassilaki 2016

Wei 2018158

Conference abstract of an included article
159

Wiedemann 2018
160

Exposure is stroke, and all are MM patients

Xu 2020

All patients have MM. it is unknown the effect of mm on MCI

Yap 2018161

The outcome is subjective memory complain

MM: Multimorbidity; CSF: cerebrospinal fluid

3.3.2.1 Study quality
We needed to evaluate every study included in the systematic review, and for this purpose, we used
a critical appraisal tool. This appraisal process aims to objectively assess and understand a study’s
strengths and weaknesses and analyze which evidence has more certainty. These tools are
composed of structured, standardized questions that have been previously validated162. One
challenge is there are several different appraisal tools available. We wanted a tool that has been
developed to appraise different types of study designs and has been widely recognized and used in
research. The Critical Appraisal Tools from the Joanna Briggs Institute (JBI) fulfilled this
characteristic 163. Consequently, we evaluated study quality using the Critical Appraisal Tools from
the JBI. These are specific instruments for cohorts/longitudinal, case-control and cross-sectional
studies.
For the cohort/longitudinal studies, we evaluated 13 studies. We appraised five of them as low risk
of bias4,97,98,115,116; we judged three as unclear risk of bias owing to unclear explanation of attrition
bias or its handle 108,109,118. Also, we evaluated five as high risk of bias owing to statistical analysis
111,119,123

, high risk of attrition bias117,122, and high risk of bias owing to confounding 119.
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Table 3-3: Complete Critical Appraisal Tools from the Joanna Briggs Institute

a)Cohorts and Longitudinal Studies
Author & Year - Cohorts and Longitudinal Studies

Aarts
2011

Aubert
2015

Bratzke
2018

Fabbry
2016

Grande
2021

Ihle
2018

Kao
2021

Koroukian
2017

Melis
2013

Shang
2019

Solomon
2011

Vassilaki
2015

Wei
2019

Were the two groups similar and recruited from the
same population?

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Were the exposures measured similarly to assign people
to both exposed and unexposed groups?

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Was the exposure measured in a valid and reliable way?

Yes

Yes

Yes

Yes

Yes

Unclear

Yes

Yes

Yes

Unclear

Yes

Yes

Yes

Were confounding factors identified?

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Unclear

Yes

Yes

Yes

Yes

Yes

Were strategies to deal with confounding factors stated?

Yes

Yes

Unclear

Yes

Yes

Yes

Yes

No

Yes

Yes

Yes

Yes

Yes

Were the groups/participants free of the outcome at the
start of the study (or at the moment of exposure)?

Yes

NA

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Yes

NA

Yes

Yes

Were the outcomes measured in a valid and reliable
way?

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Unclear

Unclear

Yes

Yes

Was the follow-up time reported and sufficient to be
long enough for outcomes to occur?

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Was follow-up complete, and if not, were the reasons to
lose to follow-up described and explored?

Unclear

Unclear

Unclear

Yes

Yes

Yes

Unclear

Yes

NA

No

Unclear

Yes

NA

Were strategies to address incomplete follow-up
utilized?

NA

Unclear

Unclear

NA

NA

No

Unclear

NA

NA

No

Unclear

NA

NA

Was appropriate statistical analysis used?

Yes

Yes

No

Yes

Yes

Yes

Yes

No

Yes

Yes

No

Yes

Yes

Overall Appraisal Risk of Bias

Unclear

Unclear

High

Low

Low

High

Unclear

High

Low

High

High

Low

Low
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b) Case-Control studies
Author & Year - Case-Control Studies

Bayen 2018

Caracciolo 2013

Were the groups comparable other than the presence of disease in cases of the absence of disease in controls?

Yes

Yes

Were cases and controls matched appropriately?

Yes

Yes

Were the same criteria used for identification of cases and controls?

Yes

Yes

Was exposure measured in a standard, valid and reliable way?

Yes

Yes

Was exposure measured in the same way for cases and controls?

Yes

Yes

Were confounding factors identified?

Yes

Yes

Were strategies to deal with confounding factors stated?

Unclear

Yes

Were outcomes assessed in a standard, valid and reliable way for cases and controls?

Yes

Yes

Was the exposure period of interest long enough to be meaningful?

Unclear

Yes

Was appropriate statistical analysis used?

No

Yes

Overall Appraisal Risk of Bias

High

Low
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c) Cross-sectional studies

Author & Year - Cross-Sectional

Chen 2017

Doraiswamy
2002

Koyanagi 2018

Lee 2021

Were the criteria for inclusion in the sample clearly defined?

Yes

Yes

Yes

Yes

Were the study subjects and the setting described in detail?

No

Yes

Yes

Yes

Was the exposure measured in a valid and reliable way?

Unclear

Yes

Yes

Yes

Were objective, standard criteria used for measurement of the condition?

Unclear

Yes

Yes

Yes

Were confounding factors identified?

Yes

Yes

Yes

Yes

Were strategies to deal with confounding factors stated?

Yes

Yes

Yes

Unclear

Were the outcomes measured in a valid and reliable way?

No

Yes

Yes

Yes

Was appropriate statistical analysis used?

Yes

Unclear

No

Yes

Overall Appraisal Risk of Bias

High

Unclear

High

Unclear
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In the two case-control studies, we judged one with a low risk of bias112 and the other with a high
risk of bias owing to the statistical analysis110. We appraised four cross-sectional studies. We
evaluated that two had unclear risk of bias owing to lack of information about confounding121 and
insufficient information about the statistical analysis114. Finally, we considered that two crosssectional studies had a high risk of bias owing to information bias113 and statistical analysis120. We
have presented the complete critical appraisal in Table 3-3. The objective of critically appraising
the literature is to understand it better and diminish the uncertainty around the published literature,
including detecting its potential sources of bias164.

3.3.2.2 Study population characteristics
In the present review, mean ages varied from 43.7–83.6 years; one study did not report mean age.
The proportion of female participants ranged from 48.3–100%; one study did not report sex; 15 of
the 18 (83.3%) studies that reported sex had mostly female participants. Regarding ethnicity, 10
studies reported information about White/Caucasians, two included Taiwanese Chinese, five
included different ethnicities and two did not report this information. Information on education
level, income and economic status, living facilities and marital status were lacking in many studies
and could not be summarized.
Multimorbidity assessment
In our systematic review, we found a high variability among studies in the definition and
implementation of multimorbidity. The included studies’ authors stated that they evaluated
multimorbidity in every patient. In the case of studies whose authors did not state that they were
assessing multimorbidity, we included them if the primary objective was to evaluate the association
of co-occurrence of multiple chronic diseases with the outcome. Authors of 13 studies measured
multimorbidity using a conditions sum, with counts that ranged from 4–60; of these studies, three
manuscripts’ authors also reported standardized indexes. Six study teams reported multimorbidity
using a standardized index, five the Cumulative Illness Rating Scale-Geriatric (CIRS-G), three the
Charlson Comorbidity Index (CCI) and one the Multimorbidity-Weighted Index (MWI). Three
teams reported multimorbidity clusters and their associations in the analyse.
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Of the 13 studies whose authors presented disease counts as their outcome, eight teams defined
multimorbidity as two or more chronic conditions, one defined it as three or more chronic
conditions and four evaluated the number of chronic conditions as a continuous count. For the six
studies whose authors reported multimorbidity as standardized indexes, they interpreted them as a
continuous measure, with higher scores representing higher multimorbidity. Finally, the three study
teams who evaluated multimorbidity clusters expressed the association of these specific clusters
with cognitive impairment.
The prevalence of multimorbidity was reported in seven studies, ranging from 4.7–86.6%. This
large variation in multimorbidity prevalence is due to the different sources of information. Some
studies come from ageing longitudinal cohorts, health state interviews for the general population
from middle and high-income countries, and participants in dementia cohorts. However, the study
with the lower prevalence of multimorbidity came from Melis98, which reported an unusually low
multimorbidity prevalence for an ageing longitudinal study.
Further, the mean number of chronic diseases ranged from 1.26–4.4, as reported by four study
teams. Four study teams presented the number of CIRS-G categories, ranging from 5.5–8; one
group reported only a CCI of 2.6. Finally, we could not obtain information about the prevalence of
multimorbidity in the two studies111,131. The authors expressed that they included chronic
conditions in these two, but it was difficult to assess their definition of chronic conditions.
Moreover, most study teams defined conditions as diseases, but some

included functional

limitations and geriatric syndromes. To obtain the multimorbidity data, nine teams used self- (or
proxy-)reported data, eight used medical records (or exams) and one used administrative data.
Cognition assessment
In addition, we found significant variability in the cognition assessment. In Table 3-4, we have
presented all the cognitive assessment methods used in the studies. Six groups performed complete
neuropsychological assessments using diverse test combinations. Five used the MMSE as their
only measure of cognition; along the same lines, one group used the MMSE and the clock drawing
test. Two groups used mainly the TICS test, while two used different cognitive tests. Finally, three
teams did not perform cognitive tests and relied upon the clinical diagnosis of dementia for their
association.
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1

Table 3-4: Cognitive test and batteries identified in the systematic review
Name
Acronym and related Studies
Complete Neuropsychological Assessment Batteries
Consortium to Establish a Registry for Alzheimer’s Disease CERAD

112,122

Screening Instruments
Clock Drawing Test

CDT

118

Mini-Mental State Examination

MMSE

109,112–116,118,123

Telephone Interview Cognitive Status

TICS

4,97,119

Neuropsychological tests used individually or as a part of a battery
Animal Naming Test

ANT

120

Benton Visual Retention Test

BVRT

115

Boston Naming Test

BNT

97,111,112,122

California Verbal Learning Test

CVLT

115

Card Rotations Test

CRT

115
112,122

Constructional Praxis learning / recall CERAD
Controlled Oral Word Frequency / Verbal Fluency test

COWA

97,111,112,115,122

Digit Symbol Substitution Test

DSST

97,115

Digit Span

DGS

115,120

Letter Digit Substitution Task

LDST

108

Rey Auditory Verbal Learning Test

AVLT

97,111

Stroop Color and Word Test

SCWT

111

TELE

TELE

112

Trail Making Test part A and B

TMT-A, TMT-B

97,111,115,117

Visual Verbal Learning Test

VVLT

108

Wechsler Abbreviated Scale of Intelligence

WASI

111

Wechsler Adult Intelligence Scale-III

WAIS-III

97,111

Wechsler Memory Scale

WME

97,111

Wide Range Achievement Test Reading Test

WRAT3

111

Wisconsin Card Sorting Test–64

WCST-64

111

Word List Learning / recall / recognition CERAD

112,120,122

2
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Regarding cognitive decline definition, the six teams who performed complete neuropsychological
batteries complemented them with a complete clinical assessment to perform a diagnosis of
dementia/mild cognitive impairment according to standard criteria. The six teams who used the
MMSE used it to help the clinical diagnosis of dementia or mild cognitive impairment; three teams
relied upon clinical judgment alone to diagnose cognitive impairment. Finally, four teams
measured the decline in scores of selected cognitive tests. The MMSE, the most used tool, is a
rapid screening tool that gives a score between 0 and 30, with a lower score equal to greater
cognitive decline.
Five study teams compared patients with dementia and healthy cognitive participants; five
compared data among dementia stages; four compared participants with mild cognitive impairment
with healthy cognitive participants. Five teams focused their analysis on changes in test scores and
did not describe the prevalence of dementia or mild cognitive impairment in the population.
Association of multimorbidity and cognitive impairment
Authors of eight cohort or longitudinal studies evaluated the association of multimorbidity and
cognitive decline in the general population. In the study by Aarts108, the authors classified
participants into seven multimorbidity clusters from the Maastricht Aging Study, followed up to
12 years; the cognitive outcome was a decrease in test scores. The authors found that an
unexpectedly large decrease in verbal memory was associated with cardiac diseases and
malignancies. A decrease in processing speed was associated with cerebrovascular diseases,
cardiac diseases, malignancies and movement disorders. Fabbri et al.115 used data from participants
in the Baltimore Longitudinal Study of Aging with a follow-up time of up to 4 years. The authors
concluded that after adjusting for confounders, participants with multimorbidity had a significantly
greater longitudinal rate of decline in category and letter fluency, TMT-A and TMT-B.
In the study by Grande116, up to 6 years, the authors followed participants without dementia from
the Swedish National Study on Aging and Carein Kungsholmen. The investigator clustered patients
into five multimorbidity patterns. They found that the HR of developing dementia increased by
2.09 (CI95%: 1.19–3.64) for the neuropsychiatric, 2.02 (CI95%: 1.99–3.41) for the cardiovascular,
1.67 (CI95%: 1.02–1.98) for the sensory impairment/cancer, 1.21 (CI95%: 0.73–1.98) for the
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respiratory/metabolic/musculoskeletal and 1.24 (CI95%: 0.79–1.97) for the nonspecific
multimorbidity clusters. In another study, Ihle117 evaluated data from the two waves of the Vivre–
Leben–Vivere study participants. The author assessed the association of multimorbidity count on
TMT scores, finding that an increase in the number of chronic conditions is associated with a
decrease in speed.
Melis98 followed participants from a parish in Stockholm every 3 years for up to 12 years. The
investigator measured the cognitive decline in participants with multimorbidity. They found that
multimorbidity patients had a steeper decline, which was even sharper in patients after presenting
with cognitive impairment. Shang122 used the Women’s Healthy Ageing Project data to measure
cognitive trajectories in Australia. After controlling for confounding, they found that women with
multimorbidity had an OR 3.80 (CI95%: 1.00–14.48) of developing cognitive impairment.
A stratified population sample from Olmsted County in Minnesota, followed for up to 7 years, was
analyzed by Vassilaki97 After accounting for confounding, patients with multimorbidity were at
greater risk of developing MCI or dementia with an HR of 1.38 (CI 95% 1.05–1.82). Stratified
analyses were only significant for men (HR = 1.53, CI 95% = 1.01–2.31); women (HR = 1.20, CI
95% = 0.83–1.74). Wei et al.4 analyzed data from the Health and Retirement Study with 14 years
of follow-up. They found that patients with higher scores in the multimorbidity-weighted index
presented steeper and faster global cognitive decline as measured with the TICS scale along with
greater decline in immediate memory, with delayed recalls.
Two longitudinal studies’ authors compared healthy participants and patients with cognitive
impairment. Bratzke

111

analyzed a cohort of children of Alzheimer’s disease patients with a

follow-up of 4 years. They performed a latent class analysis that rendered a four-class solution of
multimorbidity clustering, named 1-depression, 2-sleep disorders, 3-cardiovascular and 4-healthy.
They found that the proportion of aMCI was different among the classes: 13.2% for depression,
19.1% for sleep, 9.3% for cardiovascular and 11.8% for healthy. Also, for naMCI, they found that
the prevalence was 8.8% for depression, 5.9% for sleep, 4.8% for cardiovascular and 3.7% for
healthy. Koroukian119 performed an analysis of the Health and Retirement Study 2010 and 2012.
The risk of MCI and dementia was higher in participants with multimorbidity, with an OR of 1.27
(0.93–1.74) for MCI and OR of 3.66 (2.49–5.37) for dementia.
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Three cohort studies’ authors evaluated patients with cognitive impairment. Aubert109 followed
patients with Alzheimer’s disease for one year. They found that patients with multimorbidity have
an increased risk of rapid cognitive decline, defined as a decrease of at least 3 points in the MMSE,
compared with patients without multimorbidity with an OR of 1.30 (CI 95%: 1.02–1.65). In a
cohort of AD patients with an annual follow-up, Kao118 found that an increase of one point in the
CIRS-G was associated with a decrease of 3.10 (−4.96–−1.23) in the MMSE during the follow-up.
Solomon et al.123 followed a cohort of AD patients for 2 years. They found that patients with a
higher number of CIRS-G categories at the baseline had lower MMSE scores. At follow-up, every
increase in CIRS-G categories led to a significant decrease in the MMSE scores of 0.15 (p-value =
0.006).
Two case-control studies’ authors tackled the relation between multimorbidity and cognitive
decline. Caracciolo112 analyzed information from the non-demented pairs of the Swedish Twin
Registry, matching by the pair. They concluded that multimorbidity presents a trend to an increased
risk of cognitive impairment non-dementia with OR 1.3 (CI 95%: 0.9–2.0). Bayen110 analyzed data
from all medicare patients with Down syndrome in California, matching them by dementia status,
age and sex. They found that patients with dementia have a higher multimorbidity count (mean:
3.7 ± 2.7) when compared with peers without dementia (mean: 2.5 ± 2.2; p-value 0.001).
We found four cross-sectional studies. Koyanagi120 used data from the SAGE survey, which
collected information from seven countries (China, Ghana, India, Mexico, Russia and South
Africa). They concluded that multimorbidity, defined as ≥ 3, was associated with an increased risk
of MCI (OR 1.27; CI 95%: 0.93–1.74) and dementia (OR 3.66; CI 95%: 2.49–5.37). Lee121 used
information from the Aging, Demographics and Memory Study. They found that ≥ 3 chronic
conditions are associated with CIND (OR 2.47; 95% CI: 1.42–4.31). They did not find an
association between ≥ 2 multimorbidity and dementia. Chen113 evaluated patients recently
diagnosed with AD. He found that a higher number of CIRS-G categories was associated with
lower MMSE scores (p-value 0.01); however, he did not find an association with the number of
chronic conditions. Doraiswamy114 evaluated patients with AD from 13 sites across the US. The
author concluded that after adjusting for confounders, more chronic conditions were associated
with lower MMSE scores (p > 0.001).
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In synthesis, we found a statistically significant association between multimorbidity and cognitive
decline (defined as MCI, dementia or lower neuropsychological scores) in 17 of the 19 studies
included in the current review. When we break them down by design, we find the association in
12 of the 13 longitudinal/cohort studies, the two case-control studies, and three of the four crosssectional studies.

3.4 Discussion
To our knowledge, this is the first systematic review that tackles the association of suffering
multimorbidity / multiple chronic conditions on cognitive performance and dementia. We found
that suffering multimorbidity was associated with cognitive decline in almost all the evaluated
studies, irrespective of whether the population was community-dwelling participants or patients
diagnosed with dementia. Also, the association was present both in cross-sectional and cohort
studies. This association was even present in patients with Down Syndrome, a genetically
determinate cognitive syndrome.
This result is consistent with other results of the association of multimorbidity of other major
functional outcomes like independence, disability165, frailty166 and quality of life167. However, an
accurate estimate of the association strength of multimorbidity on Cognitive decline is difficult due
to the multiple definitions of the cognitive outcomes. Nevertheless, there is a trend in almost all
the studies to higher cognitive decline with a higher number of chronic diseases. This result is in
consonance with the clinical heterogeneity of the populations included in this systematic review.
We recognize that this clinical and methodological variety should induce us to be extra cautious in
reaching conclusions regarding this association.

3.4.1 Strengths and limitations
Strengths of the systematic review
There are several strengths to our systematic review. First, ours is the first systematic review
addressing the association of multimorbidity with cognitive decline. We did not restrict our study
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to any age group, setting or language of publication. Our only restriction was the publication date
because we restricted information older than 1996, the year the modern multimorbidity concept
emerged15, and including studies published previous to that data could have introduced a less
accurate definition of our primary exposure variable. Also, we strengthened our search, including
databases like LILACS – IBECS, which brings additional potential articles168 and field-specific
databases169 as per search recommendations.
Second, we retrieved information from a wide range of populations, ranging from population-level
samples to patients with dementia and specific homogeneous groups such as patients with DS. We
found a trend in the association of multimorbidity with cognitive decline in all these scenarios.
Also, we avoided the pitfall of performing a meta-analysis with highly inhomogeneous results
without a comparable definition of the outcome. This kind of meta-analysis could produce spurious
results.

Limitations of the systematic review
We also recognize some limitations. First, the different definitions of multimorbidity and the broad
range spectrum in the number of chronic conditions made it challenging to account for its severity
in light of the association with cognitive decline. Also, we recognize the potential for underdetection and under-reporting of multimorbidity because some studies endorse disease categories
(e.g., heart diseases) and non-individual categories (e.g., myocardial infarction or heart failure).
Also, not all disease categories are equally likely to be accounted for in different studies. This
challenge is ubiquitous in multimorbidity publications and is an active research topic170. Also, some
researchers used the terms multimorbidity and comorbidity interchangeably, generating a
definition challenge. We included those whom we concluded were referring to multimorbidity in
these cases. Nevertheless, many publications still have an unclear application of these terms. It is
difficult to clearly define which populations are appraised by some studies171 and, in consequence,
how to interpret them.
Second, the original plan was to synthesize the information by performing a meta-analysis.
However, the considerable heterogeneity in study design, multimorbidity definition and cognitive
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impairment precluded a meta-analysis. Finally, most studies include populations from high-income
regions of North America, Western Europe and the Pacific. This fact precludes further evaluation
of associations with low- and middle-income countries. It might constitute a potential reporting
bias because there could be an unaddressed lack of association of multimorbidity with cognition in
poorer countries. Multimorbidity and dementia are global challenges172,173, and, therefore, a
primordial knowledge gap should be resolved.

3.5 Conclusions
Cognitive decline, defined as a decrease in neuropsychological scores or diagnosis of mild
cognitive impairment/dementia, increases in patients with co-occurrence of multiple chronic
conditions. This association holds in different settings, irrespectively being a patient with dementia
or a normal cognitive participant. Future research should address the association using harmonized
criteria of multimorbidity and cognitive decline.
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Chapter 4

4

Research methods

In this section we explain the primary data sources, which variables are fundamental for the
research, and data management procedures. Then for each objective, we present the proposed study
design and statistical analysis.
When we planned this study, we decided to perform exploratory analyses because we did not have
evidence of the change in the association of multimorbidity on cognitive decline and because we
judged that the two datasets were too dissimilar, which restricted us to exploratory and qualitative
approximations.

4.1 Data sources
4.1.1 The Canadian Study of Health and Aging
The CSHA was a longitudinal study designed to tackle and acquire precise information about the
burden of dementia in Canada. It involved an initial assessment in measuring the prevalence and
risk factors for dementia and two subsequent follow-ups. The study included 10,263 participants
65 years or older from 36 urban centres and surrounding rural areas. Researchers evaluated the
participants in 18 study centres from five Canadian regions (Table 9-3 in the Appendix). It included
9,008 community-dwelling individuals and 1,255 long-term facility residents100. The study
compiled baseline evaluation in 1991 and had two follow-ups, the first in 1996 and the final in
2001.
For community-dwelling individuals, the main sample frame was made up of the provincial health
insurance records. The researchers included residents with ≥ 6 months living at long-term facilities
for the institutionalized participant set. The investigators selected participants with ratios that, in
the 75–84 age group, were twice those in the 65–74 group; those 85 or older showed ratios 2.5
times those of the 65–74 group. The objective was to increase the likelihood of suffering dementia
during the follow-up. Each centre recruited a preset number of participants in each sex and age
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group stratum. The sample size was calculated accordingly to the Canadian region. Still, for budget
and equity purposes within each region, each center was committed to collecting the same number
of participants as all the other regional centers.The investigators calculated individual weights to
correct for the oversampling of the very old population and the differences in province population
size174. The investigators estimated that the included participants were representative of the general
population of the 10 provinces.
During the evaluations, individuals participated in an assessment that included a Modified MiniMental State Screening (3MS), a clinical examination, biological sampling, caregiver interviews,
risk factors and a neuropsychological evaluation. In the case of death before the follow-up, the
investigators used a “descendent questionnaire” to evaluate the health status during the last year of
life. Investigators performed the neuropsychological evaluation only on those participants who had
a 3MS score of 50 or more (range: 0–100). We have presented the tests evaluated during each
assessment in Table 9-4 in the Appendix. The authors used the most up-to-date criteria at that
moment for the diagnosis of dementia175.

4.1.2 The Canadian Longitudinal Study on Aging
The CLSA is an ongoing longitudinal study focusing on measuring interplays in the complex
process of aging. The CLSA recruited participants 45 years and older to measure the fundamentals
of a successful transition from midlife to later years101. Investigators divided the CLSA into
comprehensive and tracking cohorts.
The sampling strategy employed several different sources. The researchers sourced the Canadian
Community Health Survey for the tracking cohort as a base. Also, the provincial health care system
databases and telephone random digit dialling were sources of participants for both cohorts. The
study included participants in the Quebec Longitudinal Study on Nutrition and Aging who wanted
to participate in Quebec. As a result of the complex sampling strategy, it was necessary to calculate
individual sample weights to account for every participant inclusion probability and ensure that the
estimates derived from the study were representative of the 10-province population. The
investigators calculated inflation weights and analytics weights. The analytic weights are
proportional to the inflation weights but rescaled to the sample size. Study designers recommended
using these analytic weights in the regression analyses 176.
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Participants are interviewed "in person" in the comprehensive cohort and have an extensive
physical and cognitive examination. Researchers follow participants in the tracking cohort through
telephonic interviews. Investigators evaluate all participants every three years, and they can follow
them for 20 years177.
The baseline assessments ended in 2015 and included 30,097 participants in the comprehensive
cohort and 21,241 in the tracking cohort. The researchers evaluated the comprehensive cohort
participants in 11 data collection centres, while investigators followed the tracking cohort
participants via four telephone interview centres (Table 9-5 in the Appendix).
Investigators successfully reassessed most patients during the first follow-up which ended in 2018,
with retention of over 90% of the original cohort177. Investigators screened individuals invited to
participate for dementia, and they excluded those with it from the CLSA. To fulfill this objective,
the CLSA relied on neuropsychological evaluations. Study designers selected neuropsychological
tests based on being validated, having no ceiling effect and appropriateness to evaluate mid-life
and older adults. We have presented the neuropsychological assessment tests in Table 9-6 in the
Appendix. The authors did not include a general cognition measurement because it was irrelevant
to the whole population, including the mid-life adults178. The investigators developed algorithms
to establish the presence of chronic diseases179. The CLSA protocol includes all the 20 categories
we planned to use to count multimorbidity.

4.1.3 Rationale for using CSHA and CLSA data and comparability between both studies
These sources were suitable to answer our research questions. The data we were using were already
available in both longitudinal studies. Both studies collected comparable data regarding chronic
conditions and neuropsychological cognitive tests, which were necessary to answer our objectives.
However, we considered that risk factors for chronic diseases and cognitive decline have changed
over the past three decades.
The CLSA coordination evaluated data accessibility and project design as a postgraduate student
research project under the supervision of a faculty member at Western. In October 2020, the CLSA
coordination accepted our project and granted us access to the data. Data from the CSHA were
already available to us because Dr. Hachinski was one of the original investigators in the CSHA.
In November 2021, we received both data sets to perform the planned analysis.
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4.2 Identification of patients with multimorbidity
There is no standard and universally accepted method to identify multimorbidity because it is a
complex and multidimensional construct. We needed to simplify this multifaceted concept into an
operative construct21. We planned to identify the patients with multimorbidity for the present study
using the list developed by the “Patient-Centered Innovations for Persons with Multimorbidity”
team. This list comprises 20 common chronic diseases in Canada (Table 9-7 in the Appendix). It
has been validated and used in previous research on multimorbidity180, including ongoing projects
of the CLSA. However, when we received and evaluated both data sets, we found that the CSHA
did not include all the conditions in the proposed list. Consequently, we decided to include the
chronic diseases reported in both datasets. These conditions present in both databases were 14 as
follows: 1) systemic hypertension, 2) diabetes, 3) any cancer, 4) coronary artery disease/heart
attack, 5) other heart diseases, 6) depression, 7) any thyroid, 8) gastric ulcer or disease, 9) stroke,
10) chronic kidney disease, 11) Parkinson’s disease, 12 ) epilepsy, 13) multiple sclerosis, and 14)
arthritis/arthrosis.
We adhered to the definition of multimorbidity as two or more chronic conditions within the same
patient. In the case of the CLSA, the assessment algorithms for chronic conditions required
information only collected in the comprehensive cohort. As a result, for the CLSA, we restricted
our research to participants in the comprehensive cohort. For the CSHA, the data collection
methods included chronic conditions and clinical assessment questionnaires during the cohort
recruitment.
We decided to analyze multimorbidity as binary and count for the following reasons. First, there is
no consensus if multimorbidity should be measured as a dichotomic or as a count of diseases. Both
approximations have their advantages and disadvantages181. The classical definition of
multimorbidity is the coexistence of two or more chronic conditions within the same patient182. In
this sense, multimorbidity is defined as a dichotomic variable. This dichotomic definition has the
advantage that it is more easily implementable, but it reduces a complex problem to only yes or no.
On the other hand, the definition of multimorbidity as a count of chronic conditions is more
biologically plausible. It has been used as a predictor of outcomes frequently. Still, counts are
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susceptible to a broad change in the number of diseases included or if they also include other
conditions like risk factors or clusters of diseases23.
Consequently, there is no standard construct to define multimorbidity. Dichotomic measurements
as two or more chronic conditions and disease counting are commonly used. In our concept, disease
counting reflects better the multimorbidity conceptual nature, but the dichotomic definition is
easier to understand and less susceptible to change. We decided to use both definitions to see if
there were qualitative differences between them. After we finished the analyses, a Delphi
consensus on the definition of multimorbidity was published. This consensus suggested using the
definition of dichotomic multimorbidity as two or more chronic conditions and also recommended
counting diseases (from a list they proposed); nevertheless, the participants could not agree about
which should be the preferred definition183.

4.3 Identifying patients without dementia at initial assessment
Both cohorts evaluated cognition at the baseline, allowing for the detection of patients already
suffering from dementia. Investigators in the CSHA retained patients with dementia during the
initial assessment to assess the condition’s evolution. Nevertheless, the investigators identified
them. Conversely, researchers in the CLSA excluded from the cohort patients with dementia at
initial evaluation. For the CSHA, we excluded patients with dementia during the initial evaluation
to increase the comparability of both cohorts; for the CLSA, we included all patients in the
comprehensive cohort.

4.4 Assessment of cognition
Both cohorts evaluated cognition through a standardized neuropsychological assessment and drew
on the test scores. The two cohorts used the same or similar tests for some cognitive domains, but
the investigators chose different neuropsychological tests for other cognitive domains. We selected
one test for each of the target cognitive domains. In the present analysis, we are going to use the
following tests.
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Executive Function: The Digit Symbol Substitution Test (DSST) in the CSHA and the Mental
Alternation Test (MAT) in the CLSA. The DSST is a test that requires patients to replace numbers
with symbols presented at the top of the test page. The score is the count of the number of correct
matchings within the test time91. The MAT is a test that measures the number of correct ascending
alternations among numbers and letters performed by a patient within 30 seconds92. Both tests
measure multiple processes within the frontal function.
Language: Both cohorts used the Animal Naming Test (ANT) to measure language semantic
fluency. The test takes one minute, and investigators have validated it in multiple clinical
scenarios95.

Memory. Both cohorts used the Rey Auditory-Verbal Learning Test (RAVLT) to measure
memory. RAVLT is a test intended to evaluate verbal memory. The neuropsychologist presents the
individual under evaluation with a 15-word list and then asks them to recall the words immediately
after the learning phase, and then there is a new evaluation with a time delay of 5 minutes96. In the
present study, we evaluated the first immediate recall after the initial presentation of words.
Investigators in the CSHA presented the initial list of words five times to every individual, while
researchers in CLSA presented the test only once. As a result, even though both studies used the
same RAVLT that measures the same construct of memory encoding, learning and retrieving96.
This change in the number of learning trials might conduce to a change in the psychometric
characteristics of the test, and it is not recommended to compare scores between both situations
directly. We accounted for this difference in learning opportunities during the analysis not
attempting any quantitative analysis specially without standardization of the scores.
For the exposure, we first analyzed multimorbidity as a dichotomic variable and then as a count of
chronic conditions. We defined multimorbidity as two or more chronic conditions within the list
of the 14 selected conditions reported in both cohorts. We measured the outcome of cognitive
decline as the scores of the chosen neuropsychology tests. We transformed results into standardized
z-scores for every individual test for every one of the three selected cognitive domains. We did not
analyze a composed global cognitive performance score because the CLSA investigators did not
measure it.
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During the design, we planned to analyze the number of patients diagnosed with dementia or mild
cognitive impairment in each study. However, we could not perform this because the CLSA
investigators have not devised an algorithm to define dementia or mild cognitive impairment with
the information collected during baseline and the first follow-up. This contingency precluded any
attempt to compare both databases in this regard. Nevertheless, we presented the results for the
association of multimorbidity with the progression to dementia and mild cognitive impairment at
the first follow-up in the CSHA.

4.5 Measure of outcomes as the change in the test scores for each domain
Test results were standardized to a z-score to allow better comparisons 184. First, we compared the
baseline scores of both cohorts. Then for the measure of the change between the baseline and the
first follow-up, we employed the Reliable Change Index (RCI)184,185. The RCI put the difference
in a standardized metric and accounted for the reliability of the test. We used the following
mathematical approximation to calculate the RCI:

Equation 1: Reliable Change Index

𝑅𝐶𝐼 =
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=
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𝑇! − 𝑇"
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Where: RCI = Reliable Change Index; T1 = Score at time 1; T2 = Score at time 2; SED = Standard
Error of the Differences; S1 = standard deviation at time 1; r1,2 = correlation between Time 1 and
2 scores

We decided to use the RCI to measure change over time because it accounts for the change in a
psychometric measure between time one and two, accounting for the standard error of the measure
differences. Also, it is a wildly use tool to assess change in neuropsychological scores, which
allows us to compare with the previous research186 and will ease the understanding by the cognitive
research community.
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We independently analyzed and reported the test scores from the selected three cognitive domains
(executive function, language, and memory). We did not evaluate a global cognitive score because
the investigators in the CLSA did not measure it. We analyzed the outcomes composed of the
standardized z-scores as continuous measures.

We constructed a directed acyclic graph (DAG) to assess potential confounders and covariables
meaningful for our research questions. The DAG is a graphical tool that allows us to represent the
variables in an analysis that previous research showed might be causal in the health process we are
analyzing. In the DAG, we plot every variable that we have found can have a potential causal effect
on our selected outcome. This graph should fulfill the following rules: First, the graph should be
directed, meaning all variables must be connected through arrows. Second, it should be acyclic,
which means it is impossible to have a close loop or bidirectional arrow in the drawing because
every arrow is causal, and causes can only go in one direction. And third, to be complete, the shared
cause of any two variables of interest should be included in the graph187.
In the DAG, we plot every variable as a node and connect the nodes with arrows called arcs. A
collection of connections of nodes between an exposition and an outcome is called a path188. These
paths can be open or closed. A path is open when you can trace a directed path from a potential
confounder into the exposition and outcome variables passing through one or more nodes; an open
path should be closed because it transmits statistical force and creates confounding. To close a
path, we must control during the analysis for one of these nodes. In a DAG, we are graphing all the
potential paths, and we have to analyze all the open paths. As a result, we construct a minimally
sufficient set that is the list of confounders that should be controlled in the analysis to close all the
open paths between exposition and outcome189.
During the DAG creation, we must identify the variables (nodes) that are the causes of the
exposition and outcome. These variables are called ancestors. Also, we must recognize the
variables that are ancestors to the ancestors of the variables of interest; all these are also ancestors
to our research variables. Likewise, we ought to identify those variables caused by our exposition
and outcomes, which are called descendants. The descendants of the exposition that are ancestors
of the outcome are part of the causal pathway; the descendants of both exposition and outcome
should not be included in the DAG190. With this information, we were able then to create our DAG.
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Figure 2 shows the DAG constructed with the recognized associations of multimorbidity and
cognitive decline. It provided the minimum sufficient set of variables needed to control
confounding in the regression models. We obtained the information to construct the DAG from the
literature191–199.
To create the DAG, we performed a systematic search using the Medline database through the
Pubmed search engine on March 4, 2021. We used the following phrase as a search term:
"Dementia and multimorbidity and risk factors"; from this search, we found 101 possible results,
one researcher (JCVG) read all titles and abstracts and then full text when necessary. We selected
six references to include in the DAG construction. Then one author (JCVG) analyzed all the
references in the included articles and found three additional articles to use in constructing the
DAG.

Figure 2: DAG of the relationship between multimorbidity and cognitive decline.
In the figure: Green node with the arrowhead within is the exposure variable under analysis
(multimorbidity). Blue node with an I within is the outcome variable under investigation (Cognitive
Decline). Green nodes are ancestors of exposure. Blue nodes are ancestors of the outcome. Red nodes are
ancestors of exposure and outcome. Green arrows are causal paths. Red arrows are biasing paths.

We concluded that age, sex and education level were three variables we had to include in the final
confounders set owing to their known significant association with cognitive impairment and
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multimorbidity. Then, using the DAG, we determined that a minimal sufficient set of confounders,
including traumatic brain injury, smoking status and alcohol consumption, would provide adequate
control for confounding. As a result, we used the previous six variables to control confounding in
our models.
Based on the literature information at the time, our variables selection to control for confounders
provides an adequate set of variables to reduce our confounding level. Nevertheless, we think future
cohorts should include new genetic techniques that allow the collection of information on various
polymorphisms that might modify the relationship between multimorbidity and cognitive decline.
This future genetic emphasis will be an important future step to complement our current minimal
sufficient set of confounders.
Variables were operationalized as follows for the analysis. We analyzed the 14 conditions selected
for the analysis as dichotomic variables and used their measurement during the baseline evaluation.
For the assessment of multimorbidity, we used two approaches. First, a dichotomic variable
aggregated all the cases when two or more conditions were present; second, we performed a count
of the 14 selected chronic conditions. Third, we aggregated participants with or without one chronic
condition as the reference category.
We presented age as an integer number of completed years. Also, we expressed sex as a dichotomic
variable. We analyzed education level as an ordinal variable with four categories (“Less than
secondary school graduation”, “Secondary school graduation, no postsecondary education”, “Some
postsecondary education” and “Postsecondary degree/diploma”). We analyzed alcohol
consumption, current smoking and lifelong history of traumatic brain injury (TBI) as dichotomic
variables.

In both cases, sampling and selection in the studies followed a process clustered into different
Canadian regions (Atlantic, Quebec, Ontario, Prairies and B.C.). We used these regions as grouping
variables for multilevel analyses. We decided to cluster by the Canadian regions because, for both
studies, investigators selected and adjusted recruitment sites and participant sample size to be
representative of the Canadian Regions200–202.
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Owing to our complex multistep sampling methods, we had to include sampling weights during
the analysis. Sampling weights appear because, in a sampling process, every individual selected
represents a specific part of the population under study. However, the probability of an individual
of been included in the study is non-equal depending on the study design, the frame under coverage
and the non-response rate203. We needed to compensate using the sampling weights in the analysis
to obtain unbiased estimators. Statistical methods for analysis assume that the inclusion of
participants is random and independent, and this condition is not met under cluster and complex
selection process. The sampling weight accounts for this unequal sampling probability rendering
less risk of bias in the estimators204

We employed the weighting method for multilevel analysis proposed by Asparouhov

205

. This

method provides an extension to any multilevel analysis of the method of pseudo maximum
likelihood (MPML). This method obtains unbiased estimators with a consistent asymptotic
variance /covariance estimate. Also, we scaled weights to the sum of the cluster sample size
because this scaling method provides the least biased estimates. Also, based on the
recommendations from the consensus in a multilevel analysis of complex data, to obtain unbiased
estimators, we fitted the analyses using scaled weights206. Both studies provided individual-level
weights that we scaled to a sum equal to the cluster size 207.
In conclusion, we expect that including the sampling weight in the analysis using the MPML
method will allow us to obtain less biased model estimators for the interpretation. Also, using this
method will enable us to get more precise Intraclass correlation coefficients (ICC), which represent
the proportion of total variance resulting from the Canada region-level of clustering208.
There were different cut-off points in the neuropsychological tests to analyze meaningful clinical
differences. It is a convention that the minimal meaningful difference is –0.5 SD in the test scores
209

. Further, previous investigators have used the cut-off points of –1.0, –1.5 and 2.0 SD to express

abnormal scores. Nevertheless, one of the commonest interpretations is that –1.0 SD is borderline,
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–1.5 SD abnormally low or at least moderate and –2.0 SD severely abnormal75. Using this
information, we decided to interpret the results as follows: a) less than –0.5 SD – No important
difference; b) –0.5 to –0.999 – Below the expected score; c) –1.0 to –1.4999 – Probably abnormally
low score (borderline); and d) lower or equal to –1.5 SD – Abnormally low score.
We received both databases for the CSHA and CLSA by email in individually encrypted secure
files. Then we decrypted them and stored the information in a USB memory key. We executed data
cleaning and analysis using R Statistical Software version 4.2.1, employing RStudio
2021.09.0+351 as an integrated development environment along with Microsoft Excel 365.
We used the following R packages (version): rmarkdown (2.11), officedown(0.2.3), officer(0.4.1),
foreign(0.8.81), dplyr(1.0.7), tidyverse(1.3.1), data.table(1.14.2), arsenal(3.6.3), lme4(1.1.27.1),
lmerTest(3.1.3), rpart(4.1.15), and rpart.plot(3.1.0). We present the R code as supplementary file
1.

4.6 Analysis of each objective
4.6.1 For the primary objective:

Summary of methods to analyze primary objective: Multilevel regression models of the
association of multimorbidity on cognitive scores or clinical diagnosis of dementia or mild
cognitive impairment controlling for meaningful confounders. We performed models using
dichotomic multimorbidity and multimorbidity count.

First, we evaluated the table presenting both cohort characteristics, including sociodemographic,
risk factors and prevalence of chronic conditions. We used the "Arsenal" package in R statistical
software.
For the primary analysis of the qualitative comparison of the CSHA and the CLSA, we evaluated
the z-standardized baseline and RCI z-standardized change scores at the first follow-up for frontal
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function, ANT and RVLT immediate recall and delayed recall. For each category, we performed
two analyses, one measuring multimorbidity as a dichotomic outcome (mm dich) and the second
measuring multimorbidity as a count (multimorbidity). For each comparison, we performed the
following subgroup analyses:
•

Female and male

•

CLSA: Female, male, 65 years and older, and younger than 65.

The rationale for the subgroup analysis by life course group in the CLSA was to compare the results
of the group participants 65 years and older with the participants of the CSHA that were all older
than 65 years.
For the analyses, we included information from participants who demonstrated they were not
demented during the baseline evaluation, using the results for the test score for the baseline and the
first follow-up.
We performed random intercept linear multilevel regression modelling analyses. Level 1 consisted
of individual participants, and Level 2 accounted for the Canadian region. We selected a random
intercept model because we wanted to adjust for the clustering level of the Canadian region, which
might affect the scores210. Also, we discarded performing a random slope model because no
biological evidence supports that the association of multimorbidity or the selected confounders
would be different in the Canadian regions. Consequently, previous multilevel modelling in
multimorbidity patterns has performed only random intercept models211–213.
We used lme4 for these analyses. We selected a random intercept modelling to account for the
clustering of the patient selection in both study designs. Nevertheless, multimorbidity and all the
variables in the minimal sufficient set selected for confounding control were individual-level.
Consequently, we did not include second-level covariables. We adjusted models using confounders
previously selected through our DAG. We calculated the intraclass correlation coefficient for each
model to assess the proportion of variance explained by the second level of analysis.
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We analyzed the baseline-collected data about initial cognitive test scores, chronic conditions, and
other sociodemographic characteristics to assess confounders for both studies. We used data
obtained during the first follow-up to measure the change in cognitive outcomes scores using the
RCI previously described.

Equation 2: Equation format for the principal objective

𝑦$% = g&& + 𝛽'' 𝑥'' $% + 𝛽)*+ 𝑥)*+ $% + 𝛽,+- 𝑥,+- $% + 𝛽+./ 𝑥+./ $% + 𝛽,'01+ 𝑥,'01+ $%
+ 𝛽2340503 𝑥2340503 $% + 𝛽678 𝑥678 $% + 𝑢&% + 𝑒$%
where: y= Dependent Variable = neuropsychological RCI-z-score; i: individual level; j: Canadian
region level; g00 = average intercept; b = Coefficient of degree of change for every x at level 1; xij
= explanatory variable at level 1; uoj = group (Canadian region) dependent variation; eij = random
errors of prediction at level 1; mm = multimorbidity; age = age in years; sex = female or male; edu
= education level in 4 categories; smoke = dichotomic current or previous smoking; Alcohol =
Alcohol consumption at least weekly; TBI = Traumatic Brain Injury
The time for the first follow-up in both studies was different. For this reason, we assessed the
results for both studies separately. After performing both models, we compared the results from
both cohorts qualitatively. The CSHA included participants 65 years and older; for this reason, we
compared those participants only with individuals 65 years and older from the CLSA.
Also, we compared results by sex in each database to explore potential differences in the
associations. We did not compare data sets stratified by sex. Finally, in the CLSA, we contrasted
the results of the groups of participants younger than 65 years with those 65 years and older.
We have presented the results of the association of multimorbidity with the z-standardized results
of the selected cognitive tests after controlling for confounding. First, we have presented the
dichotomic multimorbidity results, and then the multimorbidity count results.
Currently, the CLSA does not have an algorithm to identify participants who progressed to
dementia at the first follow-up. Consequently, we have presented only the results pertaining to the
association of multimorbidity with dementia or mild cognitive impairment progression at the first
follow-up in the CSHA. Analogous to the continuous outcomes, we performed a multilevel logistic
regression analysis with dementia and mild cognitive impairment as the outcome variable. We have
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expressed the results as odds ratios (OR) for the incidence of dementia at the first follow-up. Also,
we performed the subgroup analysis by sex. In the CSHA, mild cognitive impairment was called
Cognitive Impairment No Dementia (CIND); we used this acronym in our tables.
For the principal objective, we decided to evaluate which approximation to multimorbidity offered
a better fit in the regression models. We decided to assess the dichotomic models compared with
the count models to analyze the whole cohort. We employed the Akaike Information Criterium
(AIC), a measure of the model fit compared with other models fitted in the same data. It
approximates the possible distance between the model we fitted with the non-observable true
mechanism that created the data. To interpret the AIC, the lower the value, the better fit the model
has214. We used for our analysis the conditional on the cluster AIC that was proposed to correct for
the multilevel structure215.

4.6.2 For the first secondary objective:
Summary of methods to analyze first secondary objective: Qualitative comparison of two
methods to select the multimorbidity combinations (dyads and triads) associated with lower
cognitive test scores. The first method identified combinations through multilevel regression
analysis, including all combinations with prevalence ≥ 1%; the second method identified
combinations through CART.

We explored the multimorbidity combinations potentially associated with a larger
neuropsychological cognitive test score decline. We performed individual analyses for each
domain-specific neuropsychological standardized z-score at the baseline and the RCI standardized
z-scores of change between the baseline and the first follow-up. We analyzed the entire data set
with the baseline and the first follow-up in the CSHA. In the CLSA, we analyzed only participants
65 years and older who had test results from the baseline and the first follow-up. In the CSHA, we
performed analyses on dementia and MCI outcomes.
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To fulfill this objective, we performed two different kinds of analysis. We first detected the
multimorbidity dyads and triads with higher prevalences to perform multilevel linear regression
analyses to evaluate the association of the dyad and triad combinations in z-standardized cognitive
scores. In the CSHA data, we performed analogous multilevel logistic regression analyses to obtain
the OR of chronic disease combinations in the incidence of dementia or MCI.
Then, we performed a second analysis using a regression and classification tree analysis (CART)
to detect the multimorbidity combinations with a greater association with z-standardized cognitive
scores.
We first detected the chronic disease combinations with higher prevalences using the
Multimorbidity Analysis Tool216, a computer tool developed at Western University for this
objective. The program ranked the dyads and triads with higher prevalence independently in both
longitudinal studies at the baseline. The program and its toolkit can be downloaded from the
Western

University

Computer

Science

website

(https://www.csd.uwo.ca/~bauer/Multimorbidity.htm); it was made available to academic research
by its creators217.
The Multimorbidity Cluster Analysis Toolkit is an automatized algorithm written in JAVA that
identifies the number of individuals with specific disease combinations within a database. It can
also identify the disease permutations, but we used only the disease combinations for our present
study. It can handle up to 250 individual records and 100 individual condition diagnoses. It will
return all the combinations/permutations reported in the initial dataset CSV file216.
The Multimorbidity Analysis Tool required data preparation to run the software. We selected the
unique case ID variable and the variables with the 14 conditions of interest and exported them into
a CSV file. Then we converted the file, using Microsoft Excel, into a TXT file, comma separated,
including one line per participant, the unique case identification, each participant condition with a
maximum extension of 10 characters and a zero representing baseline evaluation after each
condition. Finally, we analyzed each TXT file with the toolkit. Each analysis provided us with four
file results. We selected for further analysis only the file containing the summary of chronic
condition combinations that include the dyads and triads present in the data set.
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We limited regression analyses to multimorbidity patterns with high prevalence. We performed
two independent analyses, one with dyads and the other with triads of chronic condition
combinations. The analysis included only the dyads and triads with a prevalence ≥ 1.0% to ensure
enough participants per group218. We analyzed it using multilevel linear regression models to
measure the change in neuropsychological cognitive test scores and multilevel logistic regression
for the dichotomic outcomes. Owing to the exploratory nature of the analyses, we did not correct
for multiple testing. We performed the regression analysis for each z-standardized score at the
baseline and the z-score of change at the first follow-up. We limited the analysis to the complete
cohorts only to ensure enough number of patients in each dyad or triad. Also, we presented the
multilevel logistic regression analyses for the outcome of dementia and MCI at the first follow-up
in the CSHA.
Second, we performed analyses using machine learning techniques. We used the CART team
method. We selected this technique because previous investigators have used it commonly in
multimorbidity combination research to explore their association with complex health
outcomes219,220. We performed stratified analysis by sex in both cohorts and by age group in the
CLSA cohort.
The CART method is a non-parametric technique that resorts to a recursive partition of the data to
obtain meaningful aggregation of variables associated with different outcome levels. Every
partition group is mutually exclusive and exhaustive, which means a single participant can only be
classified into one final group, and all the participants will be allocated to one group221. This
segmentation allowed us to classify multimorbidity combinations into different health outcome
profiles. The method consisted of a parent node that divided the cases without overlapping them in
branches conducting them into descendant nodes that repeated the process until every individual
had been assigned to one group. After the initial parent node, each intermediate node has a
condition associated with it. If the case meets the condition on it (all our intermediate conditions
were dichotomic chronic conditions), it comes down to one branch; if it does not meet the
condition, it goes down into the other branch. Then in each node, the process is repeated until all
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the intermediate categories have been split in the nodes and there are no more categories to
divide222.
For these CART analyses, we selected as outcomes for both datasets the individual cognitive test
z-standardized scores at baseline and the individual cognitive test RCI z-standardized scores at first
follow-up; also, for the CSHA, we performed analyses with the clinical diagnosis of Dementia and
CIND. The variables that we introduced in the CART were the dichotomic individual 14 conditions
that we counted in our research for multimorbidity: 1) systemic hypertension, 2) diabetes, 3) any
cancer, 4) coronary artery disease/heart attack, 5) other heart diseases, 6) depression, 7) any
thyroid, 8) gastric ulcer or disease, 9) stroke, 10) chronic kidney disease, 11) Parkinson’s disease,
12 ) epilepsy, 13) multiple sclerosis, and 14) arthritis/arthrosis.
The CART algorithms have two crucial tasks. First, how to partition the cases at each node, and
second, when to stop partitioning the cases. As a result, we will obtain How to estimate the value
of y for each x in a partition222.
To answer the first question, the algorithm uses a function to maximize the “purity” of the split.
The algorithm attempts to make the two more homogeneous groups with the cases still in each
node that better separate both groups; the algorithm evaluates all the potential partitions in each
node before selecting the result that better fits the selection rule223. The two more common
techniques to split a node are called entropy and the GINI index. Both rules are 0 when all the
elements in the node are of the same class, while its value will be higher when all the elements in
the node are of different categories. First, entropy measures the information disorder within the
node, while the GINI index measures the frequency at which an element in the node will be
mislabeled randomly 224. Both techniques result in similar but not equal splitting patterns in every
node. However, the GINI index penalizes less small datasets, and empirical data shows that the
GINI index is more accurate than other classification algorithms225. Consequently, using the
previous information and literature recommendation, we classified the groups using the GINI index
method226.
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To answer the second question about when to stop splitting and pruning, there are several methods
that can be applied. The first rule to stop is to define the minimum number of participants in the
terminal nodes, a rule of thumb is at least 1% of the sample size. However, there is no standard
rule to decide this number221; we decided to include a minimum of 5 participants per node because
that was 1% of the sample size in the smaller cohort of the CSHA, and it was the selected criteria
for the inclusion in the Multimorbidity Analysis Tool216. The second method is to prune the tree if
the node splitting does not increase the fit by at least a minimum value of the impurity index or
GINI index. We performed our analyses using the rpart package in R, which uses to prune the
Complexity Parameter (CP). Previous researchers have used different CP to analyze
multimorbidity and healthcare data. We found that a simulation using different parameters found
that a CP of 0.0001was adequate in this case of data227. For the binary outcomes of dementia and
MCI at the first follow-up in the CSHA, we have presented the dyads and triads with dementia or
MCI incidence above the whole cohort dementia prevalence. We performed the previous procedure
to calibrate our CART model to detect the dyads and triads; we did not perform after tree creation
additional pruning other than the theoretically selected CP. We did not perform validation within
the same dataset because we did not want to predict but only explore.
Finally, we compared the results of the multilevel regression analysis of dyads/triads with those of
the CART analysis. The comparison of the CSHA and the CLSA disease combinations associated
with greater cognitive decline was qualitative and descriptive. Currently, there is no gold standard
to identify the dyads and triads of multimorbidity combinations associated with cognitive scores.
Consequently, we wanted to explore whether the two methods converged to identify similar
multimorbidity combinations. We performed further comparison within dementia or MCI
outcomes at the first follow-up only the CSHA because we did not have data on dementia or MCI
in the CLSA.

4.6.3 For the second secondary objective:
Summary of methods to analyze second secondary objective: Exploration of potentially protective
factors associated with cognitive scores improvement and diminishing risk of clinical progression
to dementia or MCI using multilevel regression analysis.
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We evaluated factors associated with cognitive decline protection in patients with multimorbidity
for the second secondary objective. We selected the factors previously known to be associated with
cognitive outcomes. We performed multilevel linear models with a random intercept for each
selected cognitive test (frontal function, AFT and RVLT) and multilevel logistic models for
dementia and MCI outcomes in the CSHA. We evaluated individual patients’ data as the first level
and the Canada region as the second level. For this analysis we included as a potential protective
factor physical activity at least once a week.
Equation 3: Format to evaluate factors associated with cognitive decline protection

𝑦$% = g&& + 𝛽)*+ 𝑥)*+ $% + 𝛽,+- 𝑥,+- $% + 𝛽+./ 𝑥+./ $% + 𝛽,'01+ 𝑥,'01+ $% + 𝛽2340503 𝑥2340503 $%
+ 𝛽678 𝑥678 $% + 𝛽95:, 𝑥95:, $% + 𝑢&% + 𝑒 $%
where: y= Dependent Variable = neuropsychological RCI-z-score; i: individual level; j: Canadian
region level; g00 = average intercept; b = Coefficient of degree of change for every x at level 1; xij
= explanatory variable at level 1; uoj = group (Canadian region) dependent variation; eij = random
errors of prediction at level 1; mm = multimorbidity; age = age in years; sex = female or male; edu
= education level in 4 categories; smoke = dichotomic current or previous smoking; Alcohol =
Alcohol consumption at least weekly; TBI = Traumatic Brain Injury; phys = physical activity.

Finally, we performed a qualitative comparison of the results from both longitudinal studies to
explore the potential changes in protective factors between them. As with the previous analysis,
we reported the multilevel logistic regression analysis for the outcome of dementia onset at the first
follow-up in the CSHA.
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Chapter 5

5

Results

5.1 Principal objective results
Regarding the results for the principal objective, we have presented the description of the overall
patients’ characteristics in both cohorts, the results from the association of multimorbidity with the
test scores of each selected neuropsychological test and the comparisons between both cohorts.

5.1.1 Overall cohort description
Following the inclusion and exclusion criteria, we evaluated for inclusion patients without
dementia at the baseline who returned for neuropsychological assessment during the first followup. We included 497 participants from the CSHA and 23,654 participants from the CLSA; Figure
3 presents the flowchart with the included participants. The complete profile of patients included
appears in the following Table 5-1. The mean number of morbidities was 2.1 (SD:1.5) in the CSHA
and 1.6 (SD:1.4) in the CLSA. Multimorbidity was present in 303 (61.0%) participants in the
CSHA and in 10,887 (46.0%) in the CLSA. In both cohorts, most participants were females
(CSHA: 63.6%; CLSA: 50.9%), and the mean age was 77.4 years (SD: 6.4 years; range 65–99
years) in the CSHA and 62.3 years (SD: 10.0 years; range 45–86 years) in the CLSA. The
representation by Canada regions in the CSHA was as follows: Atlantic 23.9%, Quebec 28.0%,
Ontario 17.9%, Prairies 9.7% and B.C. 20.5%. Meanwhile, the representation of Canada regions
in the CLSA was as follows: Atlantic 16.0%, Quebec 21.0%, Ontario 21.6%, Prairies 19.4% and
B.C. 21.9%.
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CLSA

CSHA

Total Sample n= 51338

Total Sample n= 10263
No complete cognitive
assessment n= 7349

Phone follow up cohort
n= 21241
Clinical examination at
baseline n= 2914

Comprehensive cohort
at baseline n= 30097

Demented n=1132

Lost by 1st-FU n= 2332
Returned for 1st FU n=
27765

Non demented n= 1782
Evaluated at baseline &
lost by 1st FU n= 1285

Lost by first-follow up
n= 4111
Baseline & 1st FU
evaluation n= 497

Complete cases for
analysis n= 23654

Figure 3: Flowchart of participants included in this analysis and from the CSHA and CLSA

CLSA: Canadian Longitudinal Study on Aging; CSHA; CSHA: Canadian Study of Health and
Aging ; 1sr FU: First Follow-up

We had a remarkable finding, which was that the participants with a “Less than secondary school
graduation” and “Secondary school graduation, no post-secondary education” represented 75.9%
in the CSHA but only 13.5% in the CLSA. When we analyze these results in their context, we
found that the 1996 Canadian Census found that 75.8% of Canadians 65 years and older have an
education level of “secondary school graduation or less”

228

, while the 2016 Canadian Census

reported that 46.0% of Canadians have “Secondary School graduation or less”

229

. These results

suggest that the CSHA was similar to the general Canadian population’s education level at the
time, while the CLSA recruited a highly educated population. Also, we think this phenomenon in
the CLSA cannot be attributed to the immigration of highly qualified participants because they are
already accounted for in the Census, and the CLSA recruited mainly Canadian-born participants.
This challenge of recent population research recruiting highly educated participants has affected
other cohorts230, and it might be a result of increasing difficulty in recruiting participants and the
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willingness of highly educated people to participate. Also, This difference in the CLSA education
level with the current general Canadian population creates the potential for selection bias.
The alcohol consumption was twice as high in the more recent CLSA (60.5%) as in CSHA (30.0%),
whereas smoking or a history of smoking increased slightly, from 44.9% in the CSHA to 52.4% in
the CLSA. Also, the incidence of dementia between the baseline and the first follow-up at five
years in the CSHA participants with complete information was 13.7%. In the CSHA, of the total
398 participants with data on the first follow-up, 57 participants (14.3%) were diagnosed with
dementia at the first follow-up. Also, in the subgroup of the 325 participants without any cognitive
impairment at baseline, 89 participants (27.4%) were diagnosed with CIND at the first follow-up.
We could not estimate the incidence of dementia in the CLSA because the study is still devising
an algorithm that allows us to detect MCI and dementia.

Table 5-1: CSHA
(Unweighted)

and

CLSA

cohort

Description
CLSA (N=23654)

CSHA (N=497)

Mean

1.6

2.1

SD

1.4

1.5

0.0 - 9.0

0.0 - 7.0

10887 (46.0%)

303 (61.0%)

0 or 1

12767 (54.0%)

194 (39.0%)

2

5270 (22.3%)

125 (25.2%)

3

3255 (13.8%)

93 (18.7%)

4 or more

2362 (10.0%)

85 (17.1%)

11604 (49.1%)

181 (36.4%)

Mean

62.3

77.4

SD

10.0

6.4

45.0 - 86.0

65.0 - 99.0

Atlantic

3793 (16.0%)

119 (23.9%)

Quebec

4973 (21.0%)

139 (28.0%)

Ontario

5120 (21.6%)

89 (17.9%)

Multimorbidity (count)

Range
Presence of multimorbidity
Multimorbidity categorical

Sex (male)
Age (years)

Range
Canada region
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Prairies

4586 (19.4%)

48 (9.7%)

B.C.

5182 (21.9%)

102 (20.5%)

Less than secondary school graduation

1088 (4.6%)

288 (57.9%)

Secondary school graduation, no post-secondary education

2105 (8.9%)

89 (17.9%)

Some post-secondary education

1707 (7.2%)

77 (15.5%)

Post-secondary degree/diploma

18754 (79.3%)

43 (8.7%)

Alcohol consumption at least once a week

14302 (60.5%)

149 (30.0%)

Current or former Smoking

12396 (52.4%)

223 (44.9%)

Physical activity (at least once a week)

12881 (54.5%)

276 (55.5%)

Lifetime traumatic brain injury

5808 (24.6%)

79 (15.9%)

Hypertension

8466 (35.8%)

154 (31.0%)

Diabetes

3904 (16.5%)

60 (12.1%)

History of Cancer

3510 (14.8%)

52 (10.5%)

Previous coronary artery disease or acute coronary syndrome

1005 (4.2%)

65 (13.1%)

Other heart diseases (including CHF)

2521 (10.7%)

101 (20.3%)

History of depression

3858 (16.3%)

87 (17.5%)

Hypothyroidism or hyperthyroidism

3390 (14.3%)

63 (12.7%)

Gastric / duodenal ulcer

1732 (7.3%)

95 (19.1%)

History of stroke

349 (1.5%)

40 (8.0%)

Chronic kidney disease

610 (2.6%)

45 (9.1%)

Parkinson disease

90 (0.4%)

11 (2.2%)

Epilepsy

235 (1.0%)

5 (1.0%)

Multiple Sclerosis

152 (0.6%)

1 (0.2%)

8100 (34.2%)

271 (54.5%)

Mean

27.0

25.9

SD

8.6

11.8

0.0 - 51.0

0.0 - 62.0

Mean

26.7

22.2

SD

7.6

12.5

1.0 - 51.0

0.0 - 62.0

Mean

20.1

13.5

SD

5.6

4.3

0.0 - 47.0

2.0 - 27.0

19.8

12.0

Education level

Arthritis, osteoarthritis or rheumatic disease
Baseline frontal test (DSST in CSHA; MAT in CLSA)

Range
Follow-up frontal test (DSST in CSHA; MAT in CLSA)

Range
Baseline animal naming test

Range
Follow-up animal naming test
Mean
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SD

5.3

4.5

1.0 - 44.0

2.0 - 28.0

Mean

6.0

4.1

SD

1.9

1.7

0.0 - 14.0

0.0 - 10.0

Mean

6.6

3.7

SD

2.2

1.7

0.0 - 15.0

0.0 - 10.0

Mean

4.2

13.5

SD

2.1

2.0

0.0 - 14.0

1.0 - 15.0

Mean

4.8

13.0

SD

2.4

2.5

0.0 - 15.0

0.0 - 15.0

Range
Baseline RAVLT immediate recall

Range
Follow-up RAVLT immediate recall

Range
Baseline RAVLT delayed recall

Range
Follow-up RAVLT delayed recall

Range

CHF: congestive heart failure; DSST: Digit Symbol Substitution Test; CSHA: Canadian Study of Health and
Aging; MAT: Mental Alternation Test; CLSA: Canadian Longitudinal Study on Aging; RAVLT: Rey Auditory–
Verbal Learning Test

5.1.2 Multimorbidity association with cognitive scores
We present the result for each cognitive test independently.

5.1.2.1 Frontal Function
Both studies measured frontal function. Nevertheless, the test available to measure it was different
in both cohorts. In the case of CSHA, investigators used a paper-based Digit Symbol Substitution
Test (DSST). In the case of CLSA, investigators used a computer-based version of the Mental
alternation Test (MAT).

5.1.2.1.1 CSHA (Measured with DSST)
Baseline
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Dichotomic Multimorbidity
A total of 474 patients were available for the analysis for both dichotomic and continuous
multimorbidity, full results can be evaluated in the following Table 5-2. We found that
multimorbidity was not associated with differences in DSST scores with a z standardized score of
0.089 (CI95%: -0.069 to 0.24; p-value 0.27). When analysing the confounding variables, we found
that every increase of one age was associated with -0.043 (CI95%: -0.055 to -0.03) decrease in
DSST scores. Also, male sex was associated with a -0.23 (CI95%: -0.42 to -0.047) decrease on
scores. Finally, education level categories showed an increase of 0.75 (CI95%: 0.55 to 0.95) in z
standardized scores for every increase in an education category. All other confounders were non
associated with the z standardized score of DSST at baseline. The ICC for the model was of 0.14
(CI95%: 0.011 to 0.352). We can interpret that the Canada-region clustering explained 0.14 of the
total model variance.
We did not find differences in the association of dichotomic multimorbidity on z standardized
DSST scores when analyzing stratified analysis by sex. For females (
Table 5-3), we had information in 295 participants, and the association was of 0.035 (CI95%: -0.17
to 0.24; p-value: 0.73). For males (
Table 5-4) we had results from 179 participants with an association of 0.14 (CI95%: -0.11 to 0.39;
p-value: 0.28

Table 5-2: Association in the CSHA of Dichotomic Multimorbidity with Frontal Function measured
with Digit Symbol Subtraction Test at Baseline

Predictors

Estimates std. Error

CI

p

(Intercept)

3.72

0.50

2.75 – 4.70

<0.001

mm dich [Yes]

0.09

0.08

-0.07 – 0.25

0.271

age

-0.04

0.01

-0.06 – -0.03

<0.001

sex [Male]

-0.23

0.09

-0.42 – -0.05

0.014

educ level [linear]

0.75

0.10

0.55 – 0.95

<0.001
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educ level [quadratic]

-0.17

0.10

-0.36 – 0.03

0.101

educ level [cubic]

0.28

0.10

0.08 – 0.47

0.006

TBI [Yes]

0.05

0.11

-0.17 – 0.27

0.646

smoking [Yes]

0.09

0.09

-0.09 – 0.27

0.348

alcohol [Yes]

-0.07

0.09

-0.26 – 0.11

0.439

Random Effects
σ2

0.67

τ00 region

0.11 (SD: 0.33; CI95%: 0.16 to 0.67)

ICC

0.14

N region

5

Observations
2

474

Marginal R / Conditional R2

0.236 / 0.342

AIC

1292.711

AICc

1293.388

mm dich: dichotomic multimorbidity; age in years; educ level: education level categorical; TBI: Traumatic brain injury

Table 5-3: Association in the CSHA of Dichotomic Multimorbidity with Frontal Function measured
with Digit Symbol Subtraction Test at Baseline - Female

Predictors

Estimates std. Error

CI

p

(Intercept)

4.13

0.60

2.95 – 5.30

<0.001

mm dich [Yes]

0.04

0.10

-0.17 – 0.24

0.736

age

-0.05

0.01

-0.06 – -0.03

<0.001

educ level [linear]

0.64

0.14

0.36 – 0.92

<0.001

educ level [quadratic]

-0.36

0.13

-0.62 – -0.10

0.007

educ level [cubic]

0.07

0.12

-0.18 – 0.31

0.580

TBI [Yes]

0.01

0.17

-0.32 – 0.33

0.958

smoking [Yes]

0.16

0.12

-0.07 – 0.39

0.171

alcohol [Yes]

0.01

0.14

-0.27 – 0.28

0.968

Random Effects
σ2

0.65
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τ00 region

0.07 (SD 0.27; CI95: 0.10 to 0.56)

ICC

0.10

N region

5

Observations

295

Marginal R2 / Conditional R2

0.260 / 0.334

AIC

824.508

AICc

825.440

mm dich: dichotomic multimorbidity; age in years; educ level: education level categorical; TBI: Traumatic brain injury

Table 5-4: Association in the CSHA of Dichotomic Multimorbidity with Frontal Function measured
with Digit Symbol Subtraction Test at Baseline - Male

Predictors

Estimates std. Error

CI

p

(Intercept)

2.89

0.83

1.24 – 4.53

0.001

mm dich [Yes]

0.14

0.13

-0.11 – 0.39

0.279

age

-0.03

0.01

-0.06 – -0.01

0.001

educ level [linear]

0.81

0.15

0.51 – 1.12

<0.001

educ level [quadratic]

-0.06

0.17

-0.39 – 0.27

0.719

educ level [cubic]

0.54

0.18

0.19 – 0.89

0.003

TBI [Yes]

0.09

0.15

-0.21 – 0.38

0.568

smoking [Yes]

-0.02

0.15

-0.32 – 0.29

0.919

alcohol [Yes]

-0.09

0.13

-0.35 – 0.16

0.484

Random Effects
σ2

0.68

τ00 region

0.14 (SD 0.37; CI95%: 0.16 to 0.75)

ICC

0.17

N region

5

Observations
2

179
2

Marginal R / Conditional R

0.245 / 0.372

AIC

497.010

AICc

498.591

mm dich: dichotomic multimorbidity; age in years; educ level: education level categorical; TBI: Traumatic brain injury
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Multimorbidity Count
When analysing multimorbidity as a continuous count of conditions (Table 5-5), we did not find
an association of multimorbidity on z standardized scores of DSST with a result of 0.007 (CI95%:
-0.045 to 0.059; p-value: 0.79). On the case of confounders, we found a significant association in
the same variables than in the dichotomic analysis with age decreasing 0.043 (CI95%: -0.055 to 0.032) for each age, male sex decreasing 0.23 (CI95%: -0.42 to -0.048) z standardized points and
in education level increasing 0.75 for each category increase (CI95%: 0.55 to 0.95). The ICC was
0.14 (CI 95%: 0.014 to 0.36). After the stratified analysis by sex, we did not realise differences in
the multimorbidity count association with DSST score. In the female analysis (Table 5-6) we found
an association of -0.023 (CI95%: -0.086 to 0.041; p-value: 0.49), and in the male one (
Table 5-7) an association of 0.049 (CI95%: -0.042 to 0.14; p-value: 0.29). In this baseline analysis,
the multilevel analysis explains 11% of the variance in both analyses.
The dichotomic model fits better for the baseline frontal function scores on the CSHA with a cAIC
of 1293.263 vs 1296.751 on the count model.

Table 5-5: Association in the CSHA of Multimorbidity Count with Frontal Function measured with
Digit Symbol Subtraction Test at Baseline

Predictors

Estimates std. Error

CI

p

(Intercept)

3.78

0.50

2.80 – 4.75

<0.001

multimorbidity

0.01

0.03

-0.05 – 0.06

0.793

age

-0.04

0.01

-0.06 – -0.03

<0.001

sex [Male]

-0.24

0.10

-0.42 – -0.05

0.014

educ level [linear]

0.75

0.10

0.55 – 0.95

<0.001

educ level [quadratic]

-0.16

0.10

-0.36 – 0.04

0.108

educ level [cubic]

0.29

0.10

0.09 – 0.48

0.004
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TBI [Yes]

0.06

0.11

-0.16 – 0.27

0.606

smoking [Yes]

0.08

0.09

-0.10 – 0.27

0.360

alcohol [Yes]

-0.07

0.09

-0.26 – 0.11

0.444

Random Effects
σ2

0.67

τ00 region

0.11 (SD: 0.33; CI95%: 0.16 to 0.67)

ICC

0.14

N region

5

Observations

474

Marginal R2 / Conditional R2

0.232 / 0.342

AIC

1296.074

AICc

1296.751

multimorbidity: multimorbidity count; age in years; educ level: education level categorical; TBI: Traumatic brain injury

Table 5-6: Association in the CSHA of Multimorbidity Count with Frontal Function measured with
Digit Symbol Subtraction Test at Baseline - Female

Predictors

Estimates std. Error

CI

p

(Intercept)

4.21

0.59

3.04 – 5.37

<0.001

multimorbidity

-0.02

0.03

-0.09 – 0.04

0.487

age

-0.05

0.01

-0.06 – -0.03

<0.001

educ level [linear]

0.63

0.14

0.34 – 0.91

<0.001

educ level [quadratic]

-0.36

0.13

-0.62 – -0.09

0.008

educ level [cubic]

0.07

0.12

-0.17 – 0.32

0.564

TBI [Yes]

0.02

0.16

-0.30 – 0.34

0.902

smoking [Yes]

0.17

0.12

-0.06 – 0.40

0.150

alcohol [Yes]

0.01

0.14

-0.26 – 0.28

0.939

Random Effects
σ2
τ00 region

0.65
0.07 (SD: 0.27; CI95%: 0.11 to 0.57)
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ICC

0.10

N region

5

Observations

295

Marginal R2 / Conditional R2

0.257 / 0.334

AIC

826.476

AICc

827.409

multimorbidity: multimorbidity count; age in years; educ level: education level categorical; TBI: Traumatic brain injury

Table 5-7: Association in the CSHA of Multimorbidity Count with Frontal Function measured with
Digit Symbol Subtraction Test at Baseline - Male

Predictors

Estimates std. Error

CI

p

(Intercept)

2.93

0.83

1.29 – 4.58

0.001

multimorbidity

0.05

0.05

-0.04 – 0.14

0.293

age

-0.04

0.01

-0.06 – -0.01

0.001

educ level [linear]

0.82

0.15

0.51 – 1.12

<0.001

educ level [quadratic]

-0.06

0.17

-0.39 – 0.27

0.726

educ level [cubic]

0.55

0.18

0.20 – 0.90

0.002

TBI [Yes]

0.08

0.15

-0.22 – 0.38

0.593

smoking [Yes]

-0.02

0.15

-0.33 – 0.28

0.888

alcohol [Yes]

-0.09

0.13

-0.35 – 0.17

0.490

Random Effects
σ2

0.68

τ00 region

0.14 (SD: 0.38; CI95%: 0.17 to 0.76)

ICC

0.17

N region

5

Observations
2

179
2

Marginal R / Conditional R

0.243 / 0.373

AIC

499.089

AICc

500.670

multimorbidity: multimorbidity count; age in years; educ level: education level categorical; TBI: Traumatic brain injury
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Change between baseline and first follow-up
Dichotomic Multimorbidity
The first follow-up occurred five years after study beginning. We have data in 424 participants for
the multimorbidity dichotomic and count analyses. In the dichotomic analysis (Table 5-8), we
found that multimorbidity was not associated with change in RCI z standardized DSST scores with
a numeric result of -0.11 (CI95%: -0.30 to 0.087; p-value: 0.28). In this case, only age was
associated with a RCI z standardized score changes measured during first follow-up with a -0.033
(CI95%: -0.048 to -0.018) for each year of increase in age. The ICC was 0.016 (CI 95%: 0.000 to
0.074). The stratified analysis shown that both female and male analysis did not demonstrate an
association of multimorbidity on the z standardized scores of DSST.
In the case of the female stratified analysis (Table 5-9), we had information in 258 participants
with a result that was a score -0.019 (CI95%: -0.27 to 0.23; 0.88) in multimorbidity. while in the
male one analysis (
Table 5-10), the result was of -0.20 (CI95%: -0.51 to 0.11; p-value: 0.20), with information in 166
participants.

Table 5-8: Association in the CSHA of Dichotomic Multimorbidity on Change of Frontal Function
measured with Digit Symbol Subtraction Test between Baseline and First Follow-up
Fixed Effects
Predictors

Estimates std. Error

CI

p

(Intercept)

1.95

0.59

0.78 – 3.11

0.001

mm dich [Yes]

-0.11

0.10

-0.30 – 0.09

0.283

age

-0.03

0.01

-0.05 – -0.02

<0.001

sex [Male]

-0.11

0.12

-0.33 – 0.12

0.361

educ level [linear]

0.08

0.13

-0.17 – 0.32

0.544

educ level [quadratic]

0.17

0.13

-0.08 – 0.41

0.185

educ level [cubic]

-0.11

0.12

-0.36 – 0.13

0.363
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TBI [Yes]

-0.07

0.13

-0.33 – 0.20

0.629

smoking [Yes]

0.09

0.11

-0.13 – 0.32

0.406

alcohol [Yes]

-0.15

0.12

-0.38 – 0.08

0.210

Random Effects
σ2

0.93

τ00 region

0.01 (SD: 0.12; CI95%: 0 to 0.31)

ICC

0.02

N region

5

Observations

424

Marginal R2 / Conditional R2

0.061 / 0.076

AIC

1279.266

AICc

1280.025

mm dich: dichotomic multimorbidity; age in years; educ level: education level categorical; TBI: Traumatic brain injury

Table 5-9: Association in the CSHA of Dichotomic Multimorbidity on Change of Frontal Function
measured with Digit Symbol Subtraction Test between Baseline and First Follow-up - Female

Predictors

Estimates std. Error

CI

p

(Intercept)

2.00

0.73

0.56 – 3.44

0.007

mm dich [Yes]

-0.02

0.13

-0.27 – 0.23

0.884

age

-0.03

0.01

-0.05 – -0.01

0.001

educ level [linear]

0.22

0.17

-0.12 – 0.55

0.202

educ level [quadratic]

0.12

0.16

-0.20 – 0.44

0.467

educ level [cubic]

0.09

0.15

-0.21 – 0.38

0.568

TBI [Yes]

-0.08

0.20

-0.48 – 0.32

0.689

smoking [Yes]

0.03

0.15

-0.25 – 0.32

0.814

alcohol [Yes]

-0.19

0.17

-0.54 – 0.15

0.268

Random Effects
σ2

0.89

τ00 region

<0.001 (SD: <0.001; CI95%: 0 to 0.23)

N region

5
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Observations

258

Marginal R2 / Conditional R2

0.056 / NA

AIC

789.223

AICc

790.296

mm dich: dichotomic multimorbidity; age in years; educ level: education level categorical; TBI: Traumatic brain injury

Table 5-10: Association in the CSHA of Dichotomic Multimorbidity on Change of Frontal Function
measured with Digit Symbol Subtraction Test between Baseline and First Follow-up - Male

Predictors

Estimates std. Error

CI

p

(Intercept)

1.52

0.99

-0.44 – 3.47

0.129

mm dich [Yes]

-0.20

0.16

-0.51 – 0.11

0.202

age

-0.03

0.01

-0.06 – -0.01

0.017

educ level [linear]

0.01

0.19

-0.36 – 0.39

0.948

educ level [quadratic]

0.47

0.21

0.06 – 0.88

0.026

educ level [cubic]

-0.53

0.23

-0.98 – -0.08

0.020

TBI [Yes]

-0.03

0.18

-0.39 – 0.33

0.884

smoking [Yes]

0.18

0.19

-0.19 – 0.55

0.347

alcohol [Yes]

-0.13

0.16

-0.44 – 0.19

0.421

Random Effects
σ2

0.98

τ00 region

0.002 (SD: 0.04; CI95%: 0 to 0.30)

ICC

0.00

N region

5

Observations
2

166
2

Marginal R / Conditional R

0.128 / 0.130

AIC

511.432

AICc

513.146

mm dich: dichotomic multimorbidity; age in years; educ level: education level categorical; TBI: Traumatic brain injury

Multimorbidity Count
83
December 13, 2022

We evaluated the association of multimorbidity count on RCI z standardized DSST scores (Table
5-11). We observed that multimorbidity count had no association with DSST score with a z
standardized score of -0.015(CI95: -0.79 to 0.050; p-value: 0.66). Also, in this analysis the only
confounder with an association on DSST scores was age with a decrease of -0.033 (CI95%: -0.048
to -0.018) z-standardized score for each increase in one year of age. The ICC in this case was of
0.017 (CI95%: 0.000 to 0.079). In the stratified analyses, we report that in both cases
multimorbidity count was not associated with DSST scores. In the female analysis (
Table 5-12), the z standardized score was of 0.036 (CI95%: -0.044 to 0.12; p-value: 0.38) and in
the male one (
Table 5-13) was of -0.074 (IC95%: -0.19 to 0.038; p-value: 0.20).
The dichotomic model fits better for the change between baseline and first follow-up on frontal
function scores on the CSHA with a cAIC of 1280.025 vs 1283.166 on the count model.

Table 5-11: Association in the CSHA of Multimorbidity Count on Change of Frontal Function
measured with Digit Symbol Subtraction Test between Baseline and First Follow-up

Predictors

Estimates std. Error

CI

p

(Intercept)

1.91

0.59

0.74 – 3.07

0.001

multimorbidity

-0.01

0.03

-0.08 – 0.05

0.660

age

-0.03

0.01

-0.05 – -0.02

<0.001

sex [Male]

-0.11

0.12

-0.34 – 0.13

0.369

educ level [linear]

0.08

0.13

-0.17 – 0.32

0.541

educ level [quadratic]

0.16

0.13

-0.08 – 0.41

0.195

educ level [cubic]

-0.13

0.12

-0.37 – 0.12

0.304

TBI [Yes]

-0.07

0.13

-0.34 – 0.20

0.603

smoking [Yes]

0.10

0.11

-0.12 – 0.32

0.383

alcohol [Yes]

-0.15

0.12

-0.38 – 0.08

0.205

Random Effects
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σ2

0.93

τ00 region

0.02 (SD: 0.13; CI95%: 0 to 0.31)

ICC

0.02

N region

5

Observations
2

424
2

Marginal R / Conditional R

0.059 / 0.075

AIC

1282.407

AICc

1283.166

multimorbidity: multimorbidity count; age in years; educ level: education level categorical; TBI: Traumatic brain injury

Table 5-12: Association in the CSHA of Multimorbidity Count on Change of Frontal Function
measured with Digit Symbol Subtraction Test between Baseline and First Follow-up - Female

Predictors

Estimates std. Error

CI

p

(Intercept)

1.93

0.72

0.50 – 3.35

0.008

multimorbidity

0.04

0.04

-0.04 – 0.12

0.379

age

-0.03

0.01

-0.05 – -0.01

<0.001

educ level [linear]

0.23

0.17

-0.10 – 0.56

0.179

educ level [quadratic]

0.11

0.16

-0.22 – 0.43

0.519

educ level [cubic]

0.09

0.15

-0.21 – 0.39

0.543

TBI [Yes]

-0.10

0.20

-0.49 – 0.30

0.637

smoking [Yes]

0.01

0.15

-0.27 – 0.30

0.919

alcohol [Yes]

-0.19

0.17

-0.54 – 0.15

0.268

Random Effects
σ2

0.88

τ00 region

<0.001 (SD: <0.001; CI95%: 0 to 0.24)

N region

5

Observations
2

258
2

Marginal R / Conditional R

0.059 / NA

AIC

790.755

AICc

791.828

multimorbidity: multimorbidity count; age in years; educ level: education level categorical; TBI: Traumatic brain injury
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Table 5-13: Association in the CSHA of Multimorbidity Count on Change of Frontal Function
measured with Digit Symbol Subtraction Test between Baseline and First Follow-up - Male

Predictors

Estimates std. Error

CI

p

(Intercept)

1.44

1.00

-0.52 – 3.41

0.149

multimorbidity

-0.07

0.06

-0.19 – 0.04

0.197

age

-0.03

0.01

-0.06 – -0.00

0.023

educ level [linear]

0.01

0.19

-0.37 – 0.39

0.962

educ level [quadratic]

0.47

0.21

0.06 – 0.88

0.026

educ level [cubic]

-0.54

0.22

-0.98 – -0.09

0.018

TBI [Yes]

-0.02

0.18

-0.38 – 0.34

0.910

smoking [Yes]

0.19

0.19

-0.18 – 0.56

0.323

alcohol [Yes]

-0.13

0.16

-0.44 – 0.18

0.412

Random Effects
σ2

0.98

τ00 region

0.005 (SD: 0.07; CI95%: 0 to 0.31)

ICC

0.01

N region

5

Observations
2

166
2

Marginal R / Conditional R

0.128 / 0.133

AIC

513.318

AICc

515.032

multimorbidity: multimorbidity count; age in years; educ level: education level categorical; TBI: Traumatic brain injury

5.1.2.1.2 CLSA (Measured with MAT)
Baseline
Dichotomic Multimorbidity
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For the evaluation of frontal function in the CLSA we selected the MAT. We have data in 21164
participants that fulfilled inclusion criteria. For the whole cohort with participants between 45 to
85 years at recruitment (
Table 5-14), we found that suffering multimorbidity was associated with lower baseline scores in
MAT with an average decrease of 0.0485 (CI95%: -0.076 to -0.021; p-value <0.001). In this case,
the confounding variables associated with MAT baseline scores were age with a decrease of
0.01999 (CI95%: -0.021 to -0.016), male sex with an increase of 0.135 (CI95%: 0.11 to 0.16). In
the respect to education level there is an increase of 0.258 (CI95%: 0.228 to 0.288; p-value
<0.0001) z standardized units for every increase on education level category. Finally, we found
that smoking history was associated a decrease of -0.0637 (CI95%: -0.09 to -0.037 p-value
<0.0001) z standardized scores of MAT while alcohol consumption was associated with an increase
of 0.185 (CI95%: 0.159 to 0.212; p-value <0.0001) on the outcome. The ICC was small with a
proportion of 0.007 (CI95%: 0.001 to 0.019).
When we performed the subgroup analyses, we found in an analysis of 10613 females (
Table 5-15) that presenting multimorbidity was not associated with decrease (-0.0258; CI95%: 0.063 to 0.012; p-value 0.18) in MAT scores. The male analysis included 10551 participants (
Table 5-16). We found that in males, having multimorbidity was associated with a decrease of
0.069 (CI95%: -0.111 to -0.0228; p-value 0.0011) z standardized units in MAT scores. In the
analysis by age group, we did not find and association in 8177 participants 65 years and older (
Table 5-17) with a multimorbidity score of -0.0262 (CI95%: -0.068 to 0.0156; p-value 0.22). In
the 12987 participants younger than 65 years (
Table 5-18), we observed an association of multimorbidity on MAT z standardized scores with a
decrease of 0.071 (CI95%: -0.107 to -0.034; p-value <0.001).

Table 5-14: Association in the CLSA of Dichotomic Multimorbidity with Frontal Function
measured with Mental Alternation Test at Baseline

Predictors

Estimates std. Error

CI

p
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(Intercept)

0.98

0.06

0.87 – 1.09

<0.001

mm dich [Yes]

-0.05

0.01

-0.08 – -0.02

0.001

age

-0.02

0.00

-0.02 – -0.02

<0.001

sex [Male]

0.13

0.01

0.11 – 0.16

<0.001

educ level [linear]

0.26

0.02

0.23 – 0.29

<0.001

educ level [quadratic]

-0.08

0.02

-0.11 – -0.05

<0.001

educ level [cubic]

0.04

0.02

0.00 – 0.08

0.032

TBI [Yes]

0.01

0.02

-0.02 – 0.04

0.364

smoking [Yes]

-0.06

0.01

-0.09 – -0.04

<0.001

alcohol [Yes]

0.19

0.01

0.16 – 0.21

<0.001

Random Effects
σ2

0.89

τ00 region

0.01 (SD: 0.08; CI95%: 0.04 to 0.15)

ICC

0.01

N region

5

Observations
2

21164
2

Marginal R / Conditional R

0.079 / 0.085

AIC

68650.248

AICc

68650.263

mm dich: dichotomic multimorbidity; age in years; educ level: education level categorical; TBI: Traumatic brain injury

Table 5-15: Association in the CLSA of Dichotomic Multimorbidity with Frontal Function
measured with Mental Alternation Test at Baseline - Female

Predictors

Estimates std. Error

CI

p

(Intercept)

1.04

0.06

0.91 – 1.16

<0.001

mm dich [Yes]

-0.03

0.02

-0.06 – 0.01

0.176

age

-0.02

0.00

-0.02 – -0.02

<0.001

educ level [linear]

0.25

0.02

0.21 – 0.30

<0.001

educ level [quadratic]

-0.13

0.02

-0.18 – -0.09

<0.001

educ level [cubic]

0.03

0.03

-0.02 – 0.09

0.195
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TBI [Yes]

-0.03

0.02

-0.07 – 0.01

0.184

smoking [Yes]

-0.04

0.02

-0.07 – -0.00

0.038

alcohol [Yes]

0.18

0.02

0.15 – 0.22

<0.001

Random Effects
σ2

0.83

τ00 region

0.003 (SD: 0.05; CI95%: 0.02 to 0.10)

ICC

0.00

N region

5

Observations

10613

Marginal R2 / Conditional R2

0.080 / 0.082

AIC

33320.329

AICc

33320.354

mm dich: dichotomic multimorbidity; age in years; educ level: education level categorical; TBI: Traumatic brain injury

Table 5-16: Association in the CLSA of Dichotomic Multimorbidity with Frontal Function
measured with Mental Alternation Test at Baseline - Male

Predictors

Estimates std. Error

CI

p

(Intercept)

1.04

0.08

0.88 – 1.19

<0.001

mm dich [Yes]

-0.07

0.02

-0.11 – -0.03

0.001

age

-0.02

0.00

-0.02 – -0.02

<0.001

educ level [linear]

0.26

0.02

0.22 – 0.31

<0.001

educ level [quadratic]

-0.02

0.03

-0.07 – 0.03

0.431

educ level [cubic]

0.04

0.03

-0.02 – 0.10

0.152

TBI [Yes]

0.05

0.02

0.01 – 0.09

0.017

smoking [Yes]

-0.09

0.02

-0.13 – -0.05

<0.001

alcohol [Yes]

0.19

0.02

0.15 – 0.23

<0.001

Random Effects
σ2

0.94

τ00 region

0.01 (SD: 0.10; CI95%: 0.05 to 0.20)

ICC

0.01

N region

5
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Observations

10551

Marginal R2 / Conditional R2

0.068 / 0.078

AIC

35320.636

AICc

35320.661

mm dich: dichotomic multimorbidity; age in years; educ level: education level categorical; TBI: Traumatic brain injury

Table 5-17: Association inn the CLSA of Dichotomic Multimorbidity with Frontal Function
measured with Mental Alternation Test at Baseline - Participants 65 years and older

Predictors

Estimates std. Error

CI

p

(Intercept)

1.58

0.14

1.30 – 1.86

<0.001

mm dich [Yes]

-0.03

0.02

-0.07 – 0.02

0.220

age

-0.03

0.00

-0.03 – -0.03

<0.001

sex [Male]

0.16

0.02

0.12 – 0.20

<0.001

educ level [linear]

0.28

0.02

0.24 – 0.32

<0.001

educ level [quadratic]

-0.12

0.02

-0.17 – -0.07

<0.001

educ level [cubic]

0.06

0.03

0.00 – 0.12

0.039

TBI [Yes]

0.00

0.03

-0.05 – 0.05

0.937

smoking [Yes]

-0.02

0.02

-0.06 – 0.02

0.420

alcohol [Yes]

0.20

0.02

0.16 – 0.24

<0.001

Random Effects
σ2

0.56

τ00 region

0.003 (CI95%: 0.02 to 0.11)

ICC

0.00

N region

5

Observations

8177

Marginal R2 / Conditional R2

0.107 / 0.111

AIC

25768.368

AICc

25768.406

mm dich: dichotomic multimorbidity; age in years; educ level: education level categorical; TBI: Traumatic brain injury
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Table 5-18: Association in the CLSA of Dichotomic Multimorbidity with Frontal Function
measured with Mental Alternation Test at Baseline - Participants Younger than 65 years

Predictors

Estimates std. Error

CI

p

(Intercept)

0.57

0.09

0.39 – 0.76

<0.001

mm dich [Yes]

-0.07

0.02

-0.11 – -0.03

<0.001

age

-0.01

0.00

-0.01 – -0.01

<0.001

sex [Male]

0.12

0.02

0.08 – 0.15

<0.001

educ level [linear]

0.22

0.02

0.18 – 0.27

<0.001

educ level [quadratic]

-0.04

0.02

-0.09 – 0.01

0.099

educ level [cubic]

0.03

0.03

-0.03 – 0.08

0.320

TBI [Yes]

0.02

0.02

-0.02 – 0.06

0.270

smoking [Yes]

-0.09

0.02

-0.13 – -0.06

<0.001

alcohol [Yes]

0.18

0.02

0.14 – 0.21

<0.001

Random Effects
σ2

1.09

τ00 region

0.01 (SD: 0.08; CI95%: 0.06 to 0.17)

ICC

0.01

N region

5

Observations
2

12987
2

Marginal R / Conditional R

0.025 / 0.031

AIC

41843.140

AICc

41843.164

mm dich: dichotomic multimorbidity; age in years; educ level: education level categorical; TBI: Traumatic brain injury

Multimorbidity count
In the analyses using multimorbidity as a count at baseline (Table 5-19), we found that every
increase in one chronic condition was associated with a decrease of 0.0233 (CI95%: -0.0335 to 0.013; p-value <0.001) z standardized scores in MAT. Like in the dichotomic analysis, we found
that an increase of one year of age is associated with a decrease of 0.0196 (CI95%: -0.021 to 91
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0.018), male sex increased 0.134 (CI95%: 0.108 to 0.16), history of smoking decreased 0.062
(CI95%: -0.089 to -0.035) and alcohol consumption increased 0.183 (CI95%: 0.156 to 0.209) MAT
scores. In the same line, we found a and increase of 0.256 (CI95%: 0.226 to 0.286) for an increase
of one education level category. The ICC was 0.007 (CI95%: 0.001 to 0.021) similar to the
dichotomic analysis.
We performed subgroup analysis with the same number of participants than in the dichotomic
analysis. We did not observe an association of multimorbidity count on females (Table 5-20) with
a score of -0.0065 (CI95%: -0.020 to 0.0071; p-value 0.35). In the male analysis (Table 5-21), we
found an association of multimorbidity count with a decrease of 0.040 (CI95%: -0.055 to -0.024;
p-value < 0.0001) in scores. In the analysis of participants 65 years and older (Table 5-22), we
found an association of multimorbidity count on MAT scores with a decrease of 0.017 (CI95%: 0.031 to -0.003; p-value 0.0193). Finally, in patients younger than 65 years (Table 5-23), we
observed in multimorbidity count a decrease of 0.0368 (CI95%: -0.0506 to -0.0229; p-value
<0.0001) in MAT scores.
The counting model fits better for the baseline scores on frontal function on the CLSA with a cAIC
of 68644.059 vs 68650.263 on the dichotomic model.

Table 5-19: Association in the CLSA of Multimorbidity Count with Frontal Function measured
with Mental Alternation Test at Baseline

Predictors

Estimates std. Error

CI

p

(Intercept)

0.97

0.06

0.86 – 1.08

<0.001

multimorbidity

-0.02

0.01

-0.03 – -0.01

<0.001

age

-0.02

0.00

-0.02 – -0.02

<0.001

sex [Male]

0.13

0.01

0.11 – 0.16

<0.001

educ level [linear]

0.26

0.02

0.23 – 0.29

<0.001

educ level [quadratic]

-0.08

0.02

-0.11 – -0.05

<0.001

educ level [cubic]

0.04

0.02

0.00 – 0.08

0.040
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TBI [Yes]

0.02

0.02

-0.01 – 0.05

0.271

smoking [Yes]

-0.06

0.01

-0.09 – -0.04

<0.001

alcohol [Yes]

0.18

0.01

0.16 – 0.21

<0.001

Random Effects
σ2

0.89

τ00 region

0.01 (SD 0.08; CI95%: 0.04 to 0.15)

ICC

0.01

N region

5

Observations

21164

Marginal R2 / Conditional R2

0.079 / 0.085

AIC

68644.044

AICc

68644.059

multimorbidity: multimorbidity count; age in years; educ level: education level categorical; TBI: Traumatic brain injury

Table 5-20: Association in the CLSA of Multimorbidity Count with Frontal Function measured
with Mental Alternation Test at Baseline - Female

Predictors

Estimates std. Error

CI

p

(Intercept)

1.04

0.06

0.91 – 1.17

<0.001

multimorbidity

-0.01

0.01

-0.02 – 0.01

0.352

age

-0.02

0.00

-0.02 – -0.02

<0.001

educ level [linear]

0.25

0.02

0.21 – 0.30

<0.001

educ level [quadratic]

-0.13

0.02

-0.18 – -0.09

<0.001

educ level [cubic]

0.03

0.03

-0.02 – 0.09

0.192

TBI [Yes]

-0.03

0.02

-0.07 – 0.01

0.185

smoking [Yes]

-0.04

0.02

-0.07 – -0.00

0.036

alcohol [Yes]

0.19

0.02

0.15 – 0.22

<0.001

Random Effects
σ2

0.83

τ00 region

0.003 (SD: 0.05; CI95%: 0.02 to 0.10)

ICC

0.00
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N region

5

Observations
2

10613
2

Marginal R / Conditional R

0.080 / 0.082

AIC

33323.315

AICc

33323.340

multimorbidity: multimorbidity count; age in years; educ level: education level categorical; TBI: Traumatic brain injury

Table 5-21: Association in the CLSA of Multimorbidity Count with Frontal Function measured
with Mental Alternation Test at Baseline - Male

Predictors

Estimates std. Error

CI

p

(Intercept)

1.02

0.08

0.86 – 1.17

<0.001

multimorbidity

-0.04

0.01

-0.06 – -0.02

<0.001

age

-0.02

0.00

-0.02 – -0.02

<0.001

educ level [linear]

0.26

0.02

0.21 – 0.30

<0.001

educ level [quadratic]

-0.02

0.03

-0.07 – 0.03

0.504

educ level [cubic]

0.04

0.03

-0.02 – 0.10

0.197

TBI [Yes]

0.06

0.02

0.01 – 0.10

0.009

smoking [Yes]

-0.09

0.02

-0.13 – -0.05

<0.001

alcohol [Yes]

0.18

0.02

0.14 – 0.22

<0.001

Random Effects
σ2

0.94

τ00 region

0.01 (SD 0.10; CI95%: 0.05 to 0.19)

ICC

0.01

N region

5

Observations
2

10551
2

Marginal R / Conditional R

0.070 / 0.079

AIC

35307.713

AICc

35307.738

multimorbidity: multimorbidity count; age in years; educ level: education level categorical; TBI: Traumatic brain injury
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Table 5-22: Association in the CLSA of Multimorbidity Count with Frontal Function measured
with Mental Alternation Test at Baseline - Participants 65 years and older

Predictors

Estimates std. Error

CI

p

(Intercept)

1.68

0.14

1.40 – 1.96

<0.001

multimorbidity

-0.02

0.01

-0.03 – -0.00

0.019

age

-0.03

0.00

-0.03 – -0.03

<0.001

educ level [linear]

0.28

0.02

0.25 – 0.32

<0.001

educ level [quadratic]

-0.12

0.02

-0.17 – -0.07

<0.001

educ level [cubic]

0.06

0.03

0.00 – 0.12

0.048

TBI [Yes]

0.03

0.03

-0.03 – 0.08

0.337

smoking [Yes]

0.01

0.02

-0.04 – 0.05

0.800

alcohol [Yes]

0.22

0.02

0.18 – 0.26

<0.001

Random Effects
σ2

0.56

τ00 region

0.003 (SD: 0.05; CI95%: 0.02 to 0.11)

ICC

0.00

N region

5

Observations
2

8177
2

Marginal R / Conditional R

0.100 / 0.104

AIC

25815.956

AICc

25815.988

multimorbidity: multimorbidity count; age in years; educ level: education level categorical; TBI: Traumatic brain injury

Table 5-23: Association in the CLSA of Multimorbidity Count with Frontal Function measured
with Mental Alternation Test at Baseline - Participants Younger than 65 years

Predictors

Estimates std. Error

CI

p

(Intercept)

0.60

0.09

0.41 – 0.78

<0.001

multimorbidity

-0.04

0.01

-0.05 – -0.02

<0.001

age

-0.01

0.00

-0.01 – -0.01

<0.001
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educ level [linear]

0.21

0.02

0.17 – 0.25

<0.001

educ level [quadratic]

-0.03

0.02

-0.08 – 0.02

0.215

educ level [cubic]

0.02

0.03

-0.03 – 0.07

0.455

TBI [Yes]

0.04

0.02

0.01 – 0.08

0.025

smoking [Yes]

-0.09

0.02

-0.13 – -0.06

<0.001

alcohol [Yes]

0.19

0.02

0.15 – 0.22

<0.001

Random Effects
σ2

1.09

τ00 region

0.01 (SD: 0.08; CI95%: 0.04 to 0.17)

ICC

0.01

N region

5

Observations

12987

Marginal R2 / Conditional R2

0.022 / 0.029

AIC

41874.796

AICc

41874.816

multimorbidity: multimorbidity count; age in years; educ level: education level categorical; TBI: Traumatic brain injury

Change between baseline and first follow-up
Dichotomic Multimorbidity
We analyzed the RCI z standardized change between baseline and fist follow-up that occurred at
year three after recruitment. We had information on 21164 participants for the analysis. We
observed (
Table 5-24) that presenting multimorbidity did not have and association with MAT change with a
score of -0.019 (CI95%: -0.040 to 0.016; p-value 0.40). The confounders with a significant
association on the outcome were age with a decrease of 0.0044 (CI95%: -0.0058 to -0.003) for each
year of age, and alcohol consumption with a decrease of 0.029 (CI95%: -0.056 to -0.0023) on MAT
change scores. The ICC was of just 0.003 (CI95%: 0.0002 to 0.012).
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The subgroup analyses did not show association of presenting multimorbidity with a change in the
RCI z standardized MAT scores. In the female analysis (Table 5-25) with 10613 participants the
score was -0.0075 (CI95%: -0.0461 to 0.0311; p-value 0.70). The male analysis (Table 5-26)
presented data in 10551 participants and the multimorbidity score was of -0.0198 (CI95%: -0.060
to 0.021; p-value 0.34). In the 8177 participants 65 years and older (Table 5-27), the score of having
multimorbidity was -0.0081 (CI95%: -0.050 to 0.034; p-value 0.71), and finally in the 12987
patients with information and younger that 65 years (Table 5-28), multimorbidity score was -0.013
(CI95%: -0.05 to 0.024; p-value 0.49).

Table 5-24: Association in the CLSA of Dichotomic Multimorbidity on Change of Frontal Function
measured with Mental Alternation Test between Baseline and First Follow-up

Predictors

Estimates std. Error

CI

p

(Intercept)

0.20

0.05

0.10 – 0.30

<0.001

mm dich [Yes]

-0.01

0.01

-0.04 – 0.02

0.404

age

-0.00

0.00

-0.01 – -0.00

<0.001

sex [Male]

-0.01

0.01

-0.04 – 0.02

0.444

educ level [linear]

0.03

0.02

-0.00 – 0.06

0.050

educ level [quadratic]

-0.05

0.02

-0.09 – -0.02

0.002

educ level [cubic]

-0.01

0.02

-0.05 – 0.03

0.644

TBI [Yes]

-0.00

0.02

-0.03 – 0.03

0.968

smoking [Yes]

0.02

0.01

-0.01 – 0.05

0.119

alcohol [Yes]

-0.03

0.01

-0.06 – -0.00

0.033

Random Effects
σ2

0.89

τ00 region

0.003 (SD: 0.05; CI95%: 0.04 to 0.17)

ICC

0.00

N region

5

Observations
2

21164
2

Marginal R / Conditional R

0.003 / 0.006

AIC

68781.678

AICc

68781.693
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mm dich: dichotomic multimorbidity; age in years; educ level: education level categorical; TBI: Traumatic brain injury

Table 5-25: Association in the CLSA of Dichotomic Multimorbidity on Change of Frontal Function
measured with Mental Alternation Test between Baseline and First Follow-up - Female

Predictors

Estimates std. Error

CI

p

(Intercept)

0.22

0.07

0.08 – 0.35

0.002

mm dich [Yes]

-0.01

0.02

-0.05 – 0.03

0.703

age

-0.00

0.00

-0.01 – -0.00

<0.001

educ level [linear]

0.05

0.02

0.01 – 0.09

0.025

educ level [quadratic]

-0.06

0.02

-0.11 – -0.01

0.019

educ level [cubic]

-0.00

0.03

-0.06 – 0.05

0.921

TBI [Yes]

-0.00

0.02

-0.05 – 0.04

0.887

smoking [Yes]

0.04

0.02

-0.00 – 0.07

0.057

alcohol [Yes]

-0.06

0.02

-0.10 – -0.03

0.001

Random Effects
σ2

0.88

τ00 region

0.004 (SD: 0.06; CI95%: 0.03 to 0.13)

ICC

0.00

N region

5

Observations

10613

Marginal R2 / Conditional R2

0.004 / 0.009

AIC

34020.128

AICc

34020.152

mm dich: dichotomic multimorbidity; age in years; educ level: education level categorical; TBI: Traumatic brain injury

Table 5-26: Association in the CLSA of Dichotomic Multimorbidity on Change of Frontal Function
measured with Mental Alternation Test between Baseline and First Follow-up - Male

Predictors

Estimates std. Error

CI

p
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(Intercept)

0.15

0.07

0.02 – 0.29

0.028

mm dich [Yes]

-0.02

0.02

-0.06 – 0.02

0.338

age

-0.00

0.00

-0.01 – -0.00

<0.001

educ level [linear]

0.01

0.02

-0.03 – 0.05

0.689

educ level [quadratic]

-0.05

0.03

-0.10 – 0.00

0.072

educ level [cubic]

-0.02

0.03

-0.07 – 0.04

0.595

TBI [Yes]

0.00

0.02

-0.04 – 0.04

0.907

smoking [Yes]

0.00

0.02

-0.04 – 0.04

0.936

alcohol [Yes]

0.01

0.02

-0.03 – 0.05

0.709

Random Effects
σ2

0.90

τ00 region

0.004 (SD: 0.06; CI95%: 0.03 to 0.12)

ICC

0.00

N region

5

Observations

10551

Marginal R2 / Conditional R2

0.002 / 0.006

AIC

34814.319

AICc

34814.344

mm dich: dichotomic multimorbidity; age in years; educ level: education level categorical; TBI: Traumatic brain injury

Table 5-27: Association in the CLSA of Dichotomic Multimorbidity on Change of Frontal Function
measured with Mental Alternation Test between Baseline and First Follow-up - Participants 65
years and older

Predictors

Estimates std. Error

CI

p

(Intercept)

0.16

0.15

-0.13 – 0.44

0.280

mm dich [Yes]

-0.01

0.02

-0.05 – 0.03

0.707

age

-0.00

0.00

-0.01 – -0.00

0.028

sex [Male]

-0.03

0.02

-0.07 – 0.01

0.124

educ level [linear]

0.01

0.02

-0.03 – 0.04

0.800
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educ level [quadratic]

0.04

0.03

-0.01 – 0.09

0.147

educ level [cubic]

-0.02

0.03

-0.08 – 0.04

0.506

TBI [Yes]

-0.01

0.03

-0.06 – 0.04

0.629

smoking [Yes]

0.01

0.02

-0.03 – 0.05

0.622

alcohol [Yes]

0.01

0.02

-0.03 – 0.05

0.595

Random Effects
σ2

0.57

τ00 region

0.004 (SD: 0.06; CI95%: .03 to 0.13)

ICC

0.01

N region

5

Observations
2

8177
2

Marginal R / Conditional R

0.002 / 0.009

AIC

26001.601

AICc

26001.639

mm dich: dichotomic multimorbidity; age in years; educ level: education level categorical; TBI: Traumatic brain injury

Table 5-28: Association in the CLSA of Dichotomic Multimorbidity on Change of Frontal Function
measured with Mental Alternation Test between Baseline and First Follow-up - Participants
Younger than 65 years

Predictors

Estimates std. Error

CI

p

(Intercept)

0.14

0.09

-0.03 – 0.31

0.113

mm dich [Yes]

-0.01

0.02

-0.05 – 0.02

0.487

age

-0.00

0.00

-0.01 – -0.00

0.042

sex [Male]

-0.00

0.02

-0.03 – 0.03

0.965

educ level [linear]

0.05

0.02

0.01 – 0.10

0.017

educ level [quadratic]

-0.10

0.02

-0.15 – -0.05

<0.001

educ level [cubic]

0.00

0.03

-0.05 – 0.05

0.949

TBI [Yes]

0.00

0.02

-0.04 – 0.04

0.929

smoking [Yes]

0.03

0.02

-0.01 – 0.06

0.128
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alcohol [Yes]

-0.04

Random Effects
σ2

0.02

-0.08 – -0.01

0.014

1.09

τ00 region

0.003 (SD: 0.05; CI95%: 0.02 to 0.11)

ICC

0.00

N region

5

Observations
2

12987
2

Marginal R / Conditional R

0.001 / 0.004

AIC

41875.545

AICc

41875.569

mm dich: dichotomic multimorbidity; age in years; educ level: education level categorical; TBI: Traumatic brain injury

Multimorbidity Count
For the multimorbidity count analysis we had information in the same number of participants than
in the dichotomic analysis. We did not observe an association of the multimorbidity count on the
RCI z standardized MAT change scores (Table 5-29). The score change with multimorbidity count
was -0.0036 (CI95%: -1.39 to 0.007; p-value 0.48). Like the dichotomic analysis the only
significant confounders were age with -0.0044 (CI95%: -0.0058 to -0.0030) for each year of
increase, and alcohol consumption with -0.029 (CI95%: -0.056 to -0.0023). The ICC was also 0.003
(CI95%: 0.0003 to 0.011).
Also, in the subgroup analysis we did not observed associations of multimorbidity count on RCI z
standardized MAT change scores. In the female analysis (Table 5-30), we found a score of -0.0014
(CI95%: -0.015 to 0.013; p-value 0.85) and in the male one (Table 5-31) a score of -0.0082 (CI95%:
-0.023 to 0.0068; p-value 0.28). In the age group analysis, we found in participants 65 years and
older (Table 5-32) a score of 0.0005 (CI95%: -0.014 to 0.015; p-value 0.94) and in patients younger
than 65 (Table 5-33) a score of -0.0054 (CI95%: -0.019 to 0.0086; p-value 0.45).
The dichotomic model fits better for the change between baseline and first follow-up on frontal
function scores on the CLSA with a cAIC of 68781.693 vs 68783.059 on the count model.
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Table 5-29: Association in the CLSA of Multimorbidity Count on Change of Frontal Function
measured with Mental Alternation Test between Baseline and First Follow-up

Predictors

Estimates std. Error

(Intercept)

CI

p

0.20

0.05

0.10 – 0.30

<0.001

multimorbidity

<-0.00

0.01

-0.01 – 0.01

0.487

age

<-0.00

<0.001

-0.01 – -0.00

<0.001

sex [Male]

-0.01

0.01

-0.04 – 0.02

0.447

educ level [linear]

0.03

0.02

-0.00 – 0.06

0.050

educ level [quadratic]

-0.05

0.02

-0.09 – -0.02

0.002

educ level [cubic]

-0.01

0.02

-0.05 – 0.03

0.639

TBI [Yes]

-0.00

0.02

-0.03 – 0.03

0.973

smoking [Yes]

0.02

0.01

-0.01 – 0.05

0.121

alcohol [Yes]

-0.03

0.01

-0.06 – -0.00

0.034

Random Effects
σ2

0.89

τ00 region

0.003 (SD: 0.05; CI95%: 0.03 to 0.11)

ICC

0.00

N region

5

Observations
2

21164
2

Marginal R / Conditional R

0.003 / 0.006

AIC

68783.895

AICc

68783.910

multimorbidity: multimorbidity count; age in years; educ level: education level categorical; TBI: Traumatic brain injury

Table 5-30: Association in the CLSA of Multimorbidity Count on Change of Frontal Function
measured with Mental Alternation Test between Baseline and First Follow-up - Female

Predictors

Estimates std. Error

CI

p

(Intercept)

0.22

0.07

0.08 – 0.35

0.001

multimorbidity

-0.00

0.01

-0.02 – 0.01

0.850
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age

-0.00

0.00

-0.01 – -0.00

<0.001

educ level [linear]

0.05

0.02

0.01 – 0.09

0.024

educ level [quadratic]

-0.06

0.02

-0.11 – -0.01

0.019

educ level [cubic]

-0.00

0.03

-0.06 – 0.05

0.925

TBI [Yes]

-0.00

0.02

-0.05 – 0.04

0.880

smoking [Yes]

0.04

0.02

-0.00 – 0.07

0.059

alcohol [Yes]

-0.06

0.02

-0.10 – -0.03

0.001

Random Effects
σ2

0.88

τ00 region

0.004 (SD: 0.06; CI95%: .03 to 0.13)

ICC

0.00

N region

5

Observations
2

10613
2

Marginal R / Conditional R

0.004 / 0.009

AIC

34022.258

AICc

34022.283

multimorbidity: multimorbidity count; age in years; educ level: education level categorical; TBI: Traumatic brain injury

Table 5-31: Association in the CLSA of Multimorbidity Count on Change of Frontal Function
measured with Mental Alternation Test between Baseline and First Follow-up - Male

Predictors

Estimates std. Error

CI

p

(Intercept)

0.15

0.07

0.01 – 0.29

0.030

multimorbidity

-0.01

0.01

-0.02 – 0.01

0.284

age

-0.001

0.00

-0.01 – -0.00

0.001

educ level [linear]

0.01

0.02

-0.03 – 0.05

0.708

educ level [quadratic]

-0.05

0.03

-0.10 – 0.00

0.075

educ level [cubic]

-0.02

0.03

-0.07 – 0.04

0.577

TBI [Yes]

<0.001

0.02

-0.04 – 0.04

0.888

smoking [Yes]

<0.001

0.02

-0.04 – 0.04

0.918
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alcohol [Yes]

0.01

Random Effects
σ2

0.02

-0.03 – 0.05

0.731

0.90

τ00 region

0.004 (SD: 0.06; CI95%: 0.03 to 0.12)

ICC

0.00

N region

5

Observations
2

10551
2

Marginal R / Conditional R

0.002 / 0.006

AIC

34816.072

AICc

34816.097

multimorbidity: multimorbidity count; age in years; educ level: education level categorical; TBI: Traumatic brain injury

Table 5-32: Association in the CLSA of Multimorbidity Count on Change of Frontal Function
measured with Mental Alternation Test between Baseline and First Follow-up - Participants 65
years and older

Predictors

Estimates std. Error

CI

p

(Intercept)

0.16

0.15

-0.13 – 0.44

0.281

multimorbidity

0.00

0.01

-0.01 – 0.01

0.943

age

-0.00

0.00

-0.01 – -0.00

0.025

sex [Male]

-0.03

0.02

-0.07 – 0.01

0.128

educ level [linear]

0.01

0.02

-0.03 – 0.04

0.797

educ level [quadratic]

0.04

0.03

-0.01 – 0.09

0.148

educ level [cubic]

-0.02

0.03

-0.08 – 0.04

0.510

TBI [Yes]

-0.01

0.03

-0.07 – 0.04

0.605

smoking [Yes]

0.01

0.02

-0.03 – 0.05

0.644

alcohol [Yes]

0.01

0.02

-0.03 – 0.06

0.567

Random Effects
σ2

0.57

τ00 region

0.004 (SD: 0.06; CI95%: 0.03 to 0.13)

ICC

0.01
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N region

5

Observations

8177

2

2

Marginal R / Conditional R

0.002 / 0.009

AIC

26003.896

AICc

26003.934

multimorbidity: multimorbidity count; age in years; educ level: education level categorical; TBI: Traumatic brain injury

Table 5-33: Association in the CLSA of Multimorbidity Count on Change of Frontal Function
measured with Mental Alternation Test between Baseline and First Follow-up - Participants
Younger than 65 years

Predictors

Estimates std. Error

CI

p

(Intercept)

0.14

0.09

-0.04 – 0.31

0.117

multimorbidity

-0.01

0.01

-0.02 – 0.01

0.451

age

-0.00

0.00

-0.01 – -0.00

0.049

sex [Male]

-0.00

0.02

-0.03 – 0.03

0.956

educ level [linear]

0.05

0.02

0.01 – 0.10

0.018

educ level [quadratic]

-0.10

0.02

-0.15 – -0.05

<0.001

educ level [cubic]

0.00

0.03

-0.05 – 0.05

0.957

TBI [Yes]

0.00

0.02

-0.04 – 0.04

0.912

smoking [Yes]

0.03

0.02

-0.01 – 0.06

0.127

alcohol [Yes]

-0.04

0.02

-0.08 – -0.01

0.014

Random Effects
σ2

1.09

τ00 region

0.003 (SD: 0.05; CI95%: 0.03 to 0.11)

ICC

0.00

N region

5

Observations
2

12987
2

Marginal R / Conditional R

0.001 / 0.004

AIC

41877.396

AICc

41877.420
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multimorbidity: multimorbidity count; age in years; educ level: education level categorical; TBI: Traumatic brain injury

5.1.2.2 Animal Naming Test
Both studies used the Animal Naming Test (ANT). In both studies the test consisted in naming the
higher number of animals in one minute.
5.1.2.2.1 CSHA
Baseline
Dichotomic Multimorbidity
We had information in 486 participants on the CSHA at baseline for the Animal Naming Test
(ANT). We did not observe an association of dichotomic multimorbidity in with ANT (Table 5-34),
with a score of -0.013 (CI95%: -0.187 to 0.16; p-value 0.88). The only confounders significant
associated with the ANT scores were age with a decrease of 0.013 (CI95%: -0.026 to -0.00019; pvalue 0.047) per year of increase, and education level with an increase of 0.53 (CI95%: 0.32 to
0.75) in ANT for each increase in one category of education. In this analysis the ICC was 0.087
(CI95%: 0.002 to 0.24).
The subgroup analyses did not show an association of having multimorbidity on ANT scores at
baseline. The female analysis (Table 5-35) had information on 307 participants and the score was
-0.080 (CI95%: -0.30 to 0.14; p-value 0.47), and the male analysis (Table 5-36) presented
information on 179 participants and a score of 0.056 (CI95%: -0.226 to 0.338; p-value 0.70)

Table 5-34: Association in the CSHA of Dichotomic Multimorbidity with Animal Naming Test at
Baseline

Predictors

Estimates std. Error

CI

p

(Intercept)

1.32

0.54

0.25 – 2.38

0.016

mm dich [Yes]

-0.01

0.09

-0.19 – 0.16

0.880
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age

-0.01

0.01

-0.03 – -0.00

0.047

sex [Male]

0.09

0.10

-0.11 – 0.30

0.368

educ level [linear]

0.53

0.11

0.31 – 0.75

<0.001

educ level [quadratic]

-0.05

0.11

-0.26 – 0.17

0.679

educ level [cubic]

0.12

0.11

-0.09 – 0.33

0.273

TBI [Yes]

-0.02

0.12

-0.26 – 0.22

0.870

smoking [Yes]

0.02

0.10

-0.18 – 0.21

0.882

alcohol [Yes]

-0.13

0.10

-0.34 – 0.07

0.207

Random Effects
σ2

0.83

τ00 region

0.08 (SD: 0.28; CI95%: 0.13 to 0.57)

ICC

0.09

N region

5

Observations
2

486
2

Marginal R / Conditional R

0.075 / 0.156

AIC

1426.576

AICc

1427.235

mm dich: dichotomic multimorbidity; age in years; educ level: education level categorical; TBI: Traumatic brain injury

Table 5-35: Association in the CSHA of Dichotomic Multimorbidity with Animal Naming Test at
Baseline - Female

Predictors

Estimates std. Error

CI

p

(Intercept)

2.34

0.66

1.04 – 3.63

<0.001

mm dich [Yes]

-0.08

0.11

-0.30 – 0.14

0.474

age

-0.03

0.01

-0.04 – -0.01

0.001

educ level [linear]

0.45

0.15

0.15 – 0.75

0.004

educ level [quadratic]

-0.11

0.14

-0.39 – 0.17

0.428

educ level [cubic]

0.07

0.13

-0.19 – 0.33

0.574

TBI [Yes]

-0.09

0.18

-0.44 – 0.26

0.610
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smoking [Yes]

-0.11

0.13

-0.35 – 0.14

0.400

alcohol [Yes]

0.10

0.15

-0.19 – 0.39

0.501

Random Effects
σ2

0.78

τ00 region

0.10 (SD: 0.32; CI95%: 0.13 to 0.66)

ICC

0.12

N region

5

Observations

307

Marginal R2 / Conditional R2

0.083 / 0.190

AIC

913.906

AICc

914.801

mm dich: dichotomic multimorbidity; age in years; educ level: education level categorical; TBI: Traumatic brain injury

Table 5-36: Association in the CSHA of Dichotomic Multimorbidity with Animal Naming Test at
Baseline - Male

Predictors

Estimates std. Error

CI

p

(Intercept)

-0.57

0.94

-2.41 – 1.28

0.546

mm dich [Yes]

0.06

0.14

-0.23 – 0.34

0.696

age

0.01

0.01

-0.01 – 0.03

0.369

educ level [linear]

0.62

0.18

0.27 – 0.96

0.001

educ level [quadratic]

0.06

0.19

-0.32 – 0.44

0.759

educ level [cubic]

0.14

0.21

-0.26 – 0.55

0.484

TBI [Yes]

0.07

0.17

-0.26 – 0.41

0.667

smoking [Yes]

0.23

0.18

-0.12 – 0.57

0.203

alcohol [Yes]

-0.27

0.15

-0.56 – 0.02

0.069

Random Effects
σ2

0.88

τ00 region

0.07 (SD: 0.27; CI95%: 0.05 to 0.58)

ICC

0.07

N region

5
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Observations

179

Marginal R2 / Conditional R2

0.110 / 0.176

AIC

537.872

AICc

539.453

mm dich: dichotomic multimorbidity; age in years; educ level: education level categorical; TBI: Traumatic brain injury

Multimorbidity Count
For these analyses we have the same number of participants that for the dichotomic analysis.
Likewise, the dichotomic analysis, multimorbidity count score of -0.034 (CI95%: -0-092 to 0.023;
p-value 0.24) did not show an association on ANT baseline scores (Table 5-37). The only
confounder significant associated with a change in ANT score was education level that indicated
an increase of 0.52 (CI95%: 0.30 to 0.74) per an increase of one category. The ICC was 0.092
(CI95%: 0.003 to 0.25).
The subgroup analyses neither showed an association between multimorbidity count and ANT z
standardized scores. In the female analysis (Table 5-38), multimorbidity count score was -0.054
(CI95%: -0.12 to 0.016; p-value 0.13), while in the male analysis (Table 5-39), it was of -0.0046
(CI95%: -0.107 to 0.0983; p-value 0.93).
The dichotomic model fits better for the baseline scores on ANT on the CSHA with a cAIC of
1427.235 vs 1428.070 on the counting model.

Table 5-37: Association in the CSHA of Multimorbidity Count with Animal Naming Test at
Baseline

Predictors

Estimates std. Error

CI

p

(Intercept)

1.35

0.54

0.29 – 2.41

0.013

multimorbidity

-0.03

0.03

-0.09 – 0.02

0.237

age

-0.01

0.01

-0.03 – 0.00

0.055
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sex [Male]

0.07

0.11

-0.14 – 0.28

0.503

educ level [linear]

0.52

0.11

0.30 – 0.74

<0.001

educ level [quadratic]

-0.04

0.11

-0.25 – 0.18

0.748

educ level [cubic]

0.12

0.11

-0.09 – 0.33

0.258

TBI [Yes]

-0.01

0.12

-0.25 – 0.23

0.918

smoking [Yes]

0.03

0.10

-0.17 – 0.23

0.789

alcohol [Yes]

-0.13

0.10

-0.34 – 0.07

0.201

Random Effects
σ2

0.82

τ00 region

0.08 (SD: 0.29; CI95%: 0.13 to 0.58)

ICC

0.09

N region

5

Observations
2

486
2

Marginal R / Conditional R

0.076 / 0.160

AIC

1427.411

AICc

1428.070

multimorbidity: multimorbidity count; age in years; educ level: education level categorical; TBI: Traumatic brain injury

Table 5-38: Association in the CSHA of Multimorbidity Count with Animal Naming Test at
Baseline - Female

Predictors

Estimates std. Error

CI

p

(Intercept)

2.36

0.65

1.08 – 3.64

<0.001

multimorbidity

-0.05

0.04

-0.12 – 0.02

0.129

age

-0.03

0.01

-0.04 – -0.01

0.001

educ level [linear]

0.43

0.15

0.13 – 0.74

0.005

educ level [quadratic]

-0.10

0.14

-0.38 – 0.18

0.483

educ level [cubic]

0.07

0.13

-0.19 – 0.32

0.615

TBI [Yes]

-0.09

0.18

-0.44 – 0.26

0.609

smoking [Yes]

-0.08

0.13

-0.33 – 0.17

0.508
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alcohol [Yes]

0.10

Random Effects
σ2

0.15

-0.19 – 0.40

0.492

0.78

τ00 region

0.10 (SD: 0.32; CI95%: 0.13 to 0.66)

ICC

0.12

N region

5

Observations
2

307
2

Marginal R / Conditional R

0.086 / 0.194

AIC

914.430

AICc

915.325

multimorbidity: multimorbidity count; age in years; educ level: education level categorical; TBI: Traumatic brain injury

Table 5-39: Association in the CSHA of Multimorbidity Count with Animal Naming Test at
Baseline - Male

Predictors

Estimates std. Error

CI

p

(Intercept)

-0.57

0.94

-2.43 – 1.28

0.541

multimorbidity

-0.00

0.05

-0.11 – 0.10

0.931

age

0.01

0.01

-0.01 – 0.03

0.346

educ level [linear]

0.61

0.18

0.26 – 0.96

0.001

educ level [quadratic]

0.06

0.19

-0.32 – 0.45

0.739

educ level [cubic]

0.16

0.21

-0.25 – 0.56

0.448

TBI [Yes]

0.08

0.17

-0.26 – 0.42

0.654

smoking [Yes]

0.23

0.18

-0.12 – 0.58

0.199

alcohol [Yes]

-0.27

0.15

-0.56 – 0.02

0.066

Random Effects
σ2

0.88

τ00 region

0.07 (SD: 0.27; CI95%: .06 to 0.59)

ICC

0.08

N region

5

Observations

179
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Marginal R2 / Conditional R2

0.108 / 0.178

AIC

540.033

AICc

541.614

multimorbidity: multimorbidity count; age in years; educ level: education level categorical; TBI: Traumatic brain injury

Change between baseline and first follow-up
Dichotomic Multimorbidity
For the analysis of ANT change between the baseline and the first follow-up five year later we got
information on 486 participants. We did not observe a change in ANT scores in patients with
multimorbidity (Table 5-40). The dichotomic multimorbidity score was -0.168 (CI95%: -0.35
to0.014; p-value 0.071). Two confounders had a significant association with ANT change scores.
An increase of one year of age was associated with a decrease of 0.022 (CI95%: -0.0358 to -0.0083;
p-value 0.0018) in MAT change scores, and there is a decrease of 0.29 (CI95%: -0.52 to -0.061; pvalue 0.0137) in ANT change scores for every increase on education category. The ICC was 0.025
(CI95%: 0.000 to 0.10).

We executed two subgroup analyses stratified by sex with information from 307 females and 179
males. Neither the female analysis (Table 5-41) with a score of -0.132 (CI95%: -0.36 to 0.096; pvalue 0.26) or the male analysis (Table 5-42) with a score of -0.154 (CI95%: -0.45 to 0.14; p-value
0.31) presented an association with ANT change scores at first follow-up.
Table 5-40: Association in the CSHA of Dichotomic Multimorbidity on Change of Animal Naming
Test between Baseline and First Follow-up

Predictors

Estimates std. Error

CI

p

(Intercept)

1.33

0.56

0.23 – 2.43

0.017

mm dich [Yes]

-0.17

0.09

-0.35 – 0.01

0.071

age

-0.02

0.01

-0.04 – -0.01

0.002
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sex [Male]

-0.06

0.11

-0.27 – 0.16

0.600

educ level [linear]

-0.29

0.12

-0.52 – -0.06

0.014

educ level [quadratic]

-0.10

0.12

-0.33 – 0.12

0.372

educ level [cubic]

0.00

0.11

-0.22 – 0.23

0.991

TBI [Yes]

0.08

0.13

-0.17 – 0.34

0.510

smoking [Yes]

-0.11

0.11

-0.32 – 0.10

0.303

alcohol [Yes]

0.15

0.11

-0.06 – 0.37

0.159

Random Effects
σ2

0.92

τ00 region

0.02 (SD: 0.15; CI95%: to 0.35)

ICC

0.02

N region

5

Observations
2

486
2

Marginal R / Conditional R

0.046 / 0.069

AIC

1471.691

AICc

1472.351

mm dich: dichotomic multimorbidity; age in years; educ level: education level categorical; TBI: Traumatic brain injury

Table 5-41: Association in the CSHA of Dichotomic Multimorbidity on Change of Animal Naming
Test between Baseline and First Follow-up - Female

Predictors

Estimates std. Error

CI

p

(Intercept)

0.13

0.67

-1.19 – 1.44

0.850

mm dich [Yes]

-0.13

0.12

-0.36 – 0.10

0.258

age

-0.01

0.01

-0.02 – 0.01

0.474

educ level [linear]

-0.19

0.16

-0.50 – 0.12

0.231

educ level [quadratic]

0.00

0.15

-0.28 – 0.29

0.979

educ level [cubic]

0.06

0.14

-0.21 – 0.32

0.675

TBI [Yes]

0.18

0.19

-0.18 – 0.55

0.321

smoking [Yes]

-0.05

0.13

-0.30 – 0.21

0.724
113

December 13, 2022

alcohol [Yes]

-0.15

Random Effects
σ2

0.15

-0.46 – 0.15

0.84

τ00 region

0.05 (SD: 0.22; CI95%: 0 to 0.48)

ICC

0.05

N region

5

Observations
2

0.320

307
2

Marginal R / Conditional R

0.019 / 0.073

AIC

931.036

AICc

931.930

mm dich: dichotomic multimorbidity; age in years; educ level: education level categorical; TBI: Traumatic brain injury

Table 5-42: Association in the CSHA of Dichotomic Multimorbidity on Change of Animal Naming
Test between Baseline and First Follow-up - Male

Predictors

Estimates std. Error

CI

p

(Intercept)

3.49

0.97

1.58 – 5.41

<0.001

mm dich [Yes]

-0.15

0.15

-0.45 – 0.14

0.307

age

-0.05

0.01

-0.08 – -0.03

<0.001

educ level [linear]

-0.35

0.18

-0.71 – 0.02

0.061

educ level [quadratic]

-0.23

0.20

-0.63 – 0.17

0.250

educ level [cubic]

0.09

0.22

-0.34 – 0.52

0.681

TBI [Yes]

0.03

0.18

-0.32 – 0.39

0.856

smoking [Yes]

-0.20

0.19

-0.56 – 0.17

0.291

alcohol [Yes]

0.36

0.16

0.05 – 0.66

0.023

Random Effects
σ2

0.99

τ00 region

0.01 (SD: 0.11; CI95%: 0 to 0.34)

ICC

0.01

N region

5

Observations

179
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Marginal R2 / Conditional R2

0.143 / 0.153

AIC

554.004

AICc

555.585

mm dich: dichotomic multimorbidity; age in years; educ level: education level categorical; TBI: Traumatic brain injury

Multimorbidity Count
We performed the analyses in the same number of participants than in the dichotomic
multimorbidity analysis. The analysis (Table 5-43) showed no association on ANT change with a
multimorbidity count score of -0.045 (CI95%: -0.106 to 0.015; p-value 0.14). The only confounders
with a significant association in our analysis were age with a decrease of 0.021 (CI95%: -0.035 to
-0.0075) per year older, and education level with a decrease of -0.29 (CI95%: -0.53 to -0.065) for
every category increased. The ICC was 0.024 (CI95%: 0.000 to 0.11).
The subgroup analysis did not find association between multimorbidity count and ANT change
scores. The female stratified analysis (Table 5-44) shown a multimorbidity count score of -0.035
(CI95%: -0.107 to 0.037; p-value 0.34) and the male one (Table 5-45) resulted in a score of -0.042
(CI95%: -0.15 to 0.067; p-value 0.45) on ANT RCI z standardized scores.
The dichotomic model fits better for the change between baseline and first follow-up on ANT
scores on the CSHA with a cAIC of 1472.321 vs 1475.656 on the counting model.

Table 5-43: Association in the CSHA of Multimorbidity Count on Change of Animal Naming Test
between Baseline and First Follow-up

Predictors

Estimates std. Error

CI

p

(Intercept)

1.27

0.56

0.17 – 2.36

0.023

multimorbidity

-0.05

0.03

-0.11 – 0.02

0.142

age

-0.02

0.01

-0.04 – -0.01

0.003

sex [Male]

-0.07

0.11

-0.29 – 0.15

0.513
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educ level [linear]

-0.30

0.12

-0.53 – -0.06

0.013

educ level [quadratic]

-0.10

0.12

-0.33 – 0.13

0.402

educ level [cubic]

-0.01

0.11

-0.24 – 0.21

0.902

TBI [Yes]

0.08

0.13

-0.17 – 0.33

0.531

smoking [Yes]

-0.10

0.11

-0.31 – 0.12

0.374

alcohol [Yes]

0.15

0.11

-0.06 – 0.37

0.165

Random Effects
σ2

0.92

τ00 region

0.02 (SD: 0.15; CI95%: 0 to 0.35)

ICC

0.02

N region

5

Observations

486

Marginal R2 / Conditional R2

0.043 / 0.067

AIC

1474.996

AICc

1475.656

multimorbidity: multimorbidity count; age in years; educ level: education level categorical; TBI: Traumatic brain injury

Table 5-44: Association in the CSHA of Multimorbidity Count on Change of Animal Naming Test
between Baseline and First Follow-up - Female

Predictors

Estimates std. Error

CI

p

(Intercept)

0.07

0.66

-1.24 – 1.37

0.921

multimorbidity

-0.03

0.04

-0.11 – 0.04

0.342

age

-0.01

0.01

-0.02 – 0.01

0.524

educ level [linear]

-0.19

0.16

-0.50 – 0.12

0.219

educ level [quadratic]

0.01

0.15

-0.28 – 0.30

0.946

educ level [cubic]

0.05

0.14

-0.22 – 0.31

0.740

TBI [Yes]

0.17

0.18

-0.19 – 0.54

0.351

smoking [Yes]

-0.03

0.13

-0.29 – 0.23

0.809

alcohol [Yes]

-0.16

0.15

-0.46 – 0.15

0.309
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Random Effects
σ2

0.84

τ00 region

0.05 (SD: 0.22; CI95%: 0 to 0.48)

ICC

0.05

N region

5

Observations
2

307
2

Marginal R / Conditional R

0.018 / 0.071

AIC

933.726

AICc

934.621

multimorbidity: multimorbidity count; age in years; educ level: education level categorical; TBI: Traumatic brain injury

Table 5-45: Association in the CSHA of Multimorbidity Count on Change of Animal Naming Test
between Baseline and First Follow-up - Male

Predictors

Estimates std. Error

CI

p

(Intercept)

3.45

0.97

1.53 – 5.37

0.001

multimorbidity

-0.04

0.06

-0.15 – 0.07

0.452

age

-0.05

0.01

-0.08 – -0.03

<0.001

educ level [linear]

-0.35

0.18

-0.71 – 0.01

0.060

educ level [quadratic]

-0.23

0.20

-0.63 – 0.17

0.249

educ level [cubic]

0.08

0.22

-0.35 – 0.51

0.720

TBI [Yes]

0.04

0.18

-0.32 – 0.39

0.839

smoking [Yes]

-0.19

0.19

-0.56 – 0.18

0.310

alcohol [Yes]

0.35

0.16

0.05 – 0.66

0.024

Random Effects
σ2

0.99

τ00 region

0.01 (SD: 0.11; CI95%: 0 to 0.34)

ICC

0.01

N region

5

Observations

179

Marginal R2 / Conditional R2

0.141 / 0.153
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AIC

556.493

AICc

558.074

multimorbidity: multimorbidity count; age in years; educ level: education level categorical; TBI: Traumatic brain injury

5.1.2.2.2 CLSA
Baseline
Dichotomic Multimorbidity
On the case of the CLSA baseline ANT we present information on 22503 participants. Presenting
multimorbidity showed no association on ANT z standardized baseline scores (Table 5-46) with a
result of 0.0011 (CI95%: -0.025 to 0.027; p-value 0.93). The selected confounders with significant
association were age with a decrease of 0.0256 (CI95%: -0.0269 to -0.0242) in the z standardized
score for every increase of one year, male sex with an increase of 0.034 (CI95%: 0.009 to 0.058),
traumatic brain injury with increase of 0.11 (CI95%: 0.078 to 0.14), history of smoking with a
decrease of 0.068 (CI95%: -0.093 to -0.043), and alcohol consumption with an increase of 0.157
(CI95%: 0.132 to 0.182) in the ANT z standardized baseline scores. Education level presented an
increase of 0.377 (CI95%: 0.349 to 0.406) for every increase in education category. The ICC was
0.022 (CI95%: 0.002 to 0.062).
In the subgroup analyses, we did not find any association between multimorbidity and baseline
ANT scores. The female analysis (Table 5-47) included 11189 participants and the score was
0.0071 (CI95%: -0.029 to 0.043; p-value 0.70). On the other hand, the male analysis (Table 5-48)
employed information from 11314 persons with a multimorbidity score of -0.0073 (CI95%: -0.045
to 0.031; p-value 0.71). In the age group analyses, we included 8904 participants 65 years and older
(Table 5-49) that got a multimorbidity score of 0.0073 (CI95%: -0.029 to 0.043; p-value 0.69), and
we evaluated 13599 participants younger than 65 (Table 5-50) with a score of -0.0048 (CI95%: 0.04 to 0.031; p-value 0.79)
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Table 5-46: Association in the CLSA of Dichotomic Multimorbidity with Animal Naming Test at
Baseline

Predictors

Estimates std. Error

CI

p

(Intercept)

1.30

0.07

1.16 – 1.45

<0.001

mm dich [Yes]

0.00

0.01

-0.03 – 0.03

0.935

age

-0.03

0.00

-0.03 – -0.02

<0.001

sex [Male]

0.03

0.01

0.01 – 0.06

0.007

educ level [linear]

0.38

0.01

0.35 – 0.40

<0.001

educ level [quadratic]

-0.12

0.02

-0.15 – -0.08

<0.001

educ level [cubic]

0.03

0.02

-0.01 – 0.06

0.170

TBI [Yes]

0.11

0.01

0.08 – 0.14

<0.001

smoking [Yes]

-0.07

0.01

-0.09 – -0.04

<0.001

alcohol [Yes]

0.16

0.01

0.13 – 0.18

<0.001

Random Effects
σ2

0.84

τ00 region

0.02 (SD: 0.14; CI95%: 0 to 0.34)

ICC

0.02

N region

5

Observations
2

22503
2

Marginal R / Conditional R

0.112 / 0.132

AIC

71722.615

AICc

71722.629

mm dich: dichotomic multimorbidity; age in years; educ level: education level categorical; TBI: Traumatic brain injury

Table 5-47: Association in the CLSA of Dichotomic Multimorbidity with Animal Naming Test at
Baseline - Female

Predictors

Estimates std. Error

CI

p

(Intercept)

1.41

0.09

1.22 – 1.59

<0.001

mm dich [Yes]

0.01

0.02

-0.03 – 0.04

0.702
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age

-0.03

0.00

-0.03 – -0.03

<0.001

educ level [linear]

0.38

0.02

0.34 – 0.42

<0.001

educ level [quadratic]

-0.10

0.02

-0.14 – -0.05

<0.001

educ level [cubic]

0.03

0.03

-0.02 – 0.08

0.290

TBI [Yes]

0.12

0.02

0.08 – 0.16

<0.001

smoking [Yes]

-0.05

0.02

-0.09 – -0.02

0.003

alcohol [Yes]

0.15

0.02

0.12 – 0.19

<0.001

Random Effects
σ2

0.82

τ00 region

0.03 (SD: 0.16; CI95%: 0.09 to 0.32)

ICC

0.03

N region

5

Observations
2

11189
2

Marginal R / Conditional R

0.129 / 0.157

AIC

35039.210

AICc

35039.234

mm dich: dichotomic multimorbidity; age in years; educ level: education level categorical; TBI: Traumatic brain injury

Table 5-48: Association in the CLSA of Dichotomic Multimorbidity with Animal Naming Test at
Baseline - Male

Predictors

Estimates std. Error

CI

p

(Intercept)

1.21

0.08

1.06 – 1.37

<0.001

mm dich [Yes]

-0.01

0.02

-0.05 – 0.03

0.705

age

-0.02

0.00

-0.02 – -0.02

<0.001

educ level [linear]

0.36

0.02

0.32 – 0.40

<0.001

educ level [quadratic]

-0.13

0.02

-0.18 – -0.08

<0.001

educ level [cubic]

0.03

0.03

-0.03 – 0.08

0.326

TBI [Yes]

0.10

0.02

0.06 – 0.14

<0.001

smoking [Yes]

-0.10

0.02

-0.13 – -0.06

<0.001
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alcohol [Yes]

0.16

Random Effects
σ2

0.02

0.12 – 0.20

<0.001

0.85

τ00 region

0.01 (SD: 0.12; CI95%: 0.06 to 0.23)

ICC

0.02

N region

5

Observations
2

11314
2

Marginal R / Conditional R

0.094 / 0.109

AIC

36716.154

AICc

36716.178

mm dich: dichotomic multimorbidity; age in years; educ level: education level categorical; TBI: Traumatic brain injury

Table 5-49: Association in the CLSA of Dichotomic Multimorbidity with Animal Naming Test at
Baseline - Participants 65 years and older

Predictors

Estimates std. Error

CI

p

(Intercept)

1.84

0.13

1.58 – 2.10

<0.001

mm dich [Yes]

0.01

0.02

-0.03 – 0.04

0.692

age

-0.03

0.00

-0.04 – -0.03

<0.001

sex [Male]

0.11

0.02

0.07 – 0.14

<0.001

educ level [linear]

0.26

0.02

0.23 – 0.29

<0.001

educ level [quadratic]

-0.09

0.02

-0.13 – -0.05

<0.001

educ level [cubic]

0.04

0.03

-0.01 – 0.09

0.111

TBI [Yes]

0.11

0.02

0.06 – 0.15

<0.001

smoking [Yes]

-0.00

0.02

-0.04 – 0.04

0.977

alcohol [Yes]

0.15

0.02

0.11 – 0.19

<0.001

Random Effects
σ2

0.46

τ00 region

0.02 (SD: 0.13; CI95%: 0.07 to 0.25)

ICC

0.03

N region

5
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Observations

8904

Marginal R2 / Conditional R2

0.126 / 0.156

AIC

26316.435

AICc

26316.470

mm dich: dichotomic multimorbidity; age in years; educ level: education level categorical; TBI: Traumatic brain injury

Table 5-50: Association in the CLSA of Dichotomic Multimorbidity with Animal Naming Test at
Baseline - Participants Younger than 65 years

Predictors

Estimates std. Error

CI

p

(Intercept)

0.83

0.11

0.62 – 1.03

<0.001

mm dich [Yes]

-0.00

0.02

-0.04 – 0.03

0.792

age

-0.02

0.00

-0.02 – -0.01

<0.001

sex [Male]

0.01

0.02

-0.03 – 0.04

0.685

educ level [linear]

0.44

0.02

0.40 – 0.48

<0.001

educ level [quadratic]

-0.14

0.02

-0.19 – -0.10

<0.001

educ level [cubic]

0.03

0.03

-0.02 – 0.08

0.251

TBI [Yes]

0.11

0.02

0.07 – 0.15

<0.001

smoking [Yes]

-0.09

0.02

-0.13 – -0.06

<0.001

alcohol [Yes]

0.15

0.02

0.12 – 0.19

<0.001

Random Effects
σ2

1.07

τ00 region

0.02 (SD: 0.14; CI95%: 0.08 to 0.28)

ICC

0.02

N region

5

Observations

13599

Marginal R2 / Conditional R2

0.031 / 0.050

AIC

43599.601

AICc

43599.624

mm dich: dichotomic multimorbidity; age in years; educ level: education level categorical; TBI: Traumatic brain injury
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Multimorbidity Count
We evaluated the same number of participants in the multimorbidity count than in the dichotomic
multimorbidity analyses. We observed that multimorbidity count score on z standardized ANT was
-0.0084 (CI95%: -0.0179 to 0.0012; p-value 0.0864) which is not conclusive of an association
(Table 5-51). The confounders associated with ANT were age with a decreased of 0.025 (CI95%:
-0.027 to -0.0238) for each increase of one year. Also, we found that male sex increased scores on
0.032 (CI95%: 0.0076 to 0.057), history of traumatic brain injury increased score on 0.109 (CI95%:
0.08 to 0.138), history of smoking decreased scores in 0.066 (CI95%: -0.091 to -0.0411) and
alcohol consumption increased scores on 0.153 (CI95%: 0.128 to 0.179). On the same direction
than in the dichotomic analysis, we concluded that education level was associated with an increase
trend of 0.375 (CI95%: 0.347 to 0.403). The ICC was 0.022 (CI95%: 0.003 to 0.063)
On the subgroup analysis, we did not find association between multimorbidity count and ANT
baseline scores. The female analysis (Table 5-52) showed a score of -0.0079 (CI95%: -0.021 to
0.0053; p-value 0.24), the male one (Table 5-53) a score of -0.0107 (CI95%: -0.0247 to 0.0032; pvalue 0.13). The analysis of patients 65 year and older (Table 5-54) showed a score of -0.0099
(CI95%: -0.022 to 0.0023; p-value 0.112), the patients younger than 65 (Table 5-55) the score was
-0.01 (CI95%: -0.023 to 0.003; p-value 0.128).
The counting model fits better for the baseline scores on ANT on the CLSA with a cAIC of
71721.711 vs 71722.629 on the dichotomic model.

Table 5-51: Association in the CLSA of Multimorbidity Count with Animal Naming Test at Baseline

Predictors

Estimates std. Error

CI

p

(Intercept)

1.29

0.07

1.15 – 1.44

<0.001

multimorbidity

-0.01

0.00

-0.02 – 0.00

0.086

age

-0.03

0.00

-0.03 – -0.02

<0.001
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sex [Male]

0.03

0.01

0.01 – 0.06

0.010

educ level [linear]

0.38

0.01

0.35 – 0.40

<0.001

educ level [quadratic]

-0.12

0.02

-0.15 – -0.08

<0.001

educ level [cubic]

0.02

0.02

-0.01 – 0.06

0.194

TBI [Yes]

0.11

0.01

0.08 – 0.14

<0.001

smoking [Yes]

-0.07

0.01

-0.09 – -0.04

<0.001

alcohol [Yes]

0.15

0.01

0.13 – 0.18

<0.001

Random Effects
σ2

0.84

τ00 region

0.02 (SD: 0.14; CI95%: 0.07 to 0.27)

ICC

0.02

N region

5

Observations
2

22503
2

Marginal R / Conditional R

0.113 / 0.132

AIC

71721.697

AICc

71721.711

multimorbidity: multimorbidity count; age in years; educ level: education level categorical; TBI: Traumatic brain injury

Table 5-52: Association in the CLSA of Multimorbidity Count with Animal Naming Test at Baseline
- Female

Predictors

Estimates std. Error

CI

p

(Intercept)

1.40

0.09

1.21 – 1.58

<0.001

multimorbidity

-0.01

0.01

-0.02 – 0.01

0.238

age

-0.03

0.00

-0.03 – -0.03

<0.001

educ level [linear]

0.38

0.02

0.34 – 0.42

<0.001

educ level [quadratic]

-0.10

0.02

-0.14 – -0.05

<0.001

educ level [cubic]

0.03

0.03

-0.02 – 0.08

0.318

TBI [Yes]

0.12

0.02

0.08 – 0.17

<0.001

smoking [Yes]

-0.05

0.02

-0.08 – -0.02

0.004
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alcohol [Yes]

0.15

Random Effects
σ2

0.02

0.11 – 0.18

<0.001

0.82

τ00 region

0.03 (SD: 0.16; CI95%: 0.09 to 0.32)

ICC

0.03

N region

5

Observations
2

11189
2

Marginal R / Conditional R

0.129 / 0.157

AIC

35039.994

AICc

35040.018

multimorbidity: multimorbidity count; age in years; educ level: education level categorical; TBI: Traumatic brain injury

Table 5-53: Association in the CLSA of Multimorbidity Count with Animal Naming Test at Baseline
- Male

Predictors

Estimates std. Error

CI

p

(Intercept)

1.20

0.08

1.05 – 1.36

<0.001

multimorbidity

-0.01

0.01

-0.02 – 0.00

0.133

age

-0.02

0.00

-0.02 – -0.02

<0.001

educ level [linear]

0.36

0.02

0.32 – 0.40

<0.001

educ level [quadratic]

-0.13

0.02

-0.17 – -0.08

<0.001

educ level [cubic]

0.03

0.03

-0.03 – 0.08

0.353

TBI [Yes]

0.10

0.02

0.07 – 0.14

<0.001

smoking [Yes]

-0.09

0.02

-0.13 – -0.06

<0.001

alcohol [Yes]

0.16

0.02

0.12 – 0.20

<0.001

Random Effects
σ2

0.85

τ00 region

0.01 (SD: 0.12; CI95%: 0.06 to 0.23)

ICC

0.02

N region

5

Observations

11314
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Marginal R2 / Conditional R2

0.094 / 0.109

AIC

36716.044

AICc

36716.068

multimorbidity: multimorbidity count; age in years; educ level: education level categorical; TBI: Traumatic brain injury

Table 5-54: Association in the CLSA of Multimorbidity Count with Animal Naming Test at Baseline
- Participants 65 years and older

Predictors

Estimates std. Error

CI

p

(Intercept)

1.84

0.13

1.58 – 2.11

<0.001

multimorbidity

-0.01

0.01

-0.02 – 0.00

0.112

age

-0.03

0.00

-0.04 – -0.03

<0.001

sex [Male]

0.10

0.02

0.07 – 0.14

<0.001

educ level [linear]

0.26

0.02

0.23 – 0.29

<0.001

educ level [quadratic]

-0.09

0.02

-0.13 – -0.05

<0.001

educ level [cubic]

0.04

0.03

-0.01 – 0.09

0.127

TBI [Yes]

0.11

0.02

0.07 – 0.15

<0.001

smoking [Yes]

0.00

0.02

-0.03 – 0.04

0.897

alcohol [Yes]

0.15

0.02

0.11 – 0.18

<0.001

Random Effects
σ2

0.46

τ00 region

0.02 (SD: 0.13; CI95%: 0.07 to 0.25)

ICC

0.03

N region

5

Observations
2

8904
2

Marginal R / Conditional R

0.127 / 0.157

AIC

26316.233

AICc

26316.268

multimorbidity: multimorbidity count; age in years; educ level: education level categorical; TBI: Traumatic brain injury
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Table 5-55: Association in the CLSA of Multimorbidity Count with Animal Naming Test at Baseline
- Participants Younger than 65 years

Predictors

Estimates std. Error

CI

p

(Intercept)

0.81

0.11

0.60 – 1.02

<0.001

multimorbidity

-0.01

0.01

-0.02 – 0.00

0.128

age

-0.02

0.00

-0.02 – -0.01

<0.001

sex [Male]

0.01

0.02

-0.03 – 0.04

0.760

educ level [linear]

0.44

0.02

0.40 – 0.48

<0.001

educ level [quadratic]

-0.14

0.02

-0.19 – -0.09

<0.001

educ level [cubic]

0.03

0.03

-0.02 – 0.08

0.277

TBI [Yes]

0.11

0.02

0.08 – 0.15

<0.001

smoking [Yes]

-0.09

0.02

-0.13 – -0.06

<0.001

alcohol [Yes]

0.15

0.02

0.12 – 0.19

<0.001

Random Effects
σ2

1.07

τ00 region

0.02 (SD: 0.14; CI95%: 0.08 to 0.28)

ICC

0.02

N region

5

Observations
2

13599
2

Marginal R / Conditional R

0.031 / 0.050

AIC

43599.303

AICc

43599.326

multimorbidity: multimorbidity count; age in years; educ level: education level categorical; TBI: Traumatic brain injury

Change between baseline and first follow-up
Dichotomic Multimorbidity
We had information on 22503 participants about the RCI z standardized ANT change score
between the baseline and the first follow-up (Table 5-56). We did not find an association of the
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dichotomic multimorbidity score of -0.00199 (CI95%: -0.0299 to 0.259; p-value 0.89) on ANT
change score. The confounders with significant association in the model were age that decreased
the score 0.0051 (CI95%: -0.0065 to -0.0037), history of traumatic brain injury with a decrease of
0.0387 (CI95%: -0.069 to -0.0084), and history of smoking that increased 0.0326 (CI95%: 0.006
to 0.0592). Education level presented a decreased scores of 0.085 (CI95%: -0.115 to -0.055) for
each increased in on level within the category. The ICC was 0.002 (CI95%: 0.0001 to 0.003).
The subgroup analysis did not show associations between dichotomic multimorbidity and ANT
change during first follow-up. We found a multimorbidity score of -0.00765 (CI95%: -0.046 to
0.031; p-value 0.70) in the female analysis that included 11189 participants (Table 5-57). The male
analysis reports information from 11314 participants (Table 5-58), we observed a multimorbidity
score of 0.00393 (CI95%: -0.0367 to 0.0445; p-value 0.85). In the stratified analysis of 8904
participants 65 years and older (Table 5-59) the multimorbidity score was 0.00172 (IC95%: -0.037
to 0.041; p-value 0.93), and in the 13599 participants younger than 65 years (Table 5-60) the score
was -0.0113 (CI95%: -0.0489 to 0.0264; p-value 0.56).

Table 5-56: Association in the CLSA of Dichotomic Multimorbidity on Change of Animal Naming
Test between Baseline and First Follow-up

Predictors

Estimates std. Error

CI

p

(Intercept)

0.31

0.05

0.21 – 0.40

<0.001

mm dich [Yes]

-0.00

0.01

-0.03 – 0.03

0.888

age

-0.01

0.00

-0.01 – -0.00

<0.001

sex [Male]

-0.01

0.01

-0.04 – 0.02

0.512

educ level [linear]

-0.08

0.02

-0.11 – -0.06

<0.001

educ level [quadratic]

0.05

0.02

0.02 – 0.09

0.003

educ level [cubic]

-0.05

0.02

-0.09 – -0.02

0.006

TBI [Yes]

-0.04

0.02

-0.07 – -0.01

0.012

smoking [Yes]

0.03

0.01

0.01 – 0.06

0.016

alcohol [Yes]

-0.02

0.01

-0.04 – 0.01

0.194
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Random Effects
σ2

0.94

τ00 region

0.002 (SD: 0.04; CI95%: 0.02 to 0.08)

ICC

0.00

N region

5

Observations
2

22503
2

Marginal R / Conditional R

0.004 / 0.005

AIC

74410.868

AICc

74410.882

mm dich: dichotomic multimorbidity; age in years; educ level: education level categorical; TBI: Traumatic brain injury

Table 5-57: Association in the CLSA of Dichotomic Multimorbidity on Change of Animal Naming
Test between Baseline and First Follow-up - Female

Predictors

Estimates std. Error

CI

p

(Intercept)

0.27

0.06

0.15 – 0.40

<0.001

mm dich [Yes]

-0.01

0.02

-0.05 – 0.03

0.695

age

-0.00

0.00

-0.01 – -0.00

<0.001

educ level [linear]

-0.07

0.02

-0.12 – -0.03

0.001

educ level [quadratic]

0.02

0.02

-0.03 – 0.07

0.373

educ level [cubic]

-0.03

0.03

-0.09 – 0.02

0.238

TBI [Yes]

-0.04

0.02

-0.08 – 0.01

0.107

smoking [Yes]

0.00

0.02

-0.03 – 0.04

0.940

alcohol [Yes]

-0.01

0.02

-0.05 – 0.03

0.644

Random Effects
σ2

0.92

τ00 region

0.002 (SD: 0.04; CI95%: 0.01 to 0.09)

ICC

0.00

N region

5

Observations

11189

Marginal R2 / Conditional R2

0.003 / 0.004
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AIC

36295.146

AICc

36295.170

mm dich: dichotomic multimorbidity; age in years; educ level: education level categorical; TBI: Traumatic brain injury

Table 5-58: Association in the CLSA of Dichotomic Multimorbidity on Change of Animal Naming
Test between Baseline and First Follow-up - Male

Predictors

Estimates std. Error

CI

p

(Intercept)

0.33

0.07

0.20 – 0.47

<0.001

mm dich [Yes]

0.00

0.02

-0.04 – 0.04

0.849

age

-0.01

0.00

-0.01 – -0.00

<0.001

educ level [linear]

-0.09

0.02

-0.13 – -0.05

<0.001

educ level [quadratic]

0.08

0.03

0.03 – 0.13

0.001

educ level [cubic]

-0.08

0.03

-0.14 – -0.02

0.005

TBI [Yes]

-0.04

0.02

-0.08 – -0.00

0.044

smoking [Yes]

0.07

0.02

0.03 – 0.11

0.001

alcohol [Yes]

-0.03

0.02

-0.07 – 0.01

0.166

Random Effects
σ2

0.96

τ00 region

0.003 (SD: 0.05; CI95%: 0.02 to 0.10)

ICC

0.00

N region

5

Observations
2

11314
2

Marginal R / Conditional R

0.006 / 0.008

AIC

38162.596

AICc

38162.619

mm dich: dichotomic multimorbidity; age in years; educ level: education level categorical; TBI: Traumatic brain injury
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Table 5-59: Association in the CLSA of Dichotomic Multimorbidity on Change of Animal Naming
Test between Baseline and First Follow-up - Participants 65 years and older

Predictors

Estimates std. Error

CI

p

(Intercept)

0.25

0.13

-0.01 – 0.51

0.056

mm dich [Yes]

0.00

0.02

-0.04 – 0.04

0.931

age

-0.00

0.00

-0.01 – -0.00

0.040

sex [Male]

-0.03

0.02

-0.07 – 0.01

0.103

educ level [linear]

-0.00

0.02

-0.04 – 0.03

0.826

educ level [quadratic]

0.00

0.02

-0.04 – 0.05

0.967

educ level [cubic]

-0.02

0.03

-0.07 – 0.03

0.471

TBI [Yes]

-0.00

0.02

-0.05 – 0.04

0.876

smoking [Yes]

-0.05

0.02

-0.09 – -0.01

0.010

alcohol [Yes]

-0.02

0.02

-0.06 – 0.02

0.364

Random Effects
σ2

0.54

τ00 region

0.002 (SD: 0.04; CI95%: 0.01 to 0.08)

ICC

0.00

N region

5

Observations
2

8904
2

Marginal R / Conditional R

0.003 / 0.005

AIC

27649.800

AICc

27649.835

mm dich: dichotomic multimorbidity; age in years; educ level: education level categorical; TBI: Traumatic brain injury

Table 5-60: Association in the CLSA of Dichotomic Multimorbidity on Change of Animal Naming
Test between Baseline and First Follow-up - Participants Younger than 65 years

Predictors

Estimates std. Error

CI

p

(Intercept)

0.36

0.09

0.19 – 0.54

<0.001

mm dich [Yes]

-0.01

0.02

-0.05 – 0.03

0.559

age

-0.01

0.00

-0.01 – -0.00

<0.001
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sex [Male]

-0.00

0.02

-0.04 – 0.03

0.928

educ level [linear]

-0.15

0.02

-0.19 – -0.10

<0.001

educ level [quadratic]

0.10

0.02

0.05 – 0.15

<0.001

educ level [cubic]

-0.08

0.03

-0.14 – -0.03

0.002

TBI [Yes]

-0.05

0.02

-0.09 – -0.01

0.012

smoking [Yes]

0.06

0.02

0.02 – 0.09

0.002

alcohol [Yes]

-0.02

0.02

-0.05 – 0.02

0.332

Random Effects
σ2

1.21

τ00 region

0.003 (SD: 0.05; CI95%: 0.02 to 0.10)

ICC

0.00

N region

5

Observations
2

13599
2

Marginal R / Conditional R

0.003 / 0.005

AIC

45162.928

AICc

45162.951

mm dich: dichotomic multimorbidity; age in years; educ level: education level categorical; TBI: Traumatic brain injury

Multimorbidity count
For the multimorbidity count analyses on ANT change we have the same number of participants
than in the dichotomic multimorbidity analyses. We did not observe an association of
multimorbidity count on ANT RCI z standardized with 0.0294 (CI95%: -0.0072 to 0.0131; p-value
0.57) as score (Table 5-61). The confounders with significant results in the model are age with a
decrease of 0.00527 (CI95%: -0.00669 to -0.00385), history of traumatic brain injury with a
decrease of 0.0398 (CI95%: -0.070 to -0.00937) and history of smoking with an increase of 0.0317
(CI95%: 0.00508 to 0.0584). Education level displayed a trend for decreasing 0.0844 (CI95%: 0.114 to -0.055) for every increase in education level. The ICC was 0.002 (CI95%: 0.0003 to0.006).
The subgroup analysis did not show associations either between multimorbidity count and ANT
change scores. The result for the female analysis (Table 5-62) was -0.00113 (CI95%: -0.015 to
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0.013; p-value 0.87), for the male analysis (Table 5-63) was 0.00709 (CI95%: -0.0078 to 0.022; pvalue 0.35), for the patients 65 years and older (
Predictors

Estimates std. Error

CI

p

(Intercept)

0.34

0.07

0.21 – 0.47

<0.001

multimorbidity

0.01

0.01

-0.01 – 0.02

0.352

age

-0.01

0.00

-0.01 – -0.00

<0.001

educ level [linear]

-0.09

0.02

-0.13 – -0.05

<0.001

educ level [quadratic]

0.08

0.03

0.03 – 0.13

0.001

educ level [cubic]

-0.08

0.03

-0.14 – -0.02

0.006

TBI [Yes]

-0.04

0.02

-0.08 – -0.00

0.037

smoking [Yes]

0.07

0.02

0.03 – 0.11

0.001

alcohol [Yes]

-0.03

0.02

-0.07 – 0.01

0.197

Random Effects
σ2

0.96

τ00 region

0.003 (SD:0.05; CI95%: 0.02 to 0.10)

ICC

0.00

N region

5

Observations

11314

Marginal R2 / Conditional R2

0.006 / 0.008

AIC

38163.766

AICc

38163.790

multimorbidity: multimorbidity count; age in years; educ level: education level categorical; TBI: Traumatic brain injury

Table 5-64) was -0.002 (CI95%: -0.015 to 0.011; p-value 0.77) and in younger than 65 (Table
5-65), the result was 0.00361 (CI95%: -0.0106 to 0.0178; p-value 0.62).
The dichotomic model fits better for the change between baseline and first follow-up on ANT
scores on the CLSA with a cAIC of 74410.882 vs 74412.597 on the count model.
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Table 5-61: Association in the CLSA of Multimorbidity Count on Change of Animal Naming Test
between Baseline and First Follow-up

Predictors

Estimates std. Error

CI

p

(Intercept)

0.31

0.05

0.22 – 0.40

<0.001

multimorbidity

0.00

0.01

-0.01 – 0.01

0.571

age

-0.01

0.00

-0.01 – -0.00

<0.001

sex [Male]

-0.01

0.01

-0.03 – 0.02

0.540

educ level [linear]

-0.08

0.02

-0.11 – -0.05

<0.001

educ level [quadratic]

0.05

0.02

0.02 – 0.09

0.003

educ level [cubic]

-0.05

0.02

-0.09 – -0.01

0.007

TBI [Yes]

-0.04

0.02

-0.07 – -0.01

0.010

smoking [Yes]

0.03

0.01

0.01 – 0.06

0.020

alcohol [Yes]

-0.02

0.01

-0.04 – 0.01

0.228

Random Effects
σ2

0.94

τ00 region

0.002 (SD: 0.04; CI95%: .02 to 0.08)

ICC

0.00

N region

5

Observations
2

22503
2

Marginal R / Conditional R

0.004 / 0.005

AIC

74412.583

AICc

74412.597

multimorbidity: multimorbidity count; age in years; educ level: education level categorical; TBI: Traumatic brain injury

Table 5-62: Association in the CLSA of Multimorbidity Count on Change of Animal Naming Test
between Baseline and First Follow-up - Female

Predictors

Estimates std. Error

CI

p

(Intercept)

0.27

0.06

0.15 – 0.40

<0.001

multimorbidity

-0.00

0.01

-0.02 – 0.01

0.873
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age

-0.00

0.00

-0.01 – -0.00

<0.001

educ level [linear]

-0.07

0.02

-0.12 – -0.03

0.001

educ level [quadratic]

0.02

0.02

-0.03 – 0.07

0.376

educ level [cubic]

-0.03

0.03

-0.09 – 0.02

0.241

TBI [Yes]

-0.04

0.02

-0.08 – 0.01

0.105

smoking [Yes]

0.00

0.02

-0.04 – 0.04

0.952

alcohol [Yes]

-0.01

0.02

-0.04 – 0.03

0.662

Random Effects
σ2

0.92

τ00 region

0.002 (SD: 0.04; CI95%: .01 to 0.09)

ICC

0.00

N region

5

Observations
2

11189
2

Marginal R / Conditional R

0.003 / 0.004

AIC

36297.301

AICc

36297.325

multimorbidity: multimorbidity count; age in years; educ level: education level categorical; TBI: Traumatic brain injury

Table 5-63: Association in the CLSA of Multimorbidity Count on Change of Animal Naming Test
between Baseline and First Follow-up - Male
Predictors

Estimates std. Error

CI

p

(Intercept)

0.34

0.07

0.21 – 0.47

<0.001

multimorbidity

0.01

0.01

-0.01 – 0.02

0.352

age

-0.01

0.00

-0.01 – -0.00

<0.001

educ level [linear]

-0.09

0.02

-0.13 – -0.05

<0.001

educ level [quadratic]

0.08

0.03

0.03 – 0.13

0.001

educ level [cubic]

-0.08

0.03

-0.14 – -0.02

0.006

TBI [Yes]

-0.04

0.02

-0.08 – -0.00

0.037

smoking [Yes]

0.07

0.02

0.03 – 0.11

0.001
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alcohol [Yes]

-0.03

Random Effects
σ2

0.02

-0.07 – 0.01

0.197

0.96

τ00 region

0.003 (SD:0.05; CI95%: 0.02 to 0.10)

ICC

0.00

N region

5

Observations
2

11314
2

Marginal R / Conditional R

0.006 / 0.008

AIC

38163.766

AICc

38163.790

multimorbidity: multimorbidity count; age in years; educ level: education level categorical; TBI: Traumatic brain injury

Table 5-64: Association in the CLSA of Multimorbidity Count on Change of Animal Naming Test
between Baseline and First Follow-up - Participants 65 years and older

Predictors

Estimates std. Error

CI

p

(Intercept)

0.25

0.13

-0.01 – 0.51

0.055

multimorbidity

-0.00

0.01

-0.02 – 0.01

0.766

age

-0.00

0.00

-0.01 – -0.00

0.044

sex [Male]

-0.03

0.02

-0.07 – 0.01

0.100

educ level [linear]

-0.00

0.02

-0.04 – 0.03

0.821

educ level [quadratic]

0.00

0.02

-0.04 – 0.05

0.967

educ level [cubic]

-0.02

0.03

-0.07 – 0.03

0.463

TBI [Yes]

-0.00

0.02

-0.05 – 0.05

0.905

smoking [Yes]

-0.05

0.02

-0.09 – -0.01

0.011

alcohol [Yes]

-0.02

0.02

-0.06 – 0.02

0.344

Random Effects
σ2

0.54

τ00 region

0.002 (SD: 0.04; CI95%: 0.01 to 0.08)

ICC

0.00

N region

5
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Observations

8904

Marginal R2 / Conditional R2

0.003 / 0.005

AIC

27651.883

AICc

27651.918

multimorbidity: multimorbidity count; age in years; educ level: education level categorical; TBI: Traumatic brain injury

Table 5-65: Association in the CLSA of Multimorbidity Count on Change of Animal Naming Test
between Baseline and First Follow-up - Younger than 65 years

Predictors

Estimates std. Error

CI

p

(Intercept)

0.38

0.09

0.20 – 0.56

<0.001

multimorbidity

0.00

0.01

-0.01 – 0.02

0.619

age

-0.01

0.00

-0.01 – -0.00

<0.001

sex [Male]

-0.00

0.02

-0.03 – 0.03

0.992

educ level [linear]

-0.14

0.02

-0.19 – -0.10

<0.001

educ level [quadratic]

0.10

0.02

0.05 – 0.15

<0.001

educ level [cubic]

-0.08

0.03

-0.14 – -0.03

0.003

TBI [Yes]

-0.05

0.02

-0.09 – -0.01

0.009

smoking [Yes]

0.05

0.02

0.02 – 0.09

0.003

alcohol [Yes]

-0.01

0.02

-0.05 – 0.02

0.411

Random Effects
σ2

1.21

τ00 region

0.003 (SD: 0.05; CI95%: 0.02 to 0.10)

ICC

0.00

N region

5

Observations
2

13599
2

Marginal R / Conditional R

0.003 / 0.005

AIC

45164.971

AICc

45164.994

multimorbidity: multimorbidity count; age in years; educ level: education level categorical; TBI: Traumatic brain injury
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5.1.2.3 Rey Auditory Verbal Learning Test (RAVLT)
In both cohorts we evaluated the positive recognition of words, immediately after hearing the
fifteen words for the immediate recall component.
However, for the delayed recall, we found differences because in the CSHA the authors evaluated
the delayed recall after 5 learning immediate recalls while in the CLSA the authors only presented
the word list one time and only performed one immediate recall, meaning that the delayed recall
was performed after only one learning attempt.

5.1.2.3.1 Immediate Recall

5.1.2.3.1.1 CSHA
Baseline
Dichotomic Multimorbidity
We had information on 486 participants of the baseline results of the RAVLT immediate recall in
the CSHA at baseline. We did not notice an association of having multimorbidity with RAVLT
immediate recall scores (Table 5-66); Suffering multimorbidity has an z standardized RAVLT
immediate recall score of -0.09 (CI95%: -0.01 to 0.28; p-value 0.37). The only confounders
significant associated in the model was the linear relationship of education level which increased
scores by 0.40 (CI95%: 0.16 to 0.64; p-value <0.001) for each increase to the following category
and age that decreased scores 0.02 (CI95%: -0.04 to -0.0075; p value 0.004. The ICC was 0.034
(CI95%: 0.000 to 0.123).
The subgroup analyses did not show associations of multimorbidity on RAVLT immediate recall
scores. In the female analysis (Table 5-67), we have information on 307 participants with a
dichotomic multimorbidity score of -0.02 (CI95%: -0.23 to 0.27; p-value 0.89). In the male analysis
(Table 5-68), we analyzed 179 participants with a z standardized score for multimorbidity of 0.13
(CI95%: -0.18 to 0.43; p-value 0.41).
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Table 5-66: Association in the CSHA of Dichotomic Multimorbidity with Rey Auditory Verbal
Learning Test Immediate Recall at Baseline

Predictors

Estimates std. Error

CI

p

(Intercept)

2.01

0.59

0.85 – 3.18

0.001

mm dich [Yes]

0.09

0.10

-0.10 – 0.28

0.368

age

-0.02

0.01

-0.04 – -0.01

0.004

educ level [linear]

0.40

0.12

0.16 – 0.64

0.001

educ level [quadratic]

0.03

0.12

-0.21 – 0.27

0.816

educ level [cubic]

0.20

0.12

-0.03 – 0.44

0.088

TBI [Yes]

-0.31

0.14

-0.58 – -0.04

0.024

smoking [Yes]

-0.21

0.10

-0.41 – -0.01

0.042

alcohol [Yes]

-0.21

0.11

-0.43 – 0.01

0.067

Random Effects
σ2

0.90

τ00 region

0.03 (SD: 0.18; CI95%: 0.03 to 0.38)

ICC

0.03

N region

5

Observations

425

Marginal R2 / Conditional R2

0.091 / 0.121

AIC

1274.573

AICc

1275.212

mm dich: dichotomic multimorbidity; age in years; educ level: education level categorical; TBI: Traumatic brain injury

Table 5-67: Association in the CSHA of Dichotomic Multimorbidity with Rey Auditory Verbal
Learning Test Immediate Recall at Baseline - Female

Predictors
(Intercept)

Estimates std. Error
2.28

0.73

CI

p

0.84 – 3.71

0.002
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mm dich [Yes]

0.02

0.13

-0.23 – 0.27

0.889

age

-0.02

0.01

-0.04 – -0.01

0.008

educ level [linear]

0.46

0.16

0.14 – 0.77

0.005

educ level [quadratic]

-0.17

0.16

-0.48 – 0.14

0.276

educ level [cubic]

-0.07

0.15

-0.36 – 0.22

0.645

TBI [Yes]

-0.26

0.21

-0.67 – 0.15

0.210

smoking [Yes]

-0.02

0.14

-0.30 – 0.25

0.871

alcohol [Yes]

-0.16

0.16

-0.48 – 0.16

0.333

Random Effects
σ2

0.87

τ00 region

<0.001 (SD: <0.001; CI95%: 0 to 0.21)

N region

5

Observations

269

Marginal R2 / Conditional R2

0.091 / NA

AIC

823.756

AICc

824.783

mm dich: dichotomic multimorbidity; age in years; educ level: education level categorical; TBI: Traumatic brain injury

Table 5-68: Association in the CSHA of Dichotomic Multimorbidity with Rey Auditory Verbal
Learning Test Immediate Recall at Baseline - Male

Predictors

Estimates std. Error

CI

p

(Intercept)

1.82

1.00

-0.15 – 3.80

0.070

mm dich [Yes]

0.13

0.15

-0.18 – 0.43

0.418

age

-0.02

0.01

-0.05 – 0.00

0.101

educ level [linear]

0.25

0.19

-0.12 – 0.63

0.180

educ level [quadratic]

0.27

0.20

-0.14 – 0.67

0.194

educ level [cubic]

0.51

0.22

0.08 – 0.95

0.021

TBI [Yes]

-0.32

0.19

-0.70 – 0.06

0.099
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smoking [Yes]

-0.29

0.19

-0.65 – 0.08

0.127

alcohol [Yes]

-0.14

0.16

-0.46 – 0.18

0.380

Random Effects
σ2

0.89

τ00 region

0.08 (SD: 0.28; CI95%: 0.06 to 0.60)

ICC

0.08

N region

5

Observations

156

Marginal R2 / Conditional R2

0.109 / 0.181

AIC

472.401

AICc

474.235

mm dich: dichotomic multimorbidity; age in years; educ level: education level categorical; TBI: Traumatic brain injury

Multimorbidity Count
We performed the analysis of multimorbidity count with the same number of participants that in
the Dichotomic multimorbidity analysis (Table 5-69). We did not find an association of
multimorbidity count in RAVLT immediate recall scores. The score coefficient was 0.038 (CI95%:
-0.025 to 0.1; p-value 0.235). When analysing the model confounders age was associated with a
decrease of 0.023 (CI95%: -0.038 to -0.0086) and education level increased score by 0.429
(CI95%: 0.189 to 0.667) for a category increased. The ICC was 0.034 (CI95%: 0.000 to 0.125).
In the subgroup analyses, we did not find an association either. In the female analysis (Table 5-70)
the z standardized score for multimorbidity was 0.038 (CI95%: -0.038 to 0.114; p-value 0.33), and
in the male analysis (Table 5-71) score was of -0.03 (CI95%: -0.078 to 0.139; p-value 0.5).
The dichotomic model fits better for the baseline scores on RAVLT immediate recall on the CSHA
with a cAIC of 1275.212 vs 1278.272 on the counting model.
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Table 5-69: Association in the CSHA of Multimorbidity Count with Rey Auditory Verbal Learning
Test Immediate Recall at Baseline

Predictors

Estimates std. Error

CI

p

(Intercept)

2.13

0.59

0.97 – 3.30

<0.001

multimorbidity

0.04

0.03

-0.02 – 0.10

0.235

age

-0.02

0.01

-0.04 – -0.01

0.002

sex [Male]

-0.18

0.11

-0.40 – 0.05

0.125

educ level [linear]

0.43

0.12

0.19 – 0.67

0.001

educ level [quadratic]

0.05

0.12

-0.19 – 0.28

0.706

educ level [cubic]

0.19

0.12

-0.05 – 0.42

0.114

TBI [Yes]

-0.28

0.14

-0.55 – -0.01

0.045

smoking [Yes]

-0.15

0.11

-0.37 – 0.06

0.167

alcohol [Yes]

-0.17

0.11

-0.40 – 0.05

0.132

Random Effects
σ2

0.89

τ00 region

0.03 (SD: 0.18; CI95%: 0.04 to 0.39)

ICC

0.03

N region

5

Observations
2

425
2

Marginal R / Conditional R

0.098 / 0.129

AIC

1277.520

AICc

1278.277

multimorbidity: multimorbidity count; age in years; educ level: education level categorical; TBI: Traumatic brain injury

Table 5-70: Association in the CSHA of Multimorbidity Count with Rey Auditory Verbal Learning
Test Immediate Recall at Baseline - Female

Predictors

Estimates std. Error

CI

p

(Intercept)

2.22

0.72

0.80 – 3.65

0.002

multimorbidity

0.04

0.04

-0.04 – 0.11

0.328
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age

-0.02

0.01

-0.04 – -0.01

0.007

educ level [linear]

0.47

0.16

0.15 – 0.79

0.004

educ level [quadratic]

-0.18

0.16

-0.49 – 0.13

0.248

educ level [cubic]

-0.07

0.15

-0.36 – 0.22

0.644

TBI [Yes]

-0.27

0.21

-0.67 – 0.14

0.195

smoking [Yes]

-0.04

0.14

-0.32 – 0.24

0.773

alcohol [Yes]

-0.17

0.16

-0.49 – 0.15

0.303

Random Effects
σ2

0.87

τ00 region

<0.001 (SD: <0.001; CI95%: 0 to 0.21)

N region

5

Observations
2

269
2

Marginal R / Conditional R

0.096 / NA

AIC

825.192

AICc

826.219

multimorbidity: multimorbidity count; age in years; educ level: education level categorical; TBI: Traumatic brain injury

Table 5-71: Association in the CSHA of Multimorbidity Count with Rey Auditory Verbal Learning
Test Immediate Recall at Baseline - Male

Predictors

Estimates std. Error

CI

p

(Intercept)

1.88

1.00

-0.10 – 3.85

0.062

multimorbidity

0.03

0.06

-0.08 – 0.14

0.579

age

-0.02

0.01

-0.05 – 0.00

0.097

educ level [linear]

0.25

0.19

-0.12 – 0.63

0.186

educ level [quadratic]

0.27

0.20

-0.13 – 0.67

0.184

educ level [cubic]

0.52

0.22

0.09 – 0.96

0.019

TBI [Yes]

-0.32

0.19

-0.71 – 0.06

0.096

smoking [Yes]

-0.29

0.19

-0.66 – 0.08

0.122
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alcohol [Yes]

-0.15

Random Effects
σ2

0.16

-0.46 – 0.17

0.365

0.90

τ00 region

0.08 (SD: 0.29; CI95%: 0.08 to 0.62)

ICC

0.09

N region

5

Observations
2

156
2

Marginal R / Conditional R

0.107 / 0.183

AIC

474.802

AICc

476.635

multimorbidity: multimorbidity count; age in years; educ level: education level categorical; TBI: Traumatic brain injury

Change between baseline and first follow-up
Dichotomic Multimorbidity
We had information on 425 participants for this analysis. We did not find an association of
presenting multimorbidity and RAVLT immediate recall change z standardized scores (Table
5-72). The coefficient for multimorbidity was -0.05 (CI95%: -0.25 to 0.15; p-value 0.63). Two
confounders showed a significant association with RAVLT immediate recall change at 5 years.
Age decreased the score by 0.021 (CI95%: -0.036 to -0.006) for each year of increase in age, and
history of traumatic brain injury increased scores 0.412 (CI95%: 0.133 to 0.691). The ICC was
0.017 (CI95%: 0.000 to 0.079).
In the subgroup analysis we did not observe an association. For the female analysis (Table 5-73),
we had information on 269 participants and the score was -0.066 (CI95%: -0.33 to 0.2; p-value
0.62). Also, we analyzed 156 participants in the male analysis (Table 5-74) with a score of 0.022
(CI95%: -0.33 to 0.28; p-value 0.88).
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Table 5-72: Association in the CSHA of Dichotomic Multimorbidity on Change of Rey Auditory
Verbal Learning Test Immediate Recall scores between Baseline and First Follow-up

Predictors

Estimates std. Error

CI

p

(Intercept)

1.30

0.60

0.12 – 2.49

0.031

mm dich [Yes]

-0.05

0.10

-0.25 – 0.15

0.627

age

-0.02

0.01

-0.04 – -0.01

0.006

sex [Male]

-0.09

0.12

-0.32 – 0.13

0.423

educ level [linear]

-0.06

0.12

-0.30 – 0.19

0.641

educ level [quadratic]

-0.03

0.12

-0.27 – 0.21

0.803

educ level [cubic]

0.21

0.12

-0.03 – 0.45

0.091

TBI [Yes]

0.41

0.14

0.13 – 0.69

0.004

smoking [Yes]

0.16

0.11

-0.06 – 0.38

0.162

alcohol [Yes]

0.03

0.12

-0.20 – 0.26

0.818

Random Effects
σ2

0.93

τ00 region

0.02 (SD: 0.13; CI95%: 0 to 0.30)

ICC

0.02

N region

5

Observations
2

425
2

Marginal R / Conditional R

0.051 / 0.067

AIC

1292.058

AICc

1292.815

mm dich: dichotomic multimorbidity; age in years; educ level: education level categorical; TBI: Traumatic brain injury

Table 5-73: Association in the CSHA of Dichotomic Multimorbidity on Change of Rey Auditory
Verbal Learning Test Immediate Recall scores between Baseline and First Follow-up - Female

Predictors

Estimates std. Error

CI

p

(Intercept)

1.42

0.77

-0.09 – 2.93

0.066

mm dich [Yes]

-0.07

0.13

-0.33 – 0.20

0.621
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age

-0.02

0.01

-0.04 – -0.00

0.025

educ level [linear]

-0.03

0.17

-0.37 – 0.31

0.862

educ level [quadratic]

-0.01

0.16

-0.33 – 0.32

0.966

educ level [cubic]

0.38

0.16

0.07 – 0.69

0.016

TBI [Yes]

0.26

0.22

-0.17 – 0.69

0.241

smoking [Yes]

0.13

0.15

-0.16 – 0.42

0.377

alcohol [Yes]

0.01

0.17

-0.33 – 0.36

0.943

Random Effects
σ2

0.97

τ00 region

0.002 (SD: 0.04; CI95%: 0 to 0.25)

ICC

0.00

N region

5

Observations
2

269
2

Marginal R / Conditional R

0.057 / 0.058

AIC

851.515

AICc

852.542

mm dich: dichotomic multimorbidity; age in years; educ level: education level categorical; TBI: Traumatic brain injury

Table 5-74: Association in the CSHA of Dichotomic Multimorbidity on Change of Rey Auditory
Verbal Learning Test Immediate Recall scores between Baseline and First Follow-up - Male

Predictors

Estimates std. Error

CI

p

(Intercept)

0.86

0.98

-1.08 – 2.80

0.383

mm dich [Yes]

-0.02

0.15

-0.32 – 0.28

0.884

age

-0.02

0.01

-0.04 – 0.01

0.142

educ level [linear]

0.01

0.19

-0.35 – 0.38

0.943

educ level [quadratic]

0.04

0.20

-0.36 – 0.44

0.838

educ level [cubic]

-0.11

0.22

-0.54 – 0.32

0.617

TBI [Yes]

0.53

0.19

0.15 – 0.91

0.006

smoking [Yes]

0.23

0.18

-0.13 – 0.59

0.211
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alcohol [Yes]

0.02

Random Effects
σ2

0.16

-0.30 – 0.33

0.88

τ00 region

0.04 (SD: 0.21; CI95%: to 0.48)

ICC

0.05

N region

5

Observations
2

0.910

156
2

Marginal R / Conditional R

0.068 / 0.112

AIC

468.727

AICc

470.560

mm dich: dichotomic multimorbidity; age in years; educ level: education level categorical; TBI: Traumatic brain injury

Multimorbidity Count
In the case of the change in RAVLT immediate recall between baseline and first follow-up using
multimorbidity count, we did not find an association with multimorbidity (Table 5-75). The
multimorbidity count score was -0.025 (CI95%: -0.089 to 0.038; p-value 0.44). The only
confounders statistically significant for the model were age with -0.02 (CI95%: -0.036 to -0.006)
and Traumatic Brain Injury with 0.41 (CI95%: 0.13 to 0.69). The ICC was 0.017 (CI95%: 0.000
to 0.080) . We did not find an association of multimorbidity with RAVLT in the female (Table
5-76) or male analyses (Table 5-77).
The dichotomic model fits better for the change between baseline and first follow-up on RAVLT
immediate recall scores on the CSHA with a cAIC of 1292.815 vs 1294.712 on the counting model.

Table 5-75: Association in the CSHA of Multimorbidity Count on Change of Rey Auditory Verbal
Learning Test Immediate Recall scores between Baseline and First Follow-up

Predictors

Estimates std. Error

CI

p

(Intercept)

1.30

0.60

0.12 – 2.48

0.031

multimorbidity

-0.03

0.03

-0.09 – 0.04

0.438
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age

-0.02

0.01

-0.04 – -0.01

0.006

sex [Male]

-0.11

0.12

-0.34 – 0.12

0.366

educ level [linear]

-0.06

0.12

-0.31 – 0.18

0.609

educ level [quadratic]

-0.03

0.12

-0.27 – 0.22

0.835

educ level [cubic]

0.21

0.12

-0.03 – 0.44

0.092

TBI [Yes]

0.41

0.14

0.13 – 0.69

0.004

smoking [Yes]

0.17

0.11

-0.06 – 0.39

0.142

alcohol [Yes]

0.03

0.12

-0.20 – 0.26

0.814

Random Effects
σ2

0.93

τ00 region

0.02 (SD: 0.13; CI95%: 0 to 0.30)

ICC

0.02

N region

5

Observations
2

425
2

Marginal R / Conditional R

0.052 / 0.068

AIC

1293.954

AICc

1294.712

multimorbidity: multimorbidity count; age in years; educ level: education level categorical; TBI: Traumatic brain injury

Table 5-76: Association in the CSHA of Multimorbidity Count on Change of Rey Auditory Verbal
Learning Test Immediate Recall scores between Baseline and First Follow-up - Female

Predictors

Estimates std. Error

CI

p

(Intercept)

1.44

0.76

-0.06 – 2.94

0.060

multimorbidity

-0.04

0.04

-0.12 – 0.04

0.300

age

-0.02

0.01

-0.04 – -0.00

0.027

educ level [linear]

-0.04

0.17

-0.38 – 0.30

0.807

educ level [quadratic]

0.00

0.17

-0.32 – 0.33

0.984

educ level [cubic]

0.37

0.16

0.07 – 0.68

0.017

TBI [Yes]

0.26

0.22

-0.17 – 0.68

0.237
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smoking [Yes]

0.15

0.15

-0.14 – 0.44

0.311

alcohol [Yes]

0.02

0.17

-0.32 – 0.36

0.915

Random Effects
σ2

0.96

τ00 region

0.002 (SD: 0.04; CI95%: 0 to 0.25)

ICC

0.00

N region

5

Observations

269

Marginal R2 / Conditional R2

0.059 / 0.061

AIC

853.056

AICc

854.083

multimorbidity: multimorbidity count; age in years; educ level: education level categorical; TBI: Traumatic brain injury

Table 5-77: Association in the CSHA of Multimorbidity Count on Change of Rey Auditory Verbal
Learning Test Immediate Recall scores between Baseline and First Follow-up - Male

Predictors

Estimates std. Error

CI

p

(Intercept)

0.86

0.98

-1.08 – 2.80

0.383

multimorbidity

0.01

0.05

-0.10 – 0.12

0.856

age

-0.02

0.01

-0.04 – 0.01

0.136

educ level [linear]

0.02

0.19

-0.35 – 0.39

0.913

educ level [quadratic]

0.04

0.20

-0.36 – 0.44

0.843

educ level [cubic]

-0.12

0.22

-0.55 – 0.31

0.586

TBI [Yes]

0.52

0.19

0.15 – 0.90

0.007

smoking [Yes]

0.23

0.18

-0.13 – 0.59

0.213

alcohol [Yes]

0.02

0.16

-0.29 – 0.33

0.900

Random Effects
σ2

0.88

τ00 region

0.04 (SD: 0.21; CI95%: 0 to 0.48)

ICC

0.05

N region

5
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Observations

156

Marginal R2 / Conditional R2

0.069 / 0.113

AIC

470.772

AICc

472.605

multimorbidity: multimorbidity count; age in years; educ level: education level categorical; TBI: Traumatic brain injury

5.1.2.3.1.2 CLSA
Baseline
Dichotomic Multimorbidity
In the CLSA we had information in 22182 participants. Our analysis showed that multimorbidity
decreases RAVLT immediate recall scores 0.023 (CI95: -0.051 to 0.0006; p-value 0.056) but is not
significant at a 0.05 level (Table 5-78). In this model, all confounders were significant associated
with the outcome score. Age decreased 0.023 (CI95%: -0.025 to -0.022) RAVLT scores for each
year of increased age, male sex decreased 0.436 (CI95%: -0.46 to -0.412), History of traumatic
brain injury increased 0.056 (CI95%: 0.028 to 0.084), history of smoking decreased 0.089 (CI95%:
-0.114 to -0.064), and alcohol consumption increased 0.134 (CI95%: 0.109 to 0.159) RAVLT
immediate recall scores. Education level showed a significant increase The ICC was 0.010 (CI95%:
0.0012 to 0.031.
The subgroups analyses in females (Table 5-79), it included information in 11045 participants with
a multimorbidity score of -0.0343 (CI95%: -0.072 to 0.0034; p-value 0.074). In the male analysis
(Table 5-80), we evaluated 11137 participants with a score of -0.017 (CI95%: -0.053 to 0.019; pvalue 0.35). On the age group analysis, in 8710 participants 65 years and older (Table 5-81), the
score of multimorbidity was - 0.0125 (CI95%: -0.05 to0.025; p-value 0.519. Finally, in 13742
participants younger than 65 years (Table 5-82) we found a decrease of 0.0399 (CI95%: -0.075 to
-0.0052; p-value 0.024) z standardized RAVLT score.
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Table 5-78: Association in the CLSA of Dichotomic Multimorbidity with Rey Auditory Verbal
Learning Test Immediate Recall at Baseline

Predictors

Estimates std. Error

CI

p

(Intercept)

1.47

0.06

1.35 – 1.58

<0.001

mm dich [Yes]

-0.03

0.01

-0.05 – 0.00

0.056

age

-0.02

0.00

-0.02 – -0.02

<0.001

sex [Male]

-0.44

0.01

-0.46 – -0.41

<0.001

educ level [linear]

0.31

0.01

0.28 – 0.33

<0.001

educ level [quadratic]

-0.07

0.02

-0.10 – -0.04

<0.001

educ level [cubic]

0.03

0.02

-0.00 – 0.07

0.064

TBI [Yes]

0.06

0.01

0.03 – 0.08

<0.001

smoking [Yes]

-0.09

0.01

-0.11 – -0.06

<0.001

alcohol [Yes]

0.13

0.01

0.11 – 0.16

<0.001

Random Effects
σ2

0.81

τ00 region

0.01 (SD: 0.09; CI95%: 0.05 to 0.18)

ICC

0.01

N region

5

Observations
2

22182
2

Marginal R / Conditional R

0.137 / 0.147

AIC

69908.646

AICc

69908.660

mm dich: dichotomic multimorbidity; age in years; educ level: education level categorical; TBI: Traumatic brain injury

Table 5-79: Association in the CLSA of Dichotomic Multimorbidity with Rey Auditory Verbal
Learning Test Immediate Recall at Baseline - Female

Predictors

Estimates std. Error

CI

p

(Intercept)

1.39

0.08

1.25 – 1.54

<0.001

mm dich [Yes]

-0.03

0.02

-0.07 – 0.00

0.074
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age

-0.02

0.00

-0.02 – -0.02

<0.001

educ level [linear]

0.28

0.02

0.24 – 0.32

<0.001

educ level [quadratic]

-0.10

0.02

-0.15 – -0.06

<0.001

educ level [cubic]

0.07

0.03

0.01 – 0.12

0.015

TBI [Yes]

0.09

0.02

0.04 – 0.13

<0.001

smoking [Yes]

-0.09

0.02

-0.12 – -0.05

<0.001

alcohol [Yes]

0.17

0.02

0.13 – 0.21

<0.001

Random Effects
σ2

0.89

τ00 region

0.01 (SD: 0.10; CI95%: 0.05 to 0.20)

ICC

0.01

N region

5

Observations
2

11045
2

Marginal R / Conditional R

0.088 / 0.098

AIC

35371.950

AICc

35371.974

mm dich: dichotomic multimorbidity; age in years; educ level: education level categorical; TBI: Traumatic brain injury

Table 5-80: Association in the CLSA of Dichotomic Multimorbidity with Rey Auditory Verbal
Learning Test Immediate Recall at Baseline - Male

Predictors

Estimates std. Error

CI

p

(Intercept)

1.12

0.07

0.98 – 1.25

<0.001

mm dich [Yes]

-0.02

0.02

-0.05 – 0.02

0.349

age

-0.02

0.00

-0.03 – -0.02

<0.001

educ level [linear]

0.34

0.02

0.30 – 0.37

<0.001

educ level [quadratic]

-0.04

0.02

-0.08 – 0.01

0.110

educ level [cubic]

-0.00

0.03

-0.05 – 0.05

0.915

TBI [Yes]

0.03

0.02

-0.00 – 0.07

0.059

smoking [Yes]

-0.09

0.02

-0.12 – -0.05

<0.001
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alcohol [Yes]

0.10

Random Effects
σ2

0.02

0.06 – 0.13

<0.001

0.73

τ00 region

0.01 (SD: 0.09; CI95%: 0.04 to 0.17)

ICC

0.01

N region

5

Observations
2

11137
2

Marginal R / Conditional R

0.111 / 0.120

AIC

34473.102

AICc

34473.125

mm dich: dichotomic multimorbidity; age in years; educ level: education level categorical; TBI: Traumatic brain injury

Table 5-81: Association in the CLSA of Dichotomic Multimorbidity with Rey Auditory Verbal
Learning Test Immediate Recall at Baseline - Participants 65 years and older

Predictors

Estimates std. Error

CI

p

(Intercept)

2.40

0.13

2.15 – 2.66

<0.001

mm dich [Yes]

-0.01

0.02

-0.05 – 0.02

0.514

age

-0.04

0.00

-0.04 – -0.03

<0.001

sex [Male]

-0.48

0.02

-0.51 – -0.44

<0.001

educ level [linear]

0.26

0.02

0.23 – 0.30

<0.001

educ level [quadratic]

-0.06

0.02

-0.10 – -0.01

0.013

educ level [cubic]

0.01

0.03

-0.04 – 0.06

0.767

TBI [Yes]

0.08

0.02

0.03 – 0.12

0.001

smoking [Yes]

-0.04

0.02

-0.08 – -0.00

0.035

alcohol [Yes]

0.12

0.02

0.08 – 0.16

<0.001

Random Effects
σ2

0.49

τ00 region

0.01 (SD: 0.09; CI95%: 0.05 to 0.18)

ICC

0.02

N region

5
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Observations

8710

Marginal R2 / Conditional R2

0.185 / 0.198

AIC

26192.222

AICc

26192.258

mm dich: dichotomic multimorbidity; age in years; educ level: education level categorical; TBI: Traumatic brain injury

Table 5-82: Association in the CLSA of Dichotomic Multimorbidity with Rey Auditory Verbal
Learning Test Immediate Recall at Baseline - Participants Younger than 65 years

Predictors

Estimates std. Error

CI

p

(Intercept)

0.93

0.09

0.75 – 1.11

<0.001

mm dich [Yes]

-0.04

0.02

-0.07 – -0.01

0.024

age

-0.01

0.00

-0.02 – -0.01

<0.001

sex [Male]

-0.43

0.02

-0.46 – -0.39

<0.001

educ level [linear]

0.33

0.02

0.29 – 0.37

<0.001

educ level [quadratic]

-0.08

0.02

-0.12 – -0.04

<0.001

educ level [cubic]

0.05

0.03

-0.00 – 0.10

0.058

TBI [Yes]

0.05

0.02

0.02 – 0.09

0.005

smoking [Yes]

-0.11

0.02

-0.14 – -0.08

<0.001

alcohol [Yes]

0.14

0.02

0.10 – 0.17

<0.001

Random Effects
σ2

1.01

τ00 region

0.01 (SD: 0.09; CI95%: 0.05 to 0.19)

ICC

0.01

N region

5

Observations

13472

Marginal R2 / Conditional R2

0.061 / 0.069

AIC

42372.103

AICc

42372.126

mm dich: dichotomic multimorbidity; age in years; educ level: education level categorical; TBI: Traumatic brain injury
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Multimorbidity Count
For the multimorbidity count analysis we had the same number than in the dichotomic
multimorbidity analysis. We noticed that multimorbidity count was associated with RAVLT scores
(Table 5-83) with a decrease of 0.0143 (CI95%: -0.024 to -0.0047; p-value 0.0032). In this analysis
all confounders were significant associated in the model. Age decreased score by 0.023 (CI95%: 0.024 to 0.022), male sex decreased by 0.437 (CI95%: -0.461 to -0.412), history of traumatic brain
injury increased scores 0.0582 (CI95%: 0.0298 to 0.0865), history of smoking decreased scores
0.0874 (CI95%: -0.112 to -0.0626), and alcohol consumption increased scores 0.132 (CI95%:
0.107 to 0.157). Education level showed a an increase of 0.304 (CI95%: 0.276 to 0.332) by each
increased level of education. The ICC was 0.010 (CI95%: 0.0009 to 0.0299).
Subgroup analyses showed that the only significant results were in females (Table 5-84) with a
decrease of 0.0171 (CI95%: -0.031 to -0.003; p-value 0.0145). It included information on 11045
participants. Male analysis included information on 11137 participants (Table 5-85) with a score
of -0.0126 (CI95%: -0.0256 to 0.00053; p-value 0.0601. In the case of the 8710 participants 65
years and older (Table 5-86), the score of multimorbidity on RAVLT immediate recall was -0.0047
(CI95%: -0.018 to 0.0083; p-value 0.48); finally in the analysis of 13472 patients younger than 65
years (Table 5-87) multimorbidity count showed -0.0076 (CI95%: -0.021 to 0.0058; p-value 0.27).
The counting model fits better for the baseline scores on RAVLT immediate recall on the CLSA
with a cAIC of 69905.636 vs 69908.660 on the dichotomic model.

Table 5-83: Association in the CLSA of Multimorbidity Count with Rey Auditory Verbal Learning
Test Immediate Recall at Baseline

Predictors

Estimates std. Error

CI

p

(Intercept)

1.46

0.06

1.35 – 1.58

<0.001

multimorbidity

-0.01

0.00

-0.02 – -0.00

0.003

age

-0.02

0.00

-0.02 – -0.02

<0.001
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sex [Male]

-0.44

0.01

-0.46 – -0.41

<0.001

educ level [linear]

0.30

0.01

0.28 – 0.33

<0.001

educ level [quadratic]

-0.07

0.02

-0.10 – -0.04

<0.001

educ level [cubic]

0.03

0.02

-0.00 – 0.07

0.075

TBI [Yes]

0.06

0.01

0.03 – 0.09

<0.001

smoking [Yes]

-0.09

0.01

-0.11 – -0.06

<0.001

alcohol [Yes]

0.13

0.01

0.11 – 0.16

<0.001

Random Effects
σ2

0.81

τ00 region

0.01 (SD: 0.09; CI95%: 0.05 to 0.18)

ICC

0.01

N region

5

Observations
2

22182
2

Marginal R / Conditional R

0.138 / 0.147

AIC

69905.622

AICc

69905.636

multimorbidity: multimorbidity count; age in years; educ level: education level categorical; TBI: Traumatic brain injury

Table 5-84: Association in the CLSA of Multimorbidity Count with Rey Auditory Verbal Learning
Test Immediate Recall at Baseline - Female

Predictors

Estimates std. Error

CI

p

(Intercept)

1.39

0.08

1.24 – 1.54

<0.001

multimorbidity

-0.02

0.01

-0.03 – -0.00

0.015

age

-0.02

0.00

-0.02 – -0.02

<0.001

educ level [linear]

0.28

0.02

0.23 – 0.32

<0.001

educ level [quadratic]

-0.10

0.02

-0.15 – -0.06

<0.001

educ level [cubic]

0.06

0.03

0.01 – 0.12

0.017

TBI [Yes]

0.09

0.02

0.04 – 0.14

<0.001

smoking [Yes]

-0.09

0.02

-0.12 – -0.05

<0.001
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alcohol [Yes]

0.17

Random Effects
σ2

0.02

0.13 – 0.20

<0.001

0.89

τ00 region

0.01 (SD: 0.10; CI95%: 0.05 to 0.20)

ICC

0.01

N region

5

Observations
2

11045
2

Marginal R / Conditional R

0.088 / 0.099

AIC

35371.174

AICc

35371.198

multimorbidity: multimorbidity count; age in years; educ level: education level categorical; TBI: Traumatic brain injury

Table 5-85: Association in the CLSA of Multimorbidity Count with Rey Auditory Verbal Learning
Test Immediate Recall at Baseline - Male

Predictors

Estimates std. Error

CI

p

(Intercept)

1.11

0.07

0.97 – 1.24

<0.001

multimorbidity

-0.01

0.01

-0.03 – 0.00

0.060

age

-0.02

0.00

-0.03 – -0.02

<0.001

educ level [linear]

0.34

0.02

0.30 – 0.37

<0.001

educ level [quadratic]

-0.04

0.02

-0.08 – 0.01

0.118

educ level [cubic]

-0.00

0.03

-0.06 – 0.05

0.868

TBI [Yes]

0.04

0.02

0.00 – 0.07

0.048

smoking [Yes]

-0.08

0.02

-0.12 – -0.05

<0.001

alcohol [Yes]

0.10

0.02

0.06 – 0.13

<0.001

Random Effects
σ2

0.73

τ00 region

0.01 (SD: 0.09; CI95%: 0.04 to 0.17)

ICC

0.01

N region

5

Observations

11137
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Marginal R2 / Conditional R2

0.111 / 0.120

AIC

34472.445

AICc

34472.468

multimorbidity: multimorbidity count; age in years; educ level: education level categorical; TBI: Traumatic brain injury

Table 5-86: Association in the CLSA of Multimorbidity Count with Rey Auditory Verbal Learning
Test Immediate Recall at Baseline - Participants 65 years and older

Predictors

Estimates std. Error

CI

p

(Intercept)

2.11

0.14

1.85 – 2.38

<0.001

multimorbidity

-0.00

0.01

-0.02 – 0.01

0.478

age

-0.03

0.00

-0.04 – -0.03

<0.001

educ level [linear]

0.24

0.02

0.20 – 0.28

<0.001

educ level [quadratic]

-0.06

0.02

-0.10 – -0.01

0.011

educ level [cubic]

0.01

0.03

-0.04 – 0.07

0.665

TBI [Yes]

0.02

0.02

-0.02 – 0.07

0.340

smoking [Yes]

-0.10

0.02

-0.14 – -0.06

<0.001

alcohol [Yes]

0.05

0.02

0.01 – 0.09

0.017

Random Effects
σ2

0.52

τ00 region

0.01 (SD: 0.09; CI95%: 0.05 to 0.18)

ICC

0.02

N region

5

Observations

8710

Marginal R2 / Conditional R2

0.095 / 0.108

AIC

26798.373

AICc

26798.404

multimorbidity: multimorbidity count; age in years; educ level: education level categorical; TBI: Traumatic brain injury
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Table 5-87: Association in the CLSA of Multimorbidity Count with Rey Auditory Verbal Learning
Test Immediate Recall at Baseline - Participants younger than 65 years

Predictors

Estimates std. Error

CI

p

(Intercept)

0.77

0.09

0.59 – 0.96

<0.001

multimorbidity

-0.01

0.01

-0.02 – 0.01

0.265

age

-0.01

0.00

-0.02 – -0.01

<0.001

educ level [linear]

0.35

0.02

0.31 – 0.39

<0.001

educ level [quadratic]

-0.11

0.02

-0.15 – -0.06

<0.001

educ level [cubic]

0.06

0.03

0.01 – 0.11

0.020

TBI [Yes]

-0.02

0.02

-0.05 – 0.02

0.371

smoking [Yes]

-0.11

0.02

-0.15 – -0.08

<0.001

alcohol [Yes]

0.09

0.02

0.05 – 0.12

<0.001

Random Effects
σ2

1.06

τ00 region

0.01 (SD: 0.10; CI95%: 0.05 to 0.19)

ICC

0.01

N region

5

Observations
2

13472
2

Marginal R / Conditional R

0.021 / 0.029

AIC

43031.005

AICc

43031.025

multimorbidity: multimorbidity count; age in years; educ level: education level categorical; TBI: Traumatic brain injury

Change between baseline and first follow-up
Dichotomic Multimorbidity
For the RAVLT immediate recall in the CLSA we had information in 22182 participants.
Presenting multimorbidity showed a score of -0.0015 (CI95%: -0.032 to 0.029; p-value 0.93) which
is not associated with change in the RAVLT immediate recall scores (Table 5-88). We found that
of the confounders were significant in the model age that decreased 0.013 (CI95%: -0.015 to 159
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0.012) points by each year of increase in age, male sex that decreased 0.135 (CI95%: -0.163 to 0.106) and traumatic brain injury that decreased by 0.012 (CI95%: -0.100 to -0.033) the scores.
The ICC was 0.
We found that in the subgroup analyses multimorbidity increased only in participants 65 years and
older with a score of 0.06 (CI95%:0.015 to 0.106; p-value 0.0098) when analyzing 8710
participants (Table 5-91). In 13472 participants younger than 65 years (Table 5-92) multimorbidity
modified score in -0.0301 (CI95%: -0.071 to 0.011; p-value 0.15). In the female analysis (Table
5-89) we included information in 11045 participants with a score 0.0087 (CI95%: -0.036 to 0.053;
p-value 0.71) and in the male analysis (Table 5-90) including 11137 participants the score was 0.012 (CI95%: -0.054 to 0.0304; p-value 0.59)

Table 5-88: Association in the CLSA of Dichotomic Multimorbidity on Change of Rey Auditory
Verbal Learning Test Immediate Recall scores between Baseline and First Follow-up

Predictors

Estimates std. Error

CI

p

(Intercept)

1.23

0.05

1.13 – 1.32

<0.001

mm dich [Yes]

-0.00

0.02

-0.03 – 0.03

0.925

age

-0.01

0.00

-0.01 – -0.01

<0.001

sex [Male]

-0.13

0.01

-0.16 – -0.11

<0.001

educ level [linear]

0.03

0.02

-0.00 – 0.06

0.068

educ level [quadratic]

0.01

0.02

-0.02 – 0.05

0.453

educ level [cubic]

0.01

0.02

-0.03 – 0.06

0.530

TBI [Yes]

-0.07

0.02

-0.10 – -0.03

<0.001

smoking [Yes]

-0.01

0.01

-0.04 – 0.02

0.418

alcohol [Yes]

0.01

0.02

-0.01 – 0.04

0.334

Random Effects
σ2

1.14

τ00 region

<0.001 (SD: <0.001; CI95%: 0 to 0.03)

N region

5
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Observations

22182

Marginal R2 / Conditional R2

0.021 / NA

AIC

77411.970

AICc

77411.984

mm dich: dichotomic multimorbidity; age in years; educ level: education level categorical; TBI: Traumatic brain injury

Table 5-89: Association in the CLSA of Dichotomic Multimorbidity on Change of Rey Auditory
Verbal Learning Test Immediate Recall scores between Baseline and First Follow-up - Female

Predictors

Estimates std. Error

CI

p

(Intercept)

1.30

0.07

1.16 – 1.44

<0.001

mm dich [Yes]

0.01

0.02

-0.04 – 0.05

0.705

age

-0.01

0.00

-0.02 – -0.01

<0.001

educ level [linear]

0.04

0.02

-0.00 – 0.09

0.076

educ level [quadratic]

0.01

0.03

-0.04 – 0.07

0.635

educ level [cubic]

0.02

0.03

-0.04 – 0.08

0.549

TBI [Yes]

-0.11

0.03

-0.16 – -0.06

<0.001

smoking [Yes]

0.02

0.02

-0.02 – 0.07

0.277

alcohol [Yes]

-0.02

0.02

-0.06 – 0.02

0.377

Random Effects
σ2

1.26

τ00 region

<0.001 (SD: <0.001; CI95%: 0 to .03)

N region

5

Observations

11045

Marginal R2 / Conditional R2

0.018 / NA

AIC

39179.297

AICc

39179.321

mm dich: dichotomic multimorbidity; age in years; educ level: education level categorical; TBI: Traumatic brain injury
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Table 5-90: Association in the CLSA of Dichotomic Multimorbidity on Change of Rey Auditory
Verbal Learning Test Immediate Recall scores between Baseline and First Follow-up - Male

Predictors

Estimates std. Error

CI

p

(Intercept)

1.00

0.07

0.87 – 1.13

<0.001

mm dich [Yes]

-0.01

0.02

-0.05 – 0.03

0.590

age

-0.01

0.00

-0.01 – -0.01

<0.001

educ level [linear]

0.01

0.02

-0.03 – 0.06

0.581

educ level [quadratic]

0.02

0.03

-0.03 – 0.07

0.448

educ level [cubic]

0.01

0.03

-0.05 – 0.07

0.805

TBI [Yes]

-0.03

0.02

-0.07 – 0.01

0.134

smoking [Yes]

-0.06

0.02

-0.10 – -0.01

0.007

alcohol [Yes]

0.05

0.02

0.01 – 0.09

0.017

Random Effects
σ2

1.02

τ00 region

0.004 (SD: 0.02; CI95%: 0 to 0.05)

ICC

0.00

N region

5

Observations
2

11137
2

Marginal R / Conditional R

0.016 / 0.016

AIC

38159.465

AICc

38159.489

mm dich: dichotomic multimorbidity; age in years; educ level: education level categorical; TBI: Traumatic brain injury

Table 5-91: Association in the CLSA of Dichotomic Multimorbidity on Change of Rey Auditory
Verbal Learning Test Immediate Recall scores between Baseline and First Follow-up - Participants
65 years and older

Predictors

Estimates std. Error

CI

p

(Intercept)

2.13

0.15

1.83 – 2.43

<0.001

mm dich [Yes]

0.06

0.02

0.01 – 0.11

0.010
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age

-0.03

0.00

-0.03 – -0.02

<0.001

sex [Male]

-0.11

0.02

-0.16 – -0.07

<0.001

educ level [linear]

-0.04

0.02

-0.08 – 0.00

0.064

educ level [quadratic]

0.03

0.03

-0.02 – 0.08

0.293

educ level [cubic]

0.02

0.03

-0.05 – 0.08

0.587

TBI [Yes]

-0.05

0.03

-0.10 – 0.01

0.086

smoking [Yes]

-0.04

0.02

-0.08 – 0.01

0.108

alcohol [Yes]

0.07

0.02

0.03 – 0.12

0.001

Random Effects
σ2

0.72

τ00 region

0.02 (SD: 0.04; CI95%: 0.01 to 0.09)

ICC

0.00

N region

5

Observations
2

8710
2

Marginal R / Conditional R

0.035 / 0.037

AIC

29612.712

AICc

29612.748

mm dich: dichotomic multimorbidity; age in years; educ level: education level categorical; TBI: Traumatic brain injury

Table 5-92: Association in the CLSA of Dichotomic Multimorbidity on Change of Rey Auditory
Verbal Learning Test Immediate Recall scores between Baseline and First Follow-up - Participants
younger than 65 years

Predictors

Estimates std. Error

CI

p

(Intercept)

1.00

0.10

0.82 – 1.19

<0.001

mm dich [Yes]

-0.03

0.02

-0.07 – 0.01

0.148

age

-0.01

0.00

-0.01 – -0.01

<0.001

sex [Male]

-0.14

0.02

-0.18 – -0.11

<0.001

educ level [linear]

0.07

0.02

0.02 – 0.12

0.004

educ level [quadratic]

0.00

0.03

-0.05 – 0.05

0.975
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educ level [cubic]

0.02

0.03

-0.04 – 0.07

0.606

TBI [Yes]

-0.07

0.02

-0.11 – -0.03

0.001

smoking [Yes]

-0.00

0.02

-0.04 – 0.03

0.834

alcohol [Yes]

-0.01

0.02

-0.05 – 0.03

0.603

Random Effects
σ2

1.40

τ00 region

0.001 (SD: 0.01; CI95%: 0 to 0.04)

ICC

0.00

N region

5

Observations
2

13472
2

Marginal R / Conditional R

0.007 / 0.007

AIC

46733.271

AICc

46733.294

mm dich: dichotomic multimorbidity; age in years; educ level: education level categorical; TBI: Traumatic brain injury

Multimorbidity Count
For the change of RAVLT immediate recall RCI z standardized we had the same number of
participants than in the dichotomic analysis. We did not find an association of the multimorbidity
count on RAVLT scores (
Table 5-93); the multimorbidity coefficient was -0.007 (CI95%: -0.019 to 0.003; p-value 0.17). We
noticed that only age with a score of -0.0129 (CI95%: -0.0144 to -0.011), male sex with a score of
-0.136 (CI95%: -0.165 to -0.107), and history of traumatic brain injury with a score of -0.065
(CI95%: -0.098 to -0.031) were significant for the model. The ICC was 0.
In the case of subgroup analyses multimorbidity count was associated with RAVLT immediate
recall scores in females and younger than 65 years. In the female analysis (Table 5-94),
multimorbidity count decreased 0.021 (CI95%: -0.038 to -0.0052; p-value 0.0098) RAVLT
immediate recall scores. In the male analysis (Table 5-95), multimorbidity count score was 0.0078
(CI95%: -0.0076 to 0.23; p-value 0.32). In the case of patients 65 years and older (Table 5-96) the
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score was 0.0041 (CI95%: -0.011 to 0.020; p-value 0.61), and in the case of patients younger than
65 (Table 5-97), it decreased 0.0159 (CI95%: -0.0313 to -0.00045; p-value 0.044).
The dichotomic model fits slightly better for the change between baseline and first follow-up on
RAVLT immediate recall scores on the CLSA with a cAIC of 77411.984 vs 77412.116 on the
counting model.

Table 5-93: Association in the CLSA of Multimorbidity Count on Change of Rey Auditory Verbal
Learning Test Immediate Recall scores between Baseline and First Follow-up

Predictors

Estimates std. Error

CI

p

(Intercept)

1.22

0.05

1.12 – 1.32

<0.001

multimorbidity

-0.01

0.01

-0.02 – 0.00

0.169

age

-0.01

0.00

-0.01 – -0.01

<0.001

sex [Male]

-0.14

0.01

-0.16 – -0.11

<0.001

educ level [linear]

0.03

0.02

-0.00 – 0.06

0.079

educ level [quadratic]

0.01

0.02

-0.02 – 0.05

0.440

educ level [cubic]

0.01

0.02

-0.03 – 0.06

0.566

TBI [Yes]

-0.06

0.02

-0.10 – -0.03

<0.001

smoking [Yes]

-0.01

0.01

-0.04 – 0.02

0.488

alcohol [Yes]

0.01

0.02

-0.02 – 0.04

0.426

Random Effects
σ2

1.14

τ00 region

<0.001 (SD: <0.001; CI95%: 0 to 0.03)

N region

5

Observations
2

22182
2

Marginal R / Conditional R

0.021 / NA

AIC

77412.102

AICc

77412.116

multimorbidity: multimorbidity count; age in years; educ level: education level categorical; TBI: Traumatic brain injury
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Table 5-94: Association in the CLSA of Multimorbidity Count on Change of Rey Auditory Verbal
Learning Test Immediate Recall scores between Baseline and First Follow-up - Female

Predictors

Estimates std. Error

CI

p

(Intercept)

1.27

0.07

1.13 – 1.41

<0.001

multimorbidity

-0.02

0.01

-0.04 – -0.01

0.010

age

-0.01

0.00

-0.02 – -0.01

<0.001

educ level [linear]

0.04

0.02

-0.01 – 0.09

0.105

educ level [quadratic]

0.01

0.03

-0.04 – 0.07

0.621

educ level [cubic]

0.02

0.03

-0.05 – 0.08

0.627

TBI [Yes]

-0.10

0.03

-0.15 – -0.05

<0.001

smoking [Yes]

0.03

0.02

-0.01 – 0.07

0.201

alcohol [Yes]

-0.03

0.02

-0.07 – 0.01

0.200

Random Effects
σ2

1.26

τ00 region

<0.001 (SD: <0.001; CI95%: 0 to 0.03)

N region

5

Observations
2

11045
2

Marginal R / Conditional R

0.019 / NA

AIC

39174.786

AICc

39174.810

multimorbidity: multimorbidity count; age in years; educ level: education level categorical; TBI: Traumatic brain injury

Table 5-95: Association in the CLSA of Multimorbidity Count on Change of Rey Auditory Verbal
Learning Test Immediate Recall scores between Baseline and First Follow-up - Male

Predictors

Estimates std. Error

CI

p

(Intercept)

1.01

0.07

0.88 – 1.15

<0.001

multimorbidity

0.01

0.01

-0.01 – 0.02

0.321

age

-0.01

0.00

-0.01 – -0.01

<0.001
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educ level [linear]

0.01

0.02

-0.03 – 0.06

0.526

educ level [quadratic]

0.02

0.03

-0.03 – 0.07

0.472

educ level [cubic]

0.01

0.03

-0.05 – 0.07

0.764

TBI [Yes]

-0.03

0.02

-0.08 – 0.01

0.106

smoking [Yes]

-0.06

0.02

-0.10 – -0.02

0.005

alcohol [Yes]

0.05

0.02

0.01 – 0.09

0.011

Random Effects
σ2

1.02

τ00 region

0.004 (SD: 0.02; CI95%: 0 to 0.05)

ICC

0.00

N region

5

Observations

11137

Marginal R2 / Conditional R2

0.016 / 0.016

AIC

38160.773

AICc

38160.797

multimorbidity: multimorbidity count; age in years; educ level: education level categorical; TBI: Traumatic brain injury

Table 5-96: Association in the CLSA of Multimorbidity Count on Change of Rey Auditory Verbal
Learning Test Immediate Recall scores between Baseline and First Follow-up - Participants 65
years and older

Predictors

Estimates std. Error

CI

p

(Intercept)

2.13

0.15

1.83 – 2.43

<0.001

multimorbidity

0.00

0.01

-0.01 – 0.02

0.606

age

-0.03

0.00

-0.03 – -0.02

<0.001

sex [Male]

-0.11

0.02

-0.16 – -0.07

<0.001

educ level [linear]

-0.04

0.02

-0.08 – 0.00

0.063

educ level [quadratic]

0.03

0.03

-0.02 – 0.08

0.296

educ level [cubic]

0.02

0.03

-0.05 – 0.08

0.598

TBI [Yes]

-0.05

0.03

-0.10 – 0.01

0.111
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smoking [Yes]

-0.03

0.02

-0.08 – 0.01

0.135

alcohol [Yes]

0.07

0.02

0.03 – 0.12

0.002

Random Effects
σ2

0.72

τ00 region

0.004 (SD: 0.02; CI95%: 0.005 to 0.08)

ICC

0.00

N region

5

Observations

8710

Marginal R2 / Conditional R2

0.034 / 0.036

AIC

29621.263

AICc

29621.299

multimorbidity: multimorbidity count; age in years; educ level: education level categorical; TBI: Traumatic brain injury

Table 5-97: Association in the CLSA of Multimorbidity Count on Change of Rey Auditory Verbal
Learning Test Immediate Recall scores between Baseline and First Follow-up - Participants
Younger than 65 years

Predictors

Estimates std. Error

CI

p

(Intercept)

1.00

0.10

0.81 – 1.18

<0.001

multimorbidity

-0.02

0.01

-0.03 – -0.00

0.044

age

-0.01

0.00

-0.01 – -0.01

<0.001

sex [Male]

-0.14

0.02

-0.18 – -0.11

<0.001

educ level [linear]

0.07

0.02

0.02 – 0.12

0.004

educ level [quadratic]

0.00

0.03

-0.05 – 0.05

0.966

educ level [cubic]

0.01

0.03

-0.04 – 0.07

0.631

TBI [Yes]

-0.07

0.02

-0.11 – -0.02

0.002

smoking [Yes]

-0.00

0.02

-0.04 – 0.04

0.874

alcohol [Yes]

-0.01

0.02

-0.05 – 0.03

0.540

Random Effects
σ2
τ00 region

1.40
0.001 (SD: 0.01; CI95%: 0 to 0.04)
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ICC

0.00

N region

5

Observations
2

13472
2

Marginal R / Conditional R

0.007 / 0.007

AIC

46733.245

AICc

46733.268

multimorbidity: multimorbidity count; age in years; educ level: education level categorical; TBI: Traumatic brain injury

5.1.2.3.2 Delayed Recall

5.1.2.3.2.1 CSHA
Baseline
Dichotomic Multimorbidity
In the case of RAVLT delayed recall we had information in 486 participants. We found that having
multimorbidity was not associated with RAVLT delayed recall score (Table 5-98) with a
coefficient of -0.013 (CI95%: -0.187 to 0.160; p-value 0.88). When we analyzed confounders only
age with a decrease of 0.013 (CI95%: -0.026 to -0.00019) per year and education level with an
increase of 0.53 (CI95%: 0.31 to 0.751) per one increase in category were associated with RAVLT
delayed recall score. The ICC was 0.088 (CI95%: 0.002 to 0.259).
We analyzed the subgroup analyses without effect of multimorbidity on RAVLT delayed recall
score. In the female analysis (Table 5-99), including 307 participants, we did not notice an
association of multimorbidity on RAVLT delayed recall with a coefficient of -0.081 (CI95%: 0.302 to 0.14; p-value 0.47). Also, in 179 male participants (Table 5-100) we did not find an
association with a coefficient of 0.056 (CI95%: -0.23 to 0.34; p-value 0.70).

Table 5-98: Association in the CSHA of Dichotomic Multimorbidity with Rey Auditory Verbal
Learning Test Delayed Recall at Baseline
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Predictors

Estimates std. Error

CI

p

(Intercept)

1.32

0.54

0.25 – 2.38

0.016

mm dich [Yes]

-0.01

0.09

-0.19 – 0.16

0.880

age

-0.01

0.01

-0.03 – -0.00

0.047

sex [Male]

0.09

0.10

-0.11 – 0.30

0.368

educ level [linear]

0.53

0.11

0.31 – 0.75

<0.001

educ level [quadratic]

-0.05

0.11

-0.26 – 0.17

0.679

educ level [cubic]

0.12

0.11

-0.09 – 0.33

0.273

TBI [Yes]

-0.02

0.12

-0.26 – 0.22

0.870

smoking [Yes]

0.02

0.10

-0.18 – 0.21

0.882

alcohol [Yes]

-0.13

0.10

-0.34 – 0.07

0.207

Random Effects
σ2

0.83

τ00 region

0.08 (SD: 0.28; CI95%: 0.13 to 0.57)

ICC

0.09

N region

5

Observations

486

Marginal R2 / Conditional R2

0.075 / 0.156

AIC

1426.576

AICc

1427.235

mm dich: dichotomic multimorbidity; age in years; educ level: education level categorical; TBI: Traumatic brain injury

Table 5-99: Association in the CSHA of Dichotomic Multimorbidity with Rey Auditory Verbal
Learning Test Delayed Recall at Baseline - Female

Predictors

Estimates std. Error

CI

p

(Intercept)

2.34

0.66

1.04 – 3.63

<0.001

mm dich [Yes]

-0.08

0.11

-0.30 – 0.14

0.474

age

-0.03

0.01

-0.04 – -0.01

0.001

educ level [linear]

0.45

0.15

0.15 – 0.75

0.004
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educ level [quadratic]

-0.11

0.14

-0.39 – 0.17

0.428

educ level [cubic]

0.07

0.13

-0.19 – 0.33

0.574

TBI [Yes]

-0.09

0.18

-0.44 – 0.26

0.610

smoking [Yes]

-0.11

0.13

-0.35 – 0.14

0.400

alcohol [Yes]

0.10

0.15

-0.19 – 0.39

0.501

Random Effects
σ2

0.78

τ00 region

0.10 (SD: 0.32; CI95%: 0.13 to 0.66)

ICC

0.12

N region

5

Observations
2

307
2

Marginal R / Conditional R

0.083 / 0.190

AIC

913.906

AICc

914.801

mm dich: dichotomic multimorbidity; age in years; educ level: education level categorical; TBI: Traumatic brain injury

Table 5-100: Association in the CSHA of Dichotomic Multimorbidity with Rey Auditory Verbal
Learning Test Delayed Recall at Baseline - Male

Predictors

Estimates std. Error

CI

p

(Intercept)

-0.57

0.94

-2.41 – 1.28

0.546

mm dich [Yes]

0.06

0.14

-0.23 – 0.34

0.696

age

0.01

0.01

-0.01 – 0.03

0.369

educ level [linear]

0.62

0.18

0.27 – 0.96

0.001

educ level [quadratic]

0.06

0.19

-0.32 – 0.44

0.759

educ level [cubic]

0.14

0.21

-0.26 – 0.55

0.484

TBI [Yes]

0.07

0.17

-0.26 – 0.41

0.667

smoking [Yes]

0.23

0.18

-0.12 – 0.57

0.203

alcohol [Yes]

-0.27

0.15

-0.56 – 0.02

0.069

Random Effects
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σ2

0.88

τ00 region

0.07 (SD: 0.27; CI95%: 0.05 to 0.58)

ICC

0.07

N region

5

Observations
2

179
2

Marginal R / Conditional R

0.110 / 0.176

AIC

537.872

AICc

539.453

mm dich: dichotomic multimorbidity; age in years; educ level: education level categorical; TBI: Traumatic brain injury

Multimorbidity Count
In the multimorbidity count we had the same number of participants than in the multimorbidity
dichotomic analysis. We did not find an association of presenting multimorbidity on RAVLT
delayed recall scores (Table 5-101) with a coefficient of 0.046 (CI95%: -0.0097 to 0.101; p-value
0.11). The confounders significant for the model were age with a coefficient of -0.019 (CI95%: 0.032 to -0.0053), male sex with a coefficient -0.334 (CI95%: -0.535 to -0.133) and history of
traumatic brain injury with a coefficient of -0.4 (CI95%: -0.644 to -0.157); also, we found an
increase of 0.375 (CI95%: 0.162 to 0.587) with education level. The ICC was 0.03 (CI95%: 0.000
to 0.119).
In the subgroup analysis we did not find associations of multimorbidity count on RAVLT delayed
recall. The female analysis (Table 5-102) showed a coefficient of 0.058 (CI95%: -0.0047 to 0.121;
p-value 0.071) and the male analysis (Table 5-103) indicated a coefficient of 0.017 (CI95%: -0.094
to 0.128; p-value 0.76).
The counting model fits better for the baseline scores on RAVLT delayed recall on the CSHA with
a cAIC of 1127.742 vs 1427.235 on the dichotomic model.
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Table 5-101: Association in the CSHA of Multimorbidity Count with Rey Auditory Verbal Learning
Test Delayed Recall at Baseline

Predictors

Estimates std. Error

CI

p

(Intercept)

1.82

0.53

0.78 – 2.87

0.001

multimorbidity

0.05

0.03

-0.01 – 0.10

0.106

age

-0.02

0.01

-0.03 – -0.01

0.006

sex [Male]

-0.33

0.10

-0.54 – -0.13

0.001

educ level [linear]

0.37

0.11

0.16 – 0.59

0.001

educ level [quadratic]

-0.06

0.11

-0.27 – 0.15

0.583

educ level [cubic]

0.16

0.11

-0.05 – 0.37

0.138

TBI [Yes]

-0.40

0.12

-0.64 – -0.16

0.001

smoking [Yes]

-0.17

0.10

-0.37 – 0.02

0.084

alcohol [Yes]

-0.11

0.10

-0.31 – 0.09

0.295

Random Effects
σ2

0.69

τ00 region

0.02 (SD: 0.15; CI95: 0.02 to 0.32)

ICC

0.03

N region

5

Observations
2

409
2

Marginal R / Conditional R

0.153 / 0.178

AIC

1126.954

AICc

1127.742

multimorbidity: multimorbidity count; age in years; educ level: education level categorical; TBI: Traumatic brain injury

Table 5-102: Association in the CSHA of Multimorbidity Count with Rey Auditory Verbal Learning
Test Delayed Recall at Baseline - Female

Predictors

Estimates std. Error

CI

p

(Intercept)

1.97

0.60

0.79 – 3.16

0.001

multimorbidity

0.06

0.03

-0.01 – 0.12

0.071
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age

-0.02

0.01

-0.04 – -0.01

0.005

educ level [linear]

0.26

0.13

-0.01 – 0.52

0.058

educ level [quadratic]

-0.13

0.13

-0.39 – 0.12

0.313

educ level [cubic]

0.02

0.12

-0.22 – 0.27

0.841

TBI [Yes]

-0.49

0.17

-0.82 – -0.15

0.004

smoking [Yes]

-0.22

0.12

-0.45 – 0.01

0.057

alcohol [Yes]

-0.03

0.14

-0.30 – 0.24

0.825

Random Effects
σ2

0.58

τ00 region

0.01 (SD: 0.08; CI95%: 0 to 0.24)

ICC

0.01

N region

5

Observations
2

259
2

Marginal R / Conditional R

0.110 / 0.120

AIC

693.763

AICc

694.832

multimorbidity: multimorbidity count; age in years; educ level: education level categorical; TBI: Traumatic brain injury

Table 5-103: Association in the CSHA of Multimorbidity Count with Rey Auditory Verbal Learning
Test Delayed Recall at Baseline - Male

rey.delayed.blz
Predictors

Estimates std. Error

CI

p

(Intercept)

0.95

1.02

-1.06 – 2.97

0.352

multimorbidity

0.02

0.06

-0.09 – 0.13

0.761

age

-0.01

0.01

-0.04 – 0.01

0.384

educ level [linear]

0.46

0.19

0.08 – 0.84

0.018

educ level [quadratic]

-0.06

0.21

-0.47 – 0.35

0.772

educ level [cubic]

0.41

0.23

-0.03 – 0.86

0.070

TBI [Yes]

-0.27

0.20

-0.66 – 0.12

0.168
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smoking [Yes]

-0.01

0.19

-0.39 – 0.37

0.972

alcohol [Yes]

-0.14

0.16

-0.47 – 0.18

0.378

Random Effects
σ2

0.91

τ00 region

0.03 (SD: 0.17; CI95%: 0 to 0.43)

ICC

0.03

N region

5

Observations

150

Marginal R2 / Conditional R2

0.099 / 0.128

AIC

457.061

AICc

458.975

multimorbidity: multimorbidity count; age in years; educ level: education level categorical; TBI: Traumatic brain injury

Change between baseline and first follow-up
Dichotomic Multimorbidity
We had information on 409 participants. We found that having multimorbidity was not associated
with RAVLT delayed recall change at first follow-up (Table 5-104) with a coefficient of 0.039
(CI95%: -0.187 to 0.264; p-value 0.74). Also, we found that any confounder was significant for
the model. The ICC was 0.023 (CI95%: 0.000 to 0.106). The subgroup analyses by sex did not
show an association of multimorbidity on RAVLT delayed recall. The female analysis (Table
5-105) included 259 participants with a multimorbidity coefficient of -0.039 (CI95%: -0.315 to
0.237; p-value 0.78). Finally, the male analysis (Table 5-106) included 150 participants with a
multimorbidity coefficient of 0.194 (CI95%: -0.186 to 0.574; p-value 0.32).

Table 5-104: Association in the CSHA of Dichotomic Multimorbidity on Change of Rey Auditory
Verbal Learning Test Delayed Recall scores between Baseline and First Follow-up

Predictors
(Intercept)

Estimates std. Error
-0.98

0.70

CI

p

-2.35 – 0.39

0.158
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mm dich [Yes]

0.04

0.12

-0.19 – 0.27

0.738

age

0.01

0.01

-0.01 – 0.02

0.399

sex [Male]

0.23

0.13

-0.03 – 0.49

0.088

educ level [linear]

-0.05

0.14

-0.33 – 0.23

0.735

educ level [quadratic]

0.05

0.14

-0.22 – 0.33

0.703

educ level [cubic]

-0.22

0.14

-0.50 – 0.05

0.113

TBI [Yes]

-0.00

0.16

-0.32 – 0.31

0.976

smoking [Yes]

0.11

0.13

-0.14 – 0.36

0.395

alcohol [Yes]

-0.11

0.13

-0.37 – 0.16

0.434

Random Effects
σ2

1.19

τ00 region

0.03 (SD: 0.17; CI95%: 0 to 0.40)

ICC

0.02

N region

5

Observations

409

Marginal R2 / Conditional R2

0.025 / 0.047

AIC

1338.893

AICc

1339.680

mm dich: dichotomic multimorbidity; age in years; educ level: education level categorical; TBI: Traumatic brain injury

Table 5-105: Association in the CSHA of Dichotomic Multimorbidity on Change of Rey Auditory
Verbal Learning Test Delayed Recall scores between Baseline and First Follow-up - Female

Predictors

Estimates std. Error

CI

p

(Intercept)

-0.67

0.81

-2.26 – 0.92

0.407

mm dich [Yes]

-0.04

0.14

-0.32 – 0.24

0.781

age

0.00

0.01

-0.02 – 0.02

0.696

educ level [linear]

-0.12

0.18

-0.47 – 0.23

0.509

educ level [quadratic]

-0.15

0.17

-0.49 – 0.19

0.386

educ level [cubic]

-0.08

0.16

-0.41 – 0.24

0.616
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TBI [Yes]

0.18

0.23

-0.27 – 0.63

0.421

smoking [Yes]

0.12

0.15

-0.18 – 0.42

0.441

alcohol [Yes]

-0.06

0.18

-0.42 – 0.30

0.744

Random Effects
σ2

1.04

τ00 region

<0.001 (SD: <0.001; CI95%: 0 to 0.19)

N region

5

Observations
2

259
2

Marginal R / Conditional R

0.011 / NA

AIC

836.622

AICc

837.691

mm dich: dichotomic multimorbidity; age in years; educ level: education level categorical; TBI: Traumatic brain injury

Table 5-106: Association in the CSHA of Dichotomic Multimorbidity on Change of Rey Auditory
Verbal Learning Test Delayed Recall scores between Baseline and First Follow-up - Male

Predictors

Estimates std. Error

CI

p

(Intercept)

-1.33

1.26

-3.82 – 1.17

0.295

mm dich [Yes]

0.19

0.19

-0.19 – 0.58

0.319

age

0.01

0.02

-0.02 – 0.04

0.468

educ level [linear]

0.13

0.23

-0.33 – 0.59

0.579

educ level [quadratic]

0.55

0.25

0.05 – 1.05

0.033

educ level [cubic]

-0.63

0.28

-1.18 – -0.08

0.024

TBI [Yes]

-0.07

0.24

-0.54 – 0.40

0.770

smoking [Yes]

0.03

0.23

-0.43 – 0.49

0.893

alcohol [Yes]

-0.11

0.20

-0.50 – 0.28

0.583

Random Effects
σ2

1.32

τ00 region

0.29 (SD: 0.54; CI95%: 0 to 0.17)

ICC

0.18

N region

5
177

December 13, 2022

Observations

150

Marginal R2 / Conditional R2

0.064 / 0.232

AIC

512.373

AICc

514.286

mm dich: dichotomic multimorbidity; age in years; educ level: education level categorical; TBI: Traumatic brain injury

Multimorbidity count
For the multimorbidity count analyses we had the same number of participants that for the
Dichotomic multimorbidity analyses. We did not find an association of multimorbidity count on
RAVLT delayed recall change at first follow-up (Table 5-107). The multimorbidity coefficient was
-0.0054 (CI95%: -0.078 to 0.067; p-value 0.88). Also, in this case, any confounder was significant
for the model. The ICC was 0.022 (CI95%: 0.000 to 0.0978). In the subgroup analysis we did not
find associations either. In the female analysis (Table 5-108) the coefficient was -0.038 (CI95%: 0.122 to 0.046; p-value 0.38) and in the male analysis (Table 5-109) the coefficient was 0.094
(CI95%: -0.04 to 0.228; p-value 0.17).
The dichotomic model fits better for the change between baseline and first follow-up on RAVLT
delayed recall scores on the CSHA with a cAIC of 1339.680 vs 1342.041 on the counting model.

Table 5-107: Association in the CSHA of Multimorbidity Count on Change of Rey Auditory Verbal
Learning Test Delayed Recall scores between Baseline and First Follow-up

Predictors

Estimates std. Error

CI

p

(Intercept)

-0.96

0.69

-2.32 – 0.41

0.169

multimorbidity

-0.01

0.04

-0.08 – 0.07

0.883

age

0.01

0.01

-0.01 – 0.02

0.394

sex [Male]

0.22

0.13

-0.05 – 0.48

0.104

educ level [linear]

-0.05

0.14

-0.33 – 0.23

0.710

educ level [quadratic]

0.06

0.14

-0.22 – 0.34

0.683
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educ level [cubic]

-0.22

0.14

-0.49 – 0.06

0.124

TBI [Yes]

0.00

0.16

-0.32 – 0.32

0.993

smoking [Yes]

0.11

0.13

-0.14 – 0.37

0.390

alcohol [Yes]

-0.10

0.13

-0.37 – 0.16

0.437

Random Effects
σ2

1.19

τ00 region

0.03 (0.16; CI95%: 0 to 0.39)

ICC

0.02

N region

5

Observations
2

409
2

Marginal R / Conditional R

0.024 / 0.046

AIC

1341.253

AICc

1342.041

multimorbidity: multimorbidity count; age in years; educ level: education level categorical; TBI: Traumatic brain injury

Table 5-108: Association in the CSHA of Multimorbidity Count on Change of Rey Auditory Verbal
Learning Test Delayed Recall scores between Baseline and First Follow-up - Female

Predictors

Estimates std. Error

CI

p

(Intercept)

-0.64

0.80

-2.22 – 0.94

0.425

multimorbidity

-0.04

0.04

-0.12 – 0.05

0.375

age

0.00

0.01

-0.02 – 0.02

0.676

educ level [linear]

-0.13

0.18

-0.48 – 0.22

0.470

educ level [quadratic]

-0.14

0.17

-0.48 – 0.20

0.423

educ level [cubic]

-0.09

0.16

-0.41 – 0.24

0.598

TBI [Yes]

0.19

0.23

-0.26 – 0.64

0.410

smoking [Yes]

0.14

0.15

-0.17 – 0.44

0.378

alcohol [Yes]

-0.05

0.18

-0.41 – 0.31

0.776

Random Effects
σ2

1.04
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τ00 region

<0.001 (SD: <0.001; CI95%: 0 to 0.19)

N region

5

Observations

259

2

2

Marginal R / Conditional R

0.014 / NA

AIC

838.292

AICc

839.360

multimorbidity: multimorbidity count; age in years; educ level: education level categorical; TBI: Traumatic brain injury

Table 5-109: Association in the CSHA of Multimorbidity Count on Change of Rey Auditory Verbal
Learning Test Delayed Recall scores between Baseline and First Follow-up - Male

Predictors

Estimates std. Error

CI

p

(Intercept)

-1.22

1.26

-3.71 – 1.27

0.334

multimorbidity

0.09

0.07

-0.04 – 0.23

0.169

age

0.01

0.02

-0.02 – 0.04

0.551

educ level [linear]

0.15

0.23

-0.31 – 0.61

0.520

educ level [quadratic]

0.55

0.25

0.05 – 1.05

0.030

educ level [cubic]

-0.63

0.27

-1.18 – -0.09

0.023

TBI [Yes]

-0.09

0.24

-0.57 – 0.38

0.694

smoking [Yes]

0.02

0.23

-0.44 – 0.48

0.940

alcohol [Yes]

-0.11

0.20

-0.50 – 0.28

0.579

Random Effects
σ2

1.31

τ00 region

0.29 (SD 0.54; CI95%: 0 to 1.18)

ICC

0.18

N region

5

Observations
2

150
2

Marginal R / Conditional R

0.068 / 0.239

AIC

513.560

AICc

515.473

multimorbidity: multimorbidity count; age in years; educ level: education level categorical; TBI: Traumatic brain injury
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5.1.2.3.2.2 CLSA
Baseline
Dichotomic Multimorbidity
In the CLSA for the RAVLT delayed recall outcome we had information on 22057 participants.
We found that multimorbidity was associated on RAVLT delayed recall scores at baseline with a
coefficient decrease of 0.03 (CI95%: -0.056 to -0.0042; p-value 0.0229). Also, we notice that the
significant confounders for the model were age with a decrease of 0.0269 (CI95%: -0.0282 to 0.0256), male sex with a decrease of 0.469 (CI95%: -0.493 to -0.444), history of traumatic brain
injury with an increase of 0.056 (CI95%: 0.028 to 0.085) and alcohol consumption with an increase
of 0.106 (CI95%: 0.0814 to 0.131). In the case of education level, we found an increase of 0.261
(CI95%: 0.233 to 0.289) (Table 5-110). The ICC was 0.005 (CI95%: 0.0003 to 0.014).
The subgroup analyses by sex did not show any association, while the analyses by age group both
showed an association of multimorbidity on RAVLT delayed scores at baseline. The female
analysis included information on 10994 participants (Table 5-111) and the coefficient of
multimorbidity was -0.0334 (CI95%: -0.0716 to 0.0048; p-value 0.086. The male analysis (Table
5-112) included 11063 participants and the coefficient was -0.0267 (CI95%: -0.062 to 0.0086; pvalue 0.14). In the case of participants 65 years and older (Table 5-113), we had information on
8636 participants and multimorbidity increased RAVLT delayed recall scores at baseline by 0.0504
(CI95%: 0.0131 to 0.0877; p-value 0.0081), and in the 13421 participants younger than 65 years
(Table 5-114), multimorbidity decreased RAVLT delayed recall baseline scores by 0.068 (CI95%:
-0.103 to -0.033; p-value 0.0001).

Table 5-110: Association in the CLSA of Dichotomic Multimorbidity with Rey Auditory Verbal
Learning Test Delayed Recall at Baseline

Predictors
(Intercept)

Estimates std. Error
1.72

0.05

CI

p

1.62 – 1.82

<0.001
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mm dich [Yes]

-0.03

0.01

-0.06 – -0.00

0.023

age

-0.03

0.00

-0.03 – -0.03

<0.001

sex [Male]

-0.47

0.01

-0.49 – -0.44

<0.001

educ level [linear]

0.26

0.01

0.23 – 0.29

<0.001

educ level [quadratic]

-0.06

0.02

-0.09 – -0.03

<0.001

educ level [cubic]

0.00

0.02

-0.03 – 0.04

0.797

TBI [Yes]

0.06

0.01

0.03 – 0.08

<0.001

smoking [Yes]

-0.02

0.01

-0.05 – 0.00

0.057

alcohol [Yes]

0.11

0.01

0.08 – 0.13

<0.001

Random Effects
σ2

0.80

τ00 region

0.004 (SD: 0.06; CI95: 0.03 to 0.12)

ICC

0.00

N region

5

Observations

22057

Marginal R2 / Conditional R2

0.155 / 0.159

AIC

69386.930

AICc

69386.944

mm dich: dichotomic multimorbidity; age in years; educ level: education level categorical; TBI: Traumatic brain injury

Table 5-111: Association in the CLSA of Dichotomic Multimorbidity with Rey Auditory Verbal
Learning Test Delayed Recall at Baseline - Female

Predictors

Estimates std. Error

CI

p

(Intercept)

1.67

0.07

1.53 – 1.81

<0.001

mm dich [Yes]

-0.03

0.02

-0.07 – 0.00

0.086

age

-0.03

0.00

-0.03 – -0.02

<0.001

educ level [linear]

0.27

0.02

0.23 – 0.31

<0.001

educ level [quadratic]

-0.09

0.02

-0.14 – -0.04

<0.001

educ level [cubic]

0.03

0.03

-0.02 – 0.09

0.216
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TBI [Yes]

0.04

0.02

-0.00 – 0.09

0.076

smoking [Yes]

0.01

0.02

-0.03 – 0.04

0.715

alcohol [Yes]

0.12

0.02

0.08 – 0.15

<0.001

Random Effects
σ2

0.90

τ00 region

0.01 (SD: 0.08; CI95%: .04 to 0.17)

ICC

0.01

N region

5

Observations

10994

Marginal R2 / Conditional R2

0.098 / 0.105

AIC

35385.807

AICc

35385.831

mm dich: dichotomic multimorbidity; age in years; educ level: education level categorical; TBI: Traumatic brain injury

Table 5-112: Association in the CLSA of Dichotomic Multimorbidity with Rey Auditory Verbal
Learning Test Delayed Recall at Baseline - Male

Predictors

Estimates std. Error

CI

p

(Intercept)

1.29

0.06

1.17 – 1.40

<0.001

mm dich [Yes]

-0.03

0.02

-0.06 – 0.01

0.139

age

-0.03

0.00

-0.03 – -0.03

<0.001

educ level [linear]

0.26

0.02

0.22 – 0.29

<0.001

educ level [quadratic]

-0.02

0.02

-0.06 – 0.02

0.382

educ level [cubic]

-0.03

0.03

-0.08 – 0.02

0.244

TBI [Yes]

0.07

0.02

0.03 – 0.11

<0.001

smoking [Yes]

-0.06

0.02

-0.09 – -0.03

0.001

alcohol [Yes]

0.10

0.02

0.06 – 0.13

<0.001

Random Effects
σ2

0.71

τ00 region

0.002 (SD: 0.04; CI95%: 0.01 to 0.08)

ICC

0.00
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N region

5

Observations
2

11063
2

Marginal R / Conditional R

0.123 / 0.124

AIC

33892.894

AICc

33892.918

mm dich: dichotomic multimorbidity; age in years; educ level: education level categorical; TBI: Traumatic brain injury

Table 5-113: Association in the CLSA of Dichotomic Multimorbidity with Rey Auditory Verbal
Learning Test Delayed Recall at Baseline - Participants 65 years and older

Predictors

Estimates std. Error

CI

p

(Intercept)

2.28

0.13

2.03 – 2.53

<0.001

mm dich [Yes]

0.05

0.02

0.01 – 0.09

0.008

age

-0.04

0.00

-0.04 – -0.03

<0.001

sex [Male]

-0.48

0.02

-0.52 – -0.44

<0.001

educ level [linear]

0.24

0.02

0.21 – 0.28

<0.001

educ level [quadratic]

-0.05

0.02

-0.10 – -0.01

0.017

educ level [cubic]

-0.00

0.03

-0.06 – 0.05

0.887

TBI [Yes]

0.06

0.02

0.01 – 0.11

0.010

smoking [Yes]

0.03

0.02

-0.01 – 0.06

0.178

alcohol [Yes]

0.09

0.02

0.05 – 0.13

<0.001

Random Effects
σ2

0.48

τ00 region

0.005 (SD: 0.07; CI95%: 0.03 to 0.14)

ICC

0.01

N region

5

Observations

8636

Marginal R2 / Conditional R2

0.179 / 0.187

AIC

25792.448

AICc

25792.484

mm dich: dichotomic multimorbidity; age in years; educ level: education level categorical; TBI: Traumatic brain injury
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Table 5-114: Association in the CLSA of Dichotomic Multimorbidity with Rey Auditory Verbal
Learning Test Delayed Recall at Baseline - Participants Younger than 65 years

Predictors

Estimates std. Error

CI

p

(Intercept)

1.47

0.09

1.31 – 1.64

<0.001

mm dich [Yes]

-0.07

0.02

-0.10 – -0.03

<0.001

age

-0.02

0.00

-0.02 – -0.02

<0.001

sex [Male]

-0.47

0.02

-0.50 – -0.44

<0.001

educ level [linear]

0.27

0.02

0.23 – 0.31

<0.001

educ level [quadratic]

-0.06

0.02

-0.11 – -0.02

0.008

educ level [cubic]

0.01

0.03

-0.04 – 0.06

0.716

TBI [Yes]

0.06

0.02

0.02 – 0.09

0.002

smoking [Yes]

-0.04

0.02

-0.08 – -0.01

0.010

alcohol [Yes]

0.11

0.02

0.08 – 0.14

<0.001

Random Effects
σ2

1.01

τ00 region

0.004 (SD: 0.06; CI95%: 0.03 to 0.11)

ICC

0.00

N region

5

Observations
2

13421
2

Marginal R / Conditional R

0.072 / 0.075

AIC

42242.404

AICc

42242.428

mm dich: dichotomic multimorbidity; age in years; educ level: education level categorical; TBI: Traumatic brain injury

Multimorbidity Count
We had the same number of participants for the multimorbidity count analyses than for the
Multimorbidity dichotomic outcome. We found that multimorbidity count decreased RAVLT
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delayed recall score at baseline by 0.0119 (CI95%: -0.0214 to -0.0024; p-value 0.0144). The
confounder significant for the model were (Table 5-115) age with a decrease of 0.0268 (CI95%: 0.0281 to -0.0255), male sex with a decrease of 0.469 (CI95%: -0.493 to -0.445), history of
traumatic brain injury with an increase of 0.0573 (CI95%: 0.0289 to 0.0857) and alcohol
consumption with an increase of 0.105 (CI95%: 0.08 to 0.131). The conditional ICC was 0.004.
In the subgroup analyses, multimorbidity count was associated on RAVLT delayed recall at
baseline in male and younger than 65 analyses. We found a coefficient of -0.0106 (CI95%: -0.0245
to 0.0032; p-value 0.13) in the female analysis (Table 5-116) and a decrease of 0.0139 (CI95%: 0.0269 to -0.00088; p-value 0.0363) in the male analysis (Table 5-117). In the analysis by group,
we found a coefficient of 0.011 (CI95%: -0.0016 to 0.024; p-value 0.088) in the participants 65
years and older (Table 5-118) while we found a decrease of RAVLT delayed recall scores of 0.0263
(CI95%: -0.0394 to -0.0132; p-value <0.0001) in the younger of 65 years (Table 5-119). The ICC
was 0.005 (CI95%: 0.0003 to 0.014)
The dichotomic model fits better for the baseline scores on RAVLT delayed recall on the CLSA
with a cAIC of 69386.944 vs 69388.126 on the counting model.

Table 5-115: Association in the CLSA of Multimorbidity Count with Rey Auditory Verbal Learning
Test Delayed Recall at Baseline

Predictors

Estimates std. Error

CI

p

(Intercept)

1.72

0.05

1.62 – 1.82

<0.001

multimorbidity

-0.01

0.00

-0.02 – -0.00

0.014

age

-0.03

0.00

-0.03 – -0.03

<0.001

sex [Male]

-0.47

0.01

-0.49 – -0.44

<0.001

educ level [linear]

0.26

0.01

0.23 – 0.29

<0.001

educ level [quadratic]

-0.06

0.02

-0.09 – -0.03

<0.001

educ level [cubic]

0.00

0.02

-0.03 – 0.04

0.824

TBI [Yes]

0.06

0.01

0.03 – 0.09

<0.001
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smoking [Yes]

-0.02

0.01

-0.05 – 0.00

0.062

alcohol [Yes]

0.11

0.01

0.08 – 0.13

<0.001

Random Effects
σ2

0.80

τ00 region

0.004 (SD: 0.06; CI95%: 0.03 to 0.12)

ICC

0.00

N region

5

Observations

22057

Marginal R2 / Conditional R2

0.155 / 0.159

AIC

69388.126

AICc

69388.140

multimorbidity: multimorbidity count; age in years; educ level: education level categorical; TBI: Traumatic brain injury

Table 5-116: Association in the CLSA of Multimorbidity Count with Rey Auditory Verbal Learning
Test Delayed Recall at Baseline - Female

Predictors

Estimates std. Error

CI

p

(Intercept)

1.67

0.07

1.53 – 1.81

<0.001

multimorbidity

-0.01

0.01

-0.02 – 0.00

0.133

age

-0.03

0.00

-0.03 – -0.02

<0.001

educ level [linear]

0.27

0.02

0.23 – 0.31

<0.001

educ level [quadratic]

-0.09

0.02

-0.14 – -0.05

<0.001

educ level [cubic]

0.03

0.03

-0.02 – 0.09

0.215

TBI [Yes]

0.04

0.02

-0.00 – 0.09

0.072

smoking [Yes]

0.01

0.02

-0.03 – 0.04

0.722

alcohol [Yes]

0.12

0.02

0.08 – 0.15

<0.001

Random Effects
σ2

0.90

τ00 region

0.01 (SD: 0.08; CI95%: 0.04 to 0.17)

ICC

0.01

N region

5
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Observations

10994

Marginal R2 / Conditional R2

0.098 / 0.105

AIC

35388.517

AICc

35388.541

multimorbidity: multimorbidity count; age in years; educ level: education level categorical; TBI: Traumatic brain injury

Table 5-117: Association in the CLSA of Multimorbidity Count with Rey Auditory Verbal Learning
Test Delayed Recall at Baseline - Male

Predictors

Estimates std. Error

CI

p

(Intercept)

1.28

0.06

1.16 – 1.39

<0.001

multimorbidity

-0.01

0.01

-0.03 – -0.00

0.036

age

-0.03

0.00

-0.03 – -0.03

<0.001

educ level [linear]

0.25

0.02

0.22 – 0.29

<0.001

educ level [quadratic]

-0.02

0.02

-0.06 – 0.03

0.406

educ level [cubic]

-0.03

0.03

-0.08 – 0.02

0.222

TBI [Yes]

0.07

0.02

0.04 – 0.11

<0.001

smoking [Yes]

-0.06

0.02

-0.09 – -0.02

0.001

alcohol [Yes]

0.09

0.02

0.06 – 0.13

<0.001

Random Effects
σ2

0.71

τ00 region

0.002 (SD: 0.04; CI95%: 0.01 to 0.08)

ICC

0.00

N region

5

Observations

11063

Marginal R2 / Conditional R2

0.123 / 0.125

AIC

33892.707

AICc

33892.731

multimorbidity: multimorbidity count; age in years; educ level: education level categorical; TBI: Traumatic brain injury
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Table 5-118: Association in the CLSA of Multimorbidity Count with Rey Auditory Verbal Learning
Test Delayed Recall at Baseline - Participants 65 years and older

Predictors

Estimates std. Error

CI

p

(Intercept)

2.27

0.13

2.02 – 2.53

<0.001

multimorbidity

0.01

0.01

-0.00 – 0.02

0.088

age

-0.04

0.00

-0.04 – -0.03

<0.001

sex [Male]

-0.48

0.02

-0.52 – -0.44

<0.001

educ level [linear]

0.24

0.02

0.21 – 0.28

<0.001

educ level [quadratic]

-0.05

0.02

-0.10 – -0.01

0.017

educ level [cubic]

-0.00

0.03

-0.05 – 0.05

0.900

TBI [Yes]

0.06

0.02

0.01 – 0.11

0.010

smoking [Yes]

0.03

0.02

-0.01 – 0.06

0.177

alcohol [Yes]

0.09

0.02

0.05 – 0.13

<0.001

Random Effects
σ2

0.48

τ00 region

0.005 (SD: 0.07; CI95%: 0.03 to 0.14)

ICC

0.01

N region

5

Observations
2

8636
2

Marginal R / Conditional R

0.178 / 0.187

AIC

25798.687

AICc

25798.724

multimorbidity: multimorbidity count; age in years; educ level: education level categorical; TBI: Traumatic brain injury

Table 5-119: Association in the CLSA of Multimorbidity Count with Rey Auditory Verbal Learning
Test Delayed Recall at Baseline - Participants Younger than 65 years

Predictors

Estimates std. Error

CI

p

(Intercept)

1.47

0.09

1.30 – 1.64

<0.001

multimorbidity

-0.03

0.01

-0.04 – -0.01

<0.001
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age

-0.02

0.00

-0.02 – -0.02

<0.001

sex [Male]

-0.47

0.02

-0.50 – -0.44

<0.001

educ level [linear]

0.27

0.02

0.23 – 0.31

<0.001

educ level [quadratic]

-0.06

0.02

-0.11 – -0.02

0.008

educ level [cubic]

0.01

0.03

-0.04 – 0.06

0.743

TBI [Yes]

0.06

0.02

0.02 – 0.09

0.002

smoking [Yes]

-0.04

0.02

-0.08 – -0.01

0.011

alcohol [Yes]

0.11

0.02

0.08 – 0.14

<0.001

Random Effects
σ2

1.01

τ00 region

0.004 (SD: 0.06; CI95%: 0.03 to 0.11)

ICC

0.00

N region

5

Observations
2

13421
2

Marginal R / Conditional R

0.072 / 0.075

AIC

42243.567

AICc

42243.591

multimorbidity: multimorbidity count; age in years; educ level: education level categorical; TBI: Traumatic brain injury

Change between baseline and first follow-up
Dichotomic Multimorbidity
For the analysis of dichotomic multimorbidity on RAVLT delayed recall change scores at first
follow-up we had information on 22057 participants (Table 5-120). We found an association of
multimorbidity on RAVLT delayed recall change scores with a decrease of 0.0347 (CI95%: 0.0647 to -0.0047; p-value 0.023). The confounders significant for the model were age that
decreased scores 0.012 (CI95%: -0.0135 to -0.0106), male sex with a decrease of 0.0962 (CI95%:
-0.124 to -0.068), history of traumatic brain injury with a decrease of 0.0676 (CI95%: -0.1 to 0.035) and history of smoking with a decrease of 0.0836 (CI95%: -0.112 to -0.055).The ICC was
0.004 (CI95%: 0.0002 to 0.011).
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In the subgroup analyses, we found an association of multimorbidity on RAVLT delayer recall
scores at follow-up only in patients younger than 65. The female analysis included information in
10994 participants (Table 5-121) and the coefficient for multimorbidity was -0.04 (CI95%: -0.0837
to 0.0037; p-value 0.073). The male analysis (Table 5-122) had information on 11063 participants
with a multimorbidity coefficient of -0.0307 (CI95%: -0.0716 to 0.0103; p-value 0.14). We
analyzed 8636 participants 65 years and older (Table 5-123) with a multimorbidity coefficient of 0.031 (CI95%: -0.075 to 0.012; p-value 0.16). Finally, we recovered information on 13421
participants younger than 65 years (Table 5-124). In this case, we found a reduction of 0.0425
(CI95%: -0.0824 to -0.0026; p-value 0.037) in the score of RAVLT delayed recall at follow-up.

Table 5-120: Association in the CLSA of Dichotomic Multimorbidity on Change of Rey Auditory
Verbal Learning Test Delayed Recall scores between Baseline and First Follow-up

Predictors

Estimates std. Error

CI

p

(Intercept)

1.11

0.06

1.00 – 1.22

<0.001

mm dich [Yes]

-0.03

0.02

-0.06 – -0.00

0.023

age

-0.01

0.00

-0.01 – -0.01

<0.001

sex [Male]

-0.10

0.01

-0.12 – -0.07

<0.001

educ level [linear]

-0.00

0.02

-0.04 – 0.03

0.800

educ level [quadratic]

0.05

0.02

0.02 – 0.09

0.006

educ level [cubic]

0.01

0.02

-0.04 – 0.05

0.741

TBI [Yes]

-0.07

0.02

-0.10 – -0.04

<0.001

smoking [Yes]

-0.08

0.01

-0.11 – -0.06

<0.001

alcohol [Yes]

0.02

0.01

-0.01 – 0.05

0.126

Random Effects
σ2

1.07

τ00 region

0.004 (SD: 0.06; CI95%: 0.03 to 0.13)

ICC

0.00

N region

5

Observations

22057
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Marginal R2 / Conditional R2

0.021 / 0.025

AIC

75567.250

AICc

75567.265

mm dich: dichotomic multimorbidity; age in years; educ level: education level categorical; TBI: Traumatic brain injury

Table 5-121: Association in the CLSA of Dichotomic Multimorbidity on Change of Rey Auditory
Verbal Learning Test Delayed Recall scores between Baseline and First Follow-up - Female

Predictors

Estimates std. Error

CI

p

(Intercept)

1.20

0.08

1.05 – 1.35

<0.001

mm dich [Yes]

-0.04

0.02

-0.08 – 0.00

0.073

age

-0.01

0.00

-0.02 – -0.01

<0.001

educ level [linear]

-0.03

0.02

-0.07 – 0.02

0.292

educ level [quadratic]

0.04

0.03

-0.02 – 0.09

0.182

educ level [cubic]

0.02

0.03

-0.04 – 0.08

0.596

TBI [Yes]

-0.06

0.03

-0.11 – -0.00

0.037

smoking [Yes]

-0.09

0.02

-0.14 – -0.05

<0.001

alcohol [Yes]

0.03

0.02

-0.01 – 0.08

0.111

Random Effects
σ2

1.18

τ00 region

0.005 (SD: 0.07; CI95%: 0.03 to 0.14)

ICC

0.00

N region

5

Observations

10994

Marginal R2 / Conditional R2

0.020 / 0.024

AIC

38343.689

AICc

38343.713

mm dich: dichotomic multimorbidity; age in years; educ level: education level categorical; TBI: Traumatic brain injury
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Table 5-122: Association in the CLSA of Dichotomic Multimorbidity on Change of Rey Auditory
Verbal Learning Test Delayed Recall scores between Baseline and First Follow-up - Male

Predictors

Estimates std. Error

CI

p

(Intercept)

0.92

0.07

0.79 – 1.06

<0.001

mm dich [Yes]

-0.03

0.02

-0.07 – 0.01

0.142

age

-0.01

0.00

-0.01 – -0.01

<0.001

educ level [linear]

0.01

0.02

-0.03 – 0.06

0.538

educ level [quadratic]

0.07

0.03

0.02 – 0.12

0.005

educ level [cubic]

-0.01

0.03

-0.07 – 0.05

0.788

TBI [Yes]

-0.07

0.02

-0.11 – -0.03

<0.001

smoking [Yes]

-0.08

0.02

-0.12 – -0.04

<0.001

alcohol [Yes]

0.01

0.02

-0.03 – 0.05

0.630

Random Effects
σ2

0.95

τ00 region

0.004 (SD: 0.06; CI95%: 0.02 to 0.11)

ICC

0.00

N region

5

Observations
2

11063
2

Marginal R / Conditional R

0.018 / 0.021

AIC

37163.638

AICc

37163.662

mm dich: dichotomic multimorbidity; age in years; educ level: education level categorical; TBI: Traumatic brain injury

Table 5-123: Association in the CLSA of Dichotomic Multimorbidity on Change of Rey Auditory
Verbal Learning Test Delayed Recall scores between Baseline and First Follow-up - Participants 65
years and older

Predictors

Estimates std. Error

CI

p

(Intercept)

1.71

0.15

1.42 – 2.00

<0.001

mm dich [Yes]

-0.03

0.02

-0.07 – 0.01

0.164
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age

-0.02

0.00

-0.02 – -0.02

<0.001

sex [Male]

-0.06

0.02

-0.10 – -0.01

0.010

educ level [linear]

-0.05

0.02

-0.09 – -0.01

0.024

educ level [quadratic]

0.02

0.03

-0.03 – 0.07

0.417

educ level [cubic]

0.00

0.03

-0.06 – 0.06

0.944

TBI [Yes]

-0.02

0.03

-0.07 – 0.04

0.522

smoking [Yes]

-0.12

0.02

-0.17 – -0.08

<0.001

alcohol [Yes]

0.07

0.02

0.03 – 0.11

0.002

Random Effects
σ2

0.65

τ00 region

0.002 (SD: 0.04; CI95%: 0.01 to 0.09)

ICC

0.00

N region

5

Observations
2

8636
2

Marginal R / Conditional R

0.029 / 0.031

AIC

28513.898

AICc

28513.934

mm dich: dichotomic multimorbidity; age in years; educ level: education level categorical; TBI: Traumatic brain injury

Table 5-124: Association in the CLSA of Dichotomic Multimorbidity on Change of Rey Auditory
Verbal Learning Test Delayed Recall scores between Baseline and First Follow-up - Participants
Younger than 65 years

Predictors

Estimates std. Error

CI

p

(Intercept)

0.86

0.10

0.67 – 1.05

<0.001

mm dich [Yes]

-0.04

0.02

-0.08 – -0.00

0.037

age

-0.01

0.00

-0.01 – -0.00

<0.001

sex [Male]

-0.11

0.02

-0.15 – -0.07

<0.001

educ level [linear]

0.01

0.02

-0.03 – 0.06

0.609

educ level [quadratic]

0.06

0.03

0.01 – 0.12

0.013
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educ level [cubic]

0.01

0.03

-0.05 – 0.06

0.773

TBI [Yes]

-0.08

0.02

-0.12 – -0.04

<0.001

smoking [Yes]

-0.07

0.02

-0.11 – -0.04

<0.001

alcohol [Yes]

0.00

0.02

-0.03 – 0.04

0.805

Random Effects
σ2

1.33

τ00 region

0.01 (SD: 0.07; CI95%: 0.03 to 0.14)

ICC

0.00

N region

5

Observations
2

13421
2

Marginal R / Conditional R

0.007 / 0.011

AIC

45861.790

AICc

45861.813

mm dich: dichotomic multimorbidity; age in years; educ level: education level categorical; TBI: Traumatic brain injury

Multimorbidity Count
For the multimorbidity count we had the same number of participants that in the dichotomic
multimorbidity analysis. We found an association of multimorbidity count on RAVLT delayed
recall change at follow-up with a decrease of 0.0181 (CI95%: -0.029 to -0.007; p-value 0.0012).
confounders significant for the model were (Table 5-125) age with a decrease of 0.0118 (CI95%:
-0.0132 to -0.0102), male sex with a decrease of 0.097(CI95%: -0.125 to -0.0689), history of
traumatic brain injury with a decrease of 0.0652 (CI95%: -0.098 to -0.0325) and history of smoking
with a decrease of -0.082 (CI95%: -0.111 to -0.0534). The ICC was 0.004 (CI95%: 0.0003 to
0.012).
Subgroup analyses showed an association of multimorbidity count on RAVLT delayed recall
change scores in female, younger than 65 and 65 years and older. In females (Table 5-126)
multimorbidity count decreased scores by 0.029 (CI95%: -0.045 to -0.013; p-value 0.0004). In
males (Table 5-127) the coefficient was -0.0076 (CI95%: -0.0226 to 0.0075; p-value 0.32). In
patients 65 years and older (Table 5-128) multimorbidity count decreased scores by 0.016 (CI95%:
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-0.031 to -0.0012; p-value 0.034). Finally, in patients younger than 65 years (Table 5-129)
multimorbidity count decreased RAVLT delayed recall change scores by 0.022 (CI95%: -0.037 to
-0.007; p-value 0.0042).
The counting model fits better for the change between baseline and first follow-up on RAVLT
delayed recall scores on the CLSA with a cAIC of 75563.912 vs 75567.265 on the dichotomic
model.

Table 5-125: Association in the CLSA of Multimorbidity Count on Change of Rey Auditory Verbal
Learning Test Delayed Recall scores between Baseline and First Follow-up

Predictors

Estimates std. Error

CI

p

(Intercept)

1.11

0.06

1.00 – 1.21

<0.001

multimorbidity

-0.02

0.01

-0.03 – -0.01

0.001

age

-0.01

0.00

-0.01 – -0.01

<0.001

sex [Male]

-0.10

0.01

-0.13 – -0.07

<0.001

educ level [linear]

-0.01

0.02

-0.04 – 0.03

0.749

educ level [quadratic]

0.05

0.02

0.02 – 0.09

0.005

educ level [cubic]

0.01

0.02

-0.04 – 0.05

0.792

TBI [Yes]

-0.07

0.02

-0.10 – -0.03

<0.001

smoking [Yes]

-0.08

0.01

-0.11 – -0.05

<0.001

alcohol [Yes]

0.02

0.01

-0.01 – 0.05

0.176

Random Effects
σ2

1.07

τ00 region

0.004 (SD: 0.06; CI95%: 0.03 to 0.13)

ICC

0.00

N region

5

Observations
2

22057
2

Marginal R / Conditional R

0.021 / 0.025

AIC

75563.898

AICc

75563.912
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multimorbidity: multimorbidity count; age in years; educ level: education level categorical; TBI: Traumatic brain injury

Table 5-126: Association in the CLSA of Multimorbidity Count on Change of Rey Auditory Verbal
Learning Test Delayed Recall scores between Baseline and First Follow-up - Female

Predictors

Estimates std. Error

CI

p

(Intercept)

1.19

0.08

1.04 – 1.34

<0.001

multimorbidity

-0.03

0.01

-0.04 – -0.01

<0.001

age

-0.01

0.00

-0.01 – -0.01

<0.001

educ level [linear]

-0.03

0.02

-0.08 – 0.02

0.254

educ level [quadratic]

0.04

0.03

-0.02 – 0.09

0.187

educ level [cubic]

0.01

0.03

-0.05 – 0.08

0.647

TBI [Yes]

-0.05

0.03

-0.10 – 0.00

0.071

smoking [Yes]

-0.09

0.02

-0.13 – -0.05

<0.001

alcohol [Yes]

0.03

0.02

-0.01 – 0.07

0.190

Random Effects
σ2

1.18

τ00 region

0.005 (SD: 0.07; CI95%: 0.03 to 0.14)

ICC

0.00

N region

5

Observations

10994

Marginal R2 / Conditional R2

0.020 / 0.024

AIC

38336.230

AICc

38336.254

multimorbidity: multimorbidity count; age in years; educ level: education level categorical; TBI: Traumatic brain injury

Table 5-127: Association in the CLSA of Multimorbidity Count on Change of Rey Auditory Verbal
Learning Test Delayed Recall scores between Baseline and First Follow-up - Male

Predictors

Estimates std. Error

CI

p
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(Intercept)

0.93

0.07

0.79 – 1.06

<0.001

multimorbidity

-0.01

0.01

-0.02 – 0.01

0.324

age

-0.01

0.00

-0.01 – -0.01

<0.001

educ level [linear]

0.01

0.02

-0.03 – 0.06

0.534

educ level [quadratic]

0.07

0.03

0.02 – 0.12

0.005

educ level [cubic]

-0.01

0.03

-0.07 – 0.05

0.779

TBI [Yes]

-0.07

0.02

-0.11 – -0.03

<0.001

smoking [Yes]

-0.08

0.02

-0.12 – -0.04

<0.001

alcohol [Yes]

0.01

0.02

-0.03 – 0.05

0.608

Random Effects
σ2

0.95

τ00 region

0.004 (SD: 0.06; CI95%: 0.02 to 0.11)

ICC

0.00

N region

5

Observations

11063

Marginal R2 / Conditional R2

0.018 / 0.021

AIC

37166.822

AICc

37166.846

multimorbidity: multimorbidity count; age in years; educ level: education level categorical; TBI: Traumatic brain injury

Table 5-128: Association in the CLSA of Multimorbidity Count on Change of Rey Auditory Verbal
Learning Test Delayed Recall scores between Baseline and First Follow-up - Participants 65 years
and older

Predictors

Estimates std. Error

CI

p

(Intercept)

1.72

0.15

1.43 – 2.01

<0.001

multimorbidity

-0.02

0.01

-0.03 – -0.00

0.034

age

-0.02

0.00

-0.02 – -0.02

<0.001

sex [Male]

-0.06

0.02

-0.10 – -0.01

0.010

educ level [linear]

-0.05

0.02

-0.09 – -0.01

0.022
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educ level [quadratic]

0.02

0.03

-0.03 – 0.07

0.410

educ level [cubic]

0.00

0.03

-0.06 – 0.06

0.988

TBI [Yes]

-0.01

0.03

-0.07 – 0.04

0.606

smoking [Yes]

-0.12

0.02

-0.16 – -0.08

<0.001

alcohol [Yes]

0.07

0.02

0.02 – 0.11

0.003

Random Effects
σ2

0.65

τ00 region

0.002 (SD: 0.04; CI95%: 0.01 to 0.09)

ICC

0.00

N region

5

Observations
2

8636
2

Marginal R / Conditional R

0.029 / 0.032

AIC

28513.505

AICc

28513.541

multimorbidity: multimorbidity count; age in years; educ level: education level categorical; TBI: Traumatic brain injury

Table 5-129: Association in the CLSA of Multimorbidity Count on Change of Rey Auditory Verbal
Learning Test Delayed Recall scores between Baseline and First Follow-up - Participants Younger
than 65 years

Predictors

Estimates std. Error

CI

p

(Intercept)

0.85

0.10

0.65 – 1.04

<0.001

multimorbidity

-0.02

0.01

-0.04 – -0.01

0.004

age

-0.01

0.00

-0.01 – -0.00

<0.001

sex [Male]

-0.11

0.02

-0.15 – -0.08

<0.001

educ level [linear]

0.01

0.02

-0.04 – 0.06

0.660

educ level [quadratic]

0.07

0.03

0.01 – 0.12

0.013

educ level [cubic]

0.01

0.03

-0.05 – 0.06

0.814

TBI [Yes]

-0.08

0.02

-0.12 – -0.04

<0.001

smoking [Yes]

-0.07

0.02

-0.11 – -0.03

<0.001
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alcohol [Yes]

0.00

Random Effects
σ2

0.02

-0.04 – 0.04

0.907

1.33

τ00 region

0.01 (SD: 0.07; CI95%: 0.03 to 0.14)

ICC

0.00

N region

5

Observations
2

13421
2

Marginal R / Conditional R

0.008 / 0.011

AIC

45859.861

AICc

45859.884

multimorbidity: multimorbidity count; age in years; educ level: education level categorical; TBI: Traumatic brain injury

5.1.2.4 Association of Multimorbidity on Dementia Diagnosis measured at first Followup in the CSHA
Dichotomic Multimorbidity
In the CSHA for the dementia diagnosis at first follow-up outcome we had information in 466
participants. In the analysis of dichotomic multimorbidity we did not find an association on
dementia diagnosis at the first follow-up (Table 5-130). Also, we did not find any statistically
significant association with known confounders, although two variables were near statistically
significant values with age suggesting and increase with an OR of 1.05 (CI95%: 0.82 to 3.28) by
each age increase, and education level suggesting a decrease of the dementia risk with OR 0.28
(CI95%: 0.05 to 1.08). These results should be further evaluated for their clinical relevance. In the
subgroup analysis by sex (Table 5-131 and Table 5-132), we did not notice an association of
dichotomic multimorbidity, although in the case of female group increase of one year of age was
associated with an increased risk of dementia diagnosis at first follow-up with an OR of 1.11
(CI95%: 1.03 to 1.20; p-value = 0.01). The ICC was 0.
Table 5-130: Association in the CSHA of Dichotomic Multimorbidity on Dementia diagnosis at First
Follow-up

Predictors

Odds Ratios std. Error

CI

p
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(Intercept)

0.00

0.00

0.00 – 0.06

0.001

mm dich [Yes]

1.64

0.58

0.82 – 3.28

0.161

age

1.05

0.03

1.00 – 1.11

0.055

sex [Male]

1.30

0.51

0.61 – 2.79

0.501

educ level [linear]

0.23

0.18

0.05 – 1.08

0.062

educ level [quadratic]

0.72

0.48

0.19 – 2.68

0.621

educ level [cubic]

1.02

0.52

0.37 – 2.80

0.975

TBI [Yes]

1.48

0.65

0.62 – 3.49

0.374

smoking [Yes]

0.76

0.29

0.36 – 1.62

0.476

alcohol [Yes]

1.39

0.52

0.67 – 2.91

0.379

Random Effects
σ2

3.29

τ00 region

<0.001

ICC

0.00

N region

5

Observations
2

466
2

Marginal R / Conditional R

0.142 / 0.142

AIC

292.773

AICc

293.354

mm dich: dichotomic multimorbidity; age in years; educ level: education level categorical; TBI: Traumatic brain injury

Table 5-131: Association in the CSHA of Dichotomic Multimorbidity on Dementia diagnosis at First
Follow-up - Female

Predictors

Odds Ratios std. Error

CI

p

(Intercept)

0.00

0.00

0.00 – 0.01

<0.001

mm dich [Yes]

2.41

1.32

0.82 – 7.07

0.109

age

1.11

0.04

1.03 – 1.20

0.010

educ level [linear]

0.28

0.24

0.05 – 1.52

0.142

educ level [quadratic]

3.37

3.32

0.49 – 23.20

0.217
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educ level [cubic]

3.77

4.11

0.45 – 31.95

0.223

TBI [Yes]

1.09

0.83

0.25 – 4.84

0.905

smoking [Yes]

0.81

0.42

0.29 – 2.22

0.682

alcohol [Yes]

2.25

1.17

0.81 – 6.25

0.119

Random Effects
σ2

3.29

τ00 region

<0.001

ICC

0.00

N region

5

Observations
2

297
2

Marginal R / Conditional R

0.335 / 0.335

AIC

161.198

AICc

161.967

mm dich: dichotomic multimorbidity; age in years; educ level: education level categorical; TBI: Traumatic brain injury

Table 5-132: Association in the CSHA of Dichotomic Multimorbidity on Dementia diagnosis at First
Follow-up - Male

Predictors

Odds Ratios std. Error

CI

p

(Intercept)

0.07

54.91

0.00 – Inf

0.997

mm dich [Yes]

1.18

0.63

0.42 – 3.36

0.753

age

0.96

0.04

0.88 – 1.05

0.346

educ level [linear]

0.00

0.02

0.00 – Inf

0.996

educ level [quadratic]

0.00

0.22

0.00 – Inf

0.996

educ level [cubic]

0.02

15.85

0.00 – Inf

0.996

TBI [Yes]

1.42

0.84

0.44 – 4.54

0.553

smoking [Yes]

0.65

0.39

0.20 – 2.09

0.468

alcohol [Yes]

0.65

0.35

0.23 – 1.86

0.423

Random Effects
σ2

3.29
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τ00 region

0.43

ICC

0.12

N region

5

Observations

169

Marginal R2 / Conditional R2

0.899 / 0.911

AIC

132.429

AICc

133.821

mm dich: dichotomic multimorbidity; age in years; educ level: education level categorical; TBI: Traumatic brain injury

Multimorbidity Count
On the case of the analysis of multimorbidity count, we found that in the whole cohort
multimorbidity count was non-significant statistically, but the OR suggest it might be an
association with an OR of 1.18 (CI95%: 0.99 to 1.49) for each increase in the count of
multimorbidity (Table 5-133). Also, we noticed that the statistical association of other known
confounders was similar to the results in the dichotomic outcome.
However, when we evaluated the subgroup analysis of female participants that included 297
participants (Table 5-134), we found that multimorbidity count was associated with an increased
risk of dementia diagnosis measured at first follow-up with an OR of 1.41 (CI95%: 1.07 to 1.86;
p-value 0.014). Also, like in the dichotomic analysis, increase of one year of age was associated
with an increased risk of dementia with an OR of 1.13 (CI95: 1.04 to 1.22; p-value 0.005). Finally,
in the subgroup analysis in males (Table 5-135), we did not find any association on the dementia
onset outcome.
The counting model fits better for the diagnosis of dementia onset by the first follow-up on the
CSHA with a cAIC of 133.821 vs 293.354 on the dichotomic model.

Table 5-133: Association in the CSHA of Multimorbidity Count on Dementia diagnosis at First
Follow-up
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Predictors

Odds Ratios std. Error

CI

p

(Intercept)

0.07

54.91

0.00 – Inf

0.997

mm dich [Yes]

1.18

0.63

0.42 – 3.36

0.753

age

0.96

0.04

0.88 – 1.05

0.346

educ level [linear]

0.00

0.02

0.00 – Inf

0.996

educ level [quadratic]

0.00

0.22

0.00 – Inf

0.996

educ level [cubic]

0.02

15.85

0.00 – Inf

0.996

TBI [Yes]

1.42

0.84

0.44 – 4.54

0.553

smoking [Yes]

0.65

0.39

0.20 – 2.09

0.468

alcohol [Yes]

0.65

0.35

0.23 – 1.86

0.423

Random Effects
σ2

3.29

τ00 region

0.43

ICC

0.12

N region

5

Observations
2

169
2

Marginal R / Conditional R

0.899 / 0.911

AIC

132.429

AICc

133.821

mm dich: dichotomic multimorbidity; age in years; educ level: education level categorical; TBI: Traumatic brain injury

Table 5-134: Association in the CSHA of Multimorbidity Count on Dementia diagnosis at First
Follow-up - Female

Predictors

Odds Ratios std. Error

CI

p

(Intercept)

0.00

0.00

0.00 – 0.00

<0.001

multimorbidity

1.41

0.20

1.07 – 1.86

0.014

age

1.13

0.05

1.04 – 1.22

0.005

educ level [linear]

0.29

0.25

0.05 – 1.59

0.153

educ level [quadratic]

3.06

3.02

0.45 – 21.09

0.255
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educ level [cubic]

4.31

4.60

0.53 – 34.95

0.172

TBI [Yes]

1.11

0.86

0.24 – 5.03

0.893

smoking [Yes]

0.76

0.40

0.27 – 2.15

0.608

alcohol [Yes]

2.22

1.18

0.78 – 6.32

0.133

Random Effects
σ2

3.29

τ00 region

0.00

ICC

0.00

N region

5

Observations
2

297
2

Marginal R / Conditional R

0.361 / 0.362

AIC

157.691

AICc

158.461

multimorbidity: multimorbidity count; age in years; educ level: education level categorical; TBI: Traumatic brain injury

Table 5-135: Association in the CSHA of Multimorbidity Count on Dementia diagnosis at First
Follow-up - Male

Predictors

Odds Ratios std. Error

CI

p

(Intercept)

0.05

33.90

0.00 – Inf

0.996

multimorbidity

0.91

0.18

0.62 – 1.33

0.624

age

0.97

0.04

0.88 – 1.06

0.445

educ level [linear]

0.00

0.02

0.00 – Inf

0.995

educ level [quadratic]

0.00

0.21

0.00 – Inf

0.995

educ level [cubic]

0.03

15.66

0.00 – Inf

0.995

TBI [Yes]

1.49

0.88

0.47 – 4.75

0.499

smoking [Yes]

0.65

0.39

0.20 – 2.08

0.466

alcohol [Yes]

0.64

0.34

0.22 – 1.81

0.397

Random Effects
σ2

3.29
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τ00 region

0.48

ICC

0.13

N region

5

Observations

169

Marginal R2 / Conditional R2

0.894 / 0.907

AIC

132.292

AICc

133.685

multimorbidity: multimorbidity count; age in years; educ level: education level categorical; TBI: Traumatic brain injury

5.1.2.5 Association of Multimorbidity on Cognitive Impairment no Dementia Diagnosis
measured at first Follow-up in the CSHA
Dichotomic Multimorbidity
In the CSHA mild cognitive impairment was called as Cognitive Impairment no Dementia (CIND).
For this analysis we only evaluated participants with normal cognition at baseline. For the CIND
incidence at first follow-up outcome we had information in 331 participants. In the analysis of
dichotomic multimorbidity we did not find an association on CIND diagnosis at the first follow-up
(Table 5-136). We found that the only age has statistically significant association with CIND with
an OR of 1.05 (CI95%: 1.01 to 1.10; p-value = 0.023) by each age increase. In the subgroup analysis
by sex, we did not notice an association of dichotomic multimorbidity on CIND diagnosis. In the
case of female group (Table 5-137) increase we found that alcohol consumption decreased the risk
of getting CIND with an OR of 0.41 (CI95%: 0.20 to 0.83; p-value 0.013). No association in the
male group (Table 5-138).
Table 5-136: Association in the CSHA of Dichotomic Multimorbidity on CIND diagnosis at First
Follow-up

Predictors

Odds Ratios std. Error

CI

p

(Intercept)

0.05

33.90

0.00 – Inf

0.996

mm dich [Yes]

0.91

0.18

0.62 – 1.33

0.624

age

0.97

0.04

0.88 – 1.06

0.445

educ level [linear]

0.00

0.02

0.00 – Inf

0.995
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educ level [quadratic]

0.00

0.21

0.00 – Inf

0.995

educ level [cubic]

0.03

15.66

0.00 – Inf

0.995

TBI [Yes]

1.49

0.88

0.47 – 4.75

0.499

smoking [Yes]

0.65

0.39

0.20 – 2.08

0.466

alcohol [Yes]

0.64

0.34

0.22 – 1.81

0.397

Random Effects
σ2

3.29

τ00 region

0.48

ICC

0.13

N region

5

Observations
2

169
2

Marginal R / Conditional R

0.894 / 0.907

AIC

132.292

AICc

133.685

mm dich: dichotomic multimorbidity; age in years; educ level: education level categorical; TBI: Traumatic brain injury

Table 5-137: Association in the CSHA of Dichotomic Multimorbidity on CIND diagnosis at First
Follow-up - Female

Predictors

Odds Ratios std. Error

CI

p

(Intercept)

0.03

0.06

0.00 – 1.44

0.076

mm dich [Yes]

1.05

0.36

0.54 – 2.05

0.882

age

1.03

0.03

0.98 – 1.08

0.202

educ level [linear]

0.51

0.27

0.18 – 1.45

0.206

educ level [quadratic]

0.87

0.42

0.34 – 2.22

0.777

educ level [cubic]

0.45

0.18

0.20 – 0.99

0.047

TBI [Yes]

1.62

0.87

0.56 – 4.65

0.369

smoking [Yes]

1.07

0.41

0.50 – 2.29

0.856

alcohol [Yes]

0.20

0.13

0.06 – 0.69

0.012

Random Effects
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σ2

3.29

τ00 region

0.00

ICC

0.00

N region

5

Observations

214

2

2

Marginal R / Conditional R

0.177 / 0.177

AIC

242.048

AICc

243.132

mm dich: dichotomic multimorbidity; age in years; educ level: education level categorical; TBI: Traumatic brain injury

Table 5-138: Association in the CSHA of Dichotomic Multimorbidity on CIND diagnosis at First
Follow-up - Male

Predictors

Odds Ratios std. Error

CI

p

(Intercept)

0.00

0.00

0.00 – 366307.14

0.359

mm dich [Yes]

0.80

0.41

0.29 – 2.20

0.665

age

1.11

0.05

1.01 – 1.22

0.028

educ level [linear]

7.77

81.48

0.00 – 6e10

0.845

educ level [quadratic]

87.00

2037.15

0.00 – 7e23

0.849

educ level [cubic]

0.00

0.05

0.00 – 8e25

0.836

TBI [Yes]

1.10

0.67

0.33 – 3.65

0.871

smoking [Yes]

1.37

0.90

0.38 – 4.96

0.631

alcohol [Yes]

0.79

0.40

0.29 – 2.14

0.649

Random Effects
σ2

3.29

τ00 region

0.83

ICC

0.20

N region

5

Observations
2

117
2

Marginal R / Conditional R

0.691 / 0.753

AIC

136.725

AICc

138.801
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mm dich: dichotomic multimorbidity; age in years; educ level: education level categorical; TBI: Traumatic brain injury

Multimorbidity Count
Like in the dichotomic multimorbidity, we did not find an association of multimorbidity count on
the risk of developing CIND (Table 5-139). Likewise, age increased the risk of developing CIND
with an OR of 1.05 (CI95%: 1.01 to 1.10; p-value 0.02) for each year older.. In the subgroup
analyses, we did not find any association either; Table 5-140 for female and Table 5-141 for male.
The dichotomic model fits better for the CIND Diagnosis by the first follow-up on the CSHA with
a cAIC of 133.685 vs 373.558 on the counting model.

Table 5-139: Association in the CSHA of Multimorbidity Count on CIND diagnosis at First Followup

Predictors

Odds Ratios std. Error

CI

p

(Intercept)

0.01

0.01

0.00 – 0.23

0.005

multimorbidity

0.95

0.09

0.79 – 1.14

0.589

age

1.05

0.02

1.01 – 1.10

0.020

sex [Male]

1.03

0.35

0.52 – 2.01

0.939

educ level [linear]

1.02

0.37

0.51 – 2.06

0.952

educ level [quadratic]

1.24

0.45

0.61 – 2.52

0.550

educ level [cubic]

0.35

0.12

0.18 – 0.70

0.003

TBI [Yes]

1.28

0.50

0.60 – 2.74

0.530

smoking [Yes]

1.05

0.33

0.57 – 1.96

0.870

alcohol [Yes]

0.42

0.15

0.21 – 0.84

0.015

Random Effects
σ2

3.29

τ00 region

0.21

ICC

0.06
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N region

5

Observations
2

331
2

Marginal R / Conditional R

0.131 / 0.182

AIC

372.731

AICc

373.558

multimorbidity: multimorbidity count; age in years; educ level: education level categorical; TBI: Traumatic brain injury

Table 5-140: Association in the CSHA of Multimorbidity Count on CIND diagnosis at First Followup - Female

Predictors

Odds Ratios std. Error

CI

p

(Intercept)

0.03

0.06

0.00 – 1.37

0.072

multimorbidity

1.03

0.12

0.83 – 1.28

0.791

age

1.03

0.03

0.98 – 1.08

0.204

educ level [linear]

0.51

0.27

0.18 – 1.44

0.201

educ level [quadratic]

0.85

0.41

0.33 – 2.19

0.744

educ level [cubic]

0.45

0.18

0.21 – 0.99

0.048

TBI [Yes]

1.60

0.86

0.56 – 4.58

0.378

smoking [Yes]

1.04

0.41

0.49 – 2.24

0.913

alcohol [Yes]

0.19

0.12

0.05 – 0.68

0.011

Random Effects
σ2

3.29

τ00 region

0.00

ICC

0.00

N region

5

Observations
2

214
2

Marginal R / Conditional R

0.181 / 0.181

AIC

241.993

AICc

243.077

multimorbidity: multimorbidity count; age in years; educ level: education level categorical; TBI: Traumatic brain injury
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Table 5-141: Association in the CSHA of Multimorbidity Count on CIND diagnosis at First Followup - Male

Predictors

Odds Ratios std. Error

CI

p

(Intercept)

0.00

0.00

0.00 – 6.4e29

0.771

multimorbidity

0.88

0.16

0.62 – 1.25

0.467

age

1.11

0.05

1.01 – 1.22

0.024

educ level [linear]

13.29

486.90

0.00 – 2e32

0.944

educ level [quadratic]

302.31

24757.45

0.00 – 1.5e72

0.944

educ level [cubic]

0.00

0.03

0.00 – 9.6e89

0.941

TBI [Yes]

1.12

0.68

0.34 – 3.68

0.856

smoking [Yes]

1.36

0.89

0.38 – 4.87

0.634

alcohol [Yes]

0.78

0.40

0.29 – 2.11

0.630

Random Effects
σ2

3.29

τ00 region

0.81

ICC

0.20

N region

5

Observations
2

117
2

Marginal R / Conditional R

0.780 / 0.823

AIC

136.365

AICc

138.441

multimorbidity: multimorbidity count; age in years; educ level: education level categorical; TBI: Traumatic brain injury

5.2 First secondary Objective Results
5.2.1 Dyads and Triads analysis using regression methods.
Initially, we obtained the dyads and triads of multimorbidity from our list of twelve chronic
condition with prevalence ≥1%. We include patients that had information available of baseline and
first follow-up. In the CSHA we evaluated the dyads (Table 5-142) and triads (Table 5-143) in 497
participants, while in the CLSA we included 23654 participants (Table 5-144 and Table 5-145).
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5.2.1.1 Multimorbidity Analysis Tool Results
In the following tables we present the multimorbidity dyads and triads that fulfilled the criteria of
a prevalence ≥1%. We present in the supplementary files 1 and 2 the full results from the
combinations obtained using the “Multimorbidity analysis Tool”.
5.2.1.1.1 CSHA
Table 5-142: Combination of Dyads with a prevalence ≥1% in the CSHA

Chronic conditions combinations

N

Percentage

Arthritis + hypertension

21

4.23

Arthritis + cancer

9

1.81

Arthritis + diabetes

9

1.81

Arthritis + gastric ulcer

9

1.81

Arthritis + depression

8

1.61

Arthritis + thyroid disease

8

1.61

Arthritis + chronic kidney disease

7

1.41

Arthritis + other heart disease

7

1.41

Table 5-143: Combination of Triads with a prevalence ≥1% in the CSHA

Chronic conditions combinations

N

Percentage

Arthritis + chronic kidney disease + hypertension

5

1.01

Arthritis + depression + hypertension

5

1.01

Arthritis + gastric ulcer + hypertension.

5

1.01

Arthritis + other heart disease + coronary artery 5

1.01

disease
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5.2.1.1.2 CLSA
Table 5-144: Combination of Dyads with a prevalence ≥1% in the CLSA

Chronic conditions combinations

N

Percentage

Arthritis + hypertension

1049

4.43

Diabetes + hypertension

547

2.31

Arthritis + depression

456

1.93

Arthritis + thyroid disease

401

1.70

Cancer + hypertension

396

1.67

Arthritis + cancer

353

1.49

Depression + hypertension

329

1.39

Arthritis + diabetes

278

1.18

Hypertension + thyroid disease

258

1.09

Table 5-145: Combination of Triads with a prevalence ≥1% in the CLSA

Chronic conditions combinations

N

Percentage

Arthritis + diabetes + hypertension

417

1.76

Arthritis + cancer + hypertension

260

1.10

Arthritis + hypertension + thyroid disease

236

1.00

5.2.1.2 Regression Analyses of dyads and triads
We are reporting results accordingly to the individual test. We are presenting the number of
participants and the dyads / triads with an association on the test score. To interpret the effect of
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dyads and triads combinations in the regression models, we have to consider the interaction term
and the coefficients of the individual conditions in the interaction.

5.2.1.2.1 Frontal Function

5.2.1.2.1.1 CSHA
Baseline
Dyads analysis
We analyzed 474 participants at baseline in the frontal function analysis using DSST. We did not
find any dyad (Table 5-146) associated on DSST scores at baseline. The ICC was 0.12 (CI95%:
0.005 to 0.32)
Table 5-146: Multilevel Regression Analysis of Dyads associations with Frontal Function in the
CSHA at baseline

Predictors

Estimates std. Error

CI

p

(Intercept)

-0.01

0.18

-0.37 – 0.34

0.950

arthritis [Yes]

0.26

0.13

0.00 – 0.52

0.049

hypertension [Yes]

0.24

0.15

-0.05 – 0.53

0.101

cancer [Yes]

0.20

0.24

-0.28 – 0.68

0.416

diabetes [Yes]

0.49

0.25

0.00 – 0.97

0.048

gast ulcer [Yes]

0.24

0.18

-0.11 – 0.58

0.173

depression [Yes]

-0.42

0.19

-0.80 – -0.04

0.029

thyroid [Yes]

0.26

0.23

-0.19 – 0.71

0.261

ckd [Yes]

-0.42

0.30

-1.01 – 0.18

0.169

oheart [Yes]

-0.14

0.19

-0.52 – 0.24

0.459

arthritis [Yes] *
hypertension [Yes]

-0.31

0.19

-0.70 – 0.07

0.106

arthritis [Yes] * cancer
[Yes]

0.07

0.33

-0.57 – 0.72

0.823
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arthritis [Yes] *
diabetes [Yes]

-0.44

0.30

-1.03 – 0.14

0.139

arthritis [Yes] * gast
ulcer [Yes]

-0.40

0.23

-0.85 – 0.05

0.080

arthritis [Yes] *
depression [Yes]

-0.05

0.24

-0.52 – 0.43

0.844

arthritis [Yes] * thyroid
[Yes]

-0.11

0.28

-0.67 – 0.44

0.686

arthritis [Yes] * ckd
[Yes]

0.35

0.35

-0.33 – 1.04

0.312

arthritis [Yes] * oheart
[Yes]

0.26

0.24

-0.22 – 0.74

0.288

Random Effects
σ2

0.84

τ00 region

0.12 (SD: 0.35; CI95%: 0.16 to 0.69)

ICC

0.12

N region

5

Observations
2

474
2

Marginal R / Conditional R

0.064 / 0.178

AIC

1404.872

AICc

1406.727

gast ulcer: gastric ulcer; thyroid: thyroid diseases; otheart: other heart disease; ckd: chronic kidney disease

Triads analysis
We did not find any triad associated on DSST scores at baseline (Table 5-147). The ICC was 0.12
(CI95: 0.012 to 0.33)
Table 5-147: Multilevel Regression Analysis of Triads associations with Frontal Function in the
CSHA at baseline

Predictors

Estimates std. Error

CI

p

(Intercept)

0.10

0.18

-0.27 – 0.46

0.604

arthritis [Yes]

0.22

0.13

-0.05 – 0.48

0.105

ckd [Yes]

-0.34

0.36

-1.05 – 0.38

0.357
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hypertension [Yes]

0.14

0.18

-0.21 – 0.48

0.439

depression [Yes]

-0.66

0.24

-1.12 – -0.20

0.005

gast ulcer [Yes]

0.24

0.20

-0.16 – 0.64

0.244

oheart [Yes]

-0.04

0.20

-0.43 – 0.35

0.826

coronary [Yes]

-0.23

0.25

-0.72 – 0.26

0.351

arthritis [Yes] * ckd
[Yes]

0.13

0.42

-0.71 – 0.96

0.762

arthritis [Yes] *
hypertension [Yes]

-0.24

0.24

-0.71 – 0.24

0.323

ckd [Yes] * hypertension
[Yes]

-0.43

0.68

-1.78 – 0.91

0.527

arthritis [Yes] *
depression [Yes]

0.20

0.30

-0.38 – 0.78

0.501

hypertension [Yes] *
depression [Yes]

0.86

0.43

0.02 – 1.70

0.045

arthritis [Yes] * gast
ulcer [Yes]

-0.32

0.28

-0.86 – 0.22

0.247

hypertension [Yes] * gast
ulcer [Yes]

-0.21

0.40

-1.00 – 0.59

0.607

arthritis [Yes] * oheart
[Yes]

0.32

0.26

-0.19 – 0.84

0.217

arthritis [Yes] *
coronary [Yes]

0.07

0.32

-0.55 – 0.70

0.816

oheart [Yes] * coronary
[Yes]

0.76

0.52

-0.26 – 1.79

0.144

(arthritis [Yes] * ckd
[Yes]) * hypertension
[Yes]

0.91

0.77

-0.60 – 2.41

0.239

(arthritis [Yes] *
hypertension [Yes]) *
depression [Yes]

-0.86

0.53

-1.90 – 0.18

0.104

(arthritis [Yes] *
hypertension [Yes]) *
gast ulcer [Yes]

0.02

0.51

-0.98 – 1.02

0.969

(arthritis [Yes] * oheart
[Yes]) * coronary [Yes]

-1.16

0.63

-2.41 – 0.08

0.067

Random Effects
σ2

0.84

τ00 region

0.12 (SD: 0.35; CI95%: 0.17 to 0.70)
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ICC

0.13

N region

5

Observations

474

Marginal R2 / Conditional R2

0.072 / 0.190

AIC

1403.102

AICc

1405.774

gast ulcer: gastric ulcer; thyroid: thyroid diseases; otheart: other heart disease; ckd: chronic kidney disease

Change between baseline and first follow-up
Dyads analysis
We analyzed 424 participants that had information of DSST change between baseline and first
follow-up. We did not find any dyad associated with change on DSST scores between baseline and
fist follow-up (Table 5-148). The ICC was 0.008 (CI95%: 0.000 to 0.059)

Table 5-148: Multilevel Regression Analysis of Dyads associations on Frontal Function change
between Baseline and the First Follow-up in the CSHA

Predictors

Estimates std. Error

CI

p

(Intercept)

-0.55

0.11

-0.78 – -0.33

<0.001

arthritis [Yes]

-0.20

0.15

-0.49 – 0.09

0.184

hypertension [Yes]

0.05

0.16

-0.28 – 0.37

0.776

cancer [Yes]

-0.08

0.28

-0.63 – 0.46

0.761

diabetes [Yes]

-0.59

0.30

-1.18 – 0.01

0.054

gast ulcer [Yes]

-0.21

0.20

-0.61 – 0.19

0.311

depression [Yes]

0.44

0.22

0.01 – 0.86

0.043

thyroid [Yes]

-0.03

0.25

-0.53 – 0.47

0.910

ckd [Yes]

0.81

0.35

0.12 – 1.50

0.022

oheart [Yes]

-0.28

0.23

-0.73 – 0.16

0.215
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arthritis [Yes] *
hypertension [Yes]

-0.03

0.22

-0.45 – 0.40

0.899

arthritis [Yes] * cancer
[Yes]

-0.06

0.37

-0.80 – 0.67

0.864

arthritis [Yes] *
diabetes [Yes]

0.30

0.36

-0.41 – 1.00

0.409

arthritis [Yes] * gast
ulcer [Yes]

0.34

0.26

-0.17 – 0.85

0.191

arthritis [Yes] *
depression [Yes]

-0.39

0.27

-0.92 – 0.15

0.154

arthritis [Yes] * thyroid
[Yes]

0.28

0.32

-0.34 – 0.90

0.377

arthritis [Yes] * ckd
[Yes]

-0.75

0.40

-1.53 – 0.03

0.060

arthritis [Yes] * oheart
[Yes]

0.41

0.28

-0.14 – 0.96

0.147

Random Effects
σ2

0.95

τ00 region

0.01 (SD: 0.09; CI95%: 0 to 0.25)

ICC

0.01

N region

5

Observations
2

424
2

Marginal R / Conditional R

0.056 / 0.064

AIC

1292.476

AICc

1294.560

gast ulcer: gastric ulcer; thyroid: thyroid diseases; otheart: other heart disease; ckd: chronic kidney disease

Triads analysis
We did not find any triad associated with change on DSST scores between baseline and first followup (Table 5-149). The ICC was 0.013 (CI95%: 0.000 to 0.074)

Table 5-149: Multilevel Regression Analysis of Triads associations on Frontal Function change
between Baseline and the First Follow-up in the CSHA
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Predictors

Estimates std. Error

CI

p

(Intercept)

-0.60

0.12

-0.83 – -0.36

<0.001

arthritis [Yes]

-0.18

0.15

-0.47 – 0.11

0.229

ckd [Yes]

0.74

0.39

-0.02 – 1.51

0.058

hypertension [Yes]

0.03

0.20

-0.36 – 0.41

0.886

depression [Yes]

0.39

0.27

-0.14 – 0.91

0.151

gast ulcer [Yes]

-0.15

0.24

-0.62 – 0.33

0.539

oheart [Yes]

-0.35

0.23

-0.81 – 0.11

0.135

coronary [Yes]

0.03

0.27

-0.49 – 0.55

0.907

arthritis [Yes] * ckd
[Yes]

-0.39

0.46

-1.29 – 0.51

0.393

arthritis [Yes] *
hypertension [Yes]

0.11

0.27

-0.41 – 0.64

0.669

ckd [Yes] * hypertension
[Yes]

-0.25

0.94

-2.11 – 1.60

0.789

arthritis [Yes] *
depression [Yes]

-0.18

0.34

-0.86 – 0.49

0.594

hypertension [Yes] *
depression [Yes]

0.28

0.48

-0.67 – 1.23

0.565

arthritis [Yes] * gast
ulcer [Yes]

0.14

0.32

-0.49 – 0.76

0.671

hypertension [Yes] * gast
ulcer [Yes]

-0.16

0.47

-1.08 – 0.76

0.731

arthritis [Yes] * oheart
[Yes]

0.33

0.30

-0.27 – 0.92

0.277

arthritis [Yes] *
coronary [Yes]

-0.37

0.36

-1.08 – 0.33

0.296

oheart [Yes] * coronary
[Yes]

0.17

0.61

-1.02 – 1.36

0.781

(arthritis [Yes] * ckd
[Yes]) * hypertension
[Yes]

-0.36

1.02

-2.37 – 1.64

0.721

(arthritis [Yes] *
hypertension [Yes]) *
depression [Yes]

-0.51

0.59

-1.68 – 0.65

0.389

(arthritis [Yes] *
hypertension [Yes]) *
gast ulcer [Yes]

0.50

0.58

-0.64 – 1.65

0.387
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(arthritis [Yes] * oheart
[Yes]) * coronary [Yes]

0.41

0.73

-1.03 – 1.84

0.578

Random Effects
σ2

0.96

τ00 region

0.01 (SD: 0.11; CI95%: 0 to 0.29)

ICC

0.01

N region

5

Observations
2

424
2

Marginal R / Conditional R

0.054 / 0.067

AIC

1295.050

AICc

1298.058

gast ulcer: gastric ulcer; thyroid: thyroid diseases; otheart: other heart disease; ckd: chronic kidney disease

5.2.1.2.1.2 CLSA
Baseline
Dyads analysis
We analyzed 21909 participants that had information of MAT scores at baseline. We found that
only the dyad of diabetes + arthritis with a coefficient of an increase of 0.0804 (CI95%: 0.008 to
0.153; p-value 0.03) had an association on MAT scores (Table 5-150). The ICC was 0.009 (CI95%:
0.0008 to 0.026). The interpretation of this interaction is that in participants with diabetes, the
MAT scores decreased by 0.09, and in participants with arthritis, the scores decreased by 0.13.
However, when both conditions are present, scores do not decrease by the expected 0.22 SD but
only 0.14 SD.

Table 5-150: Multilevel Regression Analysis of Dyads associations with Frontal Function in the
CLSA at baseline

Predictors

Estimates std. Error

CI

p
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(Intercept)

0.12

0.04

0.03 – 0.21

0.006

diabetes [Yes]

-0.09

0.03

-0.15 – -0.03

0.003

hypertension [Yes]

-0.18

0.02

-0.22 – -0.14

<0.001

arthritis [Yes]

-0.13

0.02

-0.17 – -0.10

<0.001

depression [Yes]

-0.01

0.03

-0.07 – 0.04

0.640

thyroid [Yes]

-0.06

0.03

-0.12 – -0.01

0.031

cancer [Yes]

-0.04

0.03

-0.11 – 0.02

0.151

diabetes [Yes] *
hypertension [Yes]

-0.03

0.04

-0.10 – 0.04

0.428

arthritis [Yes] *
depression [Yes]

-0.01

0.04

-0.08 – 0.07

0.833

arthritis [Yes] * thyroid
[Yes]

0.07

0.04

-0.01 – 0.16

0.072

hypertension [Yes] *
cancer [Yes]

-0.04

0.04

-0.12 – 0.04

0.347

arthritis [Yes] * cancer
[Yes]

-0.06

0.04

-0.14 – 0.03

0.170

hypertension [Yes] *
depression [Yes]

0.01

0.04

-0.06 – 0.09

0.737

diabetes [Yes] *
arthritis [Yes]

0.08

0.04

0.01 – 0.15

0.031

hypertension [Yes] *
thyroid [Yes]

-0.03

0.04

-0.11 – 0.06

0.545

Random Effects
σ2

0.96

τ00 region

0.01 (SD: 0.09; CI95%: 0.04 to 0.19)

ICC

0.01

N region

5

Observations

21909

Marginal R2 / Conditional R2

0.018 / 0.027

AIC

72891.122

AICc

72891.150

thyroid: thyroid diseases

Triads analysis
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We did not find any triad associated with MAT scores at baseline (Table 5-151). The ICC was
0.009 (CI95%: 0.0009 to 0.026)

Table 5-151: Multilevel Regression Analysis of Triads associations with Frontal Function in the
CLSA at baseline

Predictors

Estimates std. Error

CI

p

(Intercept)

0.12

0.04

0.03 – 0.21

0.006

arthritis [Yes]

-0.14

0.02

-0.19 – -0.10

<0.001

diabetes [Yes]

-0.10

0.03

-0.16 – -0.03

0.004

hypertension [Yes]

-0.19

0.02

-0.23 – -0.14

<0.001

cancer [Yes]

-0.06

0.03

-0.12 – 0.01

0.100

thyroid [Yes]

-0.05

0.03

-0.11 – 0.01

0.131

arthritis [Yes] *
diabetes [Yes]

0.09

0.06

-0.02 – 0.20

0.092

arthritis [Yes] *
hypertension [Yes]

0.03

0.04

-0.05 – 0.11

0.458

diabetes [Yes] *
hypertension [Yes]

-0.02

0.05

-0.11 – 0.08

0.720

arthritis [Yes] * cancer
[Yes]

-0.03

0.06

-0.14 – 0.09

0.654

hypertension [Yes] *
cancer [Yes]

-0.01

0.06

-0.12 – 0.11

0.925

arthritis [Yes] * thyroid
[Yes]

0.05

0.05

-0.06 – 0.15

0.388

hypertension [Yes] *
thyroid [Yes]

-0.06

0.06

-0.17 – 0.05

0.276

(arthritis [Yes] *
diabetes [Yes]) *
hypertension [Yes]

-0.03

0.08

-0.18 – 0.12

0.678

(arthritis [Yes] *
hypertension [Yes]) *
cancer [Yes]

-0.09

0.09

-0.26 – 0.08

0.317

(arthritis [Yes] *
hypertension [Yes]) *
thyroid [Yes]

0.07

0.08

-0.10 – 0.23

0.444
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Random Effects
σ2

0.96

τ00 region

0.01 (SD: 0.10; CI95%: 0.05 to 0.19)

ICC

0.01

N region

5

Observations
2

21968
2

Marginal R / Conditional R

0.018 / 0.027

AIC

73086.904

AICc

73086.935

thyroid: thyroid diseases

Change between baseline and first follow-up
Dyads analysis
We analyzed 21909 participants that had information of the change of MAT scores between
baseline and the first follow-up. We found that only the dyad of diabetes + arthritis presented an
association on MAT scores change decreasing by 0.0758 (CI95%: -0.146 to -0.005; p-value 0.035)
the score (Table 5-152). The ICC was 0.003 (CI95%: 0.0003 to 0.011). The interpretation of this
interaction is as follows: In participants with diabetes, scores decreased by 0.03, and in participants
with arthritis, the scores increased by 0.02. However, when both conditions are present, scores do
not decrease by the expected 0.01 SD, but the diminishing of scores was amplified to -0.09 SD.

Table 5-152: Multilevel Regression Analysis of Dyads associations on Frontal Function change
between Baseline and the First Follow-up in the CLSA

Predictors

Estimates std. Error

CI

p

(Intercept)

-0.06

0.03

-0.11 – -0.01

0.025

diabetes [Yes]

-0.03

0.03

-0.08 – 0.03

0.369

hypertension [Yes]

-0.03

0.02

-0.07 – 0.01

0.095

arthritis [Yes]

0.02

0.02

-0.01 – 0.06

0.242
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depression [Yes]

0.01

0.03

-0.04 – 0.07

0.575

thyroid [Yes]

-0.04

0.03

-0.09 – 0.02

0.191

cancer [Yes]

-0.08

0.03

-0.14 – -0.02

0.009

diabetes [Yes] *
hypertension [Yes]

0.05

0.04

-0.02 – 0.12

0.175

arthritis [Yes] *
depression [Yes]

-0.01

0.04

-0.09 – 0.06

0.707

arthritis [Yes] * thyroid
[Yes]

-0.02

0.04

-0.10 – 0.06

0.640

hypertension [Yes] *
cancer [Yes]

0.06

0.04

-0.02 – 0.14

0.137

arthritis [Yes] * cancer
[Yes]

0.01

0.04

-0.08 – 0.09

0.887

hypertension [Yes] *
depression [Yes]

-0.03

0.04

-0.11 – 0.04

0.389

diabetes [Yes] *
arthritis [Yes]

-0.08

0.04

-0.15 – -0.01

0.035

hypertension [Yes] *
thyroid [Yes]

0.02

0.04

-0.06 – 0.10

0.598

Random Effects
σ2

0.90

τ00 region

0.004 (SD: 0.06; CI95%: 0.05 to 0.19)

ICC

0.00

N region

5

Observations
2

21909
2

Marginal R / Conditional R

0.001 / 0.005

AIC

71314.143

AICc

71314.171

thyroid: thyroid diseases

Triads analysis
We did not find any triad associated with change on MAT scores between baseline and the first
follow-up (Table 5-153). The ICC was 0.003 (CI95%: 0.0002 to 0.011)
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Table 5-153: Multilevel Regression Analysis of Triads associations on Frontal Function change
between Baseline and the First Follow-up in the CLSA

Predictors

Estimates std. Error

CI

p

(Intercept)

-0.06

0.03

-0.11 – -0.01

0.029

arthritis [Yes]

0.03

0.02

-0.02 – 0.07

0.229

diabetes [Yes]

-0.03

0.03

-0.09 – 0.04

0.379

hypertension [Yes]

-0.03

0.02

-0.07 – 0.01

0.147

cancer [Yes]

-0.07

0.03

-0.13 – -0.00

0.045

thyroid [Yes]

-0.03

0.03

-0.10 – 0.03

0.258

arthritis [Yes] *
diabetes [Yes]

-0.07

0.05

-0.17 – 0.04

0.206

arthritis [Yes] *
hypertension [Yes]

-0.02

0.04

-0.09 – 0.06

0.652

diabetes [Yes] *
hypertension [Yes]

0.06

0.05

-0.04 – 0.15

0.231

arthritis [Yes] * cancer
[Yes]

-0.03

0.05

-0.14 – 0.07

0.553

hypertension [Yes] *
cancer [Yes]

0.03

0.05

-0.08 – 0.13

0.641

arthritis [Yes] * thyroid
[Yes]

-0.03

0.05

-0.13 – 0.07

0.522

hypertension [Yes] *
thyroid [Yes]

-0.00

0.05

-0.11 – 0.10

0.967

(arthritis [Yes] *
diabetes [Yes]) *
hypertension [Yes]

-0.02

0.07

-0.16 – 0.13

0.809

(arthritis [Yes] *
hypertension [Yes]) *
cancer [Yes]

0.09

0.08

-0.07 – 0.25

0.277

(arthritis [Yes] *
hypertension [Yes]) *
thyroid [Yes]

0.05

0.08

-0.11 – 0.21

0.571

Random Effects
σ2

0.90

τ00 region

0.004 (SD: 0.06; CI95%: 0.03 to 0.11)

ICC

0.00

N region

5
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Observations

21968

Marginal R2 / Conditional R2

0.001 / 0.005

AIC

71536.625

AICc

71536.656

thyroid: thyroid diseases

5.2.1.2.2 Animal Naming Test

5.2.1.2.2.1 CSHA
Baseline
Dyads analysis
We analyzed 486 participants at baseline in the ANT scores. We found that the dyad of arthritis +
thyroid disease was associated with a decrease of 1.02 (CI95%: -1.65 to -0.39; p-value 0.002) with
ANT scores (Table 5-154). The ICC was 0.092 (CI95%: 0.003 to 0.271).
The interpretation of this interaction is as follows: In participants with arthritis, the ANT scores
increased by 0.27, and in participants with thyroid disease, the scores increased by 0.86. We
expected that for participants with both conditions, coefficients would be 1.09 SD higher, but due
to the interaction, the scores just were 0.07 SD higher.

Table 5-154: Multilevel Regression Analysis of Dyads associations with Animal Naming Test in the
CSHA at baseline
Predictors

Estimates std. Error

CI

p

(Intercept)

0.08

0.16

-0.24 – 0.40

0.629

arthritis [Yes]

0.27

0.13

0.00 – 0.53

0.046

hypertension [Yes]

0.00

0.14

-0.28 – 0.29

0.994

cancer [Yes]

0.01

0.23

-0.44 – 0.45

0.973

diabetes [Yes]

0.24

0.23

-0.21 – 0.70

0.289

gast ulcer [Yes]

0.22

0.17

-0.13 – 0.56

0.214

depression [Yes]

-0.71

0.21

-1.11 – -0.30

0.001

thyroid [Yes]

0.86

0.26

0.34 – 1.37

0.001
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ckd [Yes]

-0.22

0.30

-0.81 – 0.38

0.469

oheart [Yes]

0.04

0.19

-0.34 – 0.41

0.852

arthritis [Yes] *
hypertension [Yes]

-0.31

0.19

-0.69 – 0.06

0.103

arthritis [Yes] * cancer
[Yes]

-0.14

0.31

-0.76 – 0.47

0.651

arthritis [Yes] *
diabetes [Yes]

-0.37

0.28

-0.92 – 0.19

0.198

arthritis [Yes] * gast
ulcer [Yes]

-0.32

0.23

-0.76 – 0.13

0.160

arthritis [Yes] *
depression [Yes]

0.36

0.26

-0.15 – 0.87

0.164

arthritis [Yes] * thyroid
[Yes]

-1.02

0.32

-1.65 – -0.39

0.002

depression [Yes] *
thyroid [Yes]

-0.46

0.52

-1.48 – 0.55

0.370

arthritis [Yes] * ckd
[Yes]

0.16

0.35

-0.52 – 0.85

0.640

arthritis [Yes] * oheart
[Yes]

0.02

0.24

-0.45 – 0.50

0.925

(arthritis [Yes] *
depression [Yes]) *
thyroid [Yes]

0.78

0.64

-0.48 – 2.03

0.227

Random Effects
σ2

0.83

τ00 region

0.08 (SD: 0.29; CI95%: 0.13 to 0.59)

ICC

0.09

N region

5

Observations
2

486
2

Marginal R / Conditional R

0.086 / 0.171

AIC

1439.318

AICc

1441.504

gast ulcer: gastric ulcer; thyroid: thyroid diseases; otheart: other heart disease; ckd: chronic kidney disease

Triad analysis
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We did not find any triad associated with ANT scores at baseline (Table 5-155). The ICC was 0.10
(CI95%: 0.008 to 0.28)

Table 5-155: Multilevel Regression Analysis of Triads associations with Animal Naming Test in the
CSHA at baseline

Predictors

Estimates std. Error

CI

p

(Intercept)

0.21

0.17

-0.13 – 0.54

0.224

arthritis [Yes]

0.13

0.13

-0.13 – 0.39

0.343

ckd [Yes]

-0.36

0.35

-1.06 – 0.34

0.309

hypertension [Yes]

-0.07

0.17

-0.41 – 0.27

0.690

depression [Yes]

-0.86

0.23

-1.31 – -0.40

<0.001

gast ulcer [Yes]

0.13

0.20

-0.26 – 0.53

0.512

oheart [Yes]

0.27

0.20

-0.12 – 0.67

0.170

coronary [Yes]

-0.18

0.25

-0.66 – 0.31

0.476

arthritis [Yes] * ckd
[Yes]

0.20

0.42

-0.62 – 1.02

0.629

arthritis [Yes] *
hypertension [Yes]

-0.27

0.24

-0.75 – 0.20

0.259

ckd [Yes] * hypertension
[Yes]

0.12

0.73

-1.31 – 1.55

0.865

arthritis [Yes] *
depression [Yes]

0.65

0.29

0.08 – 1.23

0.026

hypertension [Yes] *
depression [Yes]

0.38

0.43

-0.47 – 1.23

0.377

arthritis [Yes] * gast
ulcer [Yes]

-0.24

0.27

-0.78 – 0.30

0.377

hypertension [Yes] * gast
ulcer [Yes]

0.13

0.41

-0.68 – 0.93

0.760

arthritis [Yes] * oheart
[Yes]

-0.28

0.26

-0.80 – 0.23

0.276

arthritis [Yes] *
coronary [Yes]

-0.12

0.31

-0.73 – 0.50

0.706

oheart [Yes] * coronary
[Yes]

-0.43

0.52

-1.46 – 0.60

0.415
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(arthritis [Yes] * ckd
[Yes]) * hypertension
[Yes]

0.25

0.81

-1.34 – 1.84

0.758

(arthritis [Yes] *
hypertension [Yes]) *
depression [Yes]

-0.50

0.53

-1.54 – 0.53

0.340

(arthritis [Yes] *
hypertension [Yes]) *
gast ulcer [Yes]

-0.10

0.51

-1.11 – 0.91

0.847

(arthritis [Yes] * oheart
[Yes]) * coronary [Yes]

0.75

0.64

-0.51 – 2.00

0.242

Random Effects
σ2

0.85

τ00 region

0.09 (SD: 0.31; CI95%: 0.14 to 0.62)

ICC

0.10

N region

5

Observations

486

Marginal R2 / Conditional R2

0.069 / 0.162

AIC

1445.252

AICc

1447.855

gast ulcer: gastric ulcer; thyroid: thyroid diseases; otheart: other heart disease; ckd: chronic kidney disease

Change between baseline and first follow-up
Dyads analysis
We found that the dyad of arthritis + diabetes was associated with an increase of 0.599 (CI95%:
0.008 to 1.19; p-value 0.048) on the ANT scores comparing baseline and first follow-up (Table
5-156). The ICC was 0.011 (CI95%: 0.000 to 0.071)
The interpretation of this interaction is as follows: In participants with arthritis, the ANT scores
decrease by 0.16, and in participants with diabetes, the scores decrease by 0.69. We expected that
for participants with both conditions, coefficients would be 1.09 SD lower, but due to the
interaction, the scores just were 0.25 SD lower.
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Table 5-156: Multilevel Regression Analysis of Dyads associations on Animal Naming Test change
between Baseline and the First Follow-up in the CSHA

Predictors

Estimates std. Error

CI

p

(Intercept)

-0.29

0.11

-0.50 – -0.07

0.010

arthritis [Yes]

-0.16

0.14

-0.44 – 0.12

0.258

hypertension [Yes]

-0.03

0.15

-0.33 – 0.27

0.844

cancer [Yes]

-0.14

0.24

-0.62 – 0.33

0.547

diabetes [Yes]

-0.69

0.24

-1.17 – -0.21

0.005

gast ulcer [Yes]

0.02

0.18

-0.34 – 0.39

0.896

depression [Yes]

0.14

0.22

-0.29 – 0.58

0.514

thyroid [Yes]

-0.31

0.28

-0.86 – 0.23

0.261

ckd [Yes]

-0.00

0.32

-0.64 – 0.63

0.991

oheart [Yes]

-0.18

0.20

-0.57 – 0.22

0.384

arthritis [Yes] *
hypertension [Yes]

0.33

0.20

-0.07 – 0.73

0.105

arthritis [Yes] * cancer
[Yes]

0.15

0.33

-0.51 – 0.80

0.656

arthritis [Yes] *
diabetes [Yes]

0.60

0.30

0.01 – 1.19

0.048

arthritis [Yes] * gast
ulcer [Yes]

-0.20

0.24

-0.68 – 0.27

0.394

arthritis [Yes] *
depression [Yes]

-0.23

0.27

-0.77 – 0.31

0.411

arthritis [Yes] * thyroid
[Yes]

0.45

0.34

-0.22 – 1.11

0.188

depression [Yes] *
thyroid [Yes]

0.25

0.55

-0.83 – 1.33

0.648

arthritis [Yes] * ckd
[Yes]

0.04

0.37

-0.69 – 0.76

0.921

arthritis [Yes] * oheart
[Yes]

0.25

0.26

-0.25 – 0.76

0.319

(arthritis [Yes] *
depression [Yes]) *
thyroid [Yes]

-0.52

0.68

-1.85 – 0.81

0.445

Random Effects
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σ2

0.94

τ00 region

0.01 (SD: 0.10; CI95%: 0 to 0.27)

ICC

0.01

N region

5

Observations

486

Marginal R2 / Conditional R2

0.045 / 0.056

AIC

1489.478

AICc

1491.664

gast ulcer: gastric ulcer; thyroid: thyroid diseases; otheart: other heart disease; ckd: chronic kidney disease

Triad analysis
We did not find any triad associated with change on ANT scores between baseline and the first
follow-up (Table 5-157). The ICC was 0.012 (CI95%: 0.000 to 0.069)

Table 5-157: Multilevel Regression Analysis of Triads associations on Animal Naming Test change
between Baseline and the First Follow-up in the CSHA

Predictors

Estimates std. Error

CI

p

(Intercept)

-0.37

0.11

-0.59 – -0.16

0.001

arthritis [Yes]

-0.09

0.14

-0.36 – 0.19

0.536

ckd [Yes]

-0.09

0.37

-0.81 – 0.64

0.817

hypertension [Yes]

-0.14

0.18

-0.49 – 0.22

0.448

depression [Yes]

0.13

0.24

-0.35 – 0.60

0.602

gast ulcer [Yes]

0.05

0.21

-0.37 – 0.46

0.829

oheart [Yes]

-0.42

0.21

-0.83 – -0.01

0.042

coronary [Yes]

0.15

0.26

-0.36 – 0.66

0.560

arthritis [Yes] * ckd
[Yes]

0.59

0.43

-0.26 – 1.45

0.174

arthritis [Yes] *
hypertension [Yes]

0.58

0.25

0.09 – 1.08

0.021
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ckd [Yes] * hypertension
[Yes]

-0.12

0.76

-1.62 – 1.37

0.869

arthritis [Yes] *
depression [Yes]

-0.34

0.31

-0.94 – 0.26

0.272

hypertension [Yes] *
depression [Yes]

0.39

0.45

-0.49 – 1.28

0.386

arthritis [Yes] * gast
ulcer [Yes]

-0.14

0.29

-0.70 – 0.42

0.634

hypertension [Yes] * gast
ulcer [Yes]

0.18

0.43

-0.66 – 1.01

0.677

arthritis [Yes] * oheart
[Yes]

0.59

0.27

0.06 – 1.13

0.031

arthritis [Yes] *
coronary [Yes]

-0.46

0.33

-1.10 – 0.18

0.155

oheart [Yes] * coronary
[Yes]

0.81

0.55

-0.26 – 1.88

0.138

(arthritis [Yes] * ckd
[Yes]) * hypertension
[Yes]

-0.92

0.84

-2.57 – 0.74

0.276

(arthritis [Yes] *
hypertension [Yes]) *
depression [Yes]

-0.10

0.55

-1.19 – 0.98

0.849

(arthritis [Yes] *
hypertension [Yes]) *
gast ulcer [Yes]

-0.31

0.53

-1.36 – 0.73

0.557

(arthritis [Yes] * oheart
[Yes]) * coronary [Yes]

-1.01

0.67

-2.32 – 0.29

0.128

Random Effects
σ2

0.93

τ00 region

0.01 (SD: 0.10; CI95%: 0 to 0.27)

ICC

0.01

N region

5

Observations

486

Marginal R2 / Conditional R2

0.065 / 0.076

AIC

1478.702

AICc

1481.305

gast ulcer: gastric ulcer; thyroid: thyroid diseases; otheart: other heart disease; ckd: chronic kidney disease
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5.2.1.2.2.2 CLSA
Baseline
Dyads analysis
We analyzed 23343 participants. We found five dyads associated with ANT scores at baseline
(Table 5-158); also, the ICC was 0.031 (CI95%: 0.004 to 0.085). The dyads were:
-

Diabetes + hypertension: 0.085(CI95%: 0.014 to 0.155; p-value 0.018)

-

Arthritis + thyroid disease: -0.109 (CI95%: -0.187 to -0.030; p-value 0.006)

-

Arthritis + cancer: -0.0816 (CI95%: -0.161 to -0.0017; p-value 0.045)

-

Diabetes + arthritis: 0.13 (CI95%: 0.06 to 0.2; p-value 0.0003)

-

Hypertension + thyroid disease -0.114 (CI95%: -0.194 to -0.035; p-value 0.005)

In these cases, the interpretations are as follows:
-

In participants with diabetes and hypertension, we expected a score of -0.41 SD, but the
interaction ameliorates the loss to just -0.33 SD

-

In participants with arthritis and thyroid disease, we expected a score of -0.08 SD, but the
interaction potentiates the low score up to -0.19 SD.

-

In participants with arthritis and cancer, we expected a score of -0.21 SD, but the interaction
potentiates the diminishing score to -0.29 SD.

-

In participants with diabetes and arthritis, we expected a score of -0.28 SD, but the
interaction ameliorates the score to just -0.15 SD.

-

In participants with hypertension and thyroid disease, we expected a score of -0.21 SD, but
the interaction decreased the score to -0.32 SD.

Table 5-158: Multilevel Regression Analysis of Dyads associations with Animal Naming Test in the
CLSA at baseline
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Predictors

Estimates std. Error

CI

p

(Intercept)

0.10

0.08

-0.05 – 0.26

0.189

diabetes [Yes]

-0.18

0.03

-0.24 – -0.13

<0.001

hypertension [Yes]

-0.23

0.02

-0.27 – -0.19

<0.001

arthritis [Yes]

-0.10

0.02

-0.13 – -0.06

<0.001

depression [Yes]

0.11

0.03

0.06 – 0.16

<0.001

thyroid [Yes]

0.02

0.03

-0.03 – 0.08

0.385

cancer [Yes]

-0.11

0.03

-0.17 – -0.05

<0.001

diabetes [Yes] *
hypertension [Yes]

0.08

0.04

0.01 – 0.15

0.018

arthritis [Yes] *
depression [Yes]

-0.06

0.04

-0.13 – 0.02

0.134

arthritis [Yes] * thyroid
[Yes]

-0.11

0.04

-0.19 – -0.03

0.006

hypertension [Yes] *
cancer [Yes]

-0.03

0.04

-0.11 – 0.05

0.529

arthritis [Yes] * cancer
[Yes]

-0.08

0.04

-0.16 – -0.00

0.045

hypertension [Yes] *
depression [Yes]

0.02

0.04

-0.06 – 0.09

0.636

diabetes [Yes] *
arthritis [Yes]

0.13

0.04

0.06 – 0.20

<0.001

hypertension [Yes] *
thyroid [Yes]

-0.11

0.04

-0.19 – -0.03

0.005

Random Effects
σ2

0.95

τ00 region

0.03 (SD: 0.18; CI95%: 0.09 to 0.34)

ICC

0.03

N region

5

Observations

23343

Marginal R2 / Conditional R2

0.027 / 0.058

AIC

77391.555

AICc

77391.581

thyroid: thyroid diseases
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Triads analysis
We did not find any triad associated with ANT scores at baseline (Table 5-159). The ICC was
0.031 (CI95%: 0.004 to 0.086)

Table 5-159: Multilevel Regression Analysis of Triads associations with Animal Naming Test in the
CLSA at baseline

Predictors

Estimates std. Error

CI

p

(Intercept)

0.11

0.08

-0.04 – 0.27

0.148

arthritis [Yes]

-0.09

0.02

-0.13 – -0.05

<0.001

diabetes [Yes]

-0.17

0.03

-0.23 – -0.11

<0.001

hypertension [Yes]

-0.21

0.02

-0.25 – -0.17

<0.001

cancer [Yes]

-0.12

0.03

-0.18 – -0.06

<0.001

thyroid [Yes]

0.05

0.03

-0.01 – 0.11

0.116

arthritis [Yes] *
diabetes [Yes]

0.11

0.05

0.00 – 0.21

0.044

arthritis [Yes] *
hypertension [Yes]

-0.04

0.04

-0.12 – 0.03

0.248

diabetes [Yes] *
hypertension [Yes]

0.06

0.05

-0.03 – 0.15

0.225

arthritis [Yes] * cancer
[Yes]

-0.06

0.05

-0.17 – 0.04

0.236

hypertension [Yes] *
cancer [Yes]

-0.01

0.05

-0.12 – 0.09

0.819

arthritis [Yes] * thyroid
[Yes]

-0.14

0.05

-0.24 – -0.04

0.006

hypertension [Yes] *
thyroid [Yes]

-0.15

0.05

-0.25 – -0.04

0.007

(arthritis [Yes] *
diabetes [Yes]) *
hypertension [Yes]

0.06

0.07

-0.08 – 0.21

0.377

(arthritis [Yes] *
hypertension [Yes]) *
cancer [Yes]

-0.03

0.08

-0.19 – 0.13

0.719
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(arthritis [Yes] *
hypertension [Yes]) *
thyroid [Yes]

0.07

0.08

-0.09 – 0.23

0.425

Random Effects
σ2

0.96

τ00 region

0.03 (SD: 0.18; CI95%: 0.09 to 0.34)

ICC

0.03

N region

5

Observations
2

23405
2

Marginal R / Conditional R

0.026 / 0.057

AIC

77660.535

AICc

77660.564

thyroid: thyroid diseases

Change between baseline and first follow-up
Dyads analysis
We analyzed information from 23343 participants. We found three dyads associated with ANT
scores at baseline (Table 5-160); the ICC was 0.001 (CI95%: 0.00003 to 0.007).
The identified dyads were:
-

Hypertension + depression: 0.0744 (CI95%: 0.0018 to 0.147; p-value 0.0447)

-

Diabetes + arthritis: 0.0708 (CI95%: 0.0015 to 0.14; p-value 0.0453)

-

Hypertension + thyroid disease: 0.0874 (CI95%: 0.0084 to 0.166; p-value 0.0302)

In these cases, the interpretations are as follows:
-

In participants with depression and hypertension, we expected a score of -0.04 SD, but the
interaction increased scores to + 0.03 SD.

-

In participants with arthritis and diabetes, we expected a score of -0.05 SD, but the
interaction increased the score to +0.02 SD.
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-

In participants with hypertension and thyroid disease, we expected a score of -0.05 SD, but
the interaction increased the score to +0.04 SD.

Table 5-160: Multilevel Regression Analysis of Dyads associations on Animal Naming Test change
between Baseline and the First Follow-up in the CLSA

Predictors

Estimates std. Error

CI

p

(Intercept)

-0.01

0.02

-0.05 – 0.03

0.730

diabetes [Yes]

-0.04

0.03

-0.10 – 0.01

0.129

hypertension [Yes]

-0.02

0.02

-0.06 – 0.02

0.258

arthritis [Yes]

-0.01

0.02

-0.04 – 0.03

0.651

depression [Yes]

-0.02

0.03

-0.07 – 0.03

0.451

thyroid [Yes]

-0.03

0.03

-0.08 – 0.03

0.320

cancer [Yes]

-0.01

0.03

-0.07 – 0.04

0.661

diabetes [Yes] *
hypertension [Yes]

-0.04

0.04

-0.11 – 0.03

0.292

arthritis [Yes] *
depression [Yes]

-0.06

0.04

-0.14 – 0.01

0.082

arthritis [Yes] * thyroid
[Yes]

0.06

0.04

-0.01 – 0.14

0.105

hypertension [Yes] *
cancer [Yes]

-0.01

0.04

-0.09 – 0.07

0.752

arthritis [Yes] * cancer
[Yes]

0.06

0.04

-0.02 – 0.14

0.143

hypertension [Yes] *
depression [Yes]

0.07

0.04

0.00 – 0.15

0.045

diabetes [Yes] *
arthritis [Yes]

0.07

0.04

0.00 – 0.14

0.045

hypertension [Yes] *
thyroid [Yes]

0.09

0.04

0.01 – 0.17

0.030

Random Effects
σ2

0.94

τ00 region

0.002 (SD: 0.04; CI95%: 0.02 to 0.08)

ICC

0.00

N region

5
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Observations

23343

Marginal R2 / Conditional R2

0.001 / 0.003

AIC

77135.347

AICc

77135.374

thyroid: thyroid diseases

Triads analysis
We did not find any triad associated with change on ANT scores between baseline and first followup (Table 5-161). The ICC was 0.002 (CI95%: 0.0004 to 0.006)

Table 5-161: Multilevel Regression Analysis of Triads associations on Animal Naming Test change
between Baseline and the First Follow-up in the CLSA

Predictors

Estimates std. Error

CI

p

(Intercept)

-0.01

0.02

-0.05 – 0.03

0.714

arthritis [Yes]

-0.03

0.02

-0.07 – 0.01

0.146

diabetes [Yes]

-0.05

0.03

-0.11 – 0.01

0.120

hypertension [Yes]

-0.02

0.02

-0.06 – 0.02

0.370

cancer [Yes]

-0.02

0.03

-0.08 – 0.05

0.596

thyroid [Yes]

-0.06

0.03

-0.12 – 0.00

0.066

arthritis [Yes] *
diabetes [Yes]

0.07

0.05

-0.03 – 0.18

0.169

arthritis [Yes] *
hypertension [Yes]

0.03

0.04

-0.04 – 0.10

0.430

diabetes [Yes] *
hypertension [Yes]

-0.03

0.05

-0.12 – 0.06

0.532

arthritis [Yes] * cancer
[Yes]

0.08

0.05

-0.03 – 0.18

0.149

hypertension [Yes] *
cancer [Yes]

0.00

0.05

-0.10 – 0.10

0.991

arthritis [Yes] * thyroid
[Yes]

0.12

0.05

0.03 – 0.22

0.014
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hypertension [Yes] *
thyroid [Yes]

0.16

0.05

0.06 – 0.27

0.002

(arthritis [Yes] *
diabetes [Yes]) *
hypertension [Yes]

-0.01

0.07

-0.15 – 0.14

0.930

(arthritis [Yes] *
hypertension [Yes]) *
cancer [Yes]

-0.04

0.08

-0.20 – 0.12

0.629

(arthritis [Yes] *
hypertension [Yes]) *
thyroid [Yes]

-0.15

0.08

-0.31 – 0.00

0.056

Random Effects
σ2

0.94

τ00 region

0.002 (SD: 0.04; CI95%: 0.02 to 0.08)

ICC

0.00

N region

5

Observations

23405

Marginal R2 / Conditional R2

0.001 / 0.003

AIC

77348.488

AICc

77348.518

thyroid: thyroid diseases

5.2.1.2.3 Rey Auditory Verbal learning Test (RAVLT)

5.2.1.2.3.1 Immediate Recall
5.2.1.2.3.1.1

CSHA

Baseline
Dyads analysis
We analyzed 425 participants. We found that the dyad of arthritis + thyroid disease decreased 0.68
(CI95%: - 1.31 to -0.05 ) the scores of RAVLT immediate recall scores at baseline (Table 5-162).
The ICC was 0.024 (CI95%: 0.000 to 0.10). The interpretation of this interaction is as follows: In
participants with arthritis and thyroid disease, we expected a score of 0.76 SD above the group
mean, but with the interaction, the result is only 0.08 SD.
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Table 5-162: Multilevel Regression Analysis of Dyads associations with Rey Auditory Learning Test
Immediate Recall in the CSHA at baseline

Predictors

Estimates std. Error

CI

p

(Intercept)

-0.14

0.13

-0.39 – 0.12

0.287

arthritis [Yes]

0.26

0.15

-0.04 – 0.56

0.088

hypertension [Yes]

0.14

0.17

-0.19 – 0.47

0.398

cancer [Yes]

0.19

0.26

-0.32 – 0.70

0.469

diabetes [Yes]

0.27

0.28

-0.29 – 0.82

0.344

gast ulcer [Yes]

0.20

0.20

-0.19 – 0.59

0.321

depression [Yes]

-0.43

0.22

-0.86 – 0.00

0.051

thyroid [Yes]

0.50

0.26

-0.02 – 1.02

0.059

ckd [Yes]

0.49

0.36

-0.22 – 1.19

0.176

oheart [Yes]

0.02

0.23

-0.42 – 0.47

0.918

arthritis [Yes] *
hypertension [Yes]

-0.07

0.22

-0.51 – 0.36

0.739

arthritis [Yes] * cancer
[Yes]

-0.03

0.36

-0.73 – 0.67

0.935

arthritis [Yes] *
diabetes [Yes]

-0.38

0.34

-1.04 – 0.28

0.254

arthritis [Yes] * gast
ulcer [Yes]

-0.37

0.26

-0.87 – 0.14

0.157

arthritis [Yes] *
depression [Yes]

0.53

0.27

-0.01 – 1.06

0.053

arthritis [Yes] * thyroid
[Yes]

-0.68

0.32

-1.31 – -0.05

0.034

arthritis [Yes] * ckd
[Yes]

-0.44

0.41

-1.24 – 0.36

0.278

arthritis [Yes] * oheart
[Yes]

-0.04

0.28

-0.59 – 0.51

0.887

Random Effects
σ2

0.97

τ00 region

0.02 (SD 0.13; CI95%: 0 to 0.31)

ICC

0.02
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N region

5

Observations

425

Marginal R2 / Conditional R2

0.042 / 0.065

AIC

1314.543

AICc

1316.622

gast ulcer: gastric ulcer; thyroid: thyroid diseases; otheart: other heart disease; ckd: chronic kidney disease

Triads analysis
We did not find any triad associated with RAVLT immediate recall scores at baseline (Table
5-163). The ICC was 0.026 (CI95%: 0.000to 0.11)

Table 5-163: Multilevel Regression Analysis of Triads associations with Rey Auditory Learning Test
Immediate Recall in the CSHA at baseline

Predictors

Estimates std. Error

CI

p

(Intercept)

0.02

0.13

-0.23 – 0.28

0.851

arthritis [Yes]

0.12

0.15

-0.17 – 0.41

0.419

ckd [Yes]

0.12

0.43

-0.73 – 0.96

0.785

hypertension [Yes]

0.09

0.20

-0.31 – 0.48

0.663

depression [Yes]

-0.67

0.27

-1.19 – -0.15

0.012

gast ulcer [Yes]

0.20

0.22

-0.24 – 0.64

0.376

oheart [Yes]

0.26

0.23

-0.21 – 0.72

0.277

coronary [Yes]

-0.67

0.29

-1.24 – -0.11

0.020

arthritis [Yes] * ckd
[Yes]

-0.03

0.49

-1.00 – 0.95

0.957

arthritis [Yes] *
hypertension [Yes]

-0.13

0.27

-0.67 – 0.40

0.622

ckd [Yes] * hypertension
[Yes]

0.73

0.81

-0.86 – 2.33

0.366

arthritis [Yes] *
depression [Yes]

0.79

0.34

0.12 – 1.46

0.021
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hypertension [Yes] *
depression [Yes]

0.68

0.49

-0.28 – 1.65

0.164

arthritis [Yes] * gast
ulcer [Yes]

-0.44

0.31

-1.05 – 0.18

0.162

hypertension [Yes] * gast
ulcer [Yes]

-0.53

0.47

-1.45 – 0.39

0.260

arthritis [Yes] * oheart
[Yes]

-0.29

0.30

-0.89 – 0.30

0.336

arthritis [Yes] *
coronary [Yes]

0.34

0.36

-0.37 – 1.04

0.349

oheart [Yes] * coronary
[Yes]

0.29

0.61

-0.91 – 1.49

0.634

(arthritis [Yes] * ckd
[Yes]) * hypertension
[Yes]

-0.71

0.90

-2.47 – 1.06

0.430

(arthritis [Yes] *
hypertension [Yes]) *
depression [Yes]

-0.56

0.59

-1.73 – 0.60

0.343

(arthritis [Yes] *
hypertension [Yes]) *
gast ulcer [Yes]

0.80

0.58

-0.34 – 1.94

0.169

(arthritis [Yes] * oheart
[Yes]) * coronary [Yes]

-0.19

0.73

-1.63 – 1.25

0.795

Random Effects
σ2

0.96

τ00 region

0.03 (SD 0.16; CI95%: 0 to 0.36)

ICC

0.03

N region

5

Observations

425

Marginal R2 / Conditional R2

0.056 / 0.081

AIC

1309.682

AICc

1312.682

gast ulcer: gastric ulcer; thyroid: thyroid diseases; otheart: other heart disease; ckd: chronic kidney disease

Change between baseline and first follow-up
Dyads analysis
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We did not find any dyad associated with change on RAVLT immediate recall scores between
baseline and first follow-up (Table 5-164). The ICC was 0.012 (CI95%: 0.000 to 0.078)

Table 5-164: Multilevel Regression Analysis of Dyads associations on Rey Auditory Learning Test
Immediate Recall change between Baseline and the First Follow-up in the CSHA

Predictors

Estimates std. Error

CI

p

(Intercept)

-0.16

0.12

-0.40 – 0.07

0.176

arthritis [Yes]

-0.13

0.15

-0.43 – 0.17

0.384

hypertension [Yes]

0.00

0.17

-0.33 – 0.33

0.983

cancer [Yes]

-0.04

0.26

-0.54 – 0.47

0.889

diabetes [Yes]

-0.10

0.28

-0.65 – 0.46

0.733

gast ulcer [Yes]

-0.38

0.20

-0.77 – 0.01

0.055

depression [Yes]

0.04

0.22

-0.39 – 0.47

0.864

thyroid [Yes]

-0.21

0.26

-0.73 – 0.31

0.433

ckd [Yes]

-0.29

0.36

-1.00 – 0.41

0.415

oheart [Yes]

-0.03

0.23

-0.47 – 0.41

0.890

arthritis [Yes] *
hypertension [Yes]

0.01

0.22

-0.42 – 0.44

0.964

arthritis [Yes] * cancer
[Yes]

0.31

0.36

-0.39 – 1.02

0.382

arthritis [Yes] *
diabetes [Yes]

0.25

0.34

-0.41 – 0.91

0.459

arthritis [Yes] * gast
ulcer [Yes]

0.28

0.26

-0.23 – 0.79

0.279

arthritis [Yes] *
depression [Yes]

-0.28

0.27

-0.81 – 0.25

0.302

arthritis [Yes] * thyroid
[Yes]

0.27

0.32

-0.36 – 0.90

0.398

arthritis [Yes] * ckd
[Yes]

0.29

0.41

-0.51 – 1.09

0.475

arthritis [Yes] * oheart
[Yes]

0.37

0.28

-0.18 – 0.93

0.184

Random Effects
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σ2

0.97

τ00 region

0.01 (SD: 0.11; CI95%: 0 to 0.27)

ICC

0.01

N region

5

Observations

425

Marginal R2 / Conditional R2

0.037 / 0.049

AIC

1312.318

AICc

1314.397

gast ulcer: gastric ulcer; thyroid: thyroid diseases; otheart: other heart disease; ckd: chronic kidney disease

Triads analysis
We did not find any triad associated with change on RAVLT immediate recall scores between
baseline and first follow-up (Table 5-165). The ICC was 0.016 (CI95%: 0.000 to 0.079)

Table 5-165: Multilevel Regression Analysis of Triads associations on Rey Auditory Learning Test
Immediate Recall change between Baseline and the First Follow-up in the CSHA

Predictors

Estimates std. Error

CI

p

(Intercept)

-0.26

0.12

-0.50 – -0.02

0.034

arthritis [Yes]

0.01

0.15

-0.28 – 0.29

0.970

ckd [Yes]

0.29

0.42

-0.55 – 1.12

0.500

hypertension [Yes]

0.08

0.20

-0.31 – 0.46

0.698

depression [Yes]

0.23

0.26

-0.29 – 0.75

0.377

gast ulcer [Yes]

-0.35

0.22

-0.79 – 0.09

0.116

oheart [Yes]

-0.26

0.23

-0.71 – 0.20

0.269

coronary [Yes]

0.34

0.28

-0.22 – 0.90

0.237

arthritis [Yes] * ckd
[Yes]

-0.21

0.49

-1.17 – 0.75

0.668

arthritis [Yes] *
hypertension [Yes]

-0.13

0.27

-0.66 – 0.40

0.638
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ckd [Yes] * hypertension
[Yes]

-1.66

0.80

-3.23 – -0.08

0.039

arthritis [Yes] *
depression [Yes]

-0.77

0.34

-1.43 – -0.10

0.023

hypertension [Yes] *
depression [Yes]

-0.24

0.49

-1.19 – 0.72

0.626

arthritis [Yes] * gast
ulcer [Yes]

0.36

0.31

-0.25 – 0.97

0.250

hypertension [Yes] * gast
ulcer [Yes]

0.11

0.46

-0.79 – 1.02

0.804

arthritis [Yes] * oheart
[Yes]

0.76

0.30

0.17 – 1.35

0.012

arthritis [Yes] *
coronary [Yes]

0.01

0.36

-0.69 – 0.71

0.984

oheart [Yes] * coronary
[Yes]

0.62

0.60

-0.57 – 1.80

0.307

(arthritis [Yes] * ckd
[Yes]) * hypertension
[Yes]

1.42

0.89

-0.32 – 3.17

0.110

(arthritis [Yes] *
hypertension [Yes]) *
depression [Yes]

0.78

0.59

-0.37 – 1.94

0.184

(arthritis [Yes] *
hypertension [Yes]) *
gast ulcer [Yes]

-0.28

0.57

-1.41 – 0.85

0.628

(arthritis [Yes] * oheart
[Yes]) * coronary [Yes]

-1.28

0.72

-2.70 – 0.15

0.079

Random Effects
σ2

0.94

τ00 region

0.01 (SD: 0.12; CI95%; 0 to 0.29)

ICC

0.02

N region

5

Observations

425

Marginal R2 / Conditional R2

0.068 / 0.082

AIC

1300.507

AICc

1303.507

gast ulcer: gastric ulcer; thyroid: thyroid diseases; otheart: other heart disease; ckd: chronic kidney disease
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5.2.1.2.3.1.2

CLSA

Baseline
Dyads analysis
We analyzed information on 23007 participants. We found two dyads associated with RAVLT
immediate recall scores at baseline (Table 5-166). The ICC was 0.017 (CI95%: 0.002 to 0.051).
The dyads were:
-

Arthritis + cancer: 0.11 (CI95%: 0.03 to 0.19; p-value 0.007)

-

Hypertension + depression: 0.165 (CI95%: 0.092 to 0.234; p-value >0.001)

In these cases, the interpretations are as follows:
-

In participants with arthritis and cancer, we expected a score of -0.25 SD, but the interaction
ameliorated scores to -0.11 SD.

-

In participants with hypertension and depression, we expected a score of -0.22 SD, but the
interaction ameliorated the score to -0.06 SD.

Table 5-166: Multilevel Regression Analysis of Dyads associations with Rey Auditory Learning Test
Immediate Recall in the CLSA at baseline

Predictors

Estimates std. Error

CI

p

(Intercept)

0.11

0.06

-0.00 – 0.22

0.055

diabetes [Yes]

-0.20

0.03

-0.26 – -0.14

<0.001

hypertension [Yes]

-0.25

0.02

-0.29 – -0.22

<0.001

arthritis [Yes]

-0.08

0.02

-0.12 – -0.05

<0.001

depression [Yes]

0.03

0.03

-0.02 – 0.08

0.184

thyroid [Yes]

0.06

0.03

0.01 – 0.12

0.031

cancer [Yes]

-0.17

0.03

-0.23 – -0.12

<0.001

diabetes [Yes] *
hypertension [Yes]

0.06

0.04

-0.01 – 0.13

0.083
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arthritis [Yes] *
depression [Yes]

-0.03

0.04

-0.11 – 0.04

0.344

arthritis [Yes] * thyroid
[Yes]

0.03

0.04

-0.05 – 0.11

0.470

hypertension [Yes] *
cancer [Yes]

0.01

0.04

-0.07 – 0.09

0.770

arthritis [Yes] * cancer
[Yes]

0.11

0.04

0.03 – 0.19

0.007

hypertension [Yes] *
depression [Yes]

0.17

0.04

0.09 – 0.24

<0.001

diabetes [Yes] *
arthritis [Yes]

0.04

0.04

-0.03 – 0.11

0.281

hypertension [Yes] *
thyroid [Yes]

0.06

0.04

-0.02 – 0.14

0.129

Random Effects
σ2

0.94

τ00 region

0.02 (SD: 0.13; CI95%: 0.07 to 0.25)

ICC

0.02

N region

5

Observations
2

23007
2

Marginal R / Conditional R

0.023 / 0.040

AIC

75880.804

AICc

75880.831

thyroid: thyroid diseases

Triads analysis
We found that the triad arthritis + diabetes + hypertension increased ANT scores by 0.162 (CI95%:
0.018 to 0.305; p-value 0.027) (Table 5-167). The ICC was 0.017 (CI95%: 0.002 to 0.049). In this
case, we expected that a participant with arthritis + diabetes + hypertension scored -0.44 SD but
with the interactions scored better with -0.38 SD.
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Table 5-167: Multilevel Regression Analysis of Triads associations with Rey Auditory Learning Test
Immediate Recall in the CLSA at baseline

Predictors

Estimates std. Error

CI

p

(Intercept)

0.11

0.06

-0.00 – 0.22

0.056

arthritis [Yes]

-0.07

0.02

-0.11 – -0.03

0.001

diabetes [Yes]

-0.17

0.03

-0.24 – -0.11

<0.001

hypertension [Yes]

-0.20

0.02

-0.25 – -0.16

<0.001

cancer [Yes]

-0.16

0.03

-0.23 – -0.10

<0.001

thyroid [Yes]

0.06

0.03

0.00 – 0.12

0.046

arthritis [Yes] *
diabetes [Yes]

-0.04

0.05

-0.14 – 0.07

0.503

arthritis [Yes] *
hypertension [Yes]

-0.06

0.04

-0.13 – 0.02

0.141

diabetes [Yes] *
hypertension [Yes]

-0.00

0.05

-0.09 – 0.09

0.952

arthritis [Yes] * cancer
[Yes]

0.07

0.05

-0.03 – 0.18

0.176

hypertension [Yes] *
cancer [Yes]

-0.03

0.05

-0.14 – 0.07

0.563

arthritis [Yes] * thyroid
[Yes]

0.04

0.05

-0.06 – 0.14

0.397

hypertension [Yes] *
thyroid [Yes]

0.09

0.05

-0.02 – 0.20

0.097

(arthritis [Yes] *
diabetes [Yes]) *
hypertension [Yes]

0.16

0.07

0.02 – 0.30

0.027

(arthritis [Yes] *
hypertension [Yes]) *
cancer [Yes]

0.09

0.08

-0.07 – 0.25

0.285

(arthritis [Yes] *
hypertension [Yes]) *
thyroid [Yes]

-0.04

0.08

-0.20 – 0.12

0.647

Random Effects
σ2

0.94

τ00 region

0.02 (SD: 0.13; CI95%: 0.07 to 0.25)

ICC

0.02

N region

5
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Observations

23065

Marginal R2 / Conditional R2

0.022 / 0.039

AIC

76123.992

AICc

76124.022

thyroid: thyroid diseases

Change between baseline and first follow-up
Dyads analysis
We did not find any dyad associated with change on RAVLT immediate recall scores between
baseline and first follow-up (Table 5-168). The ICC was 0.

Table 5-168: Multilevel Regression Analysis of Dyads associations on Rey Auditory Learning Test
Immediate Recall change between Baseline and the First Follow-up in the CLSA

Predictors

Estimates std. Error

CI

p

(Intercept)

0.43

0.01

0.40 – 0.45

<0.001

diabetes [Yes]

-0.04

0.03

-0.10 – 0.03

0.254

hypertension [Yes]

-0.06

0.02

-0.10 – -0.02

0.005

arthritis [Yes]

-0.05

0.02

-0.09 – -0.01

0.014

depression [Yes]

0.06

0.03

0.01 – 0.12

0.025

thyroid [Yes]

-0.03

0.03

-0.10 – 0.03

0.293

cancer [Yes]

-0.02

0.03

-0.09 – 0.04

0.497

diabetes [Yes] *
hypertension [Yes]

-0.01

0.04

-0.09 – 0.07

0.852

arthritis [Yes] *
depression [Yes]

-0.04

0.04

-0.12 – 0.04

0.337

arthritis [Yes] * thyroid
[Yes]

-0.06

0.04

-0.15 – 0.03

0.182

hypertension [Yes] *
cancer [Yes]

-0.01

0.05

-0.10 – 0.08

0.859
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arthritis [Yes] * cancer
[Yes]

-0.02

0.05

-0.10 – 0.07

0.719

hypertension [Yes] *
depression [Yes]

-0.02

0.04

-0.10 – 0.06

0.568

diabetes [Yes] *
arthritis [Yes]

0.04

0.04

-0.04 – 0.11

0.350

hypertension [Yes] *
thyroid [Yes]

0.01

0.05

-0.08 – 0.10

0.865

Random Effects
σ2

1.16

τ00 region

<0.001 (SD: <0.01; CI95%: 0 to 0.21)

N region

5

Observations
2

23007
2

Marginal R / Conditional R

0.003 / NA

AIC

80692.493

AICc

80692.520

thyroid: thyroid diseases

Triads analysis
We did not find any dyad associated with change on RAVLT immediate recall scores between
baseline and first follow-up (Table 5-169). The ICC was 0.

Table 5-169: Multilevel Regression Analysis of Triads associations on Rey Auditory Learning Test
Immediate Recall change between Baseline and the First Follow-up in the CLSA

Predictors

Estimates std. Error

CI

p

(Intercept)

0.44

0.01

0.41 – 0.46

<0.001

arthritis [Yes]

-0.06

0.02

-0.10 – -0.01

0.014

diabetes [Yes]

-0.03

0.04

-0.10 – 0.04

0.351

hypertension [Yes]

-0.07

0.02

-0.11 – -0.02

0.006

cancer [Yes]

-0.02

0.04

-0.09 – 0.04

0.485
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thyroid [Yes]

-0.03

0.03

-0.09 – 0.04

0.447

arthritis [Yes] *
diabetes [Yes]

0.03

0.06

-0.08 – 0.15

0.590

arthritis [Yes] *
hypertension [Yes]

0.01

0.04

-0.07 – 0.10

0.739

diabetes [Yes] *
hypertension [Yes]

-0.01

0.05

-0.11 – 0.09

0.884

arthritis [Yes] * cancer
[Yes]

-0.01

0.06

-0.13 – 0.11

0.858

hypertension [Yes] *
cancer [Yes]

-0.01

0.06

-0.12 – 0.11

0.919

arthritis [Yes] * thyroid
[Yes]

-0.06

0.06

-0.18 – 0.05

0.251

hypertension [Yes] *
thyroid [Yes]

0.01

0.06

-0.10 – 0.13

0.811

(arthritis [Yes] *
diabetes [Yes]) *
hypertension [Yes]

-0.00

0.08

-0.16 – 0.16

0.996

(arthritis [Yes] *
hypertension [Yes]) *
cancer [Yes]

-0.01

0.09

-0.19 – 0.17

0.937

(arthritis [Yes] *
hypertension [Yes]) *
thyroid [Yes]

-0.01

0.09

-0.19 – 0.17

0.905

Random Effects
σ2

1.16

τ00 region

<0.001 (SD: <0.001; CI95%: 0 to 0.02)

N region

5

Observations
2

23065
2

Marginal R / Conditional R

0.003 / NA

AIC

80886.168

AICc

80886.197

thyroid: thyroid diseases

5.2.1.2.3.2 Delayed Recall
5.2.1.2.3.2.1

CSHA

Baseline
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Dyads analysis
We analyzed 409 participants. We did not find any dyad associated with RAVLT immediate recall
scores at baseline (Table 5-170). The ICC was 0.023 (CI95%: 0.000 to 0.010)

Table 5-170: Multilevel Regression Analysis of Dyads associations with Rey Auditory Learning Test
Delayed Recall in the CSHA at baseline

Predictors

Estimates std. Error

CI

p

(Intercept)

-0.06

0.12

-0.29 – 0.17

0.604

arthritis [Yes]

0.17

0.14

-0.11 – 0.44

0.227

hypertension [Yes]

0.18

0.16

-0.13 – 0.48

0.262

cancer [Yes]

0.02

0.25

-0.46 – 0.51

0.934

diabetes [Yes]

0.28

0.26

-0.23 – 0.79

0.283

gast ulcer [Yes]

-0.11

0.18

-0.47 – 0.24

0.531

depression [Yes]

-0.32

0.20

-0.71 – 0.08

0.120

thyroid [Yes]

-0.01

0.25

-0.50 – 0.48

0.973

ckd [Yes]

0.51

0.33

-0.13 – 1.16

0.119

oheart [Yes]

0.06

0.21

-0.36 – 0.48

0.777

arthritis [Yes] *
hypertension [Yes]

-0.14

0.20

-0.54 – 0.26

0.502

arthritis [Yes] * cancer
[Yes]

-0.10

0.34

-0.76 – 0.56

0.766

arthritis [Yes] *
diabetes [Yes]

-0.29

0.31

-0.90 – 0.32

0.350

arthritis [Yes] * gast
ulcer [Yes]

-0.11

0.24

-0.58 – 0.36

0.636

arthritis [Yes] *
depression [Yes]

0.35

0.25

-0.15 – 0.84

0.166

arthritis [Yes] * thyroid
[Yes]

0.22

0.30

-0.36 – 0.81

0.454

arthritis [Yes] * ckd
[Yes]

-0.54

0.37

-1.27 – 0.19

0.146
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arthritis [Yes] * oheart
[Yes]

0.02

0.26

-0.50 – 0.54

0.929

Random Effects
σ2

0.81

τ00 region

0.02 (SD: 0.13; CI95%: 0 to 0.31)

ICC

0.02

N region

5

Observations
2

409
2

Marginal R / Conditional R

0.038 / 0.060

AIC

1190.388

AICc

1192.553

gast ulcer: gastric ulcer; thyroid: thyroid diseases; otheart: other heart disease; ckd: chronic kidney disease

Triad analysis
We found that triad arthritis + hypertension + gastric ulcer increased 1.07 (CI95%: 0.03 to 2.11; pvalue 0.0445) RAVLT delayed recall scores at baseline (Table 5-171). The ICC was 0.033 (CI95%:
0.000 to 0.124). In this case, we expected that a participant with arthritis + gastric ulcer +
hypertension scored 0. SD but with the interactions scored better with +1.04 SD.

Table 5-171: Multilevel Regression Analysis of Triads associations with Rey Auditory Learning Test
Delayed Recall in the CSHA at baseline

Predictors

Estimates std. Error

CI

p

(Intercept)

-0.02

0.13

-0.27 – 0.22

0.855

arthritis [Yes]

0.16

0.14

-0.11 – 0.43

0.238

ckd [Yes]

0.67

0.39

-0.09 – 1.43

0.086

hypertension [Yes]

0.16

0.18

-0.20 – 0.52

0.393

depression [Yes]

-0.44

0.24

-0.92 – 0.04

0.070

gast ulcer [Yes]

-0.10

0.20

-0.50 – 0.30

0.620
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oheart [Yes]

0.08

0.21

-0.34 – 0.49

0.724

coronary [Yes]

-0.03

0.26

-0.54 – 0.48

0.901

arthritis [Yes] * ckd
[Yes]

-0.55

0.45

-1.43 – 0.33

0.217

arthritis [Yes] *
hypertension [Yes]

-0.23

0.25

-0.72 – 0.27

0.366

ckd [Yes] * hypertension
[Yes]

-0.83

0.73

-2.28 – 0.61

0.256

arthritis [Yes] *
depression [Yes]

0.58

0.31

-0.04 – 1.19

0.066

hypertension [Yes] *
depression [Yes]

0.52

0.45

-0.35 – 1.40

0.242

arthritis [Yes] * gast
ulcer [Yes]

-0.52

0.29

-1.08 – 0.05

0.072

hypertension [Yes] * gast
ulcer [Yes]

-0.15

0.42

-0.98 – 0.68

0.719

arthritis [Yes] * oheart
[Yes]

-0.08

0.28

-0.62 – 0.47

0.787

arthritis [Yes] *
coronary [Yes]

0.35

0.33

-0.29 – 0.99

0.282

oheart [Yes] * coronary
[Yes]

0.32

0.63

-0.92 – 1.56

0.611

(arthritis [Yes] * ckd
[Yes]) * hypertension
[Yes]

0.42

0.81

-1.18 – 2.02

0.609

(arthritis [Yes] *
hypertension [Yes]) *
depression [Yes]

-0.64

0.54

-1.71 – 0.43

0.241

(arthritis [Yes] *
hypertension [Yes]) *
gast ulcer [Yes]

1.07

0.53

0.03 – 2.11

0.044

(arthritis [Yes] * oheart
[Yes]) * coronary [Yes]

-0.44

0.73

-1.88 – 1.00

0.552

Random Effects
σ2

0.79

τ00 region

0.03 (SD: 0.17; CI95%: 0.02 to 0.37)

ICC

0.03

N region

5

Observations
2

409
2

Marginal R / Conditional R

0.063 / 0.095
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AIC

1180.658

AICc

1183.783

gast ulcer: gastric ulcer; thyroid: thyroid diseases; otheart: other heart disease; ckd: chronic kidney disease

Change between baseline and first follow-up
Dyads analysis
We did not find any dyad associated with change on RAVLT immediate recall scores comparing
baseline and first follow-up (Table 5-172). The ICC was 0.036 (CI95%: 0.000 to 0.143).

Table 5-172: Multilevel Regression Analysis of Dyads associations on Rey Auditory Learning Test
Delayed Recall change between Baseline and the First Follow-up in the CSHA

Predictors

Estimates std. Error

CI

p

(Intercept)

-0.19

0.15

-0.49 – 0.11

0.219

arthritis [Yes]

-0.07

0.17

-0.41 – 0.26

0.676

hypertension [Yes]

-0.24

0.19

-0.62 – 0.13

0.204

cancer [Yes]

-0.27

0.30

-0.86 – 0.32

0.376

diabetes [Yes]

-0.01

0.32

-0.63 – 0.61

0.974

gast ulcer [Yes]

0.13

0.22

-0.31 – 0.56

0.564

depression [Yes]

-0.00

0.25

-0.48 – 0.48

0.998

thyroid [Yes]

0.32

0.30

-0.28 – 0.91

0.295

ckd [Yes]

-0.19

0.40

-0.98 – 0.59

0.628

oheart [Yes]

-0.04

0.26

-0.55 – 0.47

0.883

arthritis [Yes] *
hypertension [Yes]

0.13

0.25

-0.35 – 0.62

0.589

arthritis [Yes] * cancer
[Yes]

0.58

0.41

-0.23 – 1.38

0.158

arthritis [Yes] *
diabetes [Yes]

-0.05

0.38

-0.79 – 0.69

0.896
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arthritis [Yes] * gast
ulcer [Yes]

-0.07

0.29

-0.64 – 0.50

0.821

arthritis [Yes] *
depression [Yes]

0.25

0.31

-0.35 – 0.85

0.410

arthritis [Yes] * thyroid
[Yes]

-0.73

0.36

-1.44 – -0.01

0.047

arthritis [Yes] * ckd
[Yes]

0.09

0.45

-0.80 – 0.98

0.837

arthritis [Yes] * oheart
[Yes]

0.32

0.32

-0.31 – 0.95

0.324

Random Effects
σ2

1.19

τ00 region

0.04 (SD 0.20; CI95%: 0 to 0.45)

ICC

0.04

N region

5

Observations
2

409
2

Marginal R / Conditional R

0.038 / 0.073

AIC

1344.524

AICc

1346.689

gast ulcer: gastric ulcer; thyroid: thyroid diseases; otheart: other heart disease; ckd: chronic kidney disease

Triads analysis
We did not find any triad associated with change on RAVLT immediate recall scores comparing
baseline and first follow-up (Table 5-173). The ICC was 0.032 (CI95%: 0.000 to 0.122)

Table 5-173: Multilevel Regression Analysis of Triads associations on Rey Auditory Learning Test
Delayed Recall change between Baseline and the First Follow-up in the CSHA

Predictors

Estimates std. Error

CI

p

(Intercept)

-0.17

0.15

-0.47 – 0.13

0.267

arthritis [Yes]

-0.10

0.17

-0.43 – 0.23

0.554

ckd [Yes]

-0.73

0.48

-1.67 – 0.21

0.126
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hypertension [Yes]

-0.34

0.23

-0.79 – 0.10

0.132

depression [Yes]

-0.10

0.30

-0.69 – 0.49

0.736

gast ulcer [Yes]

0.12

0.25

-0.37 – 0.62

0.629

oheart [Yes]

0.01

0.26

-0.51 – 0.52

0.976

coronary [Yes]

0.16

0.32

-0.47 – 0.80

0.610

arthritis [Yes] * ckd
[Yes]

0.70

0.55

-0.39 – 1.78

0.209

arthritis [Yes] *
hypertension [Yes]

0.29

0.31

-0.32 – 0.90

0.357

ckd [Yes] * hypertension
[Yes]

1.47

0.90

-0.31 – 3.25

0.104

arthritis [Yes] *
depression [Yes]

0.31

0.39

-0.45 – 1.07

0.428

hypertension [Yes] *
depression [Yes]

0.11

0.55

-0.97 – 1.19

0.843

arthritis [Yes] * gast
ulcer [Yes]

0.16

0.35

-0.54 – 0.85

0.660

hypertension [Yes] * gast
ulcer [Yes]

0.06

0.52

-0.96 – 1.09

0.904

arthritis [Yes] * oheart
[Yes]

0.16

0.34

-0.51 – 0.83

0.643

arthritis [Yes] *
coronary [Yes]

-0.69

0.40

-1.48 – 0.10

0.088

oheart [Yes] * coronary
[Yes]

-0.28

0.78

-1.81 – 1.25

0.716

(arthritis [Yes] * ckd
[Yes]) * hypertension
[Yes]

-1.59

1.00

-3.56 – 0.38

0.114

(arthritis [Yes] *
hypertension [Yes]) *
depression [Yes]

0.04

0.67

-1.27 – 1.36

0.950

(arthritis [Yes] *
hypertension [Yes]) *
gast ulcer [Yes]

-0.52

0.65

-1.80 – 0.77

0.430

(arthritis [Yes] * oheart
[Yes]) * coronary [Yes]

1.04

0.90

-0.73 – 2.82

0.250

Random Effects
σ2

1.20

τ00 region

0.04 (SD: 0.20; CI95%: 0 to 0.45)
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ICC

0.03

N region

5

Observations

409

Marginal R2 / Conditional R2

0.041 / 0.072

AIC

1342.891

AICc

1346.016

gast ulcer: gastric ulcer; thyroid: thyroid diseases; otheart: other heart disease; ckd: chronic kidney disease

5.2.1.2.3.2.2

CLSA

Baseline
Dyads analysis
We analyzed information from 22866 participants. We found three dyads associated with RAVLT
delayed recall scores (Table 5-174). The ICC was 0.008 (CI95%: 0.007 to 0.0232). The dyads were:
-

Arthritis + cancer: 0.0931 (CI95%: 0.013 to 0.174; p-value 0.023)

-

Hypertension + depression: 0.127 (CI95%: 0.053 to 0.200; p-value 0.0007)

-

Diabetes + arthritis: 0.117 (CI95%: 0.047 to 0.188; p value 0.001)

In these cases, the interpretations are as follows:
-

In participants with arthritis and cancer, we expected a score of -0.27 SD, but the interaction
ameliorated scores to -0.18 SD.

-

In participants with hypertension and depression, we expected a score of -0.18 SD, but the
interaction ameliorated the score to -0.05 SD.

-

In participants with diabetes and arthritis, we expected a score of -0.35 SD, but the
interaction ameliorated the score to -0.23 SD.
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Table 5-174: Multilevel Regression Analysis of Dyads associations with Rey Auditory Learning Test
Delayed Recall in the CLSA at baseline

Predictors

Estimates std. Error

CI

p

(Intercept)

0.14

0.04

0.07 – 0.22

<0.001

diabetes [Yes]

-0.24

0.03

-0.30 – -0.18

<0.001

hypertension [Yes]

-0.26

0.02

-0.29 – -0.22

<0.001

arthritis [Yes]

-0.11

0.02

-0.14 – -0.07

<0.001

depression [Yes]

0.08

0.03

0.03 – 0.13

0.002

thyroid [Yes]

0.11

0.03

0.05 – 0.17

<0.001

cancer [Yes]

-0.16

0.03

-0.22 – -0.10

<0.001

diabetes [Yes] *
hypertension [Yes]

0.06

0.04

-0.01 – 0.13

0.094

arthritis [Yes] *
depression [Yes]

-0.03

0.04

-0.10 – 0.05

0.466

arthritis [Yes] * thyroid
[Yes]

-0.02

0.04

-0.10 – 0.06

0.668

hypertension [Yes] *
cancer [Yes]

0.02

0.04

-0.06 – 0.10

0.684

arthritis [Yes] * cancer
[Yes]

0.09

0.04

0.01 – 0.17

0.023

hypertension [Yes] *
depression [Yes]

0.13

0.04

0.05 – 0.20

0.001

diabetes [Yes] *
arthritis [Yes]

0.12

0.04

0.05 – 0.19

0.001

hypertension [Yes] *
thyroid [Yes]

0.02

0.04

-0.06 – 0.10

0.589

Random Effects
σ2

0.94

τ00 region

0.01 (SD: 0.09; CI95%: 0 to 0.45)

ICC

0.01

N region

5

Observations
2

22866
2

Marginal R / Conditional R

0.027 / 0.035

AIC

75364.646

AICc

75364.673

thyroid: thyroid diseases
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Triads analysis
We did not find any triad associated with change on RAVLT delayed recall scores between baseline
and first follow-up (Table 5-175). The ICC was 0.007 (CI95%: 0.0008 to 0.023).

Table 5-175: Multilevel Regression Analysis of Triads associations with Rey Auditory Learning Test
Delayed Recall in the CLSA at baseline

Predictors

Estimates std. Error

CI

p

(Intercept)

0.15

0.04

0.07 – 0.22

<0.001

arthritis [Yes]

-0.08

0.02

-0.12 – -0.03

<0.001

diabetes [Yes]

-0.25

0.03

-0.31 – -0.18

<0.001

hypertension [Yes]

-0.20

0.02

-0.24 – -0.16

<0.001

cancer [Yes]

-0.15

0.03

-0.21 – -0.09

<0.001

thyroid [Yes]

0.12

0.03

0.06 – 0.18

<0.001

arthritis [Yes] *
diabetes [Yes]

0.13

0.05

0.02 – 0.24

0.016

arthritis [Yes] *
hypertension [Yes]

-0.10

0.04

-0.17 – -0.03

0.008

diabetes [Yes] *
hypertension [Yes]

0.05

0.05

-0.04 – 0.14

0.267

arthritis [Yes] * cancer
[Yes]

0.05

0.05

-0.06 – 0.16

0.359

hypertension [Yes] *
cancer [Yes]

-0.04

0.05

-0.14 – 0.07

0.515

arthritis [Yes] * thyroid
[Yes]

-0.03

0.05

-0.13 – 0.07

0.511

hypertension [Yes] *
thyroid [Yes]

0.02

0.05

-0.09 – 0.13

0.708

(arthritis [Yes] *
diabetes [Yes]) *
hypertension [Yes]

0.03

0.07

-0.12 – 0.17

0.696
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(arthritis [Yes] *
hypertension [Yes]) *
cancer [Yes]

0.12

0.08

-0.04 – 0.28

0.153

(arthritis [Yes] *
hypertension [Yes]) *
thyroid [Yes]

0.04

0.08

-0.12 – 0.20

0.615

Random Effects
σ2

0.94

τ00 region

0.01 (SD: 0.08; CI95%: 0.04 to 0.17)

ICC

0.01

N region

5

Observations
2

22923
2

Marginal R / Conditional R

0.026 / 0.033

AIC

75611.931

AICc

75611.961

thyroid: thyroid diseases

Change between baseline and first follow-up
Dyads analysis
We analyzed data from 22866 participants. We found three dyads associated with change on
RAVLT delayed recall scores between baseline and first follow-up (Table 5-176). The ICC was
0.0035 (CI95%: 0.0003 to 0.016) The dyads were:
-

Diabetes + hypertension: 0.0895 (CI95%: 0.0136 to 0.166; p-value 0.021)

-

Arthritis + depression: -0.0884 (-0.167 to -0.0103; p-value 0.27)

-

Hypertension + thyroid disease: 0.0899 (CI95%: 0.0041 to 0.176; p-value 0.04)

In these cases, the interpretations are as follows:
-

In participants with diabetes and hypertension, we expected a score of -0.18 SD, but the
interaction ameliorated scores to -0.09 SD.

-

In participants with arthritis and depression, we expected a score of 0.06 SD, but the
interaction decreased the score to -0.06 SD.
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-

In participants with hypertension and thyroid disease, we expected a score of -0.20 SD, but
the interaction ameliorated the score to -0.11 SD.

Table 5-176: Multilevel Regression Analysis of Dyads associations on Rey Auditory Learning Test
Delayed Recall change between Baseline and the First Follow-up in the CLSA

rey.delayed.diffz
Predictors

Estimates std. Error

CI

p

(Intercept)

0.37

0.03

0.31 – 0.43

<0.001

diabetes [Yes]

-0.06

0.03

-0.12 – -0.00

0.038

hypertension [Yes]

-0.12

0.02

-0.16 – -0.08

<0.001

arthritis [Yes]

-0.03

0.02

-0.07 – 0.01

0.156

depression [Yes]

0.06

0.03

0.01 – 0.12

0.026

thyroid [Yes]

-0.08

0.03

-0.14 – -0.02

0.008

cancer [Yes]

-0.08

0.03

-0.14 – -0.01

0.015

diabetes [Yes] *
hypertension [Yes]

0.09

0.04

0.01 – 0.17

0.021

arthritis [Yes] *
depression [Yes]

-0.09

0.04

-0.17 – -0.01

0.027

arthritis [Yes] * thyroid
[Yes]

0.02

0.04

-0.07 – 0.10

0.713

hypertension [Yes] *
cancer [Yes]

-0.00

0.04

-0.09 – 0.08

0.921

arthritis [Yes] * cancer
[Yes]

-0.02

0.04

-0.11 – 0.06

0.576

hypertension [Yes] *
depression [Yes]

0.06

0.04

-0.02 – 0.14

0.160

diabetes [Yes] *
arthritis [Yes]

-0.01

0.04

-0.09 – 0.06

0.763

hypertension [Yes] *
thyroid [Yes]

0.09

0.04

0.00 – 0.18

0.040

Random Effects
σ2

1.08

τ00 region

0.004 (SD: 0.06; CI95%: 0.03 to 0.13)
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ICC

0.00

N region

5

Observations

22866

Marginal R2 / Conditional R2

0.005 / 0.008

AIC

78721.455

AICc

78721.482

thyroid: thyroid diseases

Triads analysis
We did not find any triad associated with change on RAVLT delayed recall scores between baseline
and first follow-up (Table 5-177).The ICC was 0.004 (CI95%: 0.0002 to 0.011).

Table 5-177: Multilevel Regression Analysis of Triads associations on Rey Auditory Learning Test
Delayed Recall change between Baseline and the First Follow-up in the CLSA

Predictors

Estimates std. Error

CI

p

(Intercept)

0.39

0.03

0.33 – 0.45

<0.001

arthritis [Yes]

-0.08

0.02

-0.13 – -0.04

<0.001

diabetes [Yes]

-0.04

0.03

-0.11 – 0.03

0.230

hypertension [Yes]

-0.16

0.02

-0.20 – -0.11

<0.001

cancer [Yes]

-0.09

0.03

-0.16 – -0.02

0.011

thyroid [Yes]

-0.07

0.03

-0.13 – -0.00

0.044

arthritis [Yes] *
diabetes [Yes]

-0.06

0.06

-0.17 – 0.06

0.340

arthritis [Yes] *
hypertension [Yes]

0.13

0.04

0.05 – 0.21

0.001

diabetes [Yes] *
hypertension [Yes]

0.08

0.05

-0.02 – 0.17

0.132

arthritis [Yes] * cancer
[Yes]

0.01

0.06

-0.11 – 0.12

0.888

hypertension [Yes] *
cancer [Yes]

0.03

0.06

-0.09 – 0.14

0.640
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arthritis [Yes] * thyroid
[Yes]

0.00

0.06

-0.11 – 0.11

0.975

hypertension [Yes] *
thyroid [Yes]

0.07

0.06

-0.05 – 0.18

0.262

(arthritis [Yes] *
diabetes [Yes]) *
hypertension [Yes]

0.02

0.08

-0.14 – 0.17

0.819

(arthritis [Yes] *
hypertension [Yes]) *
cancer [Yes]

-0.09

0.09

-0.27 – 0.08

0.299

(arthritis [Yes] *
hypertension [Yes]) *
thyroid [Yes]

0.02

0.09

-0.15 – 0.19

0.834

Random Effects
σ2

1.09

τ00 region

0.004 (SD: 0.06; CI95%: 0.03 to 0.13)

ICC

0.00

N region

5

Observations

22923

Marginal R2 / Conditional R2

0.005 / 0.009

AIC

78918.712

AICc

78918.742

thyroid: thyroid diseases

5.2.1.2.4 Dementia diagnosis at first follow-up in the CSHA
We did not find any association in the analysis of dyads or triads associated with dementia
diagnosis at first follow-up in the CSHA (Table 5-178 and Table 5-179).

Table 5-178: Multilevel Regression Analysis of Dyads associations on Dementia Diagnosis at the
First Follow-up in the CSHA

Predictors

Odds Ratios std. Error

CI

p

(Intercept)

0.11

0.04

0.05 – 0.22

<0.001

arthritis [Yes]

1.23

0.63

0.45 – 3.34

0.682
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hypertension [Yes]

0.69

0.44

0.20 – 2.44

0.567

cancer [Yes]

1.52

1.46

0.23 – 9.95

0.664

diabetes [Yes]

0.82

0.87

0.10 – 6.54

0.850

gast ulcer [Yes]

0.48

0.42

0.09 – 2.68

0.401

depression [Yes]

1.84

1.39

0.42 – 8.05

0.417

thyroid [Yes]

0.00

0.00

0.00 – 6,48e110

0.911

ckd [Yes]

0.65

0.97

0.03 – 12.22

0.773

oheart [Yes]

1.04

0.91

0.19 – 5.74

0.965

*

0.36

0.32

0.06 – 2.04

0.249

arthritis [Yes] * cancer
[Yes]

0.48

0.65

0.04 – 6.65

0.588

arthritis
[Yes]
diabetes [Yes]

*

1.53

1.81

0.15 – 15.65

0.721

gast

4.44

4.54

0.60 – 32.96

0.145

*

0.38

0.38

0.05 – 2.73

0.338

arthritis [Yes] * thyroid
[Yes]

1,47e8

2,0e10

0.00 – 4,42e123

0.904

depression
thyroid [Yes]

8,69e7

1,19e10

0.00 – 2,62e124

0.907

ckd

2.04

3.28

0.09 – 47.47

0.657

oheart

0.37

0.41

0.04 – 3.24

0.367

*
*

0.00

0.00

0.00 – 1,e111

0.913

arthritis
[Yes]
hypertension [Yes]

arthritis [Yes]
ulcer [Yes]

*

arthritis
[Yes]
depression [Yes]

arthritis
[Yes]
arthritis
[Yes]

[Yes]

[Yes]
[Yes]

*
*

(arthritis
[Yes]
depression
[Yes])
thyroid [Yes]

*

Random Effects
σ2

3.29

τ00 region

0.00

ICC

0.00

N region

5

Observations

455

Marginal R2/ Conditional R2

0.724 / 0.724

AIC

298.718
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AICc

300.852

gast ulcer: gastric ulcer; thyroid: thyroid diseases; otheart: other heart disease; ckd: chronic kidney disease

Table 5-179: Multilevel Regression Analysis of Triads associations on Dementia Diagnosis at the
First Follow-up in the CSHA

Predictors

Odds Ratios std. Error

CI

p

(Intercept)

0.09

0.03

0.04 – 0.19

<0.001

arthritis [Yes]

1.40

0.70

0.52 – 3.73

0.505

ckd [Yes]

0.00

0.00

0.00 – Inf

0.997

hypertension [Yes]

0.89

0.62

0.23 – 3.49

0.863

depression [Yes]

2.64

1.87

0.66 – 10.60

0.170

gast ulcer [Yes]

0.61

0.54

0.11 – 3.42

0.574

oheart [Yes]

1.31

1.00

0.29 – 5.84

0.724

coronary [Yes]

2.19

1.70

0.48 – 10.00

0.311

5,11e7

2,53e11

0.00 – Inf

0.998

*

0.08

0.10

0.01 – 1.01

0.051

ckd [Yes] * hypertension
[Yes]

8,1e8

4,01e12

0.00 – Inf

0.997

arthritis
[Yes]
depression [Yes]

*

0.19

0.18

0.03 – 1.27

0.087

hypertension
[Yes]
depression [Yes]

*

0.23

0.42

0.01 – 8.16

0.422

gast

2.77

2.95

0.34 – 22.32

0.338

hypertension [Yes] * gast
ulcer [Yes]

0.00

0.00

0.00 – Inf

0.997

arthritis
[Yes]

arthritis
[Yes]

[Yes]

*

ckd

arthritis
[Yes]
hypertension [Yes]

arthritis [Yes]
ulcer [Yes]

[Yes]

*

*

oheart

0.87

0.89

0.12 – 6.45

0.892

arthritis
[Yes]
coronary [Yes]

*

8.90

8.71

1.31 – 60.60

0.025

oheart [Yes] * coronary
[Yes]

0.00

0.00

0.00 – Inf

0.996
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(arthritis [Yes] * ckd
[Yes])
*
hypertension
[Yes]

0.00

0.00

0.00 – Inf

0.998

(arthritis
[Yes]
hypertension
[Yes])
depression [Yes]

*
*

3.59

9.18

0.02 – 538.54

0.617

(arthritis
[Yes]
hypertension
[Yes])
gast ulcer [Yes]

*
*

1,25e8

4,97e11

0.00 – Inf

0.997

3.76

10987.47

0.00 – Inf

1.000

(arthritis [Yes] * oheart
[Yes]) * coronary [Yes]
Random Effects
σ2

3.29

τ00 region

0.00

ICC

0.00

N region

5

Observations

455

Marginal R2/ Conditional R2

0.823 / 0.823

AIC

277.271

AICc

279.832

gast ulcer: gastric ulcer; thyroid: thyroid diseases; otheart: other heart disease; ckd: chronic kidney disease

5.2.1.2.5 CIND diagnosis at first follow-up in the CSHA
We did not find any association in the analysis of dyads or triads associated with dementia
diagnosis at first follow-up in the CSHA participants with normal cognition at baseline (Table
5-180 and Table 5-181).

Table 5-180: Multilevel Regression Analysis of Dyads associations on CIND Diagnosis at the First
Follow-up in the CSHA

Predictors

Odds Ratios std. Error

CI

p

(Intercept)

0.37

0.12

0.19 – 0.71

0.003

arthritis [Yes]

1.41

0.56

0.65 – 3.08

0.384

hypertension [Yes]

2.14

1.03

0.83 – 5.52

0.115
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cancer [Yes]

0.19

0.24

0.02 – 2.21

0.184

diabetes [Yes]

3.13

2.55

0.64 – 15.42

0.160

gast ulcer [Yes]

0.75

0.46

0.23 – 2.49

0.644

depression [Yes]

4.23

3.31

0.92 – 19.59

0.065

thyroid [Yes]

0.36

0.32

0.06 – 2.11

0.257

ckd [Yes]

1.66

1.62

0.25 – 11.16

0.600

oheart [Yes]

0.20

0.17

0.04 – 1.07

0.060

arthritis [Yes] *
hypertension [Yes]

0.40

0.25

0.12 – 1.35

0.140

arthritis [Yes] * cancer
[Yes]

0.62

1.09

0.02 – 18.88

0.786

arthritis [Yes] *
diabetes [Yes]

0.32

0.31

0.05 – 2.07

0.233

arthritis [Yes] * gast
ulcer [Yes]

1.08

0.82

0.24 – 4.82

0.919

arthritis [Yes] *
depression [Yes]

0.48

0.42

0.08 – 2.72

0.405

arthritis [Yes] * thyroid
[Yes]

0.67

0.73

0.08 – 5.64

0.711

arthritis [Yes] * ckd
[Yes]

0.30

0.34

0.03 – 2.76

0.286

arthritis [Yes] * oheart
[Yes]

3.25

3.15

0.48 – 21.81

0.226

Random Effects
σ2

3.29

τ00 region

0.13

ICC

0.04

N region

5

Observations

325

Marginal R2 / Conditional R2

0.213 / 0.243

AIC

381.231

AICc

383.723

gast ulcer: gastric ulcer; thyroid: thyroid diseases; otheart: other heart disease; ckd: chronic kidney disease
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Table 5-181: Multilevel Regression Analysis of Triads associations on CIND Diagnosis at the First
Follow-up in the CSHA

Predictors

Odds Ratios std. Error

CI

p

(Intercept)

0.04

0.02

0.01 – 0.13

<0.001

arthritis [Yes]

2.86

2.12

0.67 – 12.19

0.155

ckd [Yes]

0.00

0.00

0.00 – Inf

0.999

hypertension [Yes]

0.54

0.73

0.04 – 7.41

0.648

depression [Yes]

1.95

3.11

0.09 – 44.44

0.675

gast ulcer [Yes]

0.83

1.10

0.06 – 11.34

0.886

oheart [Yes]

4.00

4.58

0.42 – 37.74

0.226

coronary [Yes]

0.00

0.00

0.00 – Inf

0.999

ckd

8,0e8

1,49e13

0.00 – Inf

0.999

*

0.17

0.29

0.01 – 5.27

0.310

3,75e8

1,82e13

0.00 – Inf

1.000

arthritis
[Yes]

[Yes]

*

arthritis
[Yes]
hypertension [Yes]

ckd [Yes] * hypertension
[Yes]
arthritis
[Yes]
depression [Yes]

*

0.57

1.06

0.02 – 21.10

0.763

hypertension
[Yes]
depression [Yes]

*

0.00

0.00

0.00 – Inf

0.999

gast

0.00

0.00

0.00 – Inf

0.998

hypertension [Yes] * gast
ulcer [Yes]

0.00

0.00

0.00 – Inf

0.999

arthritis
[Yes]

arthritis [Yes]
ulcer [Yes]

[Yes]

*

*

oheart

0.00

0.00

0.00 – Inf

0.997

arthritis
[Yes]
coronary [Yes]

*

9,4e9

1,22e14

0.00 – Inf

0.999

oheart [Yes] * coronary
[Yes]

2.13

3,17e5

0.00 – Inf

1.000

(arthritis [Yes] * ckd
[Yes])
*
hypertension
[Yes]

0.00

0.01

0.00 – Inf

1.000

1,99e8

4,1e14

0.00 – Inf

0.999

(arthritis
[Yes]
hypertension
[Yes])
depression [Yes]

*
*
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(arthritis
[Yes]
hypertension
[Yes])
gast ulcer [Yes]

*
*

1,45e18

3,28e22

0.00 – Inf

0.999

1.35

21707.72

0.00 – Inf

1.000

(arthritis [Yes] * oheart
[Yes]) * coronary [Yes]
Random Effects
σ2

3.29

τ00 region

0.00

ICC

0.00

N region

5

Observations
2

325
2

Marginal R / Conditional R

0.961 / 0.961

AIC

163.500

AICc

167.168

gast ulcer: gastric ulcer; thyroid: thyroid diseases; otheart: other heart disease; ckd: chronic kidney disease

5.2.2 Classification and Regression Trees (CART) Analysis of Dyads and Triads
For the CART results for our research question, we explored the multimorbidity dyads and triads
that decreased the multimorbidity combination regression coefficient. We only list these dyads and
triads after the partitioning. In the summary of results, we highlight the multimorbidity
combinations with a coefficient decrease of more than 1 SD. We intended to explore the
combinations associated with cognitive decline in the two cohorts and qualitatively compare if the
combinations are similar or have changed in the last three decades. We present the CART model
summary R output in the supplementary file 4 to support the interpretation in conjunction with the
figures of CART models.
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5.2.2.1 Frontal Function
5.2.2.1.1 Baseline

5.2.2.1.1.1 CSHA
We present the frontal function baseline results of dyads and triads in the CSHA associated with
predicted worser scores including all participants with scores (Figure 4). We found that the dyads
that scored below the mean were:
-

Depression + arthritis: -0.23

-

Arthritis + chronic kidney disease: -0.08

-

Arthritis + gastric ulcer: -0.058

Also, the triads that scored below the mean were:
-

Depression + hypertension + gastric ulcer: -0.62

-

Depression + arthritis + coronary artery disease: -0.62

-

Depression + hypertension + arthritis: -0.25

271
December 13, 2022

Figure 4: CART of CSHA Frontal Function at baseline all cohort
gast ulcer: gastric ulcer; thyroid: thyroid diseases; otheart: other heart disease; ckd: chronic kidney disease; coronary: coronary
artery disease; Parkinson: Parkinson Disease.

Female
In females (Figure 5) we found that the dyads that score below mean were:
-

Depression + arthritis: -0.35

-

Coronary artery disease + hypertension: -0.14

The triads that showed a score below the mean were:
-

Depression + hypertension + gastric ulcer: -0.62

-

Depression+ hypertension + arthritis: -0.27
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Figure 5: CART of CSHA Frontal Function at baseline Female subgroup
gast ulcer: gastric ulcer; thyroid: thyroid diseases; otheart: other heart disease; ckd: chronic kidney disease; coronary: coronary
artery disease; Parkinson: Parkinson Disease

Male
In males (Figure 6) we did not find a combination of dyad or triad that was associated with scores
below the mean.
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Figure 6: CART of CSHA Frontal Function at baseline Male subgroup
gast ulcer: gastric ulcer; thyroid: thyroid diseases; otheart: other heart disease; ckd: chronic kidney disease; coronary: coronary
artery disease; Parkinson: Parkinson Disease; MS: Multiple Sclerosis

5.2.2.1.1.2 CLSA
In all the CLSA participants (Figure 7) the dyads that scored below zero were:
-

Other heart disease + stroke: -1.8

-

Arthritis + chronic kidney disease: -0.76

-

Arthritis + coronary artery disease: -0.63

-

Hypertension + stroke: -0.58

-

Other heart + gastric ulcer: -0.53

-

Hypertension + Other heart disease: -0.35

-

Arthritis + gastric ulcer: -0.24

-

Hypertension + arthritis: -0.19

-

Arthritis + depression: -0.13
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Also, the triads that scored below the mean were:
-

Other heart disease + stoke + diabetes: -0.28

Figure 7: CART of CLSA Frontal Function at baseline all cohort
gast ulcer: gastric ulcer; thyroid: thyroid diseases; otheart: other heart disease; ckd: chronic kidney disease; coronary: coronary
artery disease; Parkinson: Parkinson Disease; MS: Multiple Sclerosis

Females
In the female analysis (Figure 8), we found that the following dyads were associated with scores
below the mean:
-

Arthritis + chronic kidney disease: -0.94

-

Arthritis + Parkinson disease: -0.85

-

Arthritis + coronary artery disease: -0.84

-

Hypertension + coronary artery disease: -0.57
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-

Arthritis + gastric ulcer: -0.53

-

Hypertension + other heart disease: -0.42

-

Arthritis + other heart disease: -0.22

-

Arthritis + depression: -0.19

We found that the following triads scored below the mean:
-

Hypertension + other heart disease + gastric ulcer: -0.97

-

Arthritis + other heart disease + gastric ulcer: -0.91

-

Hypertension + other heart disease + coronary artery disease: -0.9

-

Arthritis + gastric ulcer + thyroid disease: -0.22

Figure 8: CART of CLSA Frontal Function at baseline Female subgroup
gast ulcer: gastric ulcer; thyroid: thyroid diseases; otheart: other heart disease; ckd: chronic kidney disease; coronary: coronary
artery disease; Parkinson: Parkinson Disease; MS: Multiple Sclerosis

Males
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We noticed the following dyads in the male analysis (Figure 9):
-

Other heart diseases + stroke: -1.4

-

Chronic kidney disease + gastric ulcer: -1.4

-

Hypertension + coronary artery disease: -0.71

-

Other heart disease + gastric ulcer: -0.52

-

Hypertension + stroke: -0.49

-

Other heart disease + thyroid disease: -0.48

-

Other heart disease + cancer: -0.38

-

Other heart disease + coronary artery disease: -0.27

-

Other heart disease + hypertension: -0.21

-

Other heart disease + diabetes: -0.16

-

Hypertension + diabetes: -0.029

In males the triads combinations that scored less than the mean were:
-

Hypertension + diabetes + stroke: -1.1

-

Arthritis + depression + cancer: -0.71

-

Other heart disease + stroke + hypertension: -0.48

-

Hypertension + diabetes + arthritis: -0.27

-

Hypertension + diabetes + chronic kidney disease: -0.47
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Figure 9: CART of CLSA Frontal Function at baseline Male subgroup
gast ulcer: gastric ulcer; thyroid: thyroid diseases; otheart: other heart disease; ckd: chronic kidney disease; coronary: coronary
artery disease; Parkinson: Parkinson Disease; MS: Multiple Sclerosis

65 years and older
In the 65 years and older (Figure 10), we found that the following dyads scored below zero:
-

Chronic kidney disease + arthritis: -1.1

-

Hypertension + stroke: -0.8

-

Hypertension + epilepsy: -0.64

-

Gastric ulcer + arthritis: -0.63

-

Hypertension + thyroid disease: -0.57

-

Hypertension + coronary artery disease: -0.53

Also, we found that the following triads scored less than the mean:
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-

Hypertension + epilepsy + diabetes: -1.8

-

Gastric ulcer + arthritis + thyroid disease: -1.2

-

Hypertension + coronary artery disease. + arthritis: -0.96

-

Hypertension + cancer + other heart disease: -0.51

-

Hypertension + cancer + arthritis: -0.44

-

Hypertension + cancer + thyroid disease: -0.33

-

Hypertension + cancer + gastric ulcer: -0.16

Figure 10: CART of CLSA Frontal Function at baseline Participants 65 years and older subgroup
gast ulcer: gastric ulcer; thyroid: thyroid diseases; otheart: other heart disease; ckd: chronic kidney disease; coronary: coronary
artery disease; Parkinson: Parkinson Disease; MS: Multiple Sclerosis

Younger than 65
In participants younger than 65 (Figure 11),we found that the dyads that scored less than the mean
were:
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-

Coronary artery disease + stroke: -1.8

-

Chronic kidney disease + gastric ulcer: -1.4

-

Coronary artery disease + diabetes: -0.53

-

Hypertension + coronary artery disease: -0.3

Also, we found that the triads with
-

Other heart disease + thyroid disease + depression: -0.78

-

Hypertension + diabetes + stroke: -0.7

-

Hypertension + diabetes + chronic kidney disease: -0.41

-

Arthritis + depression: -0.1

-

Arthritis + gastric ulcer: -0.09

-

Hypertension + diabetes + depression: -0.099

Figure 11: CART of CLSA Frontal Function at baseline Participants younger than 65 years
gast ulcer: gastric ulcer; thyroid: thyroid diseases; otheart: other heart disease; ckd: chronic kidney disease; coronary: coronary
artery disease; Parkinson: Parkinson Disease; MS: Multiple Sclerosis
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5.2.2.1.2 Change between baseline and first follow-up

5.2.2.1.2.1 CSHA
In the complete cohort (Figure 12), the dyads that scored less than mean was:
-

Cancer + other heart disease: -1.7

-

Hypertension + coronary artery disease: -1.2

-

Gastric ulcer + arthritis: -0.96

-

Diabetes + arthritis: -0.92

-

Depression + arthritis: -0.86

-

Cancer + arthritis: -0.8

-

Chronic kidney disease + hypertension: -0.68

-

Diabetes + hypertension: -0.6

-

Hypertension + gastric ulcer: -0.59

-

Gastric ulcer + other heart disease: -0.59

-

Hypertension + stroke: -0.49

-

Thyroid disease + hypertension: -0.067

The triads that scored less than mean were:
-

Diabetes + arthritis + other heart disease: -1.3

-

Depression + arthritis + gastric ulcer: -0.24
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Figure 12: CART of CSHA Frontal Function Change between baseline and first follow-up all cohort
gast ulcer: gastric ulcer; thyroid: thyroid diseases; otheart: other heart disease; ckd: chronic kidney disease; coronary: coronary
artery disease; Parkinson: Parkinson Disease; MS: Multiple Sclerosis

Female
In the female group (Figure 13), the dyads that scored less than mean were:
-

Thyroid disease + gastric ulcer: -0.95

-

Hypertension + arthritis: -0.82

-

Chronic kidney disease + hypertension: -0.61

-

Hypertension + gastric ulcer: -0.19

-

Thyroid disease + hypertension: -0.059

We found only a triad that scored less than the mean:
-

Hypertension + arthritis + depression: -0.99
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Figure 13: CART of CSHA Frontal Function Change between baseline and first follow Female
subgroup
gast ulcer: gastric ulcer; thyroid: thyroid diseases; otheart: other heart disease; ckd: chronic kidney disease; coronary: coronary
artery disease; Parkinson: Parkinson Disease; MS: Multiple Sclerosis

Male
In the male group (Figure 14), the dyads that scored less than zero were:
-

Arthritis + hypertension: -0.74

-

Other heart disease + arthritis: -0.72

We did not notice triads that scored less than zero
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Figure 14: CART of CSHA Frontal Function Change between baseline and first follow-up Male
subgroup
gast ulcer: gastric ulcer; thyroid: thyroid diseases; otheart: other heart disease; ckd: chronic kidney disease; coronary: coronary
artery disease

5.2.2.1.2.2 CLSA
In the complete CLSA cohort (Figure 15), we found that the dyads that scored a change lower than
zero were
-

Parkinson disease + hypertension: -1.2

-

Stroke + hypertension: -0.72

-

Stroke + arthritis: -0.26

Also, we found the following triads that scored lower than zero:
-

Other heart disease + arthritis + depression: -0.26

-

Chronic kidney diseases + gastric ulcer + diabetes: -0.16
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-

Other heart disease + arthritis + stroke: -0.062

-

Other heart disease + arthritis + hypertension: -0.018

Figure 15: CART of CLSA Frontal Function Change between baseline and first follow-up - All cohort
gast ulcer: gastric ulcer; thyroid: thyroid diseases; otheart: other heart disease; ckd: chronic kidney disease; coronary: coronary
artery disease; Parkinson: Parkinson Disease; MS: Multiple Sclerosis

Females
In the subgroup of females (Figure 16), we found that the following dyads scored less than zero
-

Other heart disease + thyroid diseases: -0.67

-

Gastric ulcer + stroke: -0.46

-

Other heart disease + depression: -0.29

-

Other heart disease + cancer: -0.15

-

Other heart disease + arthritis: -0.12

-

Hypertension + thyroid diseases: -0.12
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-

Hypertension + chronic kidney disease: -0.11

-

Gastric ulcer + arthritis: -0.039

We identified the following triads that scored less than zero
-

Gastric ulcer + epilepsy + depression: -0.86

-

Gastric ulcer + arthritis + multiple sclerosis: -0.66

-

Gastric ulcer + arthritis + depression: -0.11

Figure 16: CART of CLSA Frontal Function Change between baseline and first follow-up Female
subgroup
gast ulcer: gastric ulcer; thyroid: thyroid diseases; otheart: other heart disease; ckd: chronic kidney disease; coronary: coronary
artery disease; Parkinson: Parkinson Disease; MS: Multiple Sclerosis

Males
In the male subgroup (Figure 17), we found the following dyads that scored less than zero
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-

Parkinson + hypertension: -1.1

-

Other heart disease + hypertension: -0.22

-

Chronic kidney disease + hypertension: -0.21

-

Cancer + depression: -0.12

We found the following triads that scored less than zero
-

Cancer + diabetes + other heart disease: -0.67

-

Thyroid disease + hypertension + arthritis: -0.42

-

Cancer + diabetes + thyroid disease: -0.11

Figure 17: CART of CLSA Frontal Function Change between baseline and first follow-up Male
subgroup
gast ulcer: gastric ulcer; thyroid: thyroid diseases; otheart: other heart disease; ckd: chronic kidney disease; coronary: coronary
artery disease; Parkinson: Parkinson Disease; MS: Multiple Sclerosis

65 years and older
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In the subgroup of patients 65 years and older (Figure 18), we found that the following dyads scored
less than zero:
-

Stroke + gastric ulcer: -1.2

-

Arthritis + gastric ulcer: -0.55

-

Depression + thyroid disease: -0.31

-

Arthritis + thyroid disease: -0.11

-

Stroke + hypertension: -0.13

-

Depression + diabetes: -0.12

We found that the following triads scored less than zero:
-

Stroke + hypertension + depression: -0.79

-

Depression + diabetes + arthritis: -0.62

-

Depression + arthritis + cancer: -0.51

-

Arthritis + other heart disease + thyroid disease: -0.17

-

Depression + arthritis + hypertension: -0.15

-

Arthritis + other heart + cancer: -0.13
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Figure 18: CART of CLSA Frontal Function Change between baseline and first follow-up
Participants 65 years and older
gast ulcer: gastric ulcer; thyroid: thyroid diseases; otheart: other heart disease; ckd: chronic kidney disease; coronary: coronary
artery disease; Parkinson: Parkinson Disease; MS: Multiple Sclerosis

Younger than 65 years
In the subgroup of patients younger than 65 (Figure 19), we found that the following dyads scored
less than zero:
-

Parkinson + arthritis: -0.8

-

Other heart disease + depression: -0.68

-

Gastric ulcer + depression: -0.26

-

Other heart disease + cancer: -0.24

-

Gastric ulcer + hypertension: -0.13
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We found that the following triads scored less than zero:
-

Other heart disease + cancer + depression: -0.86

Figure 19: CART of CLSA Frontal Function Change between baseline and first follow-up Participants younger than 65 years
gast ulcer: gastric ulcer; thyroid: thyroid diseases; otheart: other heart disease; ckd: chronic kidney disease; coronary: coronary
artery disease; Parkinson: Parkinson Disease; MS: Multiple Sclerosis

5.2.2.2 Animal Naming Test
5.2.2.2.1 Baseline

5.2.2.2.1.1 CSHA
In the complete CSHA cohort (Figure 20), we found that the dyads that scored less than zero were:
-

Cancer + other heart disease: -0.59

-

Coronary artery disease + hypertension: -0.56
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-

Depression + hypertension: -0.41

-

Depression + gastric ulcer: -0.36

-

Cancer + gastric ulcer: -0.22

-

Coronary artery disease + arthritis: -0.2

-

Arthritis + hypertension: -0.093

-

Depression + arthritis -0.084

We found that the triads that scored less than zero were:
-

Depression + arthritis + coronary artery disease: -0.8

-

Depression + arthritis + hypertension: -0.33

-

Thyroid disease + arthritis + hypertension: -0.19

Figure 20: CART of CSHA Animal Naming Test at baseline - All cohort
gast ulcer: gastric ulcer; thyroid: thyroid diseases; otheart: other heart disease; ckd: chronic kidney disease; coronary: coronary
artery disease; Parkinson: Parkinson Disease; MS: Multiple Sclerosis
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Female
In the female subgroup analysis (Figure 21), we found that the dyads that scored less than zero
were
-

Chronic kidney disease + hypertension: -0.96

-

Cancer + gastric ulcer: -0.47

-

Depression + hypertension: -0.35

-

Arthritis + hypertension: -0.13

-

Arthritis + cancer: -0.058

We found that the triads that scored less than zero were:
-

Depression + arthritis + other heart disease: -0.55

-

Depression + arthritis + hypertension: -0.42

-

Thyroid disease + arthritis + hypertension: -0.073

Figure 21: CART of CSHA Animal Naming Test at baseline - Females subgroup
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gast ulcer: gastric ulcer; thyroid: thyroid diseases; otheart: other heart disease; ckd: chronic kidney disease; coronary: coronary
artery disease; Parkinson: Parkinson Disease; MS: Multiple Sclerosis

Male
In the male subgroup analysis (Figure 22), we found that the dyads that scored less than zero were
-

Thyroid disease + hypertension: -0.088

-

Thyroid disease + gastric ulcer: -0.025

We found that the triads that scored less than zero were:
-

Thyroid disease + coronary artery disease: -0.48

-

Thyroid disease + arthritis + gastric ulcer: -0.34

-

Thyroid disease + arthritis + hypertension: -0.06

Figure 22: CART of CSHA Animal Naming Test at baseline - Males subgroup
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gast ulcer: gastric ulcer; thyroid: thyroid diseases; otheart: other heart disease; ckd: chronic kidney disease; coronary: coronary
artery disease.

5.2.2.2.1.2 CLSA
In the complete CLSA cohort (Figure 23), we found that the dyads that scored less than zero were:
-

Hypertension + cancer: -0.34

-

Gastric ulcer + depression: -0.34

-

Arthritis + chronic kidney disease: -0.28

-

Hypertension + thyroid disease: -0.2

-

Hypertension + arthritis: -0.19

-

Hypertension + other heart disease: -0.14

-

Hypertension + stroke: -0.094

-

Cancer + arthritis: -0.052

-

Diabetes + chronic kidney disease: -0.039

We found that the triads that scored less than zero were:
-

Hypertension + other heart disease + multiple sclerosis: -1.5

-

Hypertension + cancer + coronary artery disease: -1.4

-

Hypertension + stroke + diabetes: -0.96

-

Hypertension + chronic kidney disease + diabetes: -0.9

-

Hypertension + other heart disease + diabetes: -0.82

-

Other heart disease + coronary artery disease + stroke: -0.71

-

Hypertension + other heart disease + gastric ulcer: -0.71

-

Hypertension + other heart disease + stroke: -0.69

-

Hypertension + other heart disease + chronic kidney disease: -0.66

-

Hypertension + other heart disease + thyroid disease: -0.5

-

Cancer + arthritis + thyroid disease: -0.46

-

Hypertension + other heart disease + coronary artery disease: -0.38

-

Hypertension + arthritis + thyroid: -0.37

-

Other heart disease + depression + diabetes: -0.31
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-

Other heart disease + depression + cancer: -0.21

-

Hypertension + other heart disease + cancer: -0.11

Figure 23: CART of CLSA Animal Naming Test at baseline - All cohort
gast ulcer: gastric ulcer; thyroid: thyroid diseases; otheart: other heart disease; ckd: chronic kidney disease; coronary: coronary
artery disease; Parkinson: Parkinson Disease; MS: Multiple Sclerosis

Female
In the female subgroup analysis (Figure 24), we found that the dyads that scored less than zero
were
-

Other heart disease + cancer: -1.3

-

Hypertension + multiple sclerosis: -0.97

-

Arthritis + Parkinson disease: -0.92

-

Arthritis + chronic kidney disease: -0.74

-

Gastric ulcer + depression: -0.47
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-

Diabetes + cancer: -0.41

-

Hypertension + arthritis: -0.34

-

Hypertension + thyroid disease: -0.32

-

Hypertension + diabetes: -0.28

-

Hypertension + coronary artery disease: -0.26

-

Hypertension + depression: -0.11

We found that the triads that scored less than zero were:
-

Hypertension + coronary artery disease + thyroid disease: -1.4

-

Hypertension + coronary artery disease + gastric ulcer: -1.0

-

Hypertension + coronary artery disease + arthritis: -0.92

-

Hypertension + diabetes + cancer: -0.86

-

Hypertension + depression + epilepsy: -0.86

-

Arthritis + cancer + thyroid disease: -0.47

-

Hypertension + arthritis + thyroid disease: -0.44

-

Other heart disease + depression + arthritis: -0.4

-

Hypertension + coronary artery disease + diabetes: -0.34

-

Arthritis + cancer + depression -0.26

-

Hypertension + arthritis + other heart: -0.13

-

Hypertension + arthritis + depression: -0.1

-

Other heart disease + coronary artery disease: -0.073

-

Arthritis + depression + thyroid disease: -0.052
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Figure 24: CART of CLSA Animal Naming Test at baseline - Females subgroup
gast ulcer: gastric ulcer; thyroid: thyroid diseases; otheart: other heart disease; ckd: chronic kidney disease; coronary: coronary
artery disease; Parkinson: Parkinson Disease; MS: Multiple Sclerosis

Male
In the male subgroup analysis (Figure 25), we found that the dyads that scored less than zero were
-

Other heart disease + multiple sclerosis: -1.5

-

Diabetes + stroke: -0.71

-

Other heart disease + diabetes: -0.53

-

Other heart disease + hypertension: -0.48

-

Hypertension + cancer: -0.29

-

Other heart disease + cancer: -0.21

-

Other heart disease + arthritis: -0.19

-

Hypertension + Parkinson disease: -0.04
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We found that the triads that scored less than zero were:
-

Hypertension + chronic kidney disease + diabetes: -1.2

-

Other heart disease + arthritis + stroke: -0.97

-

Other heart disease + cancer + gastric ulcer: -0.95

-

Other heart disease + cancer + arthritis: -0.65

-

Hypertension + diabetes + stroke: -0.78

-

Hypertension + chronic kidney disease + arthritis: -0.53

-

Hypertension + coronary artery disease + depression: -0.38

-

Other heart disease + coronary artery disease + hypertension: -0.37

-

Other heart disease + hypertension + cancer: -0.36

-

Hypertension + gastric ulcer + depression: -0.36

-

Other heart disease + gastric ulcer + hypertension: -0.31

-

Hypertension + diabetes + thyroid disease: -0.29

-

Hypertension + Parkinson disease + thyroid disease: -0.11

Figure 25: CART of CLSA Animal Naming Test at baseline - Males subgroup
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gast ulcer: gastric ulcer; thyroid: thyroid diseases; otheart: other heart disease; ckd: chronic kidney disease; coronary: coronary
artery disease; Parkinson: Parkinson Disease; MS: Multiple Sclerosis

65 years and older
In the65 years and older subgroup analysis (Figure 26), we found that the dyads that scored less
than zero were:
-

Hypertension + multiple sclerosis: -1.1

-

Chronic kidney disease + arthritis: -1.1

-

Arthritis + Parkinson disease: -0.78

-

Hypertension + thyroid disease: -0.7

-

Hypertension + gastric ulcer: -0.6

-

Hypertension + cancer: -0.57

-

Hypertension + arthritis: -0.56

-

Other heart disease + arthritis: -0.49

-

Arthritis + gastric ulcer: -0.35

-

Other heart disease + coronary artery disease: -0.34

-

Other heart disease + hypertension: -0.34

-

Arthritis + diabetes: -0.32

-

Chronic kidney disease + depression: -0.3

-

Arthritis + cancer: -0.23

-

Other heart disease + depression: -0.17

-

Hypertension + arthritis: -0.14

-

Hypertension + coronary: -0.064

-

Arthritis + coronary artery disease: -0.014

We found that the triads that scored less than zero were:
-

Other heart disease + gastric ulcer + cancer: -1.3

-

Hypertension + coronary artery disease + diabetes: -1.2

-

Other heart disease + diabetes + chronic kidney disease: -1.2
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-

Other heart disease + diabetes + cancer: -0.98

-

Hypertension + gastric ulcer + diabetes: -0.95

-

Arthritis + diabetes + thyroid disease: -0.89

-

Hypertension + coronary artery disease + arthritis: -0.88

-

Hypertension + coronary artery disease + thyroid disease: -0.87

-

Other heart disease + depression + cancer: -0.83

-

Other heart disease + gastric ulcer + arthritis: -0.75

-

Other heart disease + coronary artery disease + arthritis: -0.69

-

Other heart disease + gastric ulcer + hypertension: -0.67

-

Other heart disease + hypertension + arthritis: -0.64

-

Hypertension + arthritis + gastric ulcer: -0.63

-

Hypertension + thyroid disease + cancer: -0.61

-

Other heart disease + diabetes + hypertension: -0.6

-

Hypertension + coronary artery disease + cancer: -0.59

-

Hypertension +thyroid disease + diabetes: -0.5

-

Hypertension + arthritis + cancer: -0.47

-

Arthritis + cancer + thyroid disease: -0.35

-

Other heart disease + gastric ulcer + diabetes: -0.24
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Figure 26: CART of CLSA Animal Naming Test at baseline - Participants 65 years and older
gast ulcer: gastric ulcer; thyroid: thyroid diseases; otheart: other heart disease; ckd: chronic kidney disease; coronary: coronary
artery disease; Parkinson: Parkinson Disease; MS: Multiple Sclerosis

Younger than 65 years
In the participants younger than 65 years subgroup analysis (Figure 27), we found that the dyads
that scored less than zero were:
-

Hypertension + multiple sclerosis: -0.32

-

Gastric ulcer + depression: -0.31

-

Hypertension + epilepsy: -0.25

-

Hypertension + coronary artery disease: -0.19

We found that the triads that scored less than zero were:
-

Hypertension + multiple sclerosis + depression: -1.2
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-

Hypertension + coronary artery disease + chronic kidney disease: -0.94

-

Hypertension + chronic kidney disease + diabetes: -0.6

-

Hypertension + cancer + diabetes: -0.57

-

Other heart + coronary artery disease + arthritis: -0.57

-

Arthritis + cancer + thyroid disease: -0.51

-

Gastric ulcer + arthritis + diabetes: -0.43

-

Other heart disease + coronary artery disease + gastric ulcer: -0.41

-

Hypertension + thyroid disease + other heart disease: -0.4

-

Hypertension + gastric ulcer + arthritis: -0.23

-

Arthritis + cancer + depression: -0.23

-

Other heart disease + depression + arthritis: -0.12

-

Hypertension + other heart disease + depression: -0.098

Figure 27: CART of CLSA Animal Naming Test at baseline - Participants younger than 65 years
gast ulcer: gastric ulcer; thyroid: thyroid diseases; otheart: other heart disease; ckd: chronic kidney disease; coronary: coronary
artery disease; Parkinson: Parkinson Disease; MS: Multiple Sclerosis
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5.2.2.2.2 Change between baseline and first follow-up

5.2.2.2.2.1 CSHA
In the complete CSHA cohort (Figure 28), we found that the following dyads scored less than zero:
-

Arthritis + depression: -0.96

-

Coronary artery disease + arthritis: -0.91

-

Diabetes + arthritis: -0.83

-

Hypertension + chronic kidney disease: -0.81

-

Gastric ulcer + other heart disease: -0.79

-

Gastric ulcer + arthritis: -0.65

-

Other heart disease + cancer: -0.63

-

Gastric ulcer + depression: -0.6

-

Hypertension + thyroid disease: -0.57

-

Hypertension + other heart disease: -0.5

-

Gastric ulcer + hypertension: -0.32

-

Stroke + hypertension: -0.26

-

Coronary artery disease + hypertension: -0.25

-

Arthritis + cancer: -0.15

-

Diabetes + depression: -0.03

We did not find any triad associated with scores less than zero
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Figure 28: CART of CSHA Animal Naming Test Change between baseline and first follow-up – All
Cohort
gast ulcer: gastric ulcer; thyroid: thyroid diseases; otheart: other heart disease; ckd: chronic kidney disease; coronary: coronary
artery disease; Parkinson: Parkinson Disease; MS: Multiple Sclerosis

Female
In the female subgroup analysis (Figure 29), we found that the dyads that scored less than zero
were:
-

Arthritis + depression: -0.68

-

Arthritis + coronary artery disease: -0.64

-

Arthritis + chronic kidney disease: -0.43

-

Arthritis + hypertension: -0.24

-

Arthritis + other heart disease: -0.16

-

Arthritis + thyroid disease: -0.11

-

Stroke + hypertension: -0.047
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We found only one triad that scored less than zero:
-

Arthritis + hypertension + other heart disease: -0.67

Figure 29: CART of CSHA Animal Naming Test Change between baseline and first follow-up –
Females subgroup
gast ulcer: gastric ulcer; thyroid: thyroid diseases; otheart: other heart disease; ckd: chronic kidney disease; coronary: coronary
artery disease.

Male
In the male subgroup analysis (Figure 30), we found that the dyads that scored less than zero were:
-

Gastric ulcer + other heart disease: -0.84

-

Gastric ulcer + arthritis: -0.67

-

Arthritis + coronary artery disease: -0.6

-

Diabetes + other heart -0.43
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We did not find any triad associated with scores less than zero

Figure 30: CART of CSHA Animal Naming Test Change between baseline and first follow-up – Males
subgroup
gast ulcer: gastric ulcer; thyroid: thyroid diseases; otheart: other heart disease; ckd: chronic kidney disease; coronary: coronary
artery disease

5.2.2.2.2.2 CLSA
In the complete CLSA cohort (Figure 31), we found that the following dyads scored less than zero:
-

Coronary artery disease + gastric ulcer: -0.91

-

Other heart disease + gastric ulcer: -0.75

-

Parkinson + hypertension: -0.63

-

Gastric ulcer + diabetes: -0.44

-

Other heart disease + depression: -0.43

-

Gastric ulcer + thyroid: -0.35

-

Stroke + hypertension: -0.26
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-

Coronary artery disease + depression: -0.24

-

Depression + thyroid disease: -0.24

-

Depression + chronic kidney disease: -0.22

-

Depression + multiple sclerosis: -0.22

-

Other heart disease + thyroid disease: -0.15

-

Other heart disease + diabetes: -0.14

-

Other heart disease + hypertension: -0.1

-

Gastric ulcer + arthritis: -0.07

-

Depression + arthritis: -0.015

-

Other heart disease + arthritis: -0.013

-

Coronary artery disease + stroke: -0.012

We found that the triads that scored less than zero were:
-

Coronary artery disease + depression + cancer: -0.93

-

Depression + epilepsy + thyroid disease: -0.69

-

Depression + epilepsy + arthritis: -0.51

-

Gastric ulcer + hypertension + depression: -0.44

-

Other heart disease + hypertension + depression: -0.3

-

Coronary artery disease + gastric ulcer + hypertension: -0.25

-

Coronary artery disease + stroke + diabetes: -0.22

-

Gastric ulcer + depression + diabetes: -0.17

-

Hypertension + depression + arthritis: -0.14

-

Diabetes + chronic kidney disease + thyroid disease: -0.098

-

Gastric ulcer + hypertension + cancer: -0.064

-

Coronary artery disease + gastric ulcer + diabetes: -0.047

-

Gastric ulcer + depression + arthritis: -0.0098
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Figure 31: CART of CLSA Animal Naming Test Change between baseline and first follow-up – All
cohort
gast ulcer: gastric ulcer; thyroid: thyroid diseases; otheart: other heart disease; ckd: chronic kidney disease; coronary: coronary
artery disease; Parkinson: Parkinson Disease; MS: Multiple Sclerosis

Females
In the female subgroup analysis (Figure 32), we found that the dyads that scored less than zero
were
-

Gastric ulcer + diabetes: -0.73

-

Other heart disease + coronary artery disease: -0.66

-

Diabetes + epilepsy: -0.55

-

Other heart disease + depression: -0.52

-

Other heart disease + diabetes: -0.46

-

Gastric ulcer + thyroid disease: -0.43
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-

Other heart disease + hypertension: -0.28

-

Other heart disease + thyroid disease: -0.26

-

Diabetes + cancer + arthritis: -0.25

-

Depression + diabetes: -0.22

-

Depression + thyroid disease: -0.2

-

Gastric ulcer + hypertension: -0.16

-

Other heart disease + arthritis: -0.081

-

Depression + arthritis: -0.069

-

Depression + diabetes: -0.0076

We found that the triads that scored less than zero were:
-

Depression + arthritis + thyroid disease: -0.32

-

Gastric ulcer + arthritis + cancer: -0.3

-

Depression + arthritis + hypertension: -0.25

-

Other heart disease + depression + thyroid disease: -0.076
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Figure 32: CART of CLSA Animal Naming Test Change between baseline and first follow-up –
Females subgroup
gast ulcer: gastric ulcer; thyroid: thyroid diseases; otheart: other heart disease; ckd: chronic kidney disease; coronary: coronary
artery disease; Parkinson: Parkinson Disease; MS: Multiple Sclerosis

Males
In the male subgroup analysis (Figure 33), we found that the dyads that scored less than zero were:
-

Stroke + epilepsy: -1.5

-

Stroke + cancer: -1.3

-

Other heart disease + gastric ulcer: -0.81

-

Parkinson disease + hypertension: -0.75

-

Other heart disease + depression: -0.35

-

Hypertension + coronary artery disease: -0.3

-

Diabetes + hypertension: -0.25
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-

Diabetes + cancer: -0.2

-

Other heart disease + coronary artery disease: -0.19

-

Stroke + hypertension: -0.12

-

Chronic kidney disease + gastric ulcer: -0.12

-

Diabetes + arthritis: -0.035

-

Hypertension + thyroid disease: -0.013

-

Other heart disease + arthritis: -0.012

We found that the triads that scored less than zero were:
-

Hypertension + cancer + gastric ulcer: -0.94

-

Hypertension + thyroid disease + depression: -0.66

-

Other heart disease + hypertension + depression: -0.53

-

Hypertension + depression + gastric ulcer: -0.51

-

Diabetes + chronic kidney disease + depression: -0.48

-

Diabetes + gastric ulcer + coronary artery disease: -0.23

-

Diabetes + cancer + coronary artery disease: -0.2

-

Diabetes + arthritis + depression: -0.15

-

Diabetes + chronic kidney disease + thyroid disease: -0.14

-

Other heart disease + gastric ulcer + hypertension: -0.12

-

Diabetes + thyroid disease + other heart disease: -0.11

-

Diabetes + hypertension + other heart disease: -0.068
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Figure 33: CART of CLSA Animal Naming Test Change between baseline and first follow-up – Male
subgroup
gast ulcer: gastric ulcer; thyroid: thyroid diseases; otheart: other heart disease; ckd: chronic kidney disease; coronary: coronary
artery disease; Parkinson: Parkinson Disease; MS: Multiple Sclerosis

65 years and older
In the 65 years and older subgroup analysis (Figure 34), we found that the dyads that scored less
than zero were:
-

Coronary artery disease + gastric ulcer: -1.5

-

Stroke + cancer: -1.3

-

Diabetes + gastric ulcer: -0.68

-

Diabetes + cancer: -0.38

-

Stroke + hypertension: -0.36

-

Other heart disease + hypertension: -0.34
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-

Diabetes + hypertension: -0.27

-

Coronary artery disease + cancer: -0.000007

We found that the triads that scored less than zero were:
-

Other heart disease + hypertension + depression: -0.71

-

Arthritis + hypertension + epilepsy: -0.63

-

Arthritis + gastric ulcer + coronary artery disease: -0.54

-

Hypertension + cancer + depression: -0.43

-

Arthritis + chronic kidney disease + thyroid disease: -0.32

-

Hypertension + cancer + thyroid disease: -0.3

-

Coronary artery disease + gastric ulcer + hypertension: -0.27

-

Coronary artery disease + gastric ulcer + diabetes: -0.25

-

Arthritis + hypertension + coronary artery disease: -0.2

-

Arthritis + gastric ulcer + hypertension: -0.15

-

Other heart disease + hypertension + thyroid disease: -0.12

-

Arthritis + hypertension + chronic kidney disease: -0.11

-

Arthritis + hypertension + stroke: -0.054

-

Diabetes + hypertension + cancer: -0.053

-

Arthritis + hypertension + cancer: -0.026
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Figure 34: CART of CLSA Animal Naming Test Change between baseline and first follow-up –
Participants 65 years and older subgroup
gast ulcer: gastric ulcer; thyroid: thyroid diseases; otheart: other heart disease; ckd: chronic kidney disease; coronary: coronary
artery disease; Parkinson: Parkinson Disease; MS: Multiple Sclerosis

Younger than 65 years
In the younger than 65 years subgroup analysis (Figure 35), we found that the dyads that scored
less than zero were:
-

Other heart disease + thyroid disease: -0.6

-

Other heart disease + coronary artery disease: -0.47

-

Other heart disease + depression: -0.41

-

Diabetes + other heart disease: -0.32
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-

Depression + thyroid disease: -0.25

-

Gastric ulcer + diabetes: -0.13

-

Gastric ulcer + hypertension: -0.063

-

Chronic kidney disease + hypertension: -0.025

We found that the triads that scored less than zero were:
-

Diabetes + other heart disease + depression: -0.52

-

Gastric ulcer + hypertension + depression: -0.46

-

Other heart disease + hypertension + arthritis: -0.34

-

Depression + hypertension + arthritis: -0.25

-

Diabetes + chronic kidney disease + depression: -0.24

-

Gastric ulcer + cancer + arthritis: -0.21

-

Gastric ulcer + depression + arthritis: -0.0055
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Figure 35: CART of CLSA Animal Naming Test Change between baseline and first follow-up –
Participants younger than 65 years
gast ulcer: gastric ulcer; thyroid: thyroid diseases; otheart: other heart disease; ckd: chronic kidney disease; coronary: coronary
artery disease; Parkinson: Parkinson Disease; MS: Multiple Sclerosis

5.2.2.3 Rey Auditory Verbal learning Test Immediate Recall
5.2.2.3.1 Baseline

5.2.2.3.1.1 CSHA
In the complete CSHA (Figure 36), we found that the dyads that scored lower than zero were:
-

Coronary artery disease + arthritis: -0.34

-

Gastric ulcer + hypertension: -0.34

-

Arthritis + diabetes: -0.17
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-

Cancer + hypertension: -0.12

-

Arthritis + thyroid disease: -0.06

-

Arthritis + other heart: -0.057

We found that the triads that scored less than zero were:
-

Coronary artery disease + arthritis + chronic kidney disease: -0.36

-

Depression + arthritis + other heart disease: -0.21

Figure 36CART of CSHA Rey Auditory Verbal Learning Test Immediate Recall at baseline – All
cohort
gast ulcer: gastric ulcer; thyroid: thyroid diseases; otheart: other heart disease; ckd: chronic kidney disease; coronary: coronary
artery disease; Parkinson: Parkinson Disease; MS: Multiple Sclerosis

Females
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In the female subgroup analysis (Figure 37), we found that the dyads that scored less than zero
were:
-

Coronary artery disease + arthritis: -0.47

-

Other heart disease + diabetes: -0.37

-

Other heart disease + depression: -0.22

-

Arthritis + thyroid disease: -0.046

We did not find any triad associated with scores less than zero

Figure 37: CART of CSHA Rey Auditory Verbal Learning Test Immediate Recall at baseline –
Female subgroup
gast ulcer: gastric ulcer; thyroid: thyroid diseases; otheart: other heart disease; ckd: chronic kidney disease.

Males
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In the male subgroup analysis (Figure 38), we found that the dyads that scored less than zero were:
-

Hypertension + other heart disease: -0.15

-

Hypertension + arthritis: -0.13

We did not find any triad associated with scores less than zero

Figure 38: CART of CSHA Rey Auditory Verbal Learning Test Immediate Recall at baseline – Male
subgroup
gast ulcer: gastric ulcer; thyroid: thyroid diseases; otheart: other heart disease; coronary: coronary artery disease.

5.2.2.3.1.2 CLSA
In the complete CLSA cohort (Figure 39), we found that the dyads that scored lower than zero
were:
-

Other heart disease + stroke: -1.5
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-

Diabetes + gastric ulcer: -0.65

-

Epilepsy + thyroid disease: -0.64

-

Other heart disease + coronary artery disease: -0.47

-

Hypertension + other heart disease: -0.35

-

Hypertension + stroke: -0.3

-

Diabetes + cancer: -0.29

-

Hypertension + cancer: -0.28

-

Hypertension + diabetes: -0.21

-

Cancer + gastric ulcer: -0.091

-

Coronary artery disease + arthritis: -0.045

We found that the triads that scored less than zero were:
-

Hypertension + other heart disease + multiple sclerosis: -1.3

-

Hypertension + stroke + cancer: -1.2

-

Hypertension + depression + epilepsy: -1.1

-

Diabetes + depression + chronic kidney disease: -0.85

-

Hypertension + depression + coronary artery disease: -0.81

-

Hypertension + diabetes + coronary artery disease: -0.78

-

Hypertension + diabetes + chronic kidney disease: -0.61

-

Hypertension + other heart disease + diabetes: -0.57

-

Hypertension + depression + cancer: -0.31

-

Hypertension + other heart disease + gastric ulcer: -0.27

-

Hypertension + other heart disease + depression: -0.25

-

Hypertension + depression + arthritis: -0.082

-

Diabetes + gastric ulcer + thyroid disease: -0.08
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Figure 39: CART of CLSA Rey Auditory Verbal Learning Test Immediate Recall at baseline – All
cohort
gast ulcer: gastric ulcer; thyroid: thyroid diseases; otheart: other heart disease; ckd: chronic kidney disease; coronary: coronary
artery disease; Parkinson: Parkinson Disease; MS: Multiple Sclerosis

Females
In the female subgroup analysis (Figure 40), we found that the dyads that scored less than zero
were:
-

Cancer + coronary artery disease: -1.2

-

Chronic kidney disease + depression: -1.1

-

Thyroid disease + epilepsy: -0.71

-

Arthritis + Parkinson disease: -0.67

-

Chronic kidney disease + thyroid disease: -0.58

-

Hypertension + epilepsy: -0.56
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-

Hypertension + multiple sclerosis: -0.37

-

Gastric ulcer + diabetes: -0.36

-

Hypertension + other heart disease: -0.34

-

Arthritis + multiple sclerosis: -0.33

-

Arthritis + coronary artery disease: -0.23

-

Thyroid disease + other heart disease: -0.17

-

Cancer + diabetes: -0.14

-

Hypertension + cancer: -0.074

We found that the triads that scored less than zero were:
-

Arthritis + diabetes + thyroid disease: -0.15

-

Hypertension + arthritis + thyroid disease: -0.14

-

Hypertension + arthritis + diabetes: -0.059

-

Hypertension + other heart disease + thyroid disease: -0.055
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Figure 40: CART of CLSA Rey Auditory Verbal Learning Test Immediate Recall at baseline –
Female subgroup
gast ulcer: gastric ulcer; thyroid: thyroid diseases; otheart: other heart disease; ckd: chronic kidney disease; coronary: coronary
artery disease; Parkinson: Parkinson Disease; MS: Multiple Sclerosis

Males
In the males subgroup analysis (Figure 41), we found that the dyads that scored less than zero were:
-

Other heart disease + stroke: -1.0

-

Diabetes + gastric ulcer: -0.77

-

Other heart disease + gastric ulcer: -0.65

-

Hypertension + coronary artery disease: -0.6

-

Hypertension + cancer: -0.56

-

Other heart disease + arthritis: -0.53

-

Hypertension + other heart disease: -0.43
323

December 13, 2022

-

Other heart disease + depression: -0.23

-

cancer + depression: -0.13

-

Hypertension + chronic kidney disease: -0.11

-

Other heart disease + diabetes: -0.11

-

Other heart disease + chronic kidney disease: -0.11

-

Parkinson disease + arthritis: -0.014

We found that the triads that scored less than zero were:
-

Other heart disease + arthritis + thyroid disease: -1.5

-

Hypertension + depression + multiple sclerosis: -1.4

-

Cancer + depression + arthritis: -1.1

-

Hypertension + chronic kidney disease + arthritis: -1.0

-

Other heart disease + diabetes + coronary artery disease: -0.87

-

Hypertension + chronic kidney disease + diabetes: -0.69

-

Hypertension + depression + coronary artery disease: -0.68

-

Hypertension + other heart disease + diabetes: -0.6

-

Hypertension + other heart disease + gastric ulcer: -0.35

-

Hypertension + depression + arthritis: -0.28

-

Hypertension + depression + cancer: -0.28

-

Hypertension + other heart disease + thyroid disease: -0.082
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Figure 41: CART of CLSA Rey Auditory Verbal Learning Test Immediate Recall at baseline – Male
subgroup
gast ulcer: gastric ulcer; thyroid: thyroid diseases; otheart: other heart disease; ckd: chronic kidney disease; coronary: coronary
artery disease; Parkinson: Parkinson Disease; MS: Multiple Sclerosis

65 years and older
In the 65 years and older subgroup analysis (Figure 42), we found that the dyads that scored less
than zero were:
-

Thyroid disease + stroke: -1.5

-

Coronary artery disease + depression: -1.2

-

Cancer + chronic kidney disease: -1.2

-

Thyroid disease + chronic kidney disease: -1.1

-

Diabetes + coronary artery disease: -0.94

-

Arthritis + chronic kidney disease: -0.9
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-

Other heart disease + depression: -0.84

-

Other heart disease + gastric ulcer: -0.8

-

Arthritis + stroke: -0.66

-

Diabetes + hypertension: -0.64

-

Gastric ulcer + cancer: -0.48

-

Arthritis + depression: -0.46

-

Arthritis + gastric ulcer: -0.41

-

Arthritis + hypertension: -0.37

-

Thyroid disease + other heart disease: -0.37

-

Depression + hypertension: -0.12

-

Diabetes + chronic kidney disease: -0.087

-

Thyroid disease + hypertension: -0.053

-

Thyroid disease + arthritis: 0.0078

We found that the triads that scored less than zero were:
-

Diabetes + depression + cancer: -1.3

-

Arthritis + stroke + cancer: -1.3

-

Thyroid disease + other heart disease + coronary artery disease: -1.1

-

Other heart disease + stroke + coronary artery disease: -0.86

-

Thyroid disease + stroke + arthritis: -0.84

-

Diabetes + hypertension + other heart disease: -0.81

-

Diabetes + arthritis + other heart disease: -0.74

-

Diabetes + chronic kidney disease + other heart condition: -0.61

-

Cancer + depression + hypertension: -0.61

-

Diabetes + hypertension + gastric ulcer: -0.51

-

Diabetes + arthritis + thyroid disease: -0.51

-

Other heart disease + gastric ulcer + arthritis: -0.49

-

Diabetes + coronary artery disease + cancer: -0.48

-

Arthritis + chronic kidney disease + hypertension: -0.45

-

Thyroid disease + other heart disease + depression: -0.39

-

Diabetes + depression + hypertension: -0.38
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-

Other heart disease + depression + hypertension: -0.36

-

Thyroid disease + arthritis + hypertension: -0.35

-

Thyroid disease + hypertension + cancer: -0.34

-

Diabetes + arthritis + stroke: -0.31

-

Thyroid disease + gastric ulcer + hypertension: -0.31

-

Diabetes + arthritis + depression: -0.25

-

Other heart disease + stroke: -0.15

-

Arthritis + depression + cancer: -0.11

-

Arthritis + chronic kidney disease + cancer: -0.012

Figure 42: CART of CLSA Rey Auditory Verbal Learning Test Immediate Recall at baseline –
Participants 65 years and older subgroup
gast ulcer: gastric ulcer; thyroid: thyroid diseases; otheart: other heart disease; ckd: chronic kidney disease; coronary: coronary
artery disease; Parkinson: Parkinson Disease; MS: Multiple Sclerosis
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Younger than 65 years
In the younger than 65 years subgroup analysis (Figure 43), we found that the dyads that scored
less than zero were:
-

Chronic kidney disease + depression: -0.85

-

Hypertension + multiple sclerosis: -0.74

-

Epilepsy + thyroid disease: -0.49

-

Gastric ulcer + diabetes: -0.49

-

Hypertension + other heart disease: -0.26

-

Coronary artery disease + other heart disease: -0.17

-

Hypertension + chronic kidney disease: -0.16

-

Coronary artery disease + arthritis: -0.073

-

Gastric ulcer + cancer: -0.021

We found that the triads that scored less than zero were:
-

Hypertension + depression + epilepsy: -0.63

-

Hypertension + chronic kidney disease + diabetes: -0.62

-

Cancer + depression + arthritis: -0.42

-

Hypertension + depression + coronary artery disease: -0.11
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Figure 43: CART of CLSA Rey Auditory Verbal Learning Test Immediate Recall at baseline –
Participants younger than 65 years subgroup
gast ulcer: gastric ulcer; thyroid: thyroid diseases; otheart: other heart disease; ckd: chronic kidney disease; coronary: coronary
artery disease; Parkinson: Parkinson Disease; MS: Multiple Sclerosis

5.2.2.3.2 Change between baseline and first follow-up

5.2.2.3.2.1 CSHA
In the complete CSHA cohort (Figure 44), we found that the dyads that scored lower than zero
were:
-

Stroke + hypertension: -1.2

-

Gastric ulcer + depression: -0.76

-

Arthritis + depression: -0.59

-

Gastric ulcer + arthritis: -0.58

-

Stroke + arthritis: -0.55
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-

Other heart disease + cancer: -0.53

-

Hypertension + arthritis: -0.38

-

Arthritis + diabetes: -0.24

-

Other heart disease + arthritis: -0.21

-

Gastric ulcer + chronic kidney disease: -0.12

-

Cancer + hypertension: -0.12

We found that the triad that scored less than zero was:
-

Hypertension + arthritis + depression: -0.086

Figure 44: CART of CSHA Rey Auditory Verbal Learning Test Immediate Recall Change between
baseline and first follow-up – All cohort
gast ulcer: gastric ulcer; thyroid: thyroid diseases; otheart: other heart disease; ckd: chronic kidney disease; coronary: coronary
artery disease; Parkinson: Parkinson Disease; MS: Multiple Sclerosis
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Females
In the females subgroup analysis (Figure 45), we found that the dyads that scored less than zero
were:
-

Stroke + hypertension: -1.3

-

Gastric ulcer + hypertension: -0.96

-

Arthritis + thyroid disease: -0.7

-

Arthritis + hypertension: -0.63

-

Gastric ulcer + depression: -0.38

-

Arthritis + depression: -0.3

-

Cancer + hypertension: -0.17

-

Other heart disease + hypertension: -0.1

We did not find triads that scored less than zero:

Figure 45: CART of CSHA Rey Auditory Verbal Learning Test Immediate Recall Change between
baseline and first follow-up – Female subgroup
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gast ulcer: gastric ulcer; thyroid: thyroid diseases; otheart: other heart disease; ckd: chronic kidney disease; coronary: coronary
artery disease.

Males
In the subgroup males analysis (Figure 46), we found that the dyad that scored less than zero were:
-

Arthritis + diabetes: -0.1

We did not find triads that scored less than zero:

Figure 46: CART of CSHA Rey Auditory Verbal Learning Test Immediate Recall Change between
baseline and first follow-up – Male subgroup
gast ulcer: gastric ulcer; otheart: other heart disease; ckd: chronic kidney disease; coronary: coronary artery disease.
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5.2.2.3.2.2 CLSA
In the complete CLSA cohort (Figure 47), we found that the dyads that scored lower than zero
were:
-

Parkinson disease + hypertension: -0.73

-

Hypertension + coronary artery disease: -0.27

-

Arthritis + coronary artery disease: -0.16

-

Epilepsy + diabetes: -0.11

We found that the triads that scored less than zero were:
-

Other heart disease + epilepsy + arthritis: -1.5

-

Arthritis + coronary artery disease + thyroid disease: -1.1

-

Stroke + thyroid disease + depression: -0.5

-

Chronic kidney disease + gastric ulcer+ hypertension: -0.44

-

Other heart disease + depression + diabetes: -0.31

-

Other heart disease + depression + arthritis: -0.39

-

Arthritis + gastric ulcer + chronic kidney disease: -0.28

-

Arthritis + gastric ulcer + cancer: -0.2

-

Hypertension + diabetes + gastric ulcer: -0.12

-

Arthritis + depression + chronic kidney disease: -0.011
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Figure 47: CART of CLSA Rey Auditory Verbal Learning Test Immediate Recall Change between
baseline and first follow-up – All cohort
gast ulcer: gastric ulcer; thyroid: thyroid diseases; otheart: other heart disease; ckd: chronic kidney disease; coronary: coronary
artery disease; Parkinson: Parkinson Disease; MS: Multiple Sclerosis

Females
In the females subgroup analysis (Figure 48), we found that the dyads that scored less than zero
were:
-

Other heart disease + epilepsy: -0.62

-

Other heart disease + stroke: -0.61

-

Thyroid disease + multiple sclerosis: -0.24

-

Arthritis + coronary artery disease: -0.14
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We found that the triads that scored less than zero were:
-

Arthritis + coronary artery disease + cancer: -0.99

-

Arthritis + thyroid disease + stroke: -0.7

-

Arthritis + gastric ulcer + cancer: -0.37

-

Other heart disease + depression + arthritis: -0.16

-

Arthritis + thyroid disease + cancer: -0.04

-

Hypertension + depression + thyroid disease: - 0.0045

Figure 48: CART of CLSA Rey Auditory Verbal Learning Test Immediate Recall Change between
baseline and first follow-up – Female subgroup
gast ulcer: gastric ulcer; thyroid: thyroid diseases; otheart: other heart disease; ckd: chronic kidney disease; coronary: coronary
artery disease; Parkinson: Parkinson Disease; MS: Multiple Sclerosis

Males
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In the males subgroup analysis (Figure 49), we found that the dyads that scored less than zero were:
-

Parkinson disease + hypertension: -0.6

-

Thyroid disease + Arthritis: -0.37

-

Other heart disease + depression: -0.084

We found that the triads that scored less than zero were:
-

Arthritis + depression + diabetes: -0.51

-

Other heart disease + thyroid disease + diabetes: -0.49

-

Other heart disease + depression + diabetes: -0.41

-

Arthritis + depression + chronic kidney disease: -0.39

-

Coronary artery disease + cancer: -0.2

-

Epilepsy + hypertension: -0.065
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Figure 49: CART of CLSA Rey Auditory Verbal Learning Test Immediate Recall Change between
baseline and first follow-up – Male subgroup
gast ulcer: gastric ulcer; thyroid: thyroid diseases; otheart: other heart disease; ckd: chronic kidney disease; coronary: coronary
artery disease; Parkinson: Parkinson Disease; MS: Multiple Sclerosis

65 years and older
In the 65 years and older subgroup analysis (Figure 50), we found that the dyads that scored less
than zero were:
-

Other heart disease + epilepsy: -1.4

-

Depression + stroke: -0.67

-

Depression + epilepsy: -0.49

-

Other heart disease + stroke: -0.46

-

Gastric ulcer + thyroid disease: -0.28
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-

Other heart disease + gastric ulcer: -0.12

We found that the triads that scored less than zero were:
-

Other heart disease + stroke + depression: -1.2

-

Other heart disease + cancer + thyroid disease: -1.1

-

Coronary artery disease + cancer + hypertension: -0.88

-

Other heart disease + arthritis + depression: -0.49

-

Other heart disease + stroke + arthritis: -0.13

Figure 50: CART of CLSA Rey Auditory Verbal Learning Test Immediate Recall Change between
baseline and first follow-up – Participants 65 years and older subgroup
gast ulcer: gastric ulcer; thyroid: thyroid diseases; otheart: other heart disease; ckd: chronic kidney disease; coronary: coronary
artery disease; Parkinson: Parkinson Disease; MS: Multiple Sclerosis
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Younger than 65 years
In the younger than 65 years subgroup analysis (Figure 51), we found that the dyads that scored
less than zero were:
-

Stroke + hypertension: -0.58

-

Other heart disease + gastric ulcer + depression: -0.42

-

Stroke + hypertension + diabetes: -0.34

-

Epilepsy + diabetes: -0.2

We found that the triads that scored less than zero were:
-

Other heart disease + diabetes + depression: -0.32

-

Arthrosis + chronic kidney disease + cancer: -0.3

-

Arthritis + thyroid disease + cancer: -0.23

-

Arthritis + thyroid disease + diabetes: -0.054
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Figure 51: CART of CLSA Rey Auditory Verbal Learning Test Immediate Recall Change between
baseline and first follow-up – Participants younger than 65 years subgroup
gast ulcer: gastric ulcer; thyroid: thyroid diseases; otheart: other heart disease; ckd: chronic kidney disease; coronary: coronary
artery disease; Parkinson: Parkinson Disease; MS: Multiple Sclerosis

5.2.2.4 Rey Auditory Verbal learning Test Delayed Recall
5.2.2.4.1 Baseline

5.2.2.4.1.1 CSHA
In the complete CSHA cohort (Figure 52), we found that the dyads that scored lower than zero
were:
-

Arthritis + gastric ulcer: -0.49

-

Arthritis + chronic kidney disease: -0.17

-

Arthritis + cancer: -0.11
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-

Arthritis + diabetes: -0.094

-

Arthritis + coronary artery disease: -0.034

We did not find any triad associated with scores less than zero

Figure 52: CART of CSHA Rey Auditory Verbal Learning Test Delayed Recall at baseline – All
cohort
gast ulcer: gastric ulcer; thyroid: thyroid diseases; otheart: other heart disease; ckd: chronic kidney disease; coronary: coronary
artery disease.

Females
In the females subgroup analysis (Figure 53), we found that the dyads that scored less than zero
were:
-

Arthritis + coronary artery disease: -0.19
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-

Arthritis + chronic kidney disease: -0.1

-

Arthritis + thyroid disease: -0.00018

We did not find any triad associated with scores less than zero

Figure 53: CART of CSHA Rey Auditory Verbal Learning Test Delayed Recall at baseline – Female
subgroup
gast ulcer: gastric ulcer; thyroid: thyroid diseases; otheart: other heart disease; ckd: chronic kidney disease; coronary: coronary
artery disease.

Males
In the males subgroup analysis (Figure 54), we found that the dyads that scored less than zero were:
-

Depression + arthritis: -0.015
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We found that the triads that scored less than zero were:
-

Depression + gastric ulcer + arthritis: -0.43

-

Depression + Arthritis + hypertension: -0.4

-

Depression + arthritis + diabetes: -0.08

Figure 54: CART of CSHA Rey Auditory Verbal Learning Test Delayed Recall at baseline – Male
subgroup
gast ulcer: gastric ulcer; thyroid: thyroid diseases; otheart: other heart disease; coronary: coronary artery disease.

5.2.2.4.1.2 CLSA
In the complete CLSA cohort (Figure 55), we found that the dyads that scored lower than zero
were:
-

Other heart disease + stroke: -1.5
343

December 13, 2022

-

Diabetes + gastric ulcer: -0.56

-

Arthritis + multiple sclerosis: -0.38

-

Other heart disease + coronary artery disease: -0.3

-

Thyroid disease + epilepsy: -0.29

-

Hypertension + cancer: -0.28

-

Hypertension + arthritis: -0.21

-

Hypertension + other heart disease: -0.2

-

Hypertension + chronic kidney disease: -0.16

We found that the triads that scored less than zero were:
-

Other heart disease + coronary artery disease + gastric ulcer: -0.91

-

Hypertension + chronic kidney disease + diabetes: -0.87

-

Arthritis + chronic kidney disease + depression: -0.67

-

Hypertension + other heart disease + diabetes: -0.6

-

Hypertension + other heart disease + depression: -0.58

-

Hypertension + other heart disease + cancer: -0.53

-

Other heart disease + depression + diabetes: -0.51

-

Hypertension + other heart disease + arthritis: -0.27

-

Hypertension + depression + diabetes: -0.053

-

Other heart disease + depression + coronary: -0.038

-

Hypertension + depression + arthritis: -0.027
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Figure 55: CART of CLSA Rey Auditory Verbal Learning Test Delayed Recall at baseline – All cohort
gast ulcer: gastric ulcer; thyroid: thyroid diseases; otheart: other heart disease; ckd: chronic kidney disease; coronary: coronary
artery disease; Parkinson: Parkinson Disease; MS: Multiple Sclerosis

Females
In the females subgroup analysis (Figure 56), we found that the dyads that scored less than zero
were:
-

Coronary artery disease + diabetes: -1.1

-

Arthritis + Parkinson disease: -0.48

-

Hypertension + coronary artery disease: -0.42

-

Arthritis + multiple sclerosis: -0.41

-

Hypertension + epilepsy: -0.4

-

Gastric ulcer + diabetes: -0.37
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-

Thyroid disease + epilepsy: -0.32

-

Other heart disease + thyroid disease: -0.3

-

Hypertension + multiple sclerosis: -0.28

-

Arthritis + chronic kidney disease: -0.22

-

Hypertension + cancer: -0.086

-

Cancer + diabetes: -0.084

-

Hypertension + other heart disease: -0.051

We found that the triads that scored less than zero were:
-

Arthritis + chronic kidney disease + depression: -0.85

-

Hypertension + arthritis + stroke: -0.48

-

Hypertension + diabetes + gastric ulcer: -0.41

-

Arthritis + gastric ulcer + diabetes: -0.41

-

Hypertension + other heart disease + arthritis: -0.4

-

Hypertension + other heart disease + depression: -0.34

-

Hypertension + other heart disease: -0.19

-

Hypertension + other heart disease + thyroid disease: -0.087
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Figure 56: CART of CLSA Rey Auditory Verbal Learning Test Delayed Recall at baseline – Female
subgroup
gast ulcer: gastric ulcer; thyroid: thyroid diseases; otheart: other heart disease; ckd: chronic kidney disease; coronary: coronary
artery disease; Parkinson: Parkinson Disease; MS: Multiple Sclerosis

Males
In the males subgroup analysis (Figure 57), we found that the dyads that scored less than zero were:
-

Hypertension + chronic kidney disease: -0.99

-

Other heart disease + thyroid disease: -0.85

-

Diabetes + gastric ulcer: -0.7

-

Hypertension + epilepsy: -0.61

-

Hypertension + coronary artery disease: -0.6

-

Other heart disease + cancer: -0.52
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-

Hypertension + arthritis: -0.45

-

Arthritis + thyroid disease: -0.41

-

Hypertension + cancer: -0.4

-

Hypertension + other heart disease: -0.35

-

Arthritis + depression: -0.31

-

Other heart + depression: -0.22

-

Other heart disease + diabetes: -0.14

-

Diabetes + depression: -0.093

-

Other heart disease + gastric ulcer: -0.0074

We found that the triads that scored less than zero were:
-

Hypertension + cancer + stroke: -1.2

-

Other heart disease + gastric ulcer + coronary artery disease: -1.2

-

Hypertension + depression + multiple sclerosis: -0.85

-

Other heart disease + gastric ulcer + cancer: -0.81

-

Hypertension + arthritis + cancer: -0.76

-

Hypertension + other heart disease + diabetes: -0.76

-

Diabetes + thyroid disease: -0.71

-

Other heart disease + diabetes + coronary artery disease: -0.61

-

Hypertension + cancer + diabetes: -0.55

-

Hypertension + other heart disease + cancer: -0.52

-

Hypertension + arthritis + chronic kidney disease: -0.5

-

Hypertension + depression + cancer: -0.46

-

Hypertension + depression + gastric ulcer: -0.41

-

Hypertension + depression + coronary artery disease: -0.27

-

Hypertension + other heart disease + arthritis: -0.25

-

Hypertension + depression + arthritis: -0.17

-

Hypertension + other heart disease + coronary artery disease: -0.15

-

Diabetes + thyroid disease + arthritis: -0.13

-

Other heart disease + thyroid disease + diabetes: -0.099

-

Hypertension + arthritis + gastric ulcer: -0.091
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-

Diabetes + gastric ulcer + arthritis: -0.088

-

Hypertension + depression + diabetes: -0.08

-

Other heart disease + gastric ulcer + arthritis: -0.074

-

Hypertension + arthritis + thyroid disease: -0.033

Figure 57: CART of CLSA Rey Auditory Verbal Learning Test Delayed Recall at baseline – Male
subgroup
gast ulcer: gastric ulcer; thyroid: thyroid diseases; otheart: other heart disease; ckd: chronic kidney disease; coronary: coronary
artery disease; Parkinson: Parkinson Disease; MS: Multiple Sclerosis

65 years and older
In the 65 years and older subgroup analysis (Figure 58), we found that the dyads that scored less
than zero were:
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-

Other heart disease + Parkinson disease: -1.3

-

Other heart disease + chronic kidney disease: -1.1

-

Other heart disease + gastric ulcer: -0.99

-

Arthritis + epilepsy: -0.82

-

Thyroid disease + other heart disease: -0.75

-

Diabetes + coronary artery disease: -0.6

-

Diabetes + hypertension: -0.59

-

Diabetes + cancer: -0.58

-

Arthritis + chronic kidney disease: -0.57

-

Other heart disease + depression: -0.56

-

Hypertension + cancer: -0.49

-

Arthritis + stroke: -0.48

-

Diabetes + other heart disease: -0.47

-

Other heart disease + coronary artery disease: -0.47

-

Diabetes + arthritis: -0.44

-

Arthritis + hypertension: -0.4

-

Diabetes + chronic kidney disease: -0.3

-

Gastric ulcer + hypertension: -0.3

-

Depression + cancer: -0.24

-

Hypertension + depression: -0.24

-

Other heart disease + arthritis: -0.22

-

Arthritis + cancer: -0.13

-

Thyroid disease + arthritis: -0.12

We found that the triads that scored less than zero were:
-

Thyroid disease + other heart disease + stroke: -1.5

-

Diabetes + arthritis + chronic kidney disease: -1.1

-

Diabetes + depression + gastric ulcer: -1.0

-

Other heart disease + depression + hypertension: -0.98

-

Arthritis + stroke + cancer: -0.97

-

Diabetes + coronary artery disease + hypertension: -0.88
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-

Thyroid disease + other heart disease + cancer: -0.8

-

Diabetes + hypertension + other heart disease: -0.76

-

Diabetes + arthritis + other heart disease: -0.54

-

Diabetes + depression + hypertension: -0.52

-

Diabetes + depression + other heart disease: -0.52

-

Other heart disease + arthritis + coronary artery disease: -0.51

-

Arthritis + cancer + gastric ulcer: -0.5

-

Other heart disease + arthritis + hypertension: -0.43

-

Arthritis + cancer + depression: -0.4

-

Thyroid disease + hypertension + diabetes: -0.39

-

Thyroid disease + hypertension + gastric ulcer: -0.38

-

Thyroid disease + other heart disease + cancer: -0.35

-

Arthritis + cancer + hypertension: -0.33

-

Thyroid disease + hypertension + arthritis: -0.25

-

Other heart disease + gastric ulcer + arthritis: -0.22

-

Arthritis + hypertension + depression: -0.18

-

Thyroid disease + hypertension + cancer: -0.18

-

Diabetes + cancer + coronary artery disease: -0.15

-

Thyroid disease + other heart disease + arthritis: -0.14

-

Diabetes + arthritis + depression: -0.068

-

Other heart disease + gastric ulcer + depression: -0.08

-

Other heart disease + gastric ulcer + hypertension: -0.02
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Figure 58: CART of CLSA Rey Auditory Verbal Learning Test Delayed Recall at baseline –
Participants 65 years and older subgroup
gast ulcer: gastric ulcer; thyroid: thyroid diseases; otheart: other heart disease; ckd: chronic kidney disease; coronary: coronary
artery disease; Parkinson: Parkinson Disease; MS: Multiple Sclerosis

Younger than 65
In the younger than 65 yeas subgroup analysis (Figure 59), we found that the dyads that scored less
than zero were:
-

Coronary artery disease + gastric ulcer: -0.75

-

Diabetes + gastric ulcer: -0.44

-

Hypertension + epilepsy: -0.42

-

Chronic kidney disease + depression: -0.37

-

Diabetes + chronic kidney disease: -0.34
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-

Diabetes + cancer: -0.083

-

Diabetes + thyroid disease: -0.063

-

Hypertension + arthritis: -0.027

We found that the triads that scored less than zero were:
-

Hypertension + chronic kidney disease + diabetes: -1.1

-

Hypertension + other heart disease + thyroid disease: -0.79

-

Hypertension + other heart disease + gastric ulcer: -0.55

-

Diabetes + depression + other heart disease: -0.5

-

Hypertension + arthritis + stroke: -0.48

-

Multiple sclerosis + arthritis: -0.44

-

Thyroid disease + epilepsy: -0.31

-

Hypertension + chronic kidney disease + arthritis: -0.22

-

Hypertension + diabetes + cancer: -0.16
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Figure 59: CART of CLSA Rey Auditory Verbal Learning Test Delayed Recall at baseline –
Participants younger than 65 years subgroup
gast ulcer: gastric ulcer; thyroid: thyroid diseases; otheart: other heart disease; ckd: chronic kidney disease; coronary: coronary
artery disease; Parkinson: Parkinson Disease; MS: Multiple Sclerosis

5.2.2.4.2 Change between baseline and first follow-up

5.2.2.4.2.1 CSHA
In the complete CLSA cohort (Figure 60), we found that the dyads that scored lower than zero
were:
-

Thyroid disease + coronary artery disease: -1.2

-

Thyroid disease + gastric ulcer: -1.1

-

Depression + diabetes: -0.87

-

Gastric ulcer + chronic kidney disease: -0.33
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-

Thyroid disease + hypertension: -0.28

-

Depression + other heart disease: -0.26

-

Depression + hypertension: -0.2

We found that the triads that scored less than zero were:
-

Depression + arthritis + hypertension: -0.2

-

Stroke + coronary artery disease: -0.14

-

Depression + arthritis + chronic kidney disease: -0.0096

Figure 60: CART of CSHA Rey Auditory Verbal Learning Test Delayed Recall Change between
baseline and first follow-up – All cohort
gast ulcer: gastric ulcer; thyroid: thyroid diseases; otheart: other heart disease; ckd: chronic kidney disease; coronary: coronary
artery disease; Parkinson: Parkinson Disease; MS: Multiple Sclerosis

355
December 13, 2022

Females
In the female subgroup analysis (Figure 61), we found that the dyads that scored less than zero
were:
-

Coronary artery disease + thyroid disease: -1.2

-

Hypertension + thyroid disease: -1.0

-

Hypertension + depression: -0.39

-

Coronary artery disease + depression: -0.33

-

Hypertension + arthritis: -0.21

-

Hypertension + other heart disease: -0.11

-

Depression + other heart disease: -0.11

We did not find any triad associated with scores less than zero

Figure 61: CART of CSHA Rey Auditory Verbal Learning Test Delayed Recall Change between
baseline and first follow-up – Female subgroup
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gast ulcer: gastric ulcer; thyroid: thyroid diseases; otheart: other heart disease; ckd: chronic kidney disease

Males
In the males subgroup analysis (Figure 62), we found that the dyads that scored less than zero were:
-

Arthritis + hypertension: -0.074

We did not find any triad associated with scores less than zero

Figure 62: CART of CSHA Rey Auditory Verbal Learning Test Delayed Recall Change between
baseline and first follow-up – Male subgroup
gast ulcer: gastric ulcer; otheart: other heart disease; ckd: chronic kidney diseas
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5.2.2.4.2.2 CLSA
In the complete CLSA cohort (Figure 63), we found that the dyads that scored lower than zero
were:
-

Other heart disease + arthritis: -0.71

-

Hypertension + Parkinson disease: -0.43

-

Other heart disease + epilepsy: -0.42

-

Hypertension + epilepsy: -0.33

-

Other heart disease + chronic kidney disease: -0.2

-

Arthritis + stroke: -0.16

-

Arthritis + chronic kidney disease: -0.15

We found that the triads that scored less than zero were:
-

Hypertension + cancer + epilepsy: -0.83

-

Other heart disease + thyroid disease + gastric ulcer: -0.43

-

Other heart disease + depression + arthritis: -0.086

-

Hypertension + arthritis + coronary: -0.065

-

Other heart disease + thyroid disease + cancer: -0.048

-

Hypertension + arthritis + stroke: -0.04
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Figure 63: CART of CLSA Rey Auditory Verbal Learning Test Delayed Recall Change between
baseline and first follow-up – All cohort
gast ulcer: gastric ulcer; thyroid: thyroid diseases; otheart: other heart disease; ckd: chronic kidney disease; coronary: coronary
artery disease; Parkinson: Parkinson Disease; MS: Multiple Sclerosis

Females
In the females subgroup analysis (Figure 64), we found that the dyads that scored less than zero
were:
-

Depression + chronic kidney disease: -0.37

-

Hypertension + epilepsy: -0.33

-

Hypertension + coronary artery disease: -0.33

We found that the triads that scored less than zero were:
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-

Hypertension + gastric ulcer + chronic kidney disease: -0.57

-

Arthritis + other heart disease + coronary artery disease: -0.45

-

Arthritis + other heart disease + diabetes: -0.29

-

Thyroid disease + depression + other heart disease: -0.28

-

Hypertension + other heart disease + gastric ulcer: -0.25

-

Hypertension + other heart disease + diabetes: -0.17

Figure 64: CART of CLSA Rey Auditory Verbal Learning Test Delayed Recall Change between
baseline and first follow-up – Female subgroup
gast ulcer: gastric ulcer; thyroid: thyroid diseases; otheart: other heart disease; ckd: chronic kidney disease; coronary: coronary
artery disease; Parkinson: Parkinson Disease; MS: Multiple Sclerosis

Males
In the males subgroup analysis (Figure 65), we found that the dyads that scored less than zero were:
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-

Epilepsy – hypertension: -0.6

-

Other heart disease + thyroid disease: -0.35

-

Parkinson disease + hypertension: -0.46

-

Gastric ulcer + depression: -0.11

-

Other heart disease + diabetes: -0.042

We found that the triads that scored less than zero were:
-

Other heart disease + depression + chronic kidney disease: -0.93

-

Depression + diabetes + arthritis: -0.51

-

Other heart disease + depression + hypertension: -0.41

-

Other heart disease + depression + cancer: -0.37

-

Other heart disease + thyroid disease + cancer: -0.16

-

Stroke + hypertension + cancer: -0.15

-

Thyroid disease + hypertension + gastric ulcer: -0.15

-

Other heart disease + chronic kidney disease: -0.073

-

Cancer + depression + gastric ulcer: -0.028
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Figure 65: CART of CLSA Rey Auditory Verbal Learning Test Delayed Recall Change between
baseline and first follow-up – Male subgroup
gast ulcer: gastric ulcer; thyroid: thyroid diseases; otheart: other heart disease; ckd: chronic kidney disease; coronary: coronary
artery disease; Parkinson: Parkinson Disease; MS: Multiple Sclerosis

65 years and older
In the 65 years and older subgroup analysis (Figure 66), we found that the dyads that scored less
than zero were:
-

Gastric ulcer + epilepsy: -1.0

-

Hypertension + coronary artery disease: -0.56

-

Cancer + diabetes: -0.18
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-

Other heart disease + arthritis: -0.11

-

Gastric ulcer + diabetes: -0.062

-

Coronary artery disease + thyroid disease: 0.013

We found that the triads that scored less than zero were:
-

Gastric ulcer + diabetes + arthritis: -0.85

-

Other heart disease + depression + thyroid disease: 0.78

-

Gastric ulcer + depression + other heart disease: -0.47

-

Hypertension + chronic kidney disease + arthritis: -0.2

-

Gastric ulcer + depression + cancer: -0.15

-

Gastric ulcer + diabetes + hypertension: -0.092

-

Hypertension + coronary artery disease + stroke: -0.0042

Figure 66: CART of CLSA Rey Auditory Verbal Learning Test Delayed Recall Change between
baseline and first follow-up – Participants 65 years and older subgroup
363
December 13, 2022

gast ulcer: gastric ulcer; thyroid: thyroid diseases; otheart: other heart disease; ckd: chronic kidney disease; coronary: coronary
artery disease; Parkinson: Parkinson Disease; MS: Multiple Sclerosis

Younger than 65 years
In the younger than 65 years subgroup analysis (Figure 67), we found that the dyads that scored
less than zero were:
-

Chronic kidney disease + thyroid disease: -0.47

-

Gastric ulcer + chronic kidney disease: -0.34

-

Epilepsy + diabetes: -0.18

-

Depression + chronic kidney disease: -0.048

-

Other heart disease + cancer: -0.0082

We found that the triads that scored less than zero were:
-

Other heart disease + depression + diabetes: -0.25

-

Cancer + arthritis + thyroid disease: -0.18

-

Other heart disease + thyroid disease + diabetes: -0.0069
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Figure 67: CART of CLSA Rey Auditory Verbal Learning Test Delayed Recall Change between
baseline and first follow-up – Participants Younger than 65 years subgroup
gast ulcer: gastric ulcer; thyroid: thyroid diseases; otheart: other heart disease; ckd: chronic kidney disease; coronary: coronary
artery disease; Parkinson: Parkinson Disease; MS: Multiple Sclerosis

5.2.2.5 Dementia Diagnosis at the First follow-up in the CSHA
In the complete CSHA cohort (Figure 68), we found that the combinations associated with
dementia prevalence greater than the group mean of 0.12 where for dyads as follows (with dementia
prevalence in parenthesis):
-

Coronary artery disease + thyroid disease: (0.63)

-

Arthritis + Coronary artery disease: (0.54)

-

Stroke + Arthritis: (0.48)

-

Coronary artery disease + Gastric ulcer: (0.47)
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-

Depression + Other heart disease: (0.39)

-

Arthritis + Gastric Ulcer (0.32)

-

Arthritis + Diabetes: (0.21)

-

Hypertension + Cancer: (0.20)

-

Arthritis + Thyroid disease: (0.14)

-

Arthritis + Depression: (0.14)

-

Hypertension + other heart disease: (0.13)

-

Hypertension + Coronary artery disease: (0.13)

Also, we found for the triad:
-

Other heart disease + Arthritis + Diabetes: (0.21)

Figure 68: CART of Dementia Diagnosis at the First follow-up in the CSHA all cohort
gast ulcer: gastric ulcer; thyroid: thyroid diseases; otheart: other heart disease; ckd: chronic kidney disease; coronary: coronary
artery disease; Parkinson: Parkinson Disease
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Female
In the female analysis (Figure 69), we found that the dyads with an incidence of dementia at first
follow-up greater than the female group mean of 0.12 were:
-

Coronary artery disease + thyroid disease: (0.67)

-

Coronary artery disease + Chronic kidney disease: (0.42)

-

Stroke + hypertension: (0.27)

-

Thyroid disease + arthritis: (0.23)

-

Other heart disease + Gastric ulcer: (0.17)

-

Other heart disease + arthritis: (0.15)

-

Depression + Arthritis: (.014)

-

Depression + Hypertension: (0.13)

Also, we found that the following triad had increased prevalence of dementia:
-

Coronary artery disease + Hypertension + Arthritis: (0.15)
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Figure 69: CART of Dementia Diagnosis at the First follow-up in the CSHA in the Female subgroup
gast ulcer: gastric ulcer; thyroid: thyroid diseases; otheart: other heart disease; ckd: chronic kidney disease; coronary: coronary
artery disease; Parkinson: Parkinson Disease

Male
In the male analysis (Figure 70), we noticed a prevalence of dementia of 0.13, and the dyads with
a greater prevalence were:
-

Arthritis + Gastric Ulcer: (0.29)

-

Other heart disease + arthritis: (0.24)

-

Diabetes + Arthritis: (0.24)

In this analysis, we did not find any triad associated with increased incidence of dementia.
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Figure 70: CART of Dementia Diagnosis at the First follow-up in the CSHA in the Male subgroup
gast ulcer: gastric ulcer; otheart: other heart disease; coronary: coronary artery disease

5.2.2.6 CIND Diagnosis at the First follow-up in the CSHA
In the CSHA (Figure 71) we found that the combinations associated with CIND diagnosis at the
first follow-up in participants with normal cognition at baseline greater than the group mean of
0.30 where for dyads as follows (with CIND prevalence in parenthesis):
-

Thyroid diseases + Hypertension: (0.64)

-

Gastric ulcer + Arthritis: (0.33)

-

Depression + Arthritis: (0.31)

Also, we found the triads:
-

Depression + Arthritis + Gastric Ulcer: (0.49)

-

Diabetes + Arthritis + Other heart disease: (0.43)
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-

Depression + Arthritis + Hypertension: (0.38)

Figure 71: CART of CIND Diagnosis at the First follow-up in the CSHA all cohort
gast ulcer: gastric ulcer; thyroid: thyroid diseases; otheart: other heart disease; ckd: chronic kidney disease; coronary: coronary
artery disease.

Female
In the female analysis (Figure 72), we found that the dyads with an incidence of CIND at first
follow-up greater than the female group mean of 0.3 were:
-

Coronary artery disease + hypertension: (0.66)

-

Thyroid disease + Hypertension: (0.54)

-

Gastric ulcer + Other heart disease: (0.41)

-

Depression + Arthritis: (0.37)

-

Diabetes + Hypertension: (0.33)
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We did not find any triad associated with CIND incidence at first follow-up.

Figure 72: CART of CIND Incident Diagnosis at the First follow-up in the CSHA in the Female
subgroup
gast ulcer: gastric ulcer; thyroid: thyroid diseases; otheart: other heart disease; ckd: chronic kidney disease; coronary: coronary
artery disease.

Male
In the male analysis (Figure 73), we found that the dyads with an incidence of CIND at first followup greater than the male group mean of 0.29 were:
-

Depression + Hypertension: (0.43)

-

Depression + Other heart disease: (0.42)

-

Arthritis + Hypertension: (0.32)
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In this analysis, we did not find any triad associated with increased incidence of CIND.

Figure 73: CART of CIND Incident Diagnosis at the First follow-up in the CSHA in the Male
subgroup
gast ulcer: gastric ulcer; thyroid: thyroid diseases; otheart: other heart disease;; coronary: coronary artery disease.

5.3 Second Secondary Objective Results
We analyzed potential protection from factors known to influence cognitive decline, measuring
increased performance during follow-up. We restricted the analysis to participants with
multimorbidity. Also, we report the variables associated with enhanced performance in the
cognitive scores. In the logistic regression, we report the variables that decrease the OR of
progression to dementia.
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5.3.1 Frontal Function
5.3.1.1 CSHA
We analyzed 259 participants. We did not find factors associated with increased performance on
DSST score at follow-up (Table 5-182). In the analyses by sex (Table 5-183 and Table 5-184), we
did not find any factor neither. The ICC was 0.
Table 5-182: Analysis of Potential Factors Associated with Enhanced scores on the Frontal Function
Scores between the Baseline and First Follow-up in the CSHA

Predictors

Estimates std. Error

CI

p

(Intercept)

1.54

0.87

-0.17 – 3.26

0.078

age

-0.03

0.01

-0.05 – -0.01

0.014

sex [Male]

-0.19

0.15

-0.49 – 0.10

0.203

educ level [linear]

-0.06

0.16

-0.37 – 0.26

0.733

educ level [quadratic]

0.08

0.17

-0.25 – 0.41

0.631

educ level [cubic]

-0.14

0.17

-0.48 – 0.19

0.392

TBI [Yes]

-0.09

0.18

-0.44 – 0.25

0.603

smoking [Yes]

0.17

0.15

-0.13 – 0.46

0.266

alcohol [Yes]

-0.28

0.15

-0.58 – 0.02

0.069

physical act [Yes]

-0.11

0.13

-0.37 – 0.16

0.428

Random Effects
σ2

0.97

τ00 region

<0.001 (SD: <0.001; CI95%: 0 to 0.22)

N region

5

Observations
2

259
2

Marginal R / Conditional R

0.065 / NA

AIC

808.844

AICc

810.112

age in years; educ level: education level categorical; TBI: Traumatic brain injury; physical act: Physical activity at least once a
week

373
December 13, 2022

Table 5-183: Analysis of Potential Factors Associated with Enhanced scores on the Frontal Function
Scores between the Baseline and First Follow-up in the CSHA - Female

Predictors

Estimates std. Error

CI

p

(Intercept)

2.28

1.09

0.13 – 4.43

0.037

age

-0.04

0.01

-0.06 – -0.01

0.009

educ level [linear]

-0.07

0.23

-0.51 – 0.38

0.770

educ level [quadratic]

-0.05

0.22

-0.48 – 0.38

0.814

educ level [cubic]

0.08

0.21

-0.33 – 0.50

0.691

TBI [Yes]

-0.19

0.25

-0.69 – 0.31

0.450

smoking [Yes]

0.14

0.19

-0.24 – 0.52

0.479

alcohol [Yes]

-0.31

0.22

-0.75 – 0.13

0.167

physical act [Yes]

-0.04

0.17

-0.38 – 0.31

0.836

Random Effects
σ2

0.98

τ00 region

<0.001 (SD: <0.001; CI95%: 0 to 0.33)

N region

5

Observations
2

165
2

Marginal R / Conditional R

0.068 / NA

AIC

532.841

AICc

534.566

age in years; educ level: education level categorical; TBI: Traumatic brain injury; physical act: Physical activity at least once a
week

Table 5-184: Analysis of Potential Factors Associated with Enhanced scores on the Frontal Function
Scores between the Baseline and First Follow-up in the CSHA - Male

Predictors

Estimates std. Error

CI

p

(Intercept)

0.53

1.53

-2.52 – 3.58

0.730

age

-0.02

0.02

-0.06 – 0.02

0.305

educ level [linear]

0.09

0.24

-0.39 – 0.56

0.723

educ level [quadratic]

0.45

0.27

-0.09 – 0.99

0.103

374
December 13, 2022

educ level [cubic]

-0.63

0.30

-1.21 – -0.04

0.037

TBI [Yes]

0.02

0.25

-0.48 – 0.52

0.930

smoking [Yes]

0.36

0.25

-0.15 – 0.87

0.160

alcohol [Yes]

-0.24

0.21

-0.66 – 0.19

0.271

physical act [Yes]

-0.17

0.23

-0.63 – 0.28

0.446

Random Effects
σ2

0.94

τ00 region

<0.001; CI95%: 0 to 0.27)

N region

5

Observations
2

94
2

Marginal R / Conditional R

0.128 / NA

AIC

295.146

AICc

298.365

age in years; educ level: education level categorical; TBI: Traumatic brain injury; physical act: Physical activity at least once a
week

5.3.1.2 CLSA
We analyzed 9630 participants. We did not find factors associated with increased performance on
MAT scores at follow-up (Table 5-185). The ICC was 0.008 (CI95%: 0.0004 to 0.028) In the
analyses by sex, we did not find any statistically significant association with enhanced performance
(Table 5-186 and Table 5-187). Nevertheless, in the case of female analysis, an increase in
education level, we found a near statistically significant result of an increased z score of 0.05
(CI95%: -0.0039 to 0.11); however, this increase is slight, and we think it lacks clinical relevance.

Table 5-185: Analysis of Potential Factors Associated with Enhanced scores on the Frontal Function
Scores between the Baseline and First Follow-up in the CLSA

Predictors
(Intercept)
age

Estimates std. Error

CI

p

0.18

0.08

0.03 – 0.33

0.017

-0.004

0.001

-0.006 – -0.002

<0.001
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sex [Male]

-0.02

0.02

-0.06 – 0.02

0.413

educ level [linear]

0.01

0.02

-0.03 – 0.05

0.609

educ level [quadratic]

-0.03

0.02

-0.08 – 0.02

0.239

educ level [cubic]

0.03

0.03

-0.03 – 0.08

0.343

TBI [Yes]

-0.01

0.02

-0.05 – 0.04

0.715

smoking [Yes]

0.00

0.02

-0.04 – 0.04

0.842

alcohol [Yes]

-0.03

0.02

-0.07 – 0.01

0.167

physical act [Yes]

0.02

0.02

-0.02 – 0.06

0.292

Random Effects
σ2

0.81

τ00 region

0.01 (SD: 0.08; CI95%: 0.04 to 0.16)

ICC

0.01

N region

5

Observations
2

9630
2

Marginal R / Conditional R

0.003 / 0.011

AIC

31312.076

AICc

31312.108

age in years; educ level: education level categorical; TBI: Traumatic brain injury; physical act: Physical activity at least once a
week

Table 5-186: Analysis of Potential Factors Associated with Enhanced scores on the Frontal Function
Scores between the Baseline and First Follow-up in the CLSA - Female

Predictors
(Intercept)

Estimates std. Error

CI

p

0.19

0.10

-0.01 – 0.39

0.058

-0.004

0.001

-0.007 – -0.001

0.004

educ level [linear]

0.05

0.03

-0.00 – 0.11

0.065

educ level [quadratic]

-0.03

0.03

-0.09 – 0.03

0.364

educ level [cubic]

0.06

0.04

-0.01 – 0.14

0.103

TBI [Yes]

-0.03

0.03

-0.09 – 0.03

0.382

smoking [Yes]

-0.02

0.03

-0.07 – 0.04

0.522

age
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alcohol [Yes]

-0.08

0.03

-0.13 – -0.02

0.006

physical act [Yes]

-0.00

0.03

-0.05 – 0.05

0.982

Random Effects
σ2

0.83

τ00 region

0.01 (SD: 0.09; CI95%: 0.04 to 0.18)

ICC

0.01

N region

5

Observations
2

5146
2

Marginal R / Conditional R

0.005 / 0.014

AIC

16667.537

AICc

16667.589

age in years; educ level: education level categorical; TBI: Traumatic brain injury; physical act: Physical activity at least once a
week

Table 5-187: Analysis of Potential Factors Associated with Enhanced scores on the Frontal Function
Scores between the Baseline and First Follow-up in the CLSA - Male

Predictors
(Intercept)

Estimates std. Error

CI

p

0.14

0.10

-0.07 – 0.34

0.182

age

-0.005

0.001

-0.008 – -0.002

0.001

educ level [linear]

-0.04

0.03

-0.10 – 0.02

0.191

educ level [quadratic]

-0.02

0.04

-0.09 – 0.05

0.560

educ level [cubic]

-0.02

0.04

-0.10 – 0.06

0.635

TBI [Yes]

0.01

0.03

-0.05 – 0.07

0.695

smoking [Yes]

0.04

0.03

-0.02 – 0.10

0.239

alcohol [Yes]

0.03

0.03

-0.02 – 0.09

0.251

physical act [Yes]

0.05

0.03

-0.00 – 0.11

0.067

Random Effects
σ2

0.77

τ00 region

0.005 (SD: 0.07; CI95%: 0.02 to 0.14)

ICC

0.01
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N region

5

Observations
2

4484
2

Marginal R / Conditional R

0.005 / 0.011

AIC

14686.538

AICc

14686.597

age in years; educ level: education level categorical; TBI: Traumatic brain injury; physical act: Physical activity at least once a
week

5.3.2 Animal Naming Test
5.3.2.1 CSHA
We analyzed 295 participants. We did not find factors associated with increased ANT performance
at follow-up (Table 5-188); for the complete cohort the ICC was 0.05 (CI95%: <0.001 to 0.186).
Likewise, in the subgroup analyses by sex, we did not uncover any variable associated with
enhanced performance (Table 5-189 and Table 5-190).

Table 5-188: Analysis of Potential Factors Associated with Enhanced scores on the Animal Naming
Test Scores between the Baseline and First Follow-up in the CSHA

Predictors

Estimates std. Error

CI

p

(Intercept)

0.91

0.79

-0.65 – 2.47

0.250

age

-0.02

0.01

-0.04 – 0.00

0.053

sex [Male]

-0.06

0.14

-0.33 – 0.21

0.653

educ level [linear]

-0.32

0.15

-0.62 – -0.03

0.031

educ level [quadratic]

-0.16

0.15

-0.45 – 0.13

0.287

educ level [cubic]

-0.16

0.15

-0.45 – 0.13

0.283

TBI [Yes]

0.11

0.16

-0.20 – 0.43

0.481

smoking [Yes]

-0.02

0.13

-0.29 – 0.24

0.864

alcohol [Yes]

-0.09

0.14

-0.36 – 0.18

0.519
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physical act [Yes]

0.10

Random Effects
σ2

0.12

-0.13 – 0.34

0.387

0.88

τ00 region

0.05 (SD: 0.23; CI95%: 0.05 to 0.48)

ICC

0.05

N region

5

Observations
2

295
2

Marginal R / Conditional R

0.042 / 0.091

AIC

900.155

AICc

901.261

age in years; educ level: education level categorical; TBI: Traumatic brain injury; physical act: Physical activity at least once a
week

Table 5-189: Analysis of Potential Factors Associated with Enhanced scores on the Animal Naming
Test Scores between the Baseline and First Follow-up in the CSHA - Female

Predictors

Estimates std. Error

CI

p

(Intercept)

-0.20

0.93

-2.03 – 1.64

0.833

age

-0.01

0.01

-0.03 – 0.02

0.639

educ level [linear]

-0.45

0.20

-0.83 – -0.06

0.024

educ level [quadratic]

-0.14

0.18

-0.50 – 0.22

0.445

educ level [cubic]

-0.08

0.17

-0.42 – 0.26

0.628

TBI [Yes]

0.16

0.22

-0.27 – 0.59

0.458

smoking [Yes]

-0.03

0.16

-0.35 – 0.28

0.831

alcohol [Yes]

-0.29

0.18

-0.65 – 0.06

0.105

physical act [Yes]

0.20

0.14

-0.09 – 0.48

0.173

Random Effects
σ2

0.82

τ00 region

0.06 (SD: 0.24; CI95%: 0 to 0.54)

ICC

0.07

N region

5
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Observations

195

2

2

Marginal R / Conditional R

0.056 / 0.120

AIC

599.930

AICc

601.373

age in years; educ level: education level categorical; TBI: Traumatic brain injury; physical act: Physical activity at least once a
week

Table 5-190: Analysis of Potential Factors Associated with Enhanced scores on the Animal Naming
Test Scores between the Baseline and First Follow-up in the CSHA - Male

Predictors

Estimates std. Error

CI

p

(Intercept)

4.07

1.49

1.10 – 7.03

0.008

age

-0.06

0.02

-0.10 – -0.02

0.002

educ level [linear]

-0.18

0.25

-0.67 – 0.31

0.470

educ level [quadratic]

-0.25

0.28

-0.80 – 0.30

0.363

educ level [cubic]

-0.24

0.29

-0.83 – 0.34

0.409

TBI [Yes]

0.17

0.25

-0.33 – 0.67

0.497

smoking [Yes]

-0.01

0.26

-0.53 – 0.51

0.967

alcohol [Yes]

0.20

0.22

-0.23 – 0.63

0.357

physical act [Yes]

-0.27

0.22

-0.71 – 0.17

0.221

Random Effects
σ2

0.99

τ00 region

<0.001 (SD: <0.001; CI95%: 0 to 0.31)

N region

5

Observations
2

100
2

Marginal R / Conditional R

0.117 / NA

AIC

320.194

AICc

323.194

age in years; educ level: education level categorical; TBI: Traumatic brain injury; physical act: Physical activity at least once a
week
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5.3.2.2 CLSA
We analyzed 10326 participants. We did not find factors associated with increased performance
at follow-up (Table 5-191). The ICC was 0.0021 (CI95%: >0.0001 to 0.01) In the analysis by sex
there is no association either (Table 5-192 and Table 5-193).

Table 5-191: Analysis of Potential Factors Associated with Enhanced scores on the Animal Naming
Test Scores between the Baseline and First Follow-up in the CLSA

Predictors

Estimates std. Error

(Intercept)

CI

p

0.24

0.07

0.10 – 0.38

0.001

age

-0.004

0.00

-0.006 – -0.002

<0.001

sex [Male]

-0.003

0.02

-0.04 – 0.04

0.874

educ level [linear]

-0.03

0.02

-0.07 – 0.01

0.138

educ level [quadratic]

0.03

0.02

-0.02 – 0.07

0.262

educ level [cubic]

-0.03

0.03

-0.09 – 0.02

0.210

TBI [Yes]

-0.004

0.02

-0.05 – 0.04

0.847

smoking [Yes]

-0.002

0.02

-0.04 – 0.04

0.913

alcohol [Yes]

-0.01

0.02

-0.05 – 0.02

0.448

physical act [Yes]

0.01

0.02

-0.02 – 0.05

0.441

Random Effects
σ2

0.84

τ00 region

0.002 (SD: 0.04; 0.01 to 0.09)

ICC

0.00

N region

5

Observations
2

10326
2

Marginal R / Conditional R

0.002 / 0.004

AIC

34001.562

AICc

34001.592

age in years; educ level: education level categorical; TBI: Traumatic brain injury; physical act: Physical activity at least once a
week
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Table 5-192: Analysis of Potential Factors Associated with Enhanced scores on the Animal Naming
Test Scores between the Baseline and First Follow-up in the CLSA - Female

Predictors

Estimates std. Error

(Intercept)

CI

p

0.22

0.09

0.04 – 0.41

0.017

age

-0.004

0.001

-0.01 – -0.001

0.004

educ level [linear]

-0.02

0.03

-0.07 – 0.03

0.446

educ level [quadratic]

-0.01

0.03

-0.07 – 0.05

0.696

educ level [cubic]

-0.06

0.04

-0.13 – 0.02

0.123

TBI [Yes]

0.004

0.03

-0.06 – 0.06

0.891

smoking [Yes]

-0.02

0.03

-0.07 – 0.04

0.545

alcohol [Yes]

-0.01

0.03

-0.06 – 0.04

0.754

physical act [Yes]

0.01

0.03

-0.04 – 0.06

0.639

Random Effects
σ2

0.82

τ00 region

0.004 (SD: 0.06; CI95: 0.02 to 0.13)

ICC

0.00

N region

5

Observations

5468

Marginal R2 / Conditional R2

0.002 / 0.006

AIC

17614.810

AICc

17614.859

age in years; educ level: education level categorical; TBI: Traumatic brain injury; physical act: Physical activity at least once a
week

Table 5-193: Analysis of Potential Factors Associated with Enhanced scores on the Animal Naming
Test Scores between the Baseline and First Follow-up in the CLSA - Male

Predictors

Estimates std. Error

CI

p
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(Intercept)

0.25

0.10

0.05 – 0.45

0.013

age

-0.005

0.002

-0.008 – -0.002

0.001

educ level [linear]

-0.04

0.03

-0.10 – 0.02

0.177

educ level [quadratic]

0.08

0.04

0.01 – 0.15

0.032

educ level [cubic]

-0.02

0.04

-0.10 – 0.07

0.664

TBI [Yes]

-0.01

0.03

-0.07 – 0.05

0.706

smoking [Yes]

0.02

0.03

-0.04 – 0.08

0.600

alcohol [Yes]

-0.02

0.03

-0.08 – 0.04

0.507

physical act [Yes]

0.03

0.03

-0.03 – 0.08

0.382

Random Effects
σ2

0.86

τ00 region

<0.001 (SD: <0.001; CI95%: 0 to 0.05)

N region

5

Observations

4858

Marginal R2 / Conditional R2

0.004 / NA

AIC

16438.492

AICc

16438.546

age in years; educ level: education level categorical; TBI: Traumatic brain injury; physical act: Physical activity at least once a
week

5.3.3 Rey Auditory Verbal Learning Test
5.3.3.1 Immediate Recall
5.3.3.1.1 CSHA
We analyzed 261 participants. We did not find factors associated with increased performance at
follow-up. In the case of TBI we found a borderline result of an increase of 0.37 (CI95%: 0.002 to
0.74; p-value 0.050) which might be a spurious finding (Table 5-194). The ICC was 0.023 (CI95%:
0 to 0.12) In the subgroup analysis by sex, only in men the association with TBI is present (Table
5-195 and Table 5-196). Nevertheless, this association lack a theoretical clinical support and should
be evaluated in the future in a confirmatory analysis using other dataset.
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Table 5-194: Analysis of Potential Factors Associated with Enhanced scores on the Rey Auditory
Verbal Learning Test Immediate Recall Scores between the Baseline and First Follow-up in the
CSHA

Predictors

Estimates std. Error

CI

p

(Intercept)

1.06

0.93

-0.77 – 2.90

0.256

age

-0.02

0.01

-0.04 – 0.00

0.102

sex [Male]

-0.07

0.16

-0.38 – 0.23

0.639

educ level [linear]

-0.15

0.17

-0.49 – 0.18

0.362

educ level [quadratic]

0.11

0.17

-0.22 – 0.44

0.521

educ level [cubic]

0.20

0.17

-0.13 – 0.53

0.239

TBI [Yes]

0.37

0.19

0.00 – 0.74

0.050

smoking [Yes]

0.05

0.15

-0.25 – 0.35

0.751

alcohol [Yes]

0.07

0.16

-0.24 – 0.38

0.648

physical act [Yes]

0.05

0.14

-0.22 – 0.33

0.700

Random Effects
σ2

1.06

τ00 region

0.03 (SD: 0.16; CI95%: 0 to 0.39)

ICC

0.02

N region

5

Observations

261

Marginal R2 / Conditional R2

0.039 / 0.062

AIC

840.394

AICc

841.652

age in years; educ level: education level categorical; TBI: Traumatic brain injury; physical act: Physical activity at least once a
week
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Table 5-195: Analysis of Potential Factors Associated with Enhanced scores on the Rey Auditory
Verbal Learning Test Immediate Recall Scores between the Baseline and First Follow-up in the
CSHA - Female

Predictors

Estimates std. Error

CI

p

(Intercept)

0.82

1.17

-1.48 – 3.13

0.482

age

-0.02

0.02

-0.05 – 0.01

0.287

educ level [linear]

-0.05

0.23

-0.50 – 0.40

0.825

educ level [quadratic]

0.04

0.22

-0.39 – 0.48

0.847

educ level [cubic]

0.37

0.21

-0.05 – 0.79

0.082

TBI [Yes]

0.15

0.27

-0.39 – 0.68

0.593

smoking [Yes]

-0.03

0.19

-0.41 – 0.36

0.882

alcohol [Yes]

0.16

0.21

-0.27 – 0.58

0.461

physical act [Yes]

0.16

0.17

-0.19 – 0.50

0.371

Random Effects
σ2

1.11

τ00 region

<0.001 (SD: <0.001; CI95%: 0 to 0.30)

N region

5

Observations

173

Marginal R2 / Conditional R2

0.042 / NA

AIC

578.845

AICc

580.485

age in years; educ level: education level categorical; TBI: Traumatic brain injury; physical act: Physical activity at least once a
week

Table 5-196: Analysis of Potential Factors Associated with Enhanced scores on the Rey Auditory
Verbal Learning Test Immediate Recall Scores between the Baseline and First Follow-up in the
CSHA - Male

Predictors

Estimates std. Error

CI

p

(Intercept)

2.30

1.52

-0.74 – 5.33

0.136

age

-0.04

0.02

-0.08 – -0.001

0.044
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educ level [linear]

-0.21

0.24

-0.68 – 0.27

0.391

educ level [quadratic]

0.38

0.27

-0.15 – 0.91

0.156

educ level [cubic]

-0.19

0.29

-0.77 – 0.39

0.517

TBI [Yes]

0.62

0.26

0.11 – 1.13

0.018

smoking [Yes]

0.43

0.25

-0.07 – 0.94

0.089

alcohol [Yes]

-0.10

0.22

-0.53 – 0.33

0.643

physical act [Yes]

-0.27

0.23

-0.74 – 0.19

0.247

Random Effects
σ2

0.83

τ00 region

0.22 (SD: 0.47; CI95%: 0.15 to 0.98)

ICC

0.21

N region

5

Observations

88

Marginal R2 / Conditional R2

0.149 / 0.328

AIC

274.169

AICc

277.643

age in years; educ level: education level categorical; TBI: Traumatic brain injury; physical act: Physical activity at least once a
week

5.3.3.1.2 CLSA
We analyzed 10142 participants. We found in the global analysis (Table 5-197) that females had a
minor increased performance at follow-up of 0.14 (CI95%: 0.10 to 0.18); the ICC was 0.0006 (0
to 0.006). In the subgroup analyses by sex (Table 5-198 and Table 5-199), we found that in males,
alcohol consumption increased cognitive scores by 0.08 (CI95%: 0.02 to 0.14; p-value 0.009),
which we think lacks clinical significance. Also, we found a quadratic association in males at the
education level, which suggests the relationship between education and RAVLT immediate recall
scores is non-linear.
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Table 5-197: Analysis of Potential Factors Associated with Enhanced scores on the Rey Auditory
Verbal Learning Test Immediate Recall Scores between the Baseline and First Follow-up in the
CLSA

Predictors

Estimates std. Error

CI

p

(Intercept)

1.31

0.08

1.16 – 1.46

<0.001

age

-0.01

0.001

-0.02 – -0.01

<0.001

sex [Male]

-0.14

0.02

-0.18 – -0.10

<0.001

educ level [linear]

-0.05

0.02

-0.10 – -0.01

0.016

educ level [quadratic]

0.04

0.03

-0.02 – 0.09

0.173

educ level [cubic]

-0.02

0.03

-0.08 – 0.04

0.467

TBI [Yes]

-0.06

0.02

-0.11 – -0.02

0.009

smoking [Yes]

-0.05

0.02

-0.10 – -0.01

0.020

alcohol [Yes]

0.04

0.02

-0.00 – 0.08

0.058

physical act [Yes]

0.02

0.02

-0.02 – 0.07

0.282

Random Effects
σ2

1.03

τ00 region

0.004 (SD: 0.02; CI95%: 0 to 0.06)

ICC

0.00

N region

5

Observations

10142

Marginal R2 / Conditional R2

0.025 / 0.025

AIC

35455.891

AICc

35455.922

age in years; educ level: education level categorical; TBI: Traumatic brain injury; physical act: Physical activity at least once a
week

Table 5-198: Analysis of Potential Factors Associated with Enhanced scores on the Rey Auditory
Verbal Learning Test Immediate Recall Scores between the Baseline and First Follow-up in the
CLSA - Female

Predictors

Estimates std. Error

CI

p
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(Intercept)

1.53

0.11

1.32 – 1.74

<0.001

age

-0.02

0.002

-0.02 – -0.01

<0.001

educ level [linear]

-0.01

0.03

-0.08 – 0.05

0.650

educ level [quadratic]

-0.01

0.04

-0.08 – 0.07

0.878

educ level [cubic]

-0.06

0.04

-0.15 – 0.03

0.181

TBI [Yes]

-0.14

0.04

-0.21 – -0.07

<0.001

smoking [Yes]

-0.07

0.03

-0.13 – -0.00

0.037

alcohol [Yes]

0.01

0.03

-0.06 – 0.07

0.864

physical act [Yes]

0.02

0.03

-0.04 – 0.08

0.512

Random Effects
σ2

1.16

τ00 region

0.001 (SD: 0.01; CI95%: 0 to 0.06)

ICC

0.00

N region

5

Observations
2

5381
2

Marginal R / Conditional R

0.025 / 0.025

AIC

19176.540

AICc

19176.589

age in years; educ level: education level categorical; TBI: Traumatic brain injury; physical act: Physical activity at least once a
week

Table 5-199: Analysis of Potential Factors Associated with Enhanced scores on the Rey Auditory
Verbal Learning Test Immediate Recall Scores between the Baseline and First Follow-up in the
CLSA - Male

Predictors

Estimates std. Error

CI

p

(Intercept)

0.86

0.11

0.65 – 1.07

<0.001

age

-0.01

0.002

-0.01 – -0.01

<0.001

educ level [linear]

-0.11

0.03

-0.17 – -0.05

<0.001

educ level [quadratic]

0.09

0.04

0.02 – 0.17

0.013
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educ level [cubic]

0.01

0.04

-0.07 – 0.10

0.772

TBI [Yes]

0.01

0.03

-0.05 – 0.08

0.639

smoking [Yes]

-0.05

0.03

-0.11 – 0.02

0.153

alcohol [Yes]

0.08

0.03

0.02 – 0.14

0.009

physical act [Yes]

0.03

0.03

-0.03 – 0.09

0.315

Random Effects
σ2

0.88

τ00 region

0.004 (SD: 0.06; CI95%: 0.02 to 0.13)

ICC

0.00

N region

5

Observations
2

4761
2

Marginal R / Conditional R

0.014 / 0.018

AIC

16210.009

AICc

16210.064

age in years; educ level: education level categorical; TBI: Traumatic brain injury; physical act: Physical activity at least once a
week

5.3.3.2 Delayed Recall
5.3.3.2.1 CSHA
We analyzed 252 participants. We did not find factors associated with increased performance at
follow-up (Table 5-200); the ICC was 0.018 (CI95%: 0 to 0.11). Also, in the subgroup analysis by
sex (Table 5-201 and Table 5-202), we did not find any factor associated with increased
performance in the RAVLT delayed recall.

Table 5-200: Analysis of Potential Factors Associated with Enhanced scores on the Rey Auditory
Verbal Learning Test Delayed Recall Scores between the Baseline and First Follow-up in the CSHA

Predictors
(Intercept)

Estimates std. Error
-1.04

1.10

CI

p

-3.20 – 1.12

0.346
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age

0.01

0.01

-0.02 – 0.04

0.461

sex [Male]

0.28

0.18

-0.08 – 0.64

0.124

educ level [linear]

0.01

0.19

-0.38 – 0.39

0.969

educ level [quadratic]

-0.04

0.20

-0.43 – 0.34

0.825

educ level [cubic]

-0.25

0.20

-0.64 – 0.14

0.209

TBI [Yes]

0.02

0.22

-0.41 – 0.45

0.924

smoking [Yes]

0.24

0.18

-0.11 – 0.59

0.179

alcohol [Yes]

-0.34

0.18

-0.70 – 0.02

0.067

physical act [Yes]

-0.17

0.16

-0.49 – 0.15

0.285

Random Effects
σ2

1.40

τ00 region

0.03 (SD: 0.16; CI95%: 0 to 0.44)

ICC

0.02

N region

5

Observations
2

252
2

Marginal R / Conditional R

0.045 / 0.062

AIC

879.183

AICc

880.488

age in years; educ level: education level categorical; TBI: Traumatic brain injury; physical act: Physical activity at least once a
week

Table 5-201: Analysis of Potential Factors Associated with Enhanced scores on the Rey Auditory
Verbal Learning Test Delayed Recall Scores between the Baseline and First Follow-up in the CSHA
- Female

Predictors

Estimates std. Error

CI

p

(Intercept)

-0.88

1.25

-3.34 – 1.58

0.482

age

0.01

0.02

-0.02 – 0.04

0.607

educ level [linear]

-0.07

0.24

-0.54 – 0.40

0.760

educ level [quadratic]

-0.29

0.23

-0.74 – 0.16

0.212
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educ level [cubic]

-0.06

0.22

-0.50 – 0.38

0.796

TBI [Yes]

0.13

0.28

-0.43 – 0.69

0.652

smoking [Yes]

0.08

0.20

-0.32 – 0.49

0.684

alcohol [Yes]

-0.11

0.23

-0.56 – 0.33

0.617

physical act [Yes]

-0.16

0.18

-0.52 – 0.20

0.390

Random Effects
σ2

1.19

τ00 region

0.00 (SD: 0)

N region

5

Observations

166

Marginal R2 / Conditional R2

0.023 / NA

AIC

565.550

AICc

567.264

age in years; educ level: education level categorical; TBI: Traumatic brain injury; physical act: Physical activity at least once a
week

Table 5-202: Analysis of Potential Factors Associated with Enhanced scores on the Rey Auditory
Verbal Learning Test Delayed Recall Scores between the Baseline and First Follow-up in the CSHA
- Male

Predictors

Estimates std. Error

CI

p

(Intercept)

-1.56

2.08

-5.70 – 2.58

0.454

age

0.01

0.03

-0.04 – 0.07

0.571

educ level [linear]

0.25

0.33

-0.41 – 0.91

0.451

educ level [quadratic]

0.61

0.37

-0.12 – 1.34

0.103

educ level [cubic]

-0.88

0.40

-1.67 – -0.08

0.031

TBI [Yes]

0.03

0.35

-0.68 – 0.73

0.941

smoking [Yes]

0.53

0.36

-0.18 – 1.24

0.144

alcohol [Yes]

-0.53

0.30

-1.14 – 0.07

0.081

physical act [Yes]

0.02

0.32

-0.62 – 0.66

0.943
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Random Effects
σ2

1.57

τ00 region

0.25 (SD: 0.50; CI95%: 0 to 1.16)

ICC

0.14

N region

5

Observations

86

Marginal R2 / Conditional R2

0.139 / 0.257

AIC

317.021

AICc

320.588

age in years; educ level: education level categorical; TBI: Traumatic brain injury; physical act: Physical activity at least once a
week

5.3.3.2.2

CLSA

We analyzed 10059 participants. We found that alcohol intakes increase performance 0.0514
(CI95%: 0.0097 to 0.093; p value 0.016) when compared between baseline and first follow-up,
which is a small increase, and it should be further evaluated in future research (Table 5-203). The
ICC was 0.005 (CI95%: 0.0004 to 0.0173) In the subgroup analyses by sex, we found that the
statistical association dissipated (Table 5-204 and Table 5-205).

Table 5-203: Analysis of Potential Factors Associated with Enhanced scores on the Rey Auditory
Verbal Learning Test Delayed Recall Scores between the Baseline and First Follow-up in the CLSA

Predictors

Estimates std. Error

CI

p

(Intercept)

1.22

0.08

1.06 – 1.37

<0.001

age

-0.01

0.001

-0.02 – -0.01

<0.001

sex [Male]

-0.09

0.02

-0.13 – -0.05

<0.001

educ level [linear]

-0.08

0.02

-0.12 – -0.04

<0.001

educ level [quadratic]

0.05

0.03

0.00 – 0.10

0.036

educ level [cubic]

-0.00

0.03

-0.06 – 0.06

0.936
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TBI [Yes]

-0.05

0.02

-0.10 – -0.004

0.033

smoking [Yes]

-0.08

0.02

-0.13 – -0.04

<0.001

alcohol [Yes]

0.05

0.02

0.01 – 0.09

0.016

physical act [Yes]

0.01

0.02

-0.03 – 0.06

0.499

Random Effects
σ2

0.95

τ00 region

0.005 (SD: 0.07; CI95%: 0.03 to 0.14)

ICC

0.01

N region

5

Observations
2

10059
2

Marginal R / Conditional R

0.025 / 0.030

AIC

34364.247

AICc

34364.278

age in years; educ level: education level categorical; TBI: Traumatic brain injury; physical act: Physical activity at least once a
week

Table 5-204: Analysis of Potential Factors Associated with Enhanced scores on the Rey Auditory
Verbal Learning Test Delayed Recall Scores between the Baseline and First Follow-up in the CLSA
- Female

Predictors

Estimates std. Error

CI

p

(Intercept)

1.31

0.11

1.10 – 1.52

<0.001

age

-0.02

0.002

-0.02 – -0.01

<0.001

educ level [linear]

-0.03

0.03

-0.09 – 0.03

0.397

educ level [quadratic]

0.03

0.04

-0.04 – 0.10

0.370

educ level [cubic]

-0.01

0.04

-0.09 – 0.07

0.780

TBI [Yes]

-0.09

0.04

-0.16 – -0.02

0.017

smoking [Yes]

-0.10

0.03

-0.16 – -0.05

0.001

alcohol [Yes]

0.05

0.03

-0.01 – 0.11

0.131

physical act [Yes]

-0.02

0.03

-0.07 – 0.04

0.599

Random Effects
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σ2

1.07

τ00 region

0.01 (SD: 0.08; CI95%: 0.03 to 0.16)

ICC

0.01

N region

5

Observations

5347

2

2

Marginal R / Conditional R

0.023 / 0.028

AIC

18622.938

AICc

18622.988

age in years; educ level: education level categorical; TBI: Traumatic brain injury; physical act: Physical activity at least once a
week

Table 5-205: Analysis of Potential Factors Associated with Enhanced scores on the Rey Auditory
Verbal Learning Test Delayed Recall Scores between the Baseline and First Follow-up in the CLSA
- Male
Predictors

Estimates std. Error

CI

p

(Intercept)

0.98

0.10

0.78 – 1.19

<0.001

age

-0.01

0.002

-0.02 – -0.01

<0.001

educ level [linear]

-0.15

0.03

-0.21 – -0.10

<0.001

educ level [quadratic]

0.09

0.04

0.02 – 0.16

0.017

educ level [cubic]

0.003

0.04

-0.08 – 0.09

0.948

TBI [Yes]

-0.02

0.03

-0.08 – 0.04

0.530

smoking [Yes]

-0.06

0.03

-0.12 – -0.001

0.048

alcohol [Yes]

0.05

0.03

-0.01 – 0.11

0.073

physical act [Yes]

0.06

0.03

0.001 – 0.11

0.046

Random Effects
σ2

0.81

τ00 region

0.004 (SD: 0.06; CI95%: 0.02 to 0.13)

ICC

0.00

N region

5

Observations
2

4712
2

Marginal R / Conditional R

0.022 / 0.026

AIC

15700.259
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AICc

15700.315

age in years; educ level: education level categorical; TBI: Traumatic brain injury; physical act: Physical activity at least once a
week

5.3.4 Factor Associated with Lower Dementia Diagnosis at First Follow-up in the CSHA
We evaluated all the 259 participants with multimorbidity in the CSHA for factors associated with
a lower incidence of dementia diagnosed at first follow-up (Table 5-206). We found that the only
factor associated with a lower risk of dementia was physical activity at least once a week with an
OR of 0.45 (CI95%: 0.20 to 0.98; p-value 0.046); the ICC was 0.00006. In the subgroup analysis
by sex, the protection to dementia transition appears to be greater in men with an OR of 0.26, but
the statistical significance disappears (Table 5-207 and Table 5-208). We think it could be an
association there, but it disappeared in the subgroup analysis

Table 5-206: Analysis of Potential Factors Associated with decreased progression to Dementia
measured at First Follow-up in the CSHA
Predictors

Odds Ratios std. Error

CI

p

age

1.07

0.04

0.99 – 1.15

0.083

sex [Male]

1.11

0.51

0.45 – 2.75

0.822

educ level [linear]

0.32

0.26

0.07 – 1.59

0.165

educ level [quadratic]

0.70

0.49

0.18 – 2.79

0.612

educ level [cubic]

1.21

0.71

0.39 – 3.80

0.742

TBI [Yes]

1.66

0.88

0.59 – 4.70

0.337

smoking [Yes]

0.73

0.33

0.31 – 1.77

0.491

alcohol [Yes]

1.77

0.75

0.77 – 4.05

0.178

physical act [Yes]

0.45

0.18

0.20 – 0.98

0.046

Random Effects
σ2
τ00 region

3.29
0.00
395

December 13, 2022

ICC

0.00

N region

5

Observations

303

Marginal R2 / Conditional R2

0.159 / 0.159

AIC

208.849

AICc

209.756

age in years; educ level: education level categorical; TBI: Traumatic brain injury; physical act: Physical activity at least once a
week

Table 5-207: Analysis of Potential Factors Associated with decreased progression to Dementia
measured at First Follow-up in the CSHA - Female
Predictors

Odds Ratios std. Error

CI

p

age

1.17

0.07

1.04 – 1.32

0.008

educ level [linear]

0.52

0.44

0.10 – 2.76

0.439

educ level [quadratic]

2.19

2.09

0.34 – 14.18

0.412

educ level [cubic]

2.63

2.78

0.33 – 20.90

0.360

TBI [Yes]

0.17

0.25

0.01 – 3.08

0.232

smoking [Yes]

1.31

0.74

0.43 – 3.95

0.635

alcohol [Yes]

2.70

1.52

0.89 – 8.12

0.078

physical act [Yes]

0.59

0.31

0.21 – 1.66

0.320

Random Effects
σ2

3.29

τ00 region

0.01

ICC

0.00

N region

5

Observations
2

202
2

Marginal R / Conditional R

0.357 / 0.360

AIC

121.636

AICc

122.788

age in years; educ level: education level categorical; TBI: Traumatic brain injury; physical act: Physical activity at least once a
week
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Table 5-208: Analysis of Potential Factors Associated with decreased progression to Dementia
measured at First Follow-up in the CSHA - Male

Predictors

Odds Ratios std. Error

CI

p

age

0.91

0.07

0.79 – 1.05

0.187

educ level [linear]

0.00

0.00

0.00 – Inf

0.990

educ level [quadratic]

0.00

0.03

0.00 – Inf

0.990

educ level [cubic]

0.03

8.86

2.9e-298 – 2,5e294

0.992

TBI [Yes]

3.02

2.18

0.73 – 12.46

0.127

smoking [Yes]

0.48

0.35

0.11 – 2.03

0.315

alcohol [Yes]

0.71

0.51

0.17 – 2.93

0.632

physical act [Yes]

0.26

0.20

0.06 – 1.15

0.075

Random Effects
σ2

3.29

τ00 region

0.00

ICC

0.00

N region

5

Observations

101

Marginal R2/ Conditional R2

0.918 / 0.918

AIC

84.973

AICc

87.417

age in years; educ level: education level categorical; TBI: Traumatic brain injury; physical act: Physical activity at least once a
week

5.3.5 Factor Associated with Lower CIND Diagnosis at First Follow-up in the CSHA
We evaluated all the 211 participants with multimorbidity and normal cognition at baseline in the
CSHA for factors associated with a lower incidence of CIND by the first follow-up. We did not
find an association (Table 5-209); the ICC was 0.04. In the subgroup analysis by sex (Table 5-210
and Table 5-211), we found the same result.
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Table 5-209: Analysis of Potential Factors Associated with decreased progression to CIND
measured at First Follow-up in the CSHA

Predictors

Odds Ratios std. Error

CI

p

age

1.02

0.03

0.96 – 1.09

0.468

sex [Male]

0.85

0.37

0.36 – 2.02

0.708

educ level [linear]

1.26

0.56

0.52 – 3.02

0.607

educ level [quadratic]

2.26

1.07

0.89 – 5.73

0.087

educ level [cubic]

0.25

0.13

0.09 – 0.68

0.006

TBI [Yes]

1.43

0.68

0.56 – 3.63

0.451

smoking [Yes]

1.22

0.49

0.55 – 2.69

0.631

alcohol [Yes]

0.63

0.27

0.27 – 1.48

0.292

physical act [Yes]

0.85

0.32

0.40 – 1.79

0.663

Random Effects
σ2

3.29

τ00 region

0.14

ICC

0.04

N region

5

Observations

211

Marginal R2 / Conditional R2

0.183 / 0.217

AIC

233.963

AICc

235.290

age in years; educ level: education level categorical; TBI: Traumatic brain injury; physical act: Physical activity at least once a
week

Table 5-210: Analysis of Potential Factors Associated with decreased progression to CIND
measured at First Follow-up in the CSHA - Female

Predictors

Odds Ratios std. Error

CI

p
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age

0.99

0.04

0.92 – 1.07

0.868

educ level [linear]

0.85

0.50

0.27 – 2.69

0.784

educ level [quadratic]

1.32

0.74

0.44 – 3.96

0.626

educ level [cubic]

0.30

0.17

0.10 – 0.89

0.030

TBI [Yes]

1.72

1.09

0.50 – 5.97

0.392

smoking [Yes]

1.61

0.78

0.62 – 4.18

0.331

alcohol [Yes]

0.19

0.15

0.04 – 0.85

0.030

physical act [Yes]

1.02

0.45

0.43 – 2.43

0.961

Random Effects
σ2

3.29

τ00 region

0.00

ICC

0.00

N region

5

Observations
2

144
2

Marginal R / Conditional R

0.233 / 0.233

AIC

157.250

AICc

158.904

age in years; educ level: education level categorical; TBI: Traumatic brain injury; physical act: Physical activity at least once a
week

Table 5-211: Analysis of Potential Factors Associated with decreased progression to CIND
measured at First Follow-up in the CSHA - Male

CIND.fu
Predictors

Odds Ratios std. Error

CI

p

age

1.10

0.07

0.97 – 1.25

0.126

educ level [linear]

31.44

5,3e4

0.00 – 3,6e147

0.984

educ level [quadratic]

7,3e4

2,8e6

0.00 – Inf

0.981

educ level [cubic]

3.8e-5

0.02

0.00 – Inf

0.984

2.04

1.76

0.38 – 11.06

0.408

TBI [Yes]
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smoking [Yes]

0.89

0.76

0.16 – 4.80

0.887

alcohol [Yes]

2.76

1.98

0.67 – 11.29

0.159

physical act [Yes]

0.33

0.25

0.07 – 1.48

0.148

Random Effects
σ2

3.29

τ00 region

0.00

ICC

0.00

N region

5

Observations

67

Marginal R2/ Conditional R2

0.914 / 0.914

AIC

82.367

AICc

86.295

age in years; educ level: education level categorical; TBI: Traumatic brain injury; physical act: Physical activity at least once a
week

5.4 Summary of Results
5.4.1 Summary of Findings from the Systematic Review on the Association between
Multimorbidity and Cognitive Decline
Our systematic review identified 19 publications evaluating the association of multimorbidity with
cognitive decline. Most of the authors used data from longitudinal or cohort studies. The
researchers collected information from high-income countries, with only one collecting data from
middle-income countries. Also, most information came from the United States or Western Europe,
with a mostly Caucasian population. Authors of 11 studies analyzed data from participants
recruited into population-based aging studies, which increased result applicability to the general
population. As for population characteristics, age was variable but mainly older adults in 12 of the
articles; the mean age was ≥ 70 years. Also, both studies showed a more extensive representation
of women.
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The approximation of a multimorbidity definition was variable; most studies presented a definition
of multimorbidity. It was primarily defined through a count of chronic conditions. Moreover, other
scholars used cumulative indexes of diseases as their operative definition of multimorbidity,
although these indexes’ development was for other purposes231. The most common definition of
multimorbidity was two or more diseases, but some authors used three or more. Many researchers
used predeterminate lists of diseases to collect chronic conditions’ prevalence, but the number of
diseases in the list varied from 4 to over 60. Additionally, most studies controlled for confounding,
although the list of confounders was variable among studies.
The evaluation of cognition and cognitive decline showed great variability. It ranged from only
using screening tests to define cognition to using tests to inform the clinicians to complete
neuropsychological evaluations in conjunction with clinical diagnosis to reliance upon clinical
diagnosis only. The definition of cognitive decline was also heterogeneous. Some authors focused
on individual score changes or differences, while others used a wide range of potential cognitive
outcomes ranging from cognitive impairment with no dementia to mild cognitive impairment to
dementia.

To our knowledge, this is the first systematic review to tackle the association of suffering
multimorbidity/multiple chronic conditions on cognitive performance and dementia. We found that
suffering multimorbidity was associated with cognitive decline in 17 of the 19 evaluated studies,
irrespective of whether the population was community-dwelling participants or patients diagnosed
with dementia. Further, the association was present both in cross-sectional and cohort studies. This
association was even present in patients with DS, a genetically determinate cognitive syndrome.

This result is consistent with other results on the association of multimorbidity with different major
functional outcomes such as independence, disability165, frailty166 and quality of life167. However,
an accurate estimate of the association strength of multimorbidity with cognitive decline is difficult
owing to the multiple definitions of the cognitive outcomes. Nevertheless, there is a trend in almost
all the studies toward higher cognitive decline with a higher number of chronic diseases. This result
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is in line with the clinical heterogeneity of the populations included in this systematic review. We
recognize that this clinical and methodological variety should induce us to take additional caution
in reaching conclusions regarding this association.

5.4.2 Summary of findings on Principal Objective
5.4.2.1 Frontal Function
In the CSHA, we did not find an association of multimorbidity with DSST at the baseline or change
at the first follow-up. In contrast, in the CLSA, we found an association of multimorbidity with
MAT scores at the baseline. However, these associations were small, with a decrease of 0.049 in
the z-score when measuring dichotomic multimorbidity and 0.023 z-score of multimorbidity count.
Further, we did not find an association when we analyzed multimorbidity associations with the
MAT score change at the first follow-up.
In the subgroup analysis, we found an association of multimorbidity only in the CLSA. We found
differences in the men and participants younger than 65 years at the baseline for dichotomic and
multimorbidity counts. In the case of participants 65 years and older, we noticed an association
only in the multimorbidity count analysis. In all the cases, the differences were small.
In summary, we did not find an association of multimorbidity with DSST in the CSHA. In contrast,
in the CLSA, we found small statistical associations between multimorbidity and MAT scores.
However, these associations were small.
Comparison of the CSHA and the CLSA
We analyzed the results in both cohorts. We found statistically significant differences only in the
CLSA; however, these differences are not clinically important. Unsurprisingly, in both cohorts,
increased age was associated with lower scores at the baseline and a larger decrease measured at
the first follow-up. Other variables were associated with DSST and MAT scores at the baseline.
Still, in most cases, these associations were not present and consistent in the change of scores
during the first follow-up at 5 years in the CSHA and 3 years in the CLSA.
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5.4.2.2 Animal Naming Test
In both the CSHA and the CLSA, we did not discover any association of multimorbidity with ANT
scores at the baseline or any association with ANT scores’ change at the first follow-up. Neither
did we find associations in the subgroup analysis.
From the selected confounders, in the CSHA at the baseline, increased age decreased ANT scores,
and increased education level category increased ANT scores by around half the standard deviation.
During the change at the follow-up, increased age persisted as a risk factor for decreased ANT
scores results. However, it was striking that an increased education level was associated with lower
ANT scores at the first follow-up. In the CLSA, we found multiple confounders associated with a
change in ANT scores at the baseline and score change at the first follow-up; however, these
associations with ANT scores were minor. Again, we found that a higher education level category
increased ANT scores at the baseline. Again, during the measurement of change at the first followup, a higher category of education level was associated with a decreased ANT score.
Comparison of the CSHA and the CLSA
When we compared the results in both cohorts, we did not find differences in the association of
multimorbidity with ANT scores in either cohort. Nevertheless, a noticeable finding in both cohorts
was that an increased education level category was associated with increased ANT scores. Still,
when measuring the change at the follow-up, a higher education-level category was associated with
decreased ANT scores.

5.4.2.3 Rey Auditory Verbal Learning Test Immediate Recall
In the CSHA, we did not find an association of multimorbidity with RAVLT immediate recall
scores at the baseline or during the first follow-up. We did not notice any association in subgroup
analyses.
However, we found a small association of –0.0143 (CI 95%: –0.024 to–0.0047) with RAVLT
immediate recall scores in the CLSA only when measuring multimorbidity as a continuous count.
In this case subgroup analyses, multimorbidity count had an association with RAVLT immediate
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recall at the baseline only in the stratified female analysis and in the patients 65 years and older. In
the case of change at the first follow-up, the subgroup analysis showed that multimorbidity counts
in females younger than 65 years were associated with lower RAVLT scores. Again, the
coefficients were minor in both cases.
Comparison of the CSHA and the CLSA
In this case, in the CSHA, we did not find associations of multimorbidity with RAVLT immediate
recall scores. At the same time, in the CLSA, we noticed that participants with higher
multimorbidity counts at the baseline had lower RAVLT scores. During the follow-up, in the whole
CLSA, we did not find an association of multimorbidity with the score, but a potential underlying
association emerged when we evaluated subgroup analysis. This association was consistent in the
female analysis, while it was variable in the age category analyses. Nevertheless, these associations
were minor within less than half z-score standard deviation, and they were only suggestions of
potential association.
In both cases, we used the first-minute RAVLT immediate recall of words, meaning that results
from both cohorts were compatible for the analysis.

5.4.2.4 Rey Auditory Verbal Learning Test Delayed Recall
In the CSHA, we did not find any association of multimorbidity with RAVLT-delayed recall at the
baseline or the change at the first follow-up. We did not discover associations in the subgroup
analyses either.
Both dichotomic and count multimorbidity analyses showed an association with decreased
RAVLT-delayed recall scores. This association was present in both age category groups in
dichotomic analyses. In the participants 65 years and older, it increased RAVLT-delayed recall
scores by 0.05 (CI 95%: 0.03–0.09), while in participants younger than 65 years, it decreased scores
by –0.07 (CI 95%: –0.103––0.03). In the case of multimorbidity count analysis, it decreased
RAVLT scores in stratified analysis for men (–0.011; CI 95%: –0.002–0.024) and those 65 years
old or older (–0.026; CI 95%: –0.39–0.013). In the case of the CLSA change at the first follow-up,
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both analyses showed lower scores of RAVLT in participants with multimorbidity. In the
dichotomic multimorbidity analysis, only participants younger than 65 years experienced lower
scores on RAVLT at the first follow-up, with a coefficient of –0.043 (CI 95%: –0.082–0.003).
Finally, in the multimorbidity count’s association with the RAVLT-delayed recall analysis, the
subgroup analyses showed a decrease in females.
Comparison of the CSHA and the CLSA
When comparing both cohorts, some differences in the RAVLT-delayed recall technique can make
the comparisons difficult. First, in the CSHA, participants had five opportunities to train with the
15 words, while in the CLSA, the participants were only trained once with the 15 words before the
interference with other tests and the final recall of the words. Second, the sequence of tests
contrasting immediate and delayed recall differed in both studies.
Even so, in the CLSA, participants with multimorbidity presented lower scores consistently.
However, we noticed that these differences mainly affected participants younger than 65 years. In
neither cohort did multimorbidity have a consistent association with RAVLT-delayed recall.

5.4.2.5 Association of multimorbidity with dementia diagnosis during the first follow-up
in the CSHA.
We only had the outcome of dementia diagnosis in the CSHA. We found an association of
multimorbidity count with dementia diagnosis at the first follow-up only in the female subgroup
with an OR of 1.41 (CI 95%: 1.07–1.86) for every increase on multimorbidity. Interestingly, this
result was only present in women, reinforcing the possibility that vulnerability to multimorbidity
might be different in different sexes.

5.4.2.6 Association of Multimorbidity with CIND diagnosis at first follow-up in the CSHA
We did not find an association of multimorbidity on progression to CIND at the first follow-up in
participants with normal cognition at the baseline.
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5.4.3 Summary of Findings on First Secondary Objective
5.4.3.1 Dyads and triads selection through "Multimorbidity Analysis Toolbox."
When we selected dyads and triads through the toolbox, we set up a minimum of 1% of prevalence.
This threshold is arbitrary, and we chose it to ensure enough individuals per combination. In the
case of the CSHA, it appears to be a reasonable decision because we want to have more than one
or two participants in each group. However, in the case of the CLSA, a threshold of 1% could
compromise more than 200 participants. It could be possible that some meaningful combinations
with many patients suffering from them could be below this threshold.
We found, through the toolbox in the CSHA, eight combinations of dyads and four triads to include
in the analysis. Likewise, in the CLSA, we found nine combination dyads and three triads. It raised
the challenge that this selection method is adequate, especially in the triads, because of their low
prevalence. Previous studies in a population ≥ 60 years have shown that even the most common
dyads and triads usually have low prevalence232.
In interpreting the scores, we employed the neuropsychological convention previously explained
from definitive abnormal results with a score ≥ 1.5 SD, a value between 1.0 and 1.5 SD that was
probably abnormal and a value between 0.5 and 1.0 SD that was non-abnormal but below
expectations.

5.4.3.2 Regression analysis with dyads and triads
5.4.3.2.1 Frontal function
In the analyses, only the combination of arthritis + diabetes in the CLSA had a statistically
significant association with the outcome. Even though we noticed this association, the coefficients
were small and discordant between the baseline (increased score) and the change measured at the
first follow-up (when scores decreased). We could not identify any triad associated with DSST or
MAT scores.
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5.4.3.2.2 Animal naming test
In the ANT analyses, we found that in the CSHA at the baseline, only the combination of arthritis
+ thyroid diseases was associated with a lower score at the baseline with a decrease of 1.02 SD,
which is meaningful. On the change at the first follow-up, we identified only the dyad of arthritis
+ diabetes but increased the score on ANT.
In the CLSA, we identified five dyads at the baseline (diabetes + hypertension; arthritis + thyroid
disease; arthritis + cancer; diabetes + arthritis; and hypertension + thyroid disease) associated with
ANT scores. All associations were less than 0.5 SD. In the case of the change at the first followup, we identified three dyads (hypertension + depression, diabetes + arthritis and hypertension +
thyroid disease), with all the coefficients, again, less than 0.5. As in the frontal function case, we
did not identify any triad associated with ANT.

5.4.3.2.3 Rey Auditory Verbal Learning Test Immediate recall
In the CSHA baseline, we found that the dyads of arthritis + thyroid diseases decreased by –1.13
SD in the RAVLT scores, while the combination of arthritis + depression increased by 1.85 SD in
the RAVLT scores. Nevertheless, this second result seems suspicious because depression is a
known factor that decreases immediate recall scores. We found no association with the change at
the follow-up or triads.
In the case of CLSA, we found two associations (arthritis + cancer & hypertension + depression)
at the baseline, but the coefficients were small, less than 0.5 SD. In the case of change at the first
follow-up and triads, we did not find any associations.

5.4.3.2.4 Rey Auditory Verbal Learning Test Delayed recall
In the CSHA, we found that at the baseline, only the triad of arthritis + hypertension + gastric ulcer
increased the score of RAVLT by 1.07. We did not discover dyads or triads associated with the
RAVLT scores in the follow-up analysis.
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When analyzing the CLSA results, we noticed that at the baseline, three dyads (arthritis + cancer,
hypertension + depression and diabetes + arthritis) had an association with RAVLT scores at the
baseline. While measuring the change at the first follow-up, we found that three dyads (diabetes +
hypertension, arthritis + depression and hypertension + thyroid disease) were associated with a
change in the RAVLT-delayed recall scores. All associations had a coefficient of less than 0.5 SD.

5.4.3.2.5 Dementia diagnosis at the first follow-up in the CSHA
We found no association of dyads or triads with the diagnosis of dementia at the first follow-up in
the CSHA.

5.4.3.2.6 CIND diagnosis at the first follow-up in the CSHA
As in the dementia analysis, we did not find any association of dyads or triads with the diagnosis
of CIND at the first follow-up in the CSHA in participants with normal cognition at the baseline.

5.4.3.2.7 Conclusion of dyads and triads regression analyses
We discovered a few potentially relevant combinations in the analysis of dyads’ and triads’
association with cognitive decline change through regression. One reason could be that we
evaluated all the potential combinations in the same regression analysis without known
confounders. In this instance, we could have significant interaction, but owing to the number of
terms in the regression, we might not have enough power to detect them233.
We decided to include all the potential combinations in one model because we wanted to compare
with CART, which also assigned all the combinations in one model. When we compared the results
of these statistically significant interactions with the results from the CART, we found that the
coefficients were different. For example, in the RAVLT-delayed recall at the baseline, with the
triad of arthritis + hypertension + gastric ulcer, when we analyzed with the regression analysis.
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including all the triads, we found an association with a score of 1.07, while with the CART we
identified an increase of only 0.27 SD.

5.4.3.3 CART Selection of dyads and triads
We selected trees that allowed us to explore dyads and triads in the CART analyses. We analyzed
using the same cut-off points or ≥ 1.5 SD as definitively abnormal, between 1.0 and 1.5 probably
abnormal and between 0.5 and 1.0 non-abnormal but below expectations. We allowed the model
to compute tree splits even with a few individuals in some groups because we were exploring triads
in combination with low prevalence. The program expressed the mean of each group, which might
render some results vulnerable to extreme values. Also, when we interpreted the results, we focused
on the combinations with scores abnormal or probably abnormal (below –1.5 SD and –1.0,
respectively). We present those combinations with results below expectations but not under the
threshold of abnormality. Still, we did not try to extract a conclusion from these results between –
0.5 and –0.99.

5.4.3.3.1 Frontal function

5.4.3.3.1.1 CSHA
In the whole cohort of the CSHA at the baseline, we found that only two triads scored below
expectations with a score of –0.62 SD; these triads were: a) depression + arthritis + coronary artery
disease and b) depression + hypertension + arthritis.
When we evaluated the change between the baseline and the first follow-up, we found that the dyad
of cancer + other heart diseases scored abnormally low, with –1.7. Additionally, the triad of
diabetes + arthritis + other heart diseases with a score of –1.3 and the dyad of hypertension +
coronary artery disease with scores of –1.2 were probably abnormal. Also, the expected scores of
the dyads were below: gastric ulcer + arthritis, with –0.96, diabetes + arthritis, with –0.92;
depression + arthritis, with –0.86; cancer + arthritis, with –0.8; chronic kidney disease +
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hypertension, with –0.68; diabetes + hypertension, with –0.6; hypertension + gastric ulcer, with –
0.59; and gastric ulcer + other heart diseases, with –0.59.
Female vs. male
In the CSHA female subgroup analysis at the baseline, only the triad of depression + hypertension
+ gastric ulcer scored –0.62, which is below expectations. In contrast, no dyad or triad was
associated with DSST at the baseline in the male subgroup analysis.
In the female analysis of change of DSST scores between the baseline and the first follow-up, we
found that they scored lower than expected: the triad of hypertension + arthritis + depression with
–0.99, the dyads of thyroid disease + gastric ulcer with –0.95, hypertension + arthritis with –0.82
and chronic kidney disease + hypertension with –0.61.
Conclusion: CSHA Frontal Function
When we analyzed the CSHA, we found no combination associated with DSST scores at the
baseline or subgroup analyses. However, when measuring the change at the first follow-up, the
dyad of cancer + other heart diseases had an association of scores of –1.7 SD in the cohort,
suggesting a potentially clinically important association. Also, the triad of diabetes + arthritis +
other heart diseases and the dyad of hypertension + coronary artery disease might have had an
association. This result is for the whole cohort because the subgroup analysis did not show
combinations with abnormal scores.

5.4.3.3.1.2 CLSA
In the CLSA, analyzing the whole cohort, we noticed that at the baseline, the dyad of other heart
diseases + stroke scored abnormally low with a coefficient of –1.8 SD. Additionally, the dyads of
arthritis + chronic kidney disease with a score of –0.76, arthritis + coronary artery disease with a
score of –0.63, hypertension + stroke with a score of –0.58 and other heart diseases + gastric ulcer
with a score of –0.53, all scored below expectations to be above –0.5 SD.
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Evaluating the change of scores at the first follow-up in all participants, we found that the
combination of Parkinson’s disease + hypertension could produce an abnormal MAT score of –
1.2. Also, they scored below expectations for those participants with the dyad of stroke +
hypertension with a score of –0.72.
Female vs. male
In the subgroup analyses by sex, we found that several dyads and triads scored below the expected
baseline in females. For the dyads, there were arthritis + chronic kidney disease with –0.94; arthritis
+ Parkinson’s disease with –0.85; arthritis + coronary artery disease with –0.84; hypertension +
coronary artery disease with –0.57; and arthritis + gastric ulcer with –0.53. For the triads, there
were hypertension + other heart diseases + gastric ulcer with –0.97; arthritis + other heart diseases
+ gastric ulcer with –0.91; and hypertension + other heart diseases + coronary artery disease with
–0.9.
In contrast, in the male subgroup, we found that combinations with abnormally low scores at the
baseline were for the dyads of other heart diseases + stroke with a coefficient of –1.4 and chronic
kidney disease + gastric ulcer with a score of –1.4. Conversely, for the triads, hypertension +
diabetes + stroke had scores of –1.1. Also, we found that the following combinations scored below
expectations: the dyads of hypertension + coronary artery disease with –0.71; other heart diseases
+ gastric ulcer with –0.52; and the triad of arthritis + depression + cancer with –0.7.
When evaluating the change between the baseline and the first follow-up, we found that females
scored below expectations for the dyad of other heart diseases + thyroid diseases with a score of –
0.67, and the triads of gastric ulcer + epilepsy + depression with a score of –0.86, and gastric ulcer
+ arthritis + multiple sclerosis with score of –0.66. The dyad of Parkinson’s disease + hypertension
in the male subgroup was abnormal for an MAT score, with –1.1 SD. Also, the male subgroup
scored below the expected triad of cancer + diabetes + other heart diseases with a score of –0.67.
Participants 65 years and older vs. younger than 65 years
In the subgroup analysis of participants 65 years and older at the baseline, we found that the triad
of hypertension + epilepsy + diabetes with –1.8 was associated with abnormal scores. Also, we
found that the dyad of chronic kidney disease + arthritis with scores of –1.1, and the triad of gastric
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ulcer + arthritis + thyroid disease with a score of –1.2 was probably abnormal. Also scoring below
expectations were the following dyads: hypertension + stroke, with –0.8; hypertension + epilepsy,
with –0.64; gastric ulcer + arthritis, with –0.63; hypertension + thyroid disease, with –0.57; and
hypertension + coronary artery disease, with –0.53. The following triads also scored lower than
expected: hypertension + coronary artery disease + arthritis, with –0.96 and hypertension + cancer
+ other heart diseases, with –0.51.
When we explored the participants younger than 65 years at the baseline, we found that the dyad
of coronary artery disease + stroke scored an abnormally low score of –1.8. Also, the dyad of
chronic kidney disease + gastric ulcer was abnormally low, with a score of –1.4. Also scoring
below expectations were the dyads of coronary artery disease + diabetes with –0.53 and the triads
of other heart disease + thyroid disease + depression with –0.78 and hypertension + diabetes +
stroke with –0.7.
In the case of the change of MAT scores in participants 65 years and older, we found that the dyad
of stroke + gastric ulcer was abnormally decreasing the scores by –1. Also, it scored below the
expected dyad of arthritis + gastric ulcer with –0.55, and below the triads of stroke + hypertension
+ depression with –0.79 and depression + diabetes + arthritis with –0.62, but higher than depression
+ arthritis + cancer with –0.51. In contrast, in the participants younger than 65 years, we found
only three combinations that scored below expectations, but no combination was probably
abnormal. The combinations were the dyads of Parkinson’s disease + arthritis with a score of –0.8,
other heart diseases + depression with a score of –0.68 and the triad other heart diseases + cancer
+ depression with –0.86.
Conclusion of CLSA frontal function
When analyzing the CLSA cohort as a whole, we found that participants with the dyad of other
heart diseases + stroke scored abnormally low at –1.8 SD, which could be a reflection that this
combination is probably atrial fibrillation and a large stroke234. Nevertheless, during the follow-up,
the combination was not associated with decreasing scores, suggesting that low scores are a
consequence of the initial damage and not a progressive one. That said, we discovered an abnormal
decrease in the score at follow-up with Parkinson’s disease + hypertension. This finding was
interesting because it suggests that the cognitive deterioration of neurodegenerative diseases might
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be accelerated by suffering other chronic diseases. Previous researchers have identified this
hypothesis in a cohort of Parkinson’s disease patients235.
When analyzed by sex, it is noteworthy that we did not identify a combination associated with
abnormal MAT scores at either the baseline or during the first follow-up in the female subgroup.
Some combinations scored below expectations but not under the threshold of 1.0 SD. In contrast,
the male subgroup showed that at the baseline, the identified combination of other heart diseases +
stroke was probably abnormal for the scores in men. Another dyad associated with decreased scores
at the baseline in men was chronic kidney disease + gastric ulcer, and probably the triad of
hypertension + diabetes + stroke was also associated; these are known factors associated
individually with cognitive decline236. When measuring the change of scores during the first
follow-up, we established that the association between Parkinson’s disease + hypertension affected
the men. We want to present one finding of the triads that scored below expectations but not below
1.0 SD; this combination was gastric ulcer + arthritis + multiple sclerosis, and it was present only
in women during the follow-up. This finding could be signalling in the same direction as the
Parkinson’s disease + hypertension finding that chronic neurologic diseases in combination with
other chronic conditions might increase the speed of neurological deterioration and that the
vulnerability to the acceleration might be different in women and men.
In the subgroup analysis of participants 65 years and older, we found that the triad of hypertension
+ diabetes + epilepsy was associated with abnormal MAT scores at the baseline. Also, the
combinations of chronic kidney disease + arthritis and gastric ulcer + arthritis + thyroid disease
might be linked. In younger participants, the association was with the dyad of coronary artery
disease + stroke, and probably the dyad of chronic kidney disease + gastric ulcer was associated as
well. The explanation for the combination with epilepsy might need future evaluation, and the
combination of heart diseases and stroke again might reflect a larger initial stroke with a
cardioembolic origin. When we analyze the follow-up in participants older than 65 years, only the
combination of stroke + gastric ulcer was probably associated with abnormal MAT change scores;
this might be signalling that the physical damage might have bigger consequences in an aging brain
that is also coping with other chronic conditions, possibly resulting in cognitive deterioration237.
We did not detect any relevant combination in participants younger than 65 years; however, this
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lack of association might reflect cognitive reserve in younger participants that might attenuate any
potential finding238.

Comparison of the CSHA and CLSA participants 65 years and older
When comparing both cohorts, we found that in the CSHA, we did not identify a combination
associated with lower frontal function scores at the baseline. In contrast, in the CLSA, we found
that a combination of hypertension + diabetes + epilepsy was associated with lower scores. Two
other combinations that included chronic kidney disease, arthritis, thyroid disease and gastric ulcer
were potentially involved. This result is an interesting finding because it suggests that the effect of
multimorbidity is increasing. It might also be signalling that those participants are surviving
diseases239 and developing more chronic diseases that made them more vulnerable to decreasing
ability in frontal function 4. Also, it is noteworthy that some conditions that usually are not
associated with cognitive decline are emerging in the combination, which is a finding that will need
further research in the future. When comparing the combinations associated with a greater decrease
at the follow-up, it is remarkable that in the CSHA, the combination of cancer + other heart diseases
presented it; however, nowadays, in the CLSA, it is not present. We think this could result from an
improvement in treatment and early cancer detection and treatment, which could ameliorate the
impact of serious diseases, an effect already demonstrated by cancer with other related health
outcomes such as mortality240.
Another notable finding was that we detected combinations with arthritis in both cohorts. In this
analysis, we combined in the arthritis category participants with arthritis with arthrosis, meaning
that the prevalence of this finding is high. Nevertheless, we should evaluate in future research the
potential causal pathways between arthritis and cognitive decline; previous investigations
suggested an association including specific biochemical pathways and the incidence of chronic
vascular disease with chronic inflammation241. An alternative explanation is that arthritis and
cognitive decline can be part of the increasing frailty of older adults242.
One final interesting finding is that in both groups, the dyads and triads associated with lower
frontal scores at the baseline were different from those associated with decreasing score changes
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between the baseline and the first follow-up. The potential implication of this result is that some
combinations of chronic diseases might be associated with lower frontal function levels. Still,
another different (although related) set of chronic conditions could be decreasing the cognitive
trajectories’ evolution. We should address these results using future follow-up waves in the CLSA.

5.4.3.3.2 Animal Naming Test

5.4.3.3.2.1 CSHA
We evaluated the combinations of chronic conditions associated with ANT scores at the baseline.
We did not find any combination with abnormally or probably abnormally low scores. We found
some combinations that scored lower than expected but not under our threshold. We identified the
dyads of cancer + other heart diseases at –0.59, coronary artery disease + hypertension at –0.56
and the triad of depression + arthritis + coronary artery disease at –0.8.
In the case of ANT score change between the baseline and the first follow-up, we did not find any
dyad or triad associated with abnormally decreased ANT scores at the first follow-up. We identified
the following dyads that scored below expectations but above our target of –1.0 SD. The dyads
were as follows : arthritis + depression, with –0.96; coronary artery disease + arthritis, with –0.91;
diabetes + arthritis, with –0.83; hypertension + chronic kidney disease, with –0.81; gastric ulcer +
other heart diseases, with –0.79; gastric ulcer + arthritis, with –0.65; other heart disease + cancer,
with –0.63;

gastric ulcer + depression, with –0.6; hypertension + thyroid disease, with –0.57;

and hypertension + other heart diseases, with –0.5.
Female vs. male
In the female subgroup at the baseline, we did not notice any combination associated with abnormal
scores on ANT. We found one dyad (chronic kidney disease + hypertension, with –0.96) and one
triad (depression + arthritis + other heart diseases, with –0.55) that scored below expectations. In
the male subgroup, we did not find any combination associated with an abnormal performance or
that scored below expectations. In this case, all the combinations were above –0.5 SD, and they
could be considered normal.
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Evaluating the female subgroup, in the analyses of the change in ANT scores at the first follow-up,
we did not discover any association with abnormally low scores. Nevertheless, we found some
combinations that scored below expectations. In the female group were arthritis + depression, with
–0.68; arthritis + coronary artery disease, with –0.64; and the triad of arthritis + hypertension +
other heart diseases, with –0.67. In the male subgroup the dyads were gastric ulcer + other heart
disease, with –0.84; gastric ulcer + arthritis, with –0.67; and arthritis + coronary artery disease,
with –0.6.
Conclusion: CSHA Animal Naming Test
In the CSHA, we did not find a combination of chronic diseases that suggested a strong association
with low scores with ANT during the baseline evaluation or associated with a large decremental
change between the baseline and the first follow-up. We did not find any association when we
evaluated subgroups by sex either.

5.4.3.3.2.2 CLSA
In the analysis of the ANT scores at the baseline, we found that the triad of hypertension + other
heart diseases + multiple sclerosis scored –1.5 on ANT at the baseline, which is abnormal. Also,
the triad of hypertension + cancer + coronary artery disease was probably abnormally associated
with lower ANT scores with a coefficient of –1.4. Other triads scored below expectations:
hypertension + stroke + diabetes, with –0.96; hypertension + chronic kidney disease + diabetes,
with –0.9; hypertension + other heart diseases + diabetes, with –0.82; other heart disease + coronary
artery disease + stroke, with –0.71; hypertension + other heart diseases + gastric ulcer, with –0.71;
hypertension + other heart diseases + stroke, with –0.69; hypertension + other heart diseases +
chronic kidney disease, with –0.66; and hypertension + other heart diseases + thyroid disease, with
–0.5. No dyad was associated with scores lower than –0.5.
Analyzing the ANT z-score change between the baseline and the first follow-up in the CLSA, we
did not discover any association between multimorbidity combinations on abnormal scores.
However, some combinations scored below expectations, and these combinations are the following
dyads: coronary artery disease + gastric ulcer, with –0.91; other heart disease + gastric ulcer, with
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–0.75; and Parkinson’s + hypertension, with –0.63. And for the triads: coronary artery disease +
depression + cancer, with –0.93; depression + epilepsy + thyroid disease, with –0.69; and
depression + epilepsy + arthritis, with –0.51.
Female vs. male
In the female subgroup evaluating ANT scores at the baseline, we found that the dyad of other
heart diseases + cancer with –1.3, and the triads of hypertension + coronary artery disease + thyroid
disease with –1.4 and hypertension + coronary artery disease + gastric ulcer with –1.0 were
probably abnormally associated with lower scores with ANT at the baseline. Other combinations
that scored below expectations were for dyads: hypertension + multiple sclerosis, with –0.97;
arthritis + Parkinson disease, with –0.92; and arthritis + chronic kidney disease, with –0.74. For
triads they were: hypertension + coronary artery disease + arthritis, with –0.92; hypertension +
diabetes + cancer, with –0.86; and hypertension + depression + epilepsy, with –0.86.
In the male subgroup at the baseline, only the dyad of other heart diseases + multiple sclerosis with
a score of –1.5 showed abnormally low scores on ANT. The triad of hypertension + chronic kidney
disease + diabetes with a score of –1.2 was abnormally associated with low ANT scores. Other
combinations scored below expectations for the dyads: diabetes + stroke, with –0.71; and other
heart disease + diabetes, with –0.53. For the triads they were: other heart disease + arthritis + stroke,
with –0.97; other heart disease + cancer + gastric ulcer, with –0.95; other heart disease + cancer +
arthritis, with –0.65; hypertension + diabetes + stroke, with –0.78; and hypertension + chronic
kidney disease + arthritis, with –0.53.
When analyzing the change of ANT scores at the first follow-up in the female subgroup, we did
not find any combination below the value of –1.0. Nevertheless, some dyads scored below the
expected value: gastric ulcer + diabetes, with –0.73; other heart disease + coronary artery disease,
with –0.66; diabetes + epilepsy, with –0.55, with and other heart disease + depression: –0.52. In
the male subgroup, we found one dyad of stroke + epilepsy that scored abnormally low with a
coefficient of –1.5 and one dyad of stroke + cancer with a score of –1.3, which is abnormally low.
Also, we identified some combinations that scored below expectations, which were the dyads of
other heart disease + gastric ulcer, with –0.81 and Parkinson’s disease + hypertension, with –0.75.
In addition, there were the triads of hypertension + cancer + gastric ulcer, with –0.94; hypertension
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+ thyroid disease + depression, with –0.66; other heart disease + hypertension + depression, with
–0.53; and hypertension + depression + gastric ulcer, with –0.51.
Participants 65 years and older vs. younger than 65 years
In the subgroup analysis of participants 65 years and older, we found that both the dyads of
hypertension + multiple sclerosis, and chronic kidney disease + arthritis had a score of –1.1. Also,
the triads of other health disease + gastric ulcer + cancer with a score of –1.3 and those of
hypertension + coronary artery disease + diabetes and other heart diseases + diabetes + chronic
kidney failure with scores of –1.2 were associated with abnormal low scores of ANT at the baseline.
Other combinations that scored below expectations were for dyads: arthritis + Parkinson disease,
with –0.78; hypertension + thyroid disease, with –0.7; hypertension + gastric ulcer, with –0.6;
hypertension + cancer, with –0.57; and hypertension + arthritis, with –0.56. And the lowperforming triads were other heart disease + diabetes + cancer, with –0.98; hypertension + gastric
ulcer + diabetes, with –0.95; arthritis + diabetes + thyroid disease, with –0.89; hypertension +
coronary artery disease + arthritis, with –0.88; hypertension + coronary artery disease + thyroid
disease, with –0.87; other heart disease + depression + cancer, with –0.83; other heart disease +
gastric ulcer + arthritis, with –0.75; other heart disease + coronary artery disease + arthritis, with –
0.69; other heart disease + gastric ulcer + hypertension, with –0.67; other heart disease +
hypertension + arthritis, with –0.64; hypertension + arthritis + gastric ulcer, with –0.63;
hypertension + thyroid disease + cancer, with –0.61; other heart disease + diabetes + hypertension,
with –0.6; hypertension + coronary artery disease + cancer, with –0.59; and hypertension +thyroid
disease + diabetes, with –0.5.
In the subgroup younger than 65 years, we found that the triad of hypertension + multiple sclerosis
+ depression scored –1.2, which is probably an abnormally low score for ANT at the baseline. The
triads that scored below expectations were hypertension + coronary artery disease + chronic kidney
disease: –0.94; hypertension + chronic kidney disease + diabetes: –0.6; hypertension + cancer +
diabetes: –0.57; other heart + coronary artery disease + arthritis: –0.57; and arthritis + cancer +
thyroid disease: –0.51.
In the case of the change of ANT scores between the baseline and the first follow-up in the
participants 65 years and older, we found that the dyad of coronary artery disease + gastric ulcer
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scored abnormally at –1.5 SD, and the dyad of stroke + cancer scored similarly abnormally at –1.3
SD. Other combinations scored below expectations but not below the threshold of 1 SD. In this
case, the dyad was diabetes + gastric ulcer with a score of –0.68, and the triads were other heart
disease + hypertension + depression, with –0.71; arthritis + hypertension + epilepsy, with –0.63;
and arthritis + gastric ulcer + coronary artery disease, with –0.54. In the case of participants
younger than 65 years, any combination score was below the –1.0 threshold, and only one dyad of
other heart diseases + thyroid disease scored below expectations with –0.6. In contrast, only the
triad of diabetes + other heart diseases + depression scored below expectations with –0.52.
Conclusion CLSA Animal Naming Test
In the CLSA, we found that at the baseline, there was an association of two triads with low ANT
scores. Both triads were composed of two cardiovascular diseases, one neurodegenerative disease
or a systemic challenge like cancer. When we evaluated the change in ANT scores at the first
follow-up, we did not notice any combinations associated therewith. This result raises the
possibility that chronic conditions associated with lower scores at an initial evaluation might not
necessarily predict further deterioration in cognition.
When we compare subgroups by sex at the baseline, combinations of cardiometabolic risk factors
are present in both groups, but the combination with cancer was present only in women, while the
combination with multiple sclerosis was present only in men; this greater cognitive decline in
verbal performance in men with multiple sclerosis has been previously proposed243. Future
researchers should evaluate the differential cognitive vulnerability by sex with the dyad
cardiovascular conditions coupled with cancer. However, an alternative explanation is that women
have higher survival than men after cancer244, which might show us a general phenomenon of
cognitive decline in cancer, only evident in the group that survived the neuropsychological
evaluation.
When we evaluated the change of ANT scores at follow-up, only in men did combinations of stroke
with epilepsy or cancer appear to decrease scores. This finding is interesting because the baseline
findings could suggest the future research possibility of men being more vulnerable to increased
cognitive decline after brain damage when coupled with other diseases. This finding could be in
consonance with previous research that suggests that men have less cognitive reserve245.
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When we compared participants 65 years and older with those younger than 65, we found that older
participants had more combinations associated with lower scores, including cardiometabolic
recognized risk factors for cognitive impairment. At the same time, only a triad including
hypertension + multiple sclerosis and depression decreased scores in younger participants. When
we evaluated the change in ANT scores at the first follow-up, we found dyads associated with the
decline only in the older participants. One relevant finding is that individual cardiometabolic
chronic conditions were present in the associations with lower scores at the baseline and a greater
decrease during the follow-up. Still, again, the combinations that scored lower at the baseline were
different from those associated with a greater decline in scores during the first follow-up.

Comparison between CSHA and CLSA participants 65 years and older
When we compared the results of the comparison of the CSHA and CLSA, we noticed that in the
CSHA, there were no combinations associated with lower scores on ANT. Still, in the CLSA, there
are many different combinations associated with lower scores composed of cardiometabolic
conditions coupled with cancer or neurodegenerative diseases. Currently, we know that cancer and
cardiovascular diseases share major risk factors and even pathophysiological mechanisms246. It is
possible that our success in treating cardiovascular diseases and cancer is bringing cognitive
deterioration to light as a challenge that we must face 247,248. Finally, one open question is whether
our finding shows an increased decline in cognitive trajectory among survivors of both cancer and
cardiovascular diseases, which suggests the effect of having had these combinations in the time
beyond the treatment.

5.4.3.3.3 Rey Auditory Verbal Learning Test Immediate recall

5.4.3.3.3.1 CSHA
When we evaluated the RAVLT immediate recall score at the baseline in the CSHA, we did not
find any combination associated with low scores.
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When we evaluated the change in RAVLT immediate recall scores between the baseline and the
first follow-up, we discovered that the combination of stroke + hypertension with a –1.2 score was
probably abnormally low. The following dyads scored below expectations: gastric ulcer +
depression, with –0.76; arthritis + depression, with –0.59; gastric ulcer + arthritis, with –0.58;
stroke + arthritis, with –0.55; and other heart diseases + cancer, with –0.53.
Female vs. male
When we evaluated RAVLT immediate recall scores in stratified analyses by sex, we did not find
any combination associated with low scores at the baseline.
When we evaluated the female subgroup for the change of scores between the baseline and the first
follow-up, we found that the dyad of stroke + hypertension with –1.3 scored abnormally low. Other
dyads that scored below expectations were gastric ulcer + depression, with –0.76; arthritis +
depression, with –0.59; gastric ulcer + arthritis, with –0.58; stroke + arthritis, with –0.55; and other
heart diseases + cancer, with –0.53. In contrast, in the male subgroup analysis, we did not discover
any combination associated with the change of RAVLT immediate recall scores.
Conclusion: CSHA RAVLT immediate recall
When analyzing the RAVLT immediate recall results on the CSHA, we found no combination
associated with the scores at the baseline. Nevertheless, in evaluating the change between the
baseline and the first follow-up, we found that the combination of hypertension + stroke was
probably associated with a meaningful score decrease, and this effect only affected women.

5.4.3.3.3.2 CLSA
In the CLSA cohort, when we analyzed RAVLT immediate recall scores at the baseline, we found
that the dyad of other heart diseases + stroke scored abnormally low with –1.5, while three triads
scored abnormally low: hypertension + other heart diseases + multiple sclerosis, with –1.3;
hypertension + stroke + cancer, with –1.2; and hypertension + depression + epilepsy, with –1.1.
Also, some combinations scored below expectations. The dyads were diabetes + gastric ulcer, with
–0.65 and epilepsy + thyroid disease, with –0.64. The triads were diabetes + depression + chronic
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kidney disease, with –0.85; hypertension + depression + coronary artery disease, with –0.81;
hypertension + diabetes + coronary artery disease, with –0.78; hypertension + diabetes + chronic
kidney disease, with –0.61; and hypertension + other heart diseases + diabetes: –0.57.
In the analysis of RAVLT immediate recall change between the baseline and the first follow-up,
we found that the triad of other heart diseases + epilepsy + arthritis scored –1.5, which is
abnormally low, and the triad of arthritis + coronary artery disease + thyroid disease scored –1.1,
which is abnormally low for that score change. In addition, the combinations of Parkinson’s disease
+ hypertension with –0.73 and stroke + thyroid disease + depression with –0.5 scored below
expectations.
Female vs. male
In the female subgroup analysis of RAVLT immediate recall at the baseline, we found that two
dyads scored abnormally. These dyads were cancer + coronary artery disease with –1.2 and chronic
kidney disease + depression with –1.1. Also, the following combinations scored below
expectations: thyroid disease + epilepsy: –0.71; arthritis + Parkinson’s disease: –0.67; chronic
kidney disease + thyroid disease: –0.58; and hypertension + epilepsy: –0.56.
In the male subgroup at the baseline analysis, we noticed several different combinations that scored
abnormally low. These combinations were as follows: the dyad of other heart disease + stroke, with
–1.0; and the triads of other heart disease + arthritis + thyroid disease: –1.5; hypertension +
depression + multiple sclerosis: –1.4; cancer + depression + arthritis: –1.1; and hypertension +
chronic kidney disease + arthritis: –1.0. Also scoring below expectations were the dyads diabetes
+ gastric ulcer, with –0.77; other heart disease + gastric ulcer, with –0.65; hypertension + coronary
artery disease, with –0.6; hypertension + cancer, with –0.56; and other heart diseases + arthritis: –
0.53. Triads scoring abnormally low were other heart disease + diabetes + coronary artery disease:
–0.87; hypertension + chronic kidney disease + diabetes: –0.69; hypertension + depression +
coronary artery disease: –0.68; and hypertension + other heart diseases + diabetes: –0.6.
In the analysis of RAVLT immediate recall score change between the baseline and the first followup analyses by sex, we did not notice any combination that scored abnormally low. We noticed in
the female subgroup that some combinations that scored below expectations were the dyads: other
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heart disease + epilepsy, with –0.62 and other heart diseases + stroke: –0.61. Low-performing triads
were arthritis + coronary artery disease + cancer, with –0.99, and arthritis + thyroid disease +
stroke, with –0.7. Also, in the male subgroup, we discovered the following combinations that
scored below expectations: Parkinson’s disease + hypertension, with –0.6 and arthritis + depression
+ diabetes, with –0.51.
Participants 65 years and older vs. younger than 65 years
When we analyzed the participants 65 years and older at baseline, we discovered that the
combination of thyroid disease + stroke scored abnormally low with –1.5. Also, other combinations
scoring abnormally low were the dyads coronary artery disease + depression: –1.2; cancer +
chronic kidney disease, with –1.2; and thyroid disease + chronic kidney disease: –1.1. Also with
abnormally scores were the triads diabetes + depression + cancer: –1.3; arthritis + stroke + cancer:
–1.3; and thyroid disease + other heart diseases + coronary artery disease: –1.1. Finally, other
combinations scored below expectations as well, such as the dyads: diabetes + coronary artery
disease, with –0.94; arthritis + chronic kidney disease, with –0.9; other heart disease + depression,
with –0.84; other heart disease + gastric ulcer, with –0.8; arthritis + stroke, with –0.66; and diabetes
+ hypertension, with –0.64. Low-performing triads were other heart disease + stroke + coronary
artery disease, with –0.86; thyroid disease + stroke + arthritis, with –0.84; diabetes + hypertension
+ other heart diseases: –0.81; diabetes + arthritis + other heart diseases, with –0.74; diabetes +
chronic kidney disease + other heart condition, with –0.61; cancer + depression + hypertension,
with –0.61; diabetes + hypertension + gastric ulcer, with –0.51; and diabetes + arthritis + thyroid
disease, with –0.51.
In the subgroup of participants younger than 65 years, we did not discover any combinations that
scored abnormally low. Nevertheless, some combinations scored below expectations: chronic
kidney disease + depression, with –0.85; hypertension + multiple sclerosis, with –0.74;
hypertension + depression + epilepsy, with –0.63; and hypertension + chronic kidney disease +
diabetes, with –0.62.
When we analyzed participants 65 years and older for the change of RAVLT immediate recall
scores between the baseline and the first follow-up, we found that the dyad other heart diseases +
epilepsy with –1.4 and the triads other heart diseases + stroke + depression with –1.2 and other
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heart diseases + cancer + thyroid disease with –1.1 had abnormally low scores. Also, the
combinations of depression + stroke with –0.67 and coronary artery disease + cancer +
hypertension with –0.88 scored below expectations. In the case of participants younger than 65
years, we did not notice any combination with abnormally low scores. Only the dyad of stroke +
hypertension, at –0.58, scored below expectations.
Conclusion CLSA RAVLT immediate recall
When analyzing the results in the CLSA cohort of the RAVLT immediate recall, we noticed that
some combinations were associated with abnormal scores. These combinations were mainly
combinations of stroke, heart diseases, hypertension, multiple sclerosis, cancer and thyroid disease.
When comparing the RAVLT immediate recall scores by sex at the baseline, in women, low scores
appear to be related to cardiometabolic conditions plus other systemic conditions. In contrast, men
seemed more vulnerable to cardiometabolic and primary brain conditions. When analyzing scores
at the baseline by age group, we noticed that all identified associations were in participants 65 years
and older. At the same time, the younger patients did not display any effects on their RAVLT
immediate recall scores from multimorbidity combinations.
When we explored the change in RAVLT scores between the baseline and the first follow-up, we
discovered that the combination of heart disease + arthritis + other conditions was associated with
a lower score. This result from arthritis is noteworthy because, as we referenced in the frontal
function summary section, it is a popular research topic. After all, emerging evidence suggests this
is a real problem stemming from arthritis241. The other notable finding was that multiple
combinations of multimorbidity in the older population resulted in lower scores for RAVLT
immediate recall change. In comparison, there did not seem to be a combination in the younger
population that could be associated with cognitive reserve. In the case of RAVLT immediate recall,
some diseases appeared in combinations present in the associations at the baseline and the change
between the baseline and the first follow-up. Nevertheless, the specific combinations we identified
were different in both scenarios.

Comparison of CSHA and CLSA participants 65 years and older
424
December 13, 2022

As in the previous analysis, in the CSHA, we did not identify combinations at the baseline, while
in the CLSA, we identified several. Nevertheless, we found that only one dyad encompassing
hypertension and stroke appeared in the CSHA after five years of follow-up during the evaluation
of change at the time of follow-up. In contrast, in the CLSA, with three years of follow-up, several
combinations deteriorated performance, but interestingly, strokes and cardiometabolic issues
persisted as in the CSHA. These findings could indicate that new combinations of multimorbidity
appear for the immediate recall decrease but do not replace the old ones. We have a bigger pool of
combinations that could alter cognitive performance for immediate recall.

5.4.3.3.4 Rey Auditory Verbal Learning Test Delayed recall

5.4.3.3.4.1 CSHA
We did not identify combinations associated with decreased scores when analyzing the CSHA
cohort for the RAVLT delayed recall scores. In the analysis of RAVLT delayed recall score change
between the baseline and follow-up, we found that the dyads thyroid disease + coronary artery
disease, with –1.2, and thyroid disease + gastric ulcer, with –1.1 scored abnormally low. Also, the
dyad depression + diabetes, with –0.87, scored lower than expected.

Female vs. male
As in the whole cohort analysis, we did not notice combinations associated with decreased
RAVLT-delayed recall scores in the female or male subgroups. In the analysis by sex of the change
in scores between the baseline and the first follow-up, we found that in females the dyads coronary
artery disease + thyroid disease, with –1.2, and hypertension + thyroid disease, with –1.0, scored
abnormally low. In the case of males, we did not discover any combination of interests.
Conclusion: CSHA RAVLT delayed recall
When we examined RAVLT-delayed recall scores in the CSHA cohort, we found no combinations
changing with the scores at the baseline. Nevertheless, when we evaluated the decreasing change
between the baseline and the first follow-up, we found that thyroid disease in combination with
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coronary artery disease or gastric ulcer scored abnormally low. Moreover, this effect of decreasing
score changes was only affecting women. This finding merits further research because both
combinations are unusual in association with cognitive decline.

5.4.3.3.4.2 CLSA
In the CLSA analysis of RAVLT-delayed recall scores at the baseline, we found that the dyad other
heart diseases + stroke, with –1.5, scored abnormally low. Other combinations scored below
expectations, but not under the threshold of 1.0. There was one low-performing dyad, diabetes +
gastric ulcer, with –0.56, along with the triads other heart diseases + coronary artery disease +
gastric ulcer, with –0.91; hypertension + chronic kidney disease + diabetes, with –0.87; arthritis +
chronic kidney disease + depression, with –0.67; hypertension + other heart diseases + diabetes,
with –0.6; hypertension + other heart diseases + depression, with –0.58; hypertension + other heart
diseases + cancer, with –0.53; and other heart diseases + depression + diabetes, with –0.51.
When we evaluated the change in score between the baseline and the first follow-up, we did not
find combinations abnormally low in their scores. We identified two combinations that scored
below expectations, which were the dyad other heart disease + arthritis, with –0.71, and the triad
hypertension + cancer + epilepsy, with –0.83.
Female vs. male
In the analysis by sex at baseline, we found that in women, only the dyad coronary artery disease
+ diabetes, with –1.1, was probably associated with abnormally low scores of RAVLT-delayed
recall at the baseline. In females, the triad arthritis + chronic kidney disease + depression, with a
coefficient of –0.85, scored below expectations. In males, the triads hypertension + cancer + stroke,
with –1.2, and other heart diseases + gastric ulcer + coronary artery disease, also with –1.2, were
associated with abnormally low scores at the baseline.
In the case of males, we did not find any combination that scored abnormally low; the following
combinations scored below expectations. For the dyads there were hypertension + chronic kidney
disease, with –0.99; other heart disease + thyroid disease, with –0.85; diabetes + gastric ulcer, with
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–0.7; hypertension + epilepsy, with –0.61; hypertension + coronary artery disease, with –0.6; and
other heart disease + cancer, with –0.52. For the triads there were: hypertension + depression +
multiple sclerosis, with –0.85; other heart disease + gastric ulcer + cancer, with –0.81; hypertension
+ arthritis + cancer, with –0.76; hypertension + other heart diseases + diabetes, with –0.76; diabetes
+ thyroid disease, with –0.71; other heart disease + diabetes + coronary artery disease, with –0.61;
hypertension + cancer + diabetes, with –0.55; hypertension + other heart diseases + cancer, with –
0.52; and hypertension + arthritis + chronic kidney disease, with –0.5.
In the analysis by sex, we did not find combinations that scored abnormally low in the change of
RAVLT-delayed recall scores between the baseline and the first follow-up. In females, the triad of
hypertension + gastric ulcer + chronic kidney disease with –0.57 scored below expectations. In
males low-scoring combinations included the dyad epilepsy + hypertension with –0.6 and the triads
of other heart disease + depression + chronic kidney disease with –0.93 and depression + diabetes
+ arthritis with –0.51.
Participants 65 years and older vs. younger than 65 years
In the participants older than 65 years, the triad of thyroid disease + other heart diseases + stroke,
with –1.5, scored abnormally low in the RAVLT-delayed recall at the baseline. Also, the dyads of
other heart diseases + Parkinson’s disease with –1.3, and other heart diseases + chronic kidney
disease, and the triads of diabetes + arthritis + chronic kidney disease with –1.1, and diabetes +
depression + gastric ulcer with –1.0 scored abnormally low. The following combinations scored
below expectations. For the dyads: other heart disease + gastric ulcer, with –0.99; arthritis +
epilepsy, with –0.82; thyroid disease + other heart diseases, with –0.75; diabetes + coronary artery
disease, with –0.6; diabetes + hypertension, with –0.59; diabetes + cancer, with –0.58; arthritis +
chronic kidney disease, with –0.57; and other heart disease + depression, with –0.56. Lowperforming triads included other heart disease + depression + hypertension, with –0.98; arthritis +
stroke + cancer, with –0.97; diabetes + coronary artery disease + hypertension, with –0.88; thyroid
disease + other heart diseases + cancer, with –0.8, diabetes + hypertension + other heart diseases,
with –0.76; diabetes + arthritis + other heart diseases, with –0.54; diabetes + depression +
hypertension, with –0.52; diabetes + depression + other heart diseases, with –0.52; other heart
disease + arthritis + coronary artery disease, with –0.51, and arthritis + cancer + gastric ulcer, with
–0.5.
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In contrast, in participants younger than 65 years, only the triad of hypertension + chronic kidney
disease + diabetes with –1.1 scored abnormally low on RAVLT-delayed recall. In this case, the
combinations that scored below expectations were the dyad coronary artery disease + gastric ulcer,
with –0.75, and the triads of hypertension + other heart diseases + thyroid disease with –0.79,
hypertension + other heart diseases + gastric ulcer with –0.55, and diabetes + depression + other
heart diseases with –0.5.
In the analysis by age group evaluating the score change at the first follow-up, in the participants
65 years and older, the combination of gastric ulcer + epilepsy with –1.0 scored abnormally low.
Further, it scored lower than the dyad hypertension + coronary artery disease, with –0.56, and the
triads gastric ulcer + diabetes + arthritis, with –0.85, and other heart diseases + depression + thyroid
disease, with 0.78. In the group of participants younger than 65, we did not find combinations that
scored abnormally low, nor did we find combinations that scored below expectations.
Conclusion of CLSA RAVLT delayed recall
When we analyzed the RAVLT-delayed recall in the CLSA, we found that the dyad other heart
diseases + stroke at the baseline resulted in lower scores. As previously proposed, this might
indicate memory impairment following a large stroke, probably cardioembolic. However, we could
not discover any combination when we evaluated the score change at the first follow-up. When we
compared females with males, we found that only women’s scores appeared to be affected by the
combination of diabetes and coronary artery disease in their baseline scores. We did not identify
any combination associated with score change at the first follow-up or during the whole cohort
analysis.
Finally, when we evaluated the differences by age group, we found that lower scores at the baseline
were associated with a combination that includes thyroid disease, heart disease and stroke, which
is similar to the whole cohort; nevertheless, other potential combinations in this group included,
besides the previously named Parkinson’s disease, chronic kidney disease, diabetes, depression and
arthritis. However, on observing the score change at the follow-up, any previously identified
combinations appeared to decrease it. The only combination at this follow-up was gastric ulcer +
epilepsy, which was an unexpected one. Conversely, in the participants younger than 65 years, only
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the triad hypertension + diabetes + chronic kidney disease decreased baseline scores. This
combination was expected and supported by evidence in the literature249.

Comparison of the CSHA and CLSA participants 65 years and older
In this case, the results in the CSHA and CLSA are less comparable to the four neuropsychological
tests. This challenge to comparability was ascribed to the practice effect. In the CSHA, participants
practiced five times remembering a list of 15 words before they went to other cognitive tests and
were asked for the delayed recall test some minutes later. In contrast, in the CLSA, the participants
only practiced once before going to another test and getting the delayed recall some minutes later.
This practice effect modified the performance in the retest, reducing the variability. However, there
is still uncertainty on how much these different settings affected the overall performance and the
potential effect on the cognitive score250.
When we compared the two cohort scores at the baseline in the CSHA, we did not identify relevant
combinations. In contrast, in the CLSA, we identified combinations at the baseline that decreased
the RAVLT-delayed recall scores. We hypothesized that this lack of combinations could be owing
to the increased practice effect in the CSHA that diminished the probability of getting extreme
scores by training the patients.
In the case of the CLSA, two conditions present in the main analysis and sub-analyses were other
heart diseases and stroke, leading us to conclude that we were detecting with this combination in
some participants who had survived a cardioembolic stroke, which is known to produce greater
cognitive decline than other types of stroke251.
Finally, during the evaluation of score change at the first follow-up, only a few potential
associations in the CSHA that included thyroid disease and heart disease or gastric ulcer were
detected. Nevertheless, our analysis could not replicate this finding in the CLSA, and we ought to
investigate it in the future. Again, as in the previous test, the combinations associated with lower
scores at the baseline were different from the combinations that presented the greater reduction in
scores between the baseline and the first follow-up.
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5.4.3.3.5 Dementia diagnosis at the first follow-up in the CSHA
We found that in the whole cohort of the CSHA (incidence 0.12), the dyads coronary artery disease
+ thyroid disease, arthritis + coronary artery disease and stroke + arthritis had an incidence of
dementia more than four times the group mean. The dyads coronary artery disease + gastric ulcer,
depression + other heart disease and arthritis + gastric ulcer had an incidence of dementia between
two and four times the whole group’s prevalence. We found that the other dyads with increased
incidence had an increase less than two times the group mean incidence. Also, we noticed only one
triad associated with greater prevalence; nevertheless, we found that this prevalence increase was
less than two times the group prevalence.
Female vs. male
In the analysis by sex, we found that the female group presented more dyads with increased
dementia incidence. In women, the dyad of coronary artery disease + thyroid disease had an
incidence more than four times the incidence of the group mean, and the dyads coronary artery
disease + chronic kidney disease and stroke + hypertension had an incidence of dementia between
two and four times the group’s mean. All other combinations with increased incidence dementia
had an increase of less than two times the group mean. Comparing this group with the male group,
we found that only the dyad arthritis + gastric ulcer had an incidence increased two to three times
the incidence of the whole group, while the other two combinations had an incidence increase less
than two times the male incidence.
Conclusion of combinations associated with dementia diagnosis at first follow-up in the
CSHA
We found that in the complete group and in the subgroups, the chronic condition combinations
with greater dementia incidence at the first follow-up included arthritis, coronary artery disease,
gastric ulcer and stroke. Also, when comparing the female with the male group, we noticed that in
the female group there were more combinations with increased prevalence, and this increase was
greater than in the male group.
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5.4.3.3.6 CIND Incident diagnosis at the first follow-up in the CSHA
We found that in the participants with normal cognition at the baseline in the CSHA incidence of
CIND was 0.30. The participants with the dyad thyroid disease + hypertension had twice as high
the incidence of CIND than the rest of the group Also, the participants with the triads depression +
arthritis + gastric ulcer and diabetes + arthritis + other heart disease had CIND 1.5 times the group
mean. All other frequencies of incidence were lower in the group. Also, the number of
combinations with increased incidence of CIND was lower than the number of combinations with
increased incidence of dementia.
Female vs. male
In the analysis by sex, we found that the female group presented more dyads with increased CIND
incidence. In women, the dyad of coronary artery disease + hypertension had an incidence of 0.66,
more than twice as high that of the whole group. Also, participants with the dyad thyroid disease
+ hypertension had an incidence more than 1.5 times that of CIND. All other combinations had
incidences lower than the 1.5 threshold. In males, all combinations increased the incidence by less
than 1.5 times.
Conclusion of combinations associated with CIND diagnosis at first follow-up in the CSHA
We found that participants with normal cognition at the baseline presented few combinations of
chronic conditions associated with CIND diagnosis at the first follow-up. As in the dementia
analysis, female participants showed more combinations with a higher incidence of cognitive
decline. Finally, the combinations associated with cognitive decline were scarcer in patients with
CIND than in those with dementia.

5.4.3.4 Comparison of regression analysis using high prevalence combinations of
multimorbidity with CART analysis.
When we compared the results of the two methods, some differences became evident. First, the
regression model using combinations selected with the “multimorbidity tool” restricted the analysis
to combinations with a higher prevalence. This result was a major setback because CART analysis
presented us with some combinations of dyads and triads with decreases in the scores of more than
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1.5 SD but with prevalence lower than the arbitrary threshold of 1%. Also, the regression analyses
presented us with statistically significant associations that might not be of clinical importance
owing to their small change in coefficients. That said, CART could signal some combinations with
a large decrease in the scores, but because of its nature and the small number of participants per
group, the coefficients could be vulnerable to extreme values. Additionally, CART results might
be vulnerable to overfitting.
Consequently, we concluded that both methods provided us with different information about the
nature of chronic disease combinations and cognitive scores. First, both select different
combinations for evaluation, rendering the challenge of decreased comparability. Second, the
objective of both methods was different. In the regression analyses, we evaluated the effect on
scores of the selected combination by evaluating meaningful interactions; this method should be
helpful when testing evidence in theoretical models and controlling for confounders. Conversely,
the CART model evaluates all the potential combinations informing us of the specific group means.
However, owing to its exploratory nature, it could enable us to broaden our view. Still, it will only
provide the hypothesis to evaluate for potential causal associations. This result reminds us that the
two methods offer us different information and answers.

5.4.4 Summary of findings on second secondary objective
Our exploration of the known risk factor for cognitive decline did not show a reliable category
within these risk factors that might enhance scores’ performance in patients with multimorbidity.
We obtained statistically significant variables with a coefficient above zero in only two regression
models. These results were present in the RAVLT immediate recall scores on the CSHA when
having a history of traumatic brain injury caused a score increase of 0.37 (CI 95%: 0.002–0.73)
that we thought might be spurious for multiple testing, and in RAVLT-delayed recall on the CLSA
when we found that scores increased for participants who ingested alcohol at least once weekly,
with a score of 0.0514 (CI 95%: 0.0097–0.093), which was statistically significant. Still, its clinical
relevance is unclear owing to the small magnitude of the coefficient and the conflicting data about
the effect of alcohol consumption on cognitive decline252.
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However, in the CSHA risk of progression to dementia, we found that regular engagement in
physical activity decreases the risk of dementia almost by half with an OR of 0.45 (CI 95%: 0.20–
0.98), which might be a meaningful decrease that could be tested in other cohorts. In the mild
cognitive impairment (CIND in the CSHA) outcome, we did not find any meaningful factor that
protected individuals with normal cognition at the baseline.
In conclusion, we found that physical exercise decreased the risk of progressing to dementia in the
CSHA. However, we cannot compare it with the CLSA because it does not have an algorithm to
identify dementia yet. Conversely, we did not identify any potential protective factor for the
enhancement of neuropsychological test scores in multimorbidity patients.

5.5 Answer to the proposed objective and research questions
5.5.1 Primary research objective
For the first question, the prevalence of known risk factors has changed between cohorts. First, the
education level has increased during the past three decades. In the CSHA, up to 57% of participants
had less than secondary school graduation, while in the CLSA, only 4.6% were in this category.
Consequently, the proportion of postsecondary degrees has increased from 8.7% in the CSHA to
79% in the CLSA. Also, alcohol consumption at least once a week was almost twice as high from
30–60%. Another finding is that lifelong traumatic brain injury has increased from 15–25%.
Regarding histories of smoking and physical activity, both cohorts did not have large variations,
with around half of the participants engaged in these activities. Another difference between both
cohorts was that the CSHA had a higher mean of chronic conditions, which we could explain by
considering that the CLSA included participants from 45–85 years old, while the CSHA included
participants older than 65 years.
For the second research question, we could not estimate the incidence of cognitive decline in the
CLSA. Consequently, we could not say if there has been a change in the incidence between cohorts.
However, in the CSHA, multimorbidity was not associated with dementia or mild cognitive
impairment.
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For the third and fourth questions, we found that the adjusted association of multimorbidity with
cognitive score outcomes changed depending on each outcome. We did not find an association of
multimorbidity with frontal function in the CSHA. In contrast, in the CLSA, we found a small
association with lower MAT scores in participants with multimorbidity, although the scores could
have been of no clinical importance. In the case of ANT, we did not find associations with
multimorbidity. In the case of RAVLT immediate recall, we noticed only a small association in the
female subgroup in the CLSA with lower scores in participants with multimorbidity. Finally, in the
RAVLT-delayed recall, participants with multimorbidity had lower scores in the CLSA while we
did not notice similar results in the CSHA; nevertheless, in both studies, the participants applied
and interpreted the test differently, meaning comparisons would be less reliable.
In summary, we can conclude that the prevalence of some known risk factors for cognitive
impairment has changed during the past three decades. Noticeably, education level and alcohol
consumption have increased. In the case of cognitive scores, in the CSHA, we could not find an
association of multimorbidity with cognitive scores. In contrast, in the current CLSA, we found a
small association with different cognitive scores. These results could result from a larger sample
size in the CLSA or a true association that we have unmasked.

5.5.2 Secondary Research Objective One
For the first question, we found that in the CSHA, most combinations included arthritis (which
included arthrosis), while in the CLSA, many combinations included arthritis but with more
combinations variety. Also there were prevalent combinations with cardiovascular conditions like
hypertension and diabetes, and combinations including depression, thyroid diseases and cancer.
This result was remarkable because the combinations of dyads and triads in both cohorts appeared
similar.
For the second guiding question, we found that regression methods using prevalent combinations
and the CART method identified different potential combinations of chronic diseases associated
with cognitive decline measured as cognitive scores decreased. Regression analysis identified a
few combinations potentially associated with lower cognitive scores. In comparison, the CART
analysis identified multiple combinations associated with lower scores, and the magnitude of the
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association was bigger in CART. The multimorbidity combinations identified were different for
the four cognitive tests, dementia diagnosis and CIND without a universal combination of higher
risk.
In the case of subgroup analyses by sex, we found that the combinations associated with lower
scores at the baseline and greater decrease at the first follow-up in cognitive test scores were
different in women and men. Another finding was that females were more commonly affected with
lower scores in the presence of multimorbidity in both cohorts. Also, they showed a higher
frequency of dementia or CIND diagnosis at the follow-up in the CSHA.
Finally, when comparing older adults with mid-life adults in the CLSA, we found that, more
commonly, older participants had lower scores associated with multimorbidity, and the
combinations identified with lower scores were more diverse in older adults. When we compare
the CSHA and the CLSA in older adults, we found that the number combinations and decrease in
the z-scores were more common in the current CLSA.

5.5.3 Secondary Research Objective Two
For secondary research objective two, we found that, regarding test scores, there were only
associations with a z-score increase of less than 0.5 SD, which might be of no or minimal clinical
significance. However, in the CSHA, we found that regular physical exercise decreased the risk of
developing dementia with an OR of 0.45, which was meaningful. Unfortunately, we did not have
information regarding dementia or mild cognitive impairment incidence in the CLSA, for reasons
previously exposed. Also, we did not find any other clinically meaningful results concerning
dementia when we analyzed subgroups by sex. In the case of mild cognitive impairment, called
CIND in the CSHA, we did not find any protective factors.
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Discussion

6.1 Summary of key point from the results
6.1.1 Key findings of the systematic review on the association between multimorbidity
and cognitive decline
We found 19 publications, mainly from high-income countries. We discovered that authors used
different approaches to measure multimorbidity, ranging from counts to indexes. Also, we noticed
that the definition and measurement of cognitive decline were highly variable. These two reasons
precluded us from performing a meta-analysis. Nevertheless, we observed that multimorbidity in
most studies was associated with lower cognitive scores in cross-sectional studies and greater
cognitive decline in longitudinal studies.

6.1.2 Association of multimorbidity with cognitive scores
In the frontal function analysis, we found a small association of multimorbidity with lower frontal
function scores at the baseline only in the CLSA. Likewise, in the RAVLT immediate recall, we
found a slight decrease in scores at the baseline in patients with multimorbidity in the CLSA. In
contrast, in the RAVL-delayed recall and in the ANT, we did not find an association of
multimorbidity with cognitive scores at the baseline or change at the first follow-up.
There is no consensus around using multimorbidity as a dichotomic variable, defined as two or
more chronic conditions, or as conditions count. For the principal objective analysis, we performed
models evaluating both definitions of multimorbidity. When we used the cAIC to compare
dichotomic and conditions counting models, we did not find that one approximation was
consistently better. Only in three analyses did one approximation offer a much better fit. For the
counting approximation was the RAVLT delayed recall at baseline on CLSA analysis and dementia
onset by first follow-up in the CSHA. In contrast, the dichotomic multimorbidity was a much better
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fit than the counting on the CIND by the first follow-up on the CSHA. In conclusion, there is no
evidence in our study to support the preferred use of one approximation over the other

6.1.3 Exploration of multimorbidity dyads’ and triads’ association with cognitive scores.
The regression analyses accounting for dyads and triads with a prevalence of at least 1% revealed
few combinations with a statistical association with cognitive scores with a decrease of at least 1
SD. By contrast, the CART analyses identified more potential dyads and triads associated with
decreased cognitive scores. Nevertheless, both approaches identified different combinations.
Also, the dyad and triad combinations associated with lower scores at the baseline were different
than those potentially associated with a decrease in the scores at the first follow-up. When we
evaluated subgroups, we found that the combinations associated with lower scores sometimes
differed by sex or age group. Due to the exploratory nature of our research, we cannot conclude if
the nature of the effect of the combinations identified is of a simple additive nature of the individual
effect of conditions in the multimorbidity combinations or if it is, on the contrary, a synergistic
effect between the detected conditions. Also, because we did not have access to the medication use
information, we could not analyze the potential effect of treatments of multimorbidity
combinations on cognitive decline.

6.1.4 Analysis of protective factors for cognitive scores decline at first follow-up.
We determined that regular physical activity almost halved the risk of dementia diagnosis by the
first follow-up in the CSHA, but we could not compare it with the CLSA. However, we did not
identify clinically meaningful protective factors for cognitive score decline at the first follow-up in
multimorbidity patients.
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6.2 Strengths and limitations
6.2.1 Strengths of research
There are several strengths to our research. First, we evaluated with the same methods the
association of multimorbidity with neuropsychological cognitive scores in two cohorts from the
same population separated by three decades. This unique evaluation allowed us to ponder potential
changes in the effect of multimorbidity on cognition. This approximation is vital because the past
three decades have seen the greatest increase in the quality and availability of health care for
chronic conditions. Our method and results offer a way to evaluate these outcomes.
Second, our methodology allows us to compare the distribution at the baseline of cognitive scores
in the same population while evaluating the trend of the cognitive scores at the first follow-up in
both cohorts. Analyzing both aspects allows us to understand more clearly the process of evaluation
of cognition and the effects of different combinations of chronic diseases on it.
Third, we applied different analysis techniques to obtain complementary information on outcomes
that would allow us to understand better the global multimorbidity phenomena and the specific
combinations of chronic diseases that compose them. This approach allowed us to explore
multimorbidity combinations, which should soon expand the approach to multimorbidity research.

6.2.2 Limitations of research
We acknowledge several limitations in our study. First, the databases in this research had
differences in inclusion criteria, sample size, data acquirement and results processing, making it
more difficult for data analysis. These differences diminish our certainty in the interpretation of
results when comparing the two data sets, hence any conclusions should be evaluated in other
cohorts as well. Also, our analyses were exploratory, meaning we did not correct for the random
error associated with multiple testing. We think that future analyzers of causality association should
further evaluate our findings and validate our results.
On the one hand, the chronic diseases reported in both databases were similar. The CSHA was
oriented principally toward dementia and neurological diseases, while the CLSA was a general
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study of ageing, including a significant cognitive evaluation. Consequently, in the CSHA, we did
not have information on all the chronic diseases proposed by the standardized list of the PatientCentered Innovations for Persons with Multimorbidity. We managed this challenge using all the
chronic conditions with information in both data sets, which provided us with information on 14
relevant chronic conditions, emphasizing neurological diseases. This was an important
achievement because we were able to compare information from the past three decades with a
respectable number of chronic conditions; nevertheless, this list of multimorbidity scenarios would
hamper comparison with other studies using different lists. Future researchers may address this
challenge using only standardized lists for the comparisons. Also, because we focused our analysis
on the baseline multimorbidity, we could not account for the effect of its progression and
accumulation through time.
Also, the apparent increased association of multimorbidity with cognitive decline in the CLSA may
be magnified by detection bias. Currently, diagnostic accuracy has increased in almost all chronic
conditions, which raises the possibility that the lack of diagnosis in CSHA is due to the
underdiagnosis of multimorbidity in the CSHA. Finally, the CLSA included a highly educated
population compared with the general Canadian population according to the 2016 Census; this
education-related characteristic might constitute a selection bias because educated participants tend
to participate more actively in research and have fewer diseases and access to better treatments230.
The impact of this bias should be addressed in future research. Additionally, because of the
observational nature of the longitudinal studies included in the present research and the evolving
nature of knowledge of dementia, it is possible that underrecognized factors that were not evaluated
in at least one of the two cohorts can explain additional confounding unaccounted for in our results.
This is relevant to remember when interpreting the results because both cohorts were evaluated
three decades apart and in the most recent CLSA is an overrepresentation of educated Canadians.

Second, the time in years to the first follow-up in both studies differed. The CSHA was five years,
while the CLSA was every three years. We do not have information on the second CLSA followup, which could have helped us diminish this challenge. Consequently, we could not account for
the effect of time in our analysis. Future researchers tackling similar research questions and using
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the information in further CLSA waves or other data sets with standard follow-up time could
provide information on the effect of time on the outcomes.
Third, the thresholds to diagnose multimorbidity included conditions that have changed in the past
three decades. Also, the diagnostic tests have improved their accuracy, increasing diagnostic
precision. It induced a potential level of information and selection bias when comparing the two
cohorts. Moreover, in the CSHA, many participants did not receive the first follow-up
neuropsychological assessment, which increases the risk of information bias. Furthermore, our
multimorbidity construct did not have information on the onset, duration or treatment of any
chronic condition. This lack of information includes known conditions that affect cognitive
performance, like stroke, multiple sclerosis or Parkinson's disease, or conditions that can be a
prodrome of cognitive decline like depression. Future research should address if psychiatric or
neurological disease severity, duration and treatment affect the interaction of multimorbidity on
cognitive decline.
Fourth, both source cohorts recruited mainly Caucasian individuals owing to the exclusion criteria
of participants unable to respond in good English or French. As a result, we cannot explore the
research question in immigrants, minorities or Indigenous peoples . It might increase disparities in
health information and targeted health research regarding the multimorbidity effect on cognition.
Fifth, we could not obtain information on mild cognitive impairment or dementia diagnosis in the
CLSA follow-up. The CLSA study is working on an algorithm to detect and evaluate these two
important outcomes, but this information was unavailable when we performed this analysis. We
explored different alternatives to overcome this lack of information, but we could not infer the
diagnosis of dementia. The first challenge we faced was that the diagnosis of dementia requires
“the determination of whether or not there is significant interference in the ability to function at
work or in usual daily activities” —this is the central criterion in the diagnosis, and it has to be
obtained through clinical evaluation. In this sense, it will need the CLSA team to obtain it. The
second challenge we faced was that some of the neuropsychological tests we selected in the CLSA,
the MAT and the RAVL were administered in a way no other research had done before 253. As a
result, we do not have previous population norms for the test scores, and we cannot select an a
priori cut-off point for the results, meaning that we lack the information to identify abnormally low
scores in a given age group and population. Consequently, we could not obtain reliable dementia
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or MCI diagnosis in the CLSA cohort, precluding any comparison with the CSHA. Future
researchers will have to address the potential effects of different combinations of multimorbidity
on the clinical outcomes of mild cognitive impairment and dementia.
Finally, the machine learning algorithms are likely to produce different results and classifications
with minor changes in the model parameters. For this reason, our exploratory results would need
further confirmation in subsequent research.

6.3 Implications
6.3.1 Clinical and public policy implications
Our analyses were exploratory. We performed several comparison to investigate if the effect of
multimorbidity differed between the two longitudinal studies three decades apart. Also, we
explored if the combinations have changed in during this time. Consequently, our study should not
modify the clinical practice until our results are replicated in the future and we perform hypothesis
testing designs based on our current results.
From a public health perspective, our result highly the importance of continuous investigation on
the multimorbidity effect on cognitive decline and the potential for a differential impact
accordingly to multimorbidity combinations. However, our investigation is a first exploratory step
and should not modify public health interventions at the present moment.
Our systematic review synthesizes the current information on the effect of multimorbidity on
cognitive decline. This systematic review result will help to highlight the necessity of cognitive
evaluation in people with multimorbidity.

6.3.2 Research implications
Future researchers will have to address how to compare multimorbidity’s association with
cognitive decline across different time periods. Moreover, future research will require the
validation of weighted indexes for multimorbidity in the temporal framework of the target
investigation.
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In addition, the effects of different combinations of chronic conditions on baseline evaluations and
on follow-up studies will need future confirmation alongside the important outcomes of mild
cognitive impairment and dementia onset.
The combinations of chronic conditions identified through CART should be further evaluated in
cohorts specific to some groups of combinations to assess the incremental risk of these
combinations. Moreover, future researchers will have to evaluate the factors associated with
cognitive protection in multimorbidity patients.
The conclusions and hypotheses generated by this thesis should be tested in the CLSA 6-year
follow-up and other data sets, adding further strength to the proposed associations of
multimorbidity with cognitive decline.

6.3.3 Future Directions
Overall, our results show that around half of the participants in the cohorts are living with
multimorbidity. Furthermore, when these participants were evaluated on their cognitive
performance, the factors associated with lower baseline scores were different from those associated
with greater decline. Individual evaluation of each of these profiles will allow us to understand its
evolution better. Also, in the future, we should evaluate the interaction between the baseline
combinations for lower cognitive scores and the combinations associated with a greater decrease
in cognitive scores using the 6-year and 9-year follow-up information in the CLSA. That said, using
the CLSA data set, we should evaluate the results that we found with the standardized list of 20
conditions that we planned initially to evaluate.
Furthermore, future investigators should focus on specific multimorbidity combinations and how
the clinical control of each condition modifies the risk of developing dementia. The worldwide
prevalence of dementia has almost doubled in the past 25 years, but the age-standardized incidence
has remained almost unchanged254. All this has occurred while the incidence of multimorbidity has
increased in the general population and has been increasingly to a larger degree at a younger age
255

. These results suggest that some factors diminish the risk of dementia in persons with

multimorbidity, a protective effect that could be related to better treatment of chronic conditions.
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Conclusion

This thesis provides information on the prevalence of multimorbidity in two large longitudinal
studies in Canada, whose authors evaluated the same population with a difference of three decades.
Further, it provides the combinations that appear to be associated with abnormally low scores on
three neuropsychological tests that measure frontal function, language fluency and memory,
evaluating baseline scores and the change in them between the baseline and the first follow-up.
Our systematic review consolidated the information that multimorbidity is associated with lower
cognitive scores and higher diagnostic of MCI or dementia. These results are consistent in most
studies, despite the wide methodological variability between studies that precluded the
accomplishment of a meta-analysis.
We evaluated participants in the CSHA with a baseline evaluation in 1991, with the first followup in 1996. Additionally, we evaluated results from participants in the CLSA with an initial
assessment in 2015 and a first follow-up in 2018. This time frame allowed us to compare two
similar populations in Canada with a difference of three decades between them. In concordance
with previous studies, we found a prevalence of multimorbidity between 40% and 60%, which was
higher among older participants. The CSHA included participants older than 65 years and a higher
prevalence of women (73.6%). In comparison, the participants in the CLSA were younger, with
ages between 45 and 85 years and gender parity, with women representing 51.9%.
In the association of multimorbidity with frontal function, we only found small links in the CLSA,
but the clinical significance was unclear. In the case of the evaluation of language fluency using
ANT, we did not find an association of multimorbidity in either cohort. Finally, in the RAVLT,
immediate and delayed recall showed some associations with the scores’ decrease in the CLSA,
but these decreases were small. This association will require revaluation in the subsequent CLSA
waves and replication in other ageing longitudinal studies. We only evaluated the outcomes of
dementia and mild cognitive impairment in the CSHA because there was no algorithm yet to detect
them in the CLSA. We did not find an association of multimorbidity with these two clinical
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outcomes. Future research should determine whether these associations are real or spurious owing
to the large sample size in the CLSA.
In the evaluation of dyads and triads associated with lower cognitive scores, we found that the
selection of combinations with higher prevalence and regression models yielded a different method
but one that was complementary with the CART method. The regression method showed some
minor associations measured as significant statistical interactions. In contrast, the CART method
showed that for each test, some dyads and triads were associated with lower scores at the baseline
and combinations that decreased the scores between the baseline and the first follow-up.
Nevertheless, the most salient result was that the combinations of chronic diseases associated with
lower scores at the baseline were different from those combinations that induced a greater decline
in the change between the baseline and the first follow-up. Future researchers should further
explore these targeted combinations and the effect of additional chronic disease combinations at
the baseline and follow-up.
Using the CART method, we individualized the following combination, presenting abnormally low
neuropsychological scores below the usual thresholds of ≤-1.5 SD.
•

For Frontal function scores:
o In the CSHA at baseline, the combination of other heart disease + Cancer with a
mean score of -1.7 SD
o In the CLSA at baseline, the combination of other heart diseases + stroke with a
mean score of -1.8 SD
o In the CLSA subgroup of 65 years and older at baseline, the combination of
hypertension + diabetes + epilepsy with a mean score of -1.8 SD
o In the CLSA subgroup younger than 65 years at baseline, the combination of
coronary artery disease + stroke with a mean score of -1.8 SD

•

For the Animal Naming test only in the CLSA at baseline in the male subgroup, the
combination of hypertension + other heart disease + multiple sclerosis with a mean score
of -1.5 SD

•

For the RAVLT immediate recall
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o In the CLSA at baseline, the dyad of other heart diseases + stroke with a mean score
of -1.5 SD, and the triad of other heart diseases + epilepsy + arthritis with a mean
score of -1.5 SD.
o In the CLSA subgroup of 65 years and older at baseline, the combination of thyroid
disease + stroke with a mean score of -1.5 SD.
•

For the RAVLT delayed recall
o In the CLSA at baseline, the combination of other heart diseases + stroke with a
mean score of -1.5 SD.
o In the CLSA subgroup of 65 years and older at baseline, the combination of other
heart disease + stroke + thyroid disease with a mean score of -1.5 SD.

Also, we found an incidence of dementia more than twice in the CSHA at first follow-up with the
combinations of coronary artery disease + thyroid disease, coronary artery disease + arthritis and
stroke + arthritis. In the same cohort for the incidence of CIND, the combination with a risk of
more than twice as high was hypertension + thyroid disease. In addition, in the female subgroup,
we found that the combination of coronary artery disease + hypertension increased the risk by more
than twice.
We highlight that other heart disease and stroke are part of several combinations associated with
low scores in tests evaluating different cognitive domains. In the case of dementia incidence, the
combinations with higher frequency include coronary artery disease. These results reveal that
cardiopathies, combined with a stroke, can be a marker for higher risk of cognitive impairment
development in multimorbidity patients.
In addition, when we evaluated the risk factors only in participants with multimorbidity, we found
that the only statistically significant association that could protect them from neuropsychological
scores decline was alcohol intake. However, this association with alcohol intake was small, and its
clinical significance is unclear. More remarkably, we found that in the CSHA engaging in physical
exercise reduced the risk of incidence of dementia with an OR of 0.45 (CI 95%, 0.20–0.98). This
result brings hope that lifestyle intervention can reduce the risk of cognitive decline in the highrisk multimorbidity population.
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Finally, our study synthesized the information available on the association of multimorbidity and
cognition, then we evaluated the effect of multimorbidity in two longitudinal studies separated by
three decades, evaluated the combinations of multimorbidity associated with cognitive outcomes
and evaluated the potential effect of known associated factors on cognitive preservation. Future
researchers will need to address the evaluation of the detected combinations of cognitive scores
and confirm our results regarding the important outcomes of mild cognitive impairment and
dementia.

7.1 Conclusion highlights
•

For the systematic review, authors of most studies, regardless of whether they were crosssectional or cohort studies, found an association of multimorbidity with lower cognitive
scores or a higher risk of mild cognitive impairment, or dementia.

•

The prevalence of risk factors between both cohorts has changed, with an increase in
education level, alcohol consumption and traumatic brain injury. That said, the prevalence
of regular physical activity has remained the same.

•

We found that in the CSHA, there was no association between multimorbidity and cognitive
decline. At the same time, in the current cohort of the CLSA, we observed an association
of multimorbidity with a decrease in cognitive scores in frontal function and RAVLTdelayed recall. Future research should evaluate these results to clarify the apparent finding
of the increased impact of multimorbidity on cognitive scores; the alternative explanation
is that it is a spurious association due to the larger sample size in the CLSA. We did not
find an association of multimorbidity with dementia or mild cognitive impairment in the
CSHA; we did not have information for these two outcomes in the CLSA.

•

We found that the two methods yield different results for evaluating of dyad and triad
combinations. First, the regression analysis of combinations with high prevalence showed
lower combinations with the association. However, the CART analysis generated more
potential combinations but is purely exploratory.

•

Multimorbidity combinations that include other heart diseases and stroke are associated
with scores ≤-1.5 SD in different neuropsychological tests, mainly in the CLSA. These
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combinations include combinations and combinations with other chronic conditions. Also,
in the CSHA for the incidence of dementia at first follow-up, most combinations with
higher frequency had a cardiopathy, mainly coronary artery disease.
•

For the factors associated with protection from cognitive impairment in participants with
multimorbidity, we did not notice any factor enhancing cognitive performance at the
follow-up. However, we found that engaging in physical activity decreased the risk of
dementia diagnosis by the first follow-up in the CSHA; we could not evaluate this finding
in the CLSA because we still do not have a case definition of dementia in this cohort.
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Appendix

Table 9-1: Complete search strategy for the systematic review
Medline - Pubmed
multimorbidity OR “multi-morbidity” OR “multi morbidity” OR multimorbidities
OR “multi-morbidities” OR “multi morbidities” OR multimorbid OR “multimorbid” OR “multi morbid” OR “multiple chronic conditions” OR “multiple
chronic illnesses” OR “multiple chronic diseases” OR “multiple conditions” OR
“multiple illnesses” OR “multiple diseases” OR “multiple diagnoses”
AND
“Cognitive decline” OR “Cognitive Dysfunctions” OR “Dysfunction, Cognitive”
OR ”Dysfunctions, Cognitive” OR “Cognitive Impairments” OR “Cognitive
Impairment” OR “Impairment, Cognitive” OR “Impairments, Cognitive” OR
“Mild Cognitive Impairment” OR “Cognitive Impairment, Mild” OR “Cognitive
Impairments, Mild” OR “Impairment, Mild Cognitive” OR “Impairments, Mild
Cognitive” OR “Mild Cognitive Impairments” OR “Mild Neurocognitive
Disorder” OR “Disorder, Mild Neurocognitive” OR “Disorders, Mild
Neurocognitive” OR “Mild Neurocognitive Disorders” OR “Neurocognitive
Disorder, Mild” OR “Neurocognitive Disorders, Mild” OR “Cognitive Decline”
OR “Cognitive Declines” OR “Decline, Cognitive” OR “Declines, Cognitive” OR
“Mental Deterioration” OR “Deterioration, Mental” OR “Deteriorations, Mental”
OR “Mental Deteriorations” OR “Dementia” OR “Dementias” OR “Alzheimer's
Disease” OR “Dementia, Senile” OR “Senile Dementia” OR “Dementia,
Alzheimer Type” OR “Alzheimer Type Dementia” OR “Alzheimer-Type
Dementia (ATD)” OR “Alzheimer Type Dementia (ATD)” OR “Dementia,
Alzheimer-Type (ATD)” OR “Alzheimer Type Senile Dementia” OR “Primary
Senile Degenerative Dementia” OR “Dementia, Primary Senile Degenerative”
OR “Alzheimer Sclerosis” OR “Sclerosis, Alzheimer” OR “Alzheimer
Syndrome” OR “Alzheimer Dementia” OR “Alzheimer Dementias”
AND
("1996/01/01"[Date - Completion] : "3000"[Date - Completion])
#1 AND #2 AND #3
Embase and PsychINFO - OVID
1
dementia*.mp.
2
cognitive impair*.mp.
3
alzheimer*.mp.
4
cognitive decla*.mp.
5
multimorb*.mp.
6
limit 5 to yr="1996 -Current"
7
1 or 2 or 3 or 4
8
6 and 7
CINAHL - EBSCO
S1
multimorbidity - Limiters - Published Date: 19960101-20200331
S2
dementia
S3
cognitive decline
S4
"Alzheimer's Disease"
i
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S5
S6
S7
LILACS - IBECS

"cognitive impairment"
S2 OR S3 OR S4 OR S5
S1 AND S6
(tw:(Demência OR Dementia OR Demencia OR "Doença de Alzheimer" OR
"Alzheimer Disease" OR "Enfermedad de Alzheimer" OR " Disfunção
Cognitiva" OR"Disfunción Cognitiva" OR "Deficiencias Cognitivas" OR
"Disminución Cognitiva" )) AND (tw:(Multimorbidity OR Multimorbilidad OR
Multimorbidade ))

Scopus
( TITLE-ABS-KEY ( multimorbidity ) AND TITLE-ABS-KEY ( "Cognitive
Impairment" OR "Cognitive Decline" OR dementia OR "Alzheimer's
Disease" ) ) AND PUBYEAR > 1995
ProQuest
(noft(Dementia) OR noft(alzheimers) OR noft(cognitive
noft(cognitive impairment)) AND noft(multimorbidity)
Limit: after December 31, 1995

decline)

OR

OpenGrey
Multimorbidity AND Dementia

Table 9-2: Complete inclusion and exclusion criteria for the systematic review

Criteria for selection
Inclusion criteria
-Research question related to Multimorbidity and cognition
- At least one research outcome must be dementia, mild cognitive
impairment,
cognitive
decline,
cognitive
scores,
neuropsychological results or Global Cognition Scale
- Design must be longitudinal, cohort, case-control or crosssectional
- In the case of various reports from the same study protocol, we
used the most recent report.
Exclusion criteria
- Index disease
- Unclear definition of Multimorbidity
- Cognitive outcome as exposition
- Subjective cognitive outcomes
- Editorials or reviews
- Ecological studies

Table 9-3 Study Centres in the CSHA

British Columbia
1
2

Victoria
Vancouver
The Prairies
ii
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3
4
5
6

Calgary
Edmonton
Saskatoon
Winnipeg

7
8
9
10

London
Hamilton
Toronto
Ottawa

Ontario

Quebec
11
12
13
14

Montreal
Sherbrooke
Quebec City
Chicoutimi
Atlantic Region

15
16
17
18

Fredericton
Halifax
Charlottetown
St. Jhon’s

Table 9-4 Neuropsychological Assessment applied in the CSHA

Domain

Memory

Abstract thinking
Executive
functioning
Judgment

Aphasia

Test
Buschke Cued Recall
Wechsler
Memory
Scale:
Information Subtest
Rey Auditory-Verbal Learning
Benton Visual Retention Test -R
Wechsler Digit Span
Working Memory
WAIS-R Similarities Test (short
form)
WAIS-R Digit Symbol Sub-test
Trail Making
WAIS-R Comprehension (short
form)
Tokens Test
Word Fluency
Boston Naming Test
Animal Naming

CSHA 1
Initial

CSHA 2
5 years

CSHA 3
10 years

x

x

x

x

x

x

x
x

x
x
x

x
x

x

x

x

x
x

x

x

x

x
x

x
x
x
x

x

x
x
x
iii
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Apraxia
Agnosia
Construction
Pre-morbid
intelligence

Clock Drawing
x
Gesture Execution
Buschke Visual identification
x
WAIS-R Block Design (short form) x

x
x
x

x
x

WRAT-3 Reading

x

x

Table 9-5 Data Collection Centres in the CLSA

10
11

Comprehensive Cohort Data Collection Sites
British Columbia
Victoria, BC
Vancouver, BC
Surrey, BC
The Prairies
Calgary, AB
Winnipeg, MB
Ontario
Hamilton ON
Ottawa ON
Quebec
Montreal QC
Sherbrooke, QC
Atlantic Region
Halifax, NS
St. John’s, NL

1
2
3
4

Tracking Cohort Telephone Interview Centres
Vancouver, BC
Winnipeg MB
Sherbrooke, QC
Halifax, NS

1
2
3
4
5
6
7
8
9

Table 9-6 Neuropsychological Assessment applied in the CLSA

Domain

Test

Memory

Rey Auditory-Verbal Learning
Mental Alteration Test
Prospective Memory Test
Stroop screening test

Executive
functioning

Comprehensive Tracking
x
x
x
x

x
x

iv
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Aphasia
Speed

Controlled Oral word association test
(FAS)
Animal Naming
Choice reaction time

x
x
x

x

Table 9-7: List of 20 chronic conditions that were proposed to be used in Multimorbidity count*

1. Hypertension
2. Obesity
3. Diabetes
4. Chronic bronchitis, Chronic obstructive pulmonary disease or Asthma
5. Hyperlipemia
6. Cancer
7. Cardiovascular disease
8. Heart failure
9. Anxiety or depression
10. Osteoarthritis or Rheumatoid arthritis
11. Stroke or Transient ischemic attack
12. Thyroid problem
13. Chronic kidney disease or failure
14. Osteoporosis
15. Dementia **
16. Chronic musculoskeletal problem
17. Stomach problem
18. Colon problem
19. Chronic liver disease
20. Chronic urinary problem
*Adapted from Nichols et al. 2015
** Dementia is the dependent variable in this research. It was not used in the count of
multimorbidity meaning that the count can add to a maximum of 19
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